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Ti" compounds have pronounced anticancer, antiviral and antibacterial 
activities, and titanocene dichloride (TDC) is currently on phase II clinical trials as an 
anticancer drug. However, the biological chemistry and mechanisms of action of Ti" 
are poorly understood. Proteins and nucleic acids are expected to be biological targets 
for Ti". Human transferrin (hTF) is a bilobal serum glycoprotein (80 kDa) which 
transports Fe" to cells via receptor-mediated endocytosis. A structurally similar 
periplasmic iron binding protein (FBP, 34 kDa) is present in some pathogenic bacteria 
and is required for virulence. 
In this thesis, the aqueous coordination chemistry of Ti"' with the phenolate 
ligand N,N-ethylene-bis-(o-hydroxyphenylglycjne) (H 4ehpg) was investigated as a 
model for Ti-hTF (or FBP) interactions. Ti"' forms 7-coordinate monomer (rac) and 
dimer (meso) complexes with H4ehpg (rac + meso) with novel stereo-selectivity. 'H and 
31 p NMR studies show that TDC binds selectively to H 4ehpg at neutral pH, but 
preferentially to adenosine triphosphate (ATP) at pH values below 5; Tir" transfers from 
Ti"-ehpg to ATP at acidic pH values. 
The interactions of TDC with hTF and that of Ti2-hTF with ATP have 
characteristics which could allow transferrin to act as a mediator for titanium delivery to 
tumour cells. TDC reacts rapidly with apo-hTF under extra-cellular conditions and 
binds in the specific Fe" sites with release of the Cp and Cl ligands. Ti r" is readily 
released from Ti2-hTF at endosomal pH (ca 5.0) and in the presence of ATP. Ti2-hTF 
competes effectively for cell uptake of 59Fe-hTF into BeWo cancer cells. 
1 
TDC binds strongly to the phosphate group of nucleotides in aqueous solution 
and Ti" binds to the phosphodiester groups of nucleotides in the less polar solvent N,N-
dimethylformamide. This behavior contrasts with that of the anticancer drug cisplatin 
which binds mainly to N-sites of nucleobases, and may account for the intracellular 
localisation behaviour of Ti" drugs. 
Recombinant FBP and 15N globally-labelled FBP were overexpressed in E. coli 
and characterised. This 34 kDa protein contains bound Fe" 1 and phosphate (synergistic 
anion). Carbonate, oxalate, pyrophosphate and ATP but not sulphate or perchiorate can 
also serve as synergistic anions. The bound phosphate can be displaced by at large 
excess of carbonate. Iron can be removed from FBP together with phosphate to form 
apo-FBP which exists in a different conformation. Apo-FBP binds strongly to Fe m but 
weakly to other metal ions such as Ga" and Bi'' and not to Co". However, Ti r*" binds 
apo-FBP strongly to form a specific 1:1 complex without bound synergistic anion. Of 
greater significance is that Ti" can react with holo-FBP and displace Fe" rapidly under 
physiological conditions. FBPs were crystallised. Apo-FBP crystals diffracted X-rays to 
3.0 A and Ti-FBP to 2.4 A. Preliminary refinement of Ti-FBP structure shows that Ti"' 
binds to FBP in the Fe"'-binding cleft with an open domain conformation. These novel 
findings may allow Ti"' complexes to act as inhibitors of FBP and as potential novel 
antibacterial agents. 
11 
To my family 
111 
Acknowledgements 
I would like to thank my supervisor, Professor Peter J. Sadler for his invaluable 
advice, encouragement and excellent guidance throughout my three years of PhD study. I 
am very grateful for the critical scientific training he given me and all his support and 
motivation. 
My special thanks go to Dr. Dominic Campopiano, for allowing me to undertake 
part of this project in his laboratory and for teaching me molecular biology techniques. Also 
many thanks to the people in Lab 229: Lisa Mullen, Lisa Mclver, and Lorraine Coghill for 
their assistance and friendship. 
I would like to thank all the members in PJS group, past and present, for their 
support and friendship. I am particularly grateful to Dr. John A. Parkinson for help with 
NMR experiments and molecular modelling, Drs. Hongzhe Sun, Zijian Guo, Yu Chen, 
Claudia Blindauer and Abraha Habtemariam, for their stimulating discussion, valuable 
advice and assistance. 
I am very much grateful to Dr. Dimitry Alexeev (ICMB, Edinburgh) for undertaking 
the X-ray crystallographic studies, and Dr. Ian Harvey (Central Laboratory of the Research 
Councils, Daresbury) for collecting and analyzing the EXAFS data. I would thank Prof. 
Ross T. A. McGillivary (University of British Columbia, Canada) and Prof. Robert C. 
Woodworth and Dr. Anne B. Mason (University of Vermont, USA) for supplying the FBP 
gene and labelled transferrin samples. 
I also thank Prof. Stephen K. Chapman for his encouragement and Prof. Malcolm D. 
Walkinshaw (ICMB) for allowing me to do protein crystallisation in his laboratory. 
iv 
I am indebted to my wife, daughter, my mum and parents-in-law for their constant 
support, understanding, encouragement, and patience throughout these years. 
Finally, I would like to thank the Committee of Vice-Chancellors and Principals 
(CVCP) for an ORS Award and University of Edinburgh for a Sir David Baxter 
Scholarship, which financially supported my study in Edinburgh. 
V 
Declaration 
I hereby declare that except where specific reference is made to other 
sources, the work contained in this thesis is the original work of my own 
research since registration for the PhD degree in October 1997, and any 
collaboration has been indicated clearly. This thesis has been composed by 
the candidate and not been submitted, in whole or in part, for any of other 











Chapter 1. Introduction - titanium, transferrin and 
ferric-iron binding proteins 
1.1 Titanium 1 
1.1.1 Titanium and its aqueous chemistry 1 
1.1.2 Medicinal chemistry of titanium 2 
1.2 Titanocene dichioride and related complexes as antitumour agents 4 
1.2.1 Metal complexes as antitumour agents 4 
1.2.2 Antitumour titanium complexes - descriptive chemistry 6 
1.2.3 Antitumour activity of Tn  complexes 8 
1.2.4 Toxicological properties 11 
1.2.5 Structure-activity relationships 12 
1.2.6 Mechanism of action 12 
1.2.7 Aqueous dissociation and hydrolysis reactions 20 
1.2.8 Clinical results 22 
1.3 Transferrin as a metal ion mediator 24 
1.3.1 Transferrins 24 
1.3.2 Receptor-mediated endocytosis and the transferrin cycle 24 
1.3.3 Structures 26 
vii 
1.3.4 Receptor recognition 	 29 
1.3.5 Transferrin mediated delivery of metallodrugs to tumour cells 	32 
1.4 Pathogenic ferric-iron binding proteins as potential targets for Ti(IV) 	34 
1.4.1 Iron in biological systems 	 35 
1.4.2 Iron acquisition systems in the pathogenic Neisseria 	 35 
1.4.3 The major iron regulate protein- 
Ferric-iron binding protein (FBP) 	 38 
1.4.4 Ferric-iron binding proteins (FBPs) as targets for Ti(IV)? 	40 
1.5 References 	 43 
Chapter 2. Experimental techniques 
2.1 General strategies for gene expression in E. coli 	 53 
2.2 Over-expression of proteins in E.coli 	 53 
2.2.1 General equipment 	 53 
2.2.2 General regents, solutions and buffers 	 54 
2.2.3 Media 	 55 
2.2.4 Bacterial cell lines and storage of bacterial stocks 	 56 
2.2.5 DNA vectors and plasmids 	 57 
2.2.6 Transformation of E.coli competent cells with recombinant DNA 57 
2.2.7 Handling DNA 	 59 
2.2.8 Cloning DNA fragment into plasmid vectors 	 60 
2.2.9 Over-expression of proteins 	 60 
2.3 Purification of ferric-iron binding protein (FBP) 	 61 
2.4 Protein characterisation 	 61 
2.4.1 UV absorption spectroscopy 	 61 
viii 
2.4.2 Bicinchinoic acid (BCA) assay for quantitation of total protein 	63 
2.4.3 ICP-AES 63 
2.4.4 Mass spectrometry 63 
2.4.5 NMR spectroscopy 64 
2.5 Site-directed mutagenesis 68 
2.6 In vivo 15N-labelling of protein 69 
2.7 Crystallisation of proteins 70 
2.8 Sequence alignments 71 
2.9 References 72 
Chapter 3. Model complexes of Ti(IV)-transferrin - 
stereoselective formation of seven-coordinate Ti(IV) monomer 
and dimer complexes of ethylenebis(o-hydroxyphenyl)glycine 
3.1 Abstract 75 
3.2 Introduction 76 
3.3 Experimental 78 
3.4 Results 83 
3.4.1 Preparations of [Ti(ehpg)(H 20)].1 1/3H20 (1) and 
{{Ti(Hehpg)(H20)}20].13H 20 (2) 83 
3.4.2 X-ray structure of [Ti(ehpg)(H 20)].1 1/3 H20 (1) 84 
3.4.3 X-ray structure of [(Ti(Hehpg)(H20)1 20)1•13H20 (2) 86 
3.4.4 UV-vis spectra 89 
3.4.5 NMR of ligands 91 
3.4.6 NMR of complexes 93 
lx 
3.4.7 pH stability of complexes 1 and 2 	 96 
3.4.8 Reactions in solution 	 98 
3.5 Discussion 	 100 
3.6 References 	 113 
Chapter 4. Competitive binding of titanocene dichioride to 
N,N '-ethylene-bis-(o-hydroxyphenylglycine) and adenosine 
triphosphate: a model for Ti"' uptake and release by transferrin 
4.1 Abstract 	 117 
4.2 Introduction 	 117 
4.3 Experimental 	 119 
4.4 Results 	 121 
4.4.1 pH-dependent binding of Cp2TiC1 2(aq) for EHPG and ATP 	121 
4.4.2 Intermolecular transfer of Ti(IV) 
from Ti'-EHPG complex to ATP 	 124 
4.4.3 Ti(IV) transfer at physiologically relevant pH values 	 127 
4.5 Discussion 	 128 
4.6 References 	 130 
Chapter 5. Ti" uptake and release by human serum transferrin 
and recognition of Ti"-transferrin by cancer cells: 
understanding the mechanism of action of the anticancer drug 
titanocene dichloride 
5.1 Abstract 	 132 
5.2 Introduction 	 133 
x 
5.3 Materials and methods 136 
5.4 Results 140 
5.4.1 Uptake of Ti¼  by apo-hTF 140 
5.4.2 Order of lobe loading of apo-hTF with Ti' s' 148 
5.4.3 Ti"' release from Ti 2-hTF 150 
5.4.4 Fe" displacement of Ti" from Ti2-hTF 153 
5.4.5 ICP-AES studies ' 	 156 
5.4.5 Cell uptake studies 158 
5.5 Discussion 159 
5.6 Conclusion 167 
5.7 References 169 
Chapter 	6. Ti(IV) 	targets 	phosphoesters 	on 	nucleotides: 
implications for the mechanism of action of the anticancer drug 
titanocene dichioride 
6.1 Abstract 174 
6.2 Introduction 174 
6.3 Materials and methods 177 
6.4 Results and discussion 178 
6.4.1 Reactions of Cp 2TiCl 2 with nucleoside monophosphates 178 
6.4.2 pH dependent interactions between titanocene dichloride with 
nucleoside monophosphates 183 
6.4.3 Competitive reactions of dAMP, dGMP, dCMP, TMP with 
titanocene dichloride 	 192 
6.4.4 Interactions with dGMP constituents 	 192 
6.4.5 Interactions with nucleoside phosphodiesters in aqueous solution 193 
6.4.6 Binding to nucleoside phosphodiesters in 
N,N-dimethylformamide (DMF) 	 194 
xl 
6.4.7 pH dependent interactions between titanocene dichioride 
and nucleoside triphosphates 	 197 
6.4.8 Cleavage of ATP phospho-ester bonds by titanocene dichloride 	200 
6.4.9 The titanocene-ATP-Mg ternary system 	 201 
6.4.10 Solid state investigation of coordination between GMP 
and titanocene dichioride 	 203 
6.4.11 Relevance to the mode of action of titanocene dichloride 	203 
6.5 Conclusion 	 206 
6.6 References 	 207 
Chapter 7. Ferric-iron binding protein (FBP) - over-expression, 
biochemical characterision, crystallisation, site-directed mutagenesis, 
N-15 labelling, synergistic anion binding and metal binding studies 
7.1 Abstract 210 
7.2 Introduction 211 
7.3 Experimental 213 
7.4 Results and Discussion 220 
7.4.1 Cloning and over-expression of FBP gene in E. coli 220 
7.4.2 Purification of FBP 221 
7.4.3 Characterisation of FBP 222 
7.4.4 Synergistic anion binding properties of FBP 226 
7.4.5 Synergistic anion exchange studies 233 
7.4.6 Fe(Ill) transfer from FBP to human transferrin in vitro 241 
7.4.7 Metal binding properties of FBP 242 
7.4.8 Homology model of FBP 247 
7.4.9 N-iS labelling and 2D, 3D NMR spectra 248 
7.4.10 Site-directed mutagenesis studies 253 
7.4.11 Crystallisation of FBP 255 
xii 
7.5 Discussion 	 256' 
7.6 References 	 262 
Chapter 8. Ferric-iron binding protein (FBP) as a target for 
titanium(IV) - spectroscopic, NMR, EXAFS and crystallographic 
studies 
8.1 Abstract 265 
8.2 Introduction 266 
8.3 Experimental 268 
8.4 Results and discussion 270 
8.4.1 Ti'v binds to apo-FBP under physiologically relevant conditions 272 
8.4.2 Reactions of Fe(ffi) with Ti-FBP 275 
8.4.3 Displacement of Fe(ffl) from holo-FBP by Ti(IV) 276 
8.4.4 NMR studies 277 
8.4.5 X-ray spectroscopy 284 
8.4.6 Crystallisation of Ti-FBP 287 
8.4.7 Structure solution of Ti-FBP complex by molecular replacement 290 
8.5 Discussion 295 
8.6 References 299 
Appendix 
Table Al 	 I 
Table A2 	 II 
Table A3 	 ifi 
Publication list 	 IV 
xiii 
Abbreviations: 
Ala (A) L-alanine 
AMP Adenosine 5 -monophosphate 
Apo-FBP, apo-FBP Metal-free FBP 
Apo-hTF, apo-hTF Metal-free human serum transferrin 
Asp L-aspartic acid 
ATP Adenosine 5 -triphosphate 
BCA Bicinchinoic acid 
Ca. circa (about) 
CMP Cytidine 5 '-monophosphate 
COSY 2D correlation spectroscopy 
Cp 1 5-05H5 
CTAB Cetyltrimethylammonium bromide 
DMF N,N-dimethylformamide 
DMSO Dimethyl sulfoxide 
D20 Deuterium oxide 
DTPA Diethylene-triaminepentaacetate 
DQF Double-quantum filtered 
E. co/i Escherichia coli 
EHPG (ehpg) N,N'-ethylene-bis-(o-hydroxyphenylglycine) 
ESI-Mass Electrospray ionisation mass spectrometry 
EXAFS Extended X-ray absorption fine structure 
EXSY 2D exchange spectroscopy 
FBP Ferric-iron binding protein 
FPLC Fast protein liquid chromatography 
Glu (E) L-glutamic acid 
Glutathione y-L-Glu-L-Cys-Gly 
GMP Guanosine 5-monophosphate 
GTP Guanosine 5'-triphosphate 
xiv 
Hepes 4-(2-hydroxyethyl)- 1 -piperazineethanesulfonic acid 
His (H) L-histidine 
HMQC, HSQC Heteronuclear multiple-quantum (or single quantum) coherence 
HPLC High performance liquid chromatography 
hTF Human serum transferrin 
ICMB Institute of Cellular and Molecular Biology 
ICP-AES Inductively coupled plasma atomic emission spectroscopy 
INEPT Insensitive nuclei enhanced by polarisation transfer 
IPTG Isopropy1-3-D-thiogalactoside 
LB broth Luria Bertani broth 
Lys (L) L-lysine 
Me3tacn 1 ,4,7-trimethyl- 1 ,4,7-triazacyclonane 
Met (M) L-methionine 
MW Molecular weight 
NOESY 2D nuclear overhauser effect spectroscopy 
NOE Nuclear overhauser effect 
NTA Nitrilotriacetate 
cit citrate 
PCR Polymerase chain reaction 
PDB Protein data bank (http://www.rcsb.org/pdb/)  
PEG Poly (ethylene glycol) 
Phe (F) L-phenylalanine 
RMSD Root-mean-square deviation 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TDC Titanocene dichioride 
TMP Thymidine 5-monophosphate 
TOCSY Total correlation spectroscopy 
Tris Tn [hydroxymethyl] aminomethane 
TROSY Transverse relaxation-optimised spectroscopy 
Trp (W) L-tryptophan 
xv 
TSP 	 Sodium trimethylsilyl-d4-propionate 
Tyr (Y) 	 L-tyrosine 
UMP 	 Uridine 5'-monophosphate 
UV-vis 	 Ultraviolet visible spectroscopy 
Val (V) 	 L-valine 
WATERGATE 	Water suppression by gradient-tailored excitation 
xvi 
Chapter 1 Introduction 
Chapter 1 
Introduction -Titanium, Transferrin and 
Ferric-iron Binding Proteins 
1.1 Titanium 
1.1.1 Titanium and Its Aqueous Chemistry 
Titanium, atomic number 22 and atomic weight of 47.88, is the second 
element in the first transition series, in group 4 together with zirconium and hafnium. 
Titanium is relatively abundant in the earth's crust (0.6%). The main ores are ilmenite 
(FeTiO3) and rutile, one of the several crystalline varieties of Ti0 2. Titanium has four 
valence electrons 3d24s2 and five common oxidation states, -I, 0, H, ifi and W. The 
most stable and most common oxidation state is Ti"; compounds in lower oxidation 
states are quite readily oxidised to Ti"' by air, water, or other reagents. Ti 4l  ion may 
not exist in isolation since the energy for removal of four electrons is high and Ti"' 
compounds are generally covalent [1]. The estimated Pauling ionic radius for Ti 4 is 
0.68 A, 6-coordinate ionic radius for TiIV  is 0.605 A [2] and the octahedral covalent 
radius for TiIV  is 1.36 A. The spherical symmetry of the d ° configuration allows a 
variety of stereochemistries for Ti". Its coordination number can vary from 4, 5, 6, 7 
to 8, common geometries being tetrahedral (TiC1 4), trigonal bipyramidal (TiC1 51 
square pyramidal ([TiO(porphyrin)]), octahedral (TiF 62 , Ti02), pentagonal 
bipyramidal ([TiCl(S 2CNMe2)3]), capped trigonal prismatic ([Ti(0 2)F5] 3 '), 
dodecahedral (Ti(C10 4)4) or slightly distorted. 
Ti4 is a hard metal ion in the hard-soft classification [2]. Ti" compounds 
normally undergo hydrolysis to give species with Ti—O bonds, in many of which 
1 
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there is octahedral coordination by oxygen; compounds with Ti—O--Ti, Ti—C, 
Ti—O---Si, and Ti—O---Sn bonds are known [1]. No aquated Ti 4 salts can be 
isolated, but Ti4l  may exist in solution though the main species are hydrolysed forms 
such as Ti(OH) 22 , Ti(OH)Cl2 , or possibly Ti2(OH)62 [3]. Polymeric species with 
—OH— or —0-- bridges are common for Ti'' in aqueous solution [2]. There has 
been considerable discussion as to whether the Ti=021  ion exists in solutions since 
compounds with Ti=0 bonds are quite rare. However, Raman and 170  NMR spectra 
confirm that in strong acid the Ti0 2 ion is in equilibrium with Ti(OH)2 and Ti4 (aq). 
At higher pH, there are species such as Ti 3044 , leading eventually to colloidal or 
precipitated Ti02•nH20 [4]. Recently, quite a few compounds containing Ti=0 
double bonds have been structurally characterised by X-ray crystallography [5,6,7,8]. 
The Ti=0 bond length is quite short ranging from 1.61 A to 1.70 A, depending on the 
coordination number and hydrogen bonding scheme. In five-coordinate titanium 
porphyrin complexes, Ti=0 is 1.613 A [5],  in the 6-coordinate [(Me 3-tacn)Ti(0)C1 2 ] 
(3 N, 1 0, 2 Cl donors), Ti=0 is 1.638 A [7], whereas in the 7-coordinate 
[C(NH 2) 3 ] 4 [TiO(CO3 )3}, the Ti=0 bond is longer at 1.680 A, which is a consequence 
of two relatively strong hydrogen bonding contacts to the Ti=0 group [8]. 
1.1.2 Medicinal Chemistry of Titanium 
The earliest reference to use of titanium for medicinal purposes was made by 
the German physician Julius Pick in 1911 [9]. He found that some Ti"' compounds 
such as hydrolysed Ti(SO 4)2 and Ti" mono-and di-salicylates were effective topical 
and oral treatments for Tuberkelbacillen infections. During World War I, the French 
tried to use hydrous Ti02 for treating mustard gas wounds [10]. As the Second World 
74 
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War started, the French physician Dinah Abragam was exploring the potential 
anticancer activity of Ti" complexes. He found that hydrous Ti0 2 and Ti" citrate 
could prolong the life of rats with Jensen sarcoma compared with the control group 
[11]. In 1963, Buenemann, Kiosteckoette and Ritzerfeld reported that Ti0 2 powder 
inhibited the growth of bacteria such as Staphylococcus aureus, Escherichia coli, and 
Mycobacterium tuberculosis in culture [12]. This effect from Ti0 2 has been 
suggested to result from photocatalyzed generation of oxygen free radicals that can 
kill bacteria growing in culture medium [13]. Recently, promoted by their finding 
that hydrolysed Ti(SO4)2 inhibits the activity of trypsin by binding to its active site 
[14], McCue et al investigated its antibacterial activity by measuring the affect of Ti" 
on the growth of Escherichia coli, Salmonella lyphimurium, and Pseudomonas 
aeruginosa. They found that titanyl sulfate completely inhibited the growth of these 
organisms [14,15]. 
Discovery of the pronounced antitumour activities of the biscyclopentadienyl-
Ti'v complex, titanocene dichloride (Cp 2TiC12, Cp= 1 5-05H5) by Kopf and Kopf-
Maier in 1979 [16], together with the discovery of antitumour activity of the bis(-
diketonato)-Ti"' compound, Budotitane [Ti(bzac) 2(OEt)2] (Hbzac = 1-phenylbutane-
1,3-dinato), by Keppler et al in the middle 1980s [17], stimulated much interest in the 
research on the biological activities of Ti' v complexes. Due to their promising 
antitumour activities and low toxic side effects, titanocene dichloride and Budotitane 
are currently being on phase I and phase II clinical trials as anticancer drugs 
[18,19,20]. Moreover, significant antiviral activity was shown in vitro for titanocene 
dichloride against DNA and RNA viruses in the extracellular phase [21]. The DNA 
3 
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viruses tested which were sensitive to titanocene dichloride include orthopox virus 
(vaccinia) and herpes virus (pseudorabies), and RNA viruses include rhabdovirus 
(vesicular stomatitis), paramyxovirus (Newcastle disease) and diverse 
orthomyxoviruses (e.g. influenza A and B) [21]. Insecticidal activities and anti-
inflammatory properties have also been reported for cyclopentadienyl titanium(IV) 
complexes [22,23]. 
1.2 Titanocene dichioride and related complexes as antitumour 
agents 
1.2.1 Metal Complexes as Antitumour Agents 
The discovery of the antitumour properties of the metal complexes cis-
diaminedichloroplatinum(II) (cisplatin) in 1965 by Rosenberg and co-workers [24,25] 
and its subsequent introduction into clinical trials in 1971 was the catalyst for a major 
international research effort to investigate the potential of metal compounds in cancer 
therapy. Cisplatin and related platinum compounds have turned out to be highly 
effective and useful cytostatic drugs. By the end of 1999, four platinum complexes 
have been approved as clinical antitumour drugs [26]. Cisplatin and carboplatin have 
high efficacy against a relatively narrow range of tumours such as human testicular, 
ovarian, bladder, and head and neck carcinomas, and can effect a cure in most cases 
of testicular carcinoma [26]. The discovery of the antitumour efficacy of cisplatin and 
some related platinum compounds prompted an immediate broad search for other 
platinum metal complexes, the latter containing ruthenium, osmium, rhodium, iridium 
or palladium. Subsequently, non-platinum-metal compounds of other transition and 
main group metal or metalloids were also investigated. Experimental trials showed 
4 
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Figure 1.1 Examples of diverse metal-containing antitumour agents. Complexes 
containing Pt, Ti, Ru, Ga, Ge have been used clinically or are in clinical trials as 
arititumour drugs. 
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that diverse main-group metal compounds as well as early-transition and late-
transition metal complexes had antineoplastic properties. These compounds comprise 
main-group metallic compounds of gallium, germanium, tin, and bismuth, early-
transition metal complexes of titanium, vanadium, niobium, molybdenum, and 
rhenium, and late-transition metal complexes of ruthenium, rhodium, iridium, 
platinum, copper, and gold. Figure 1.1 shows some of the compounds that have been 
proved to be active against experimental tumours. 
1.2.2 Antitumour Titanium Complexes - Descriptive Chemistry 
Following the therapeutical success of cisplatin, a large number of complexes 
of other metals have been studied. Some promising examples of such complexes are 
the titanium complexes including bis(-diketonato)-Ti"" compounds and 
biscyclopentadienyl-Ti"' (and also VIV,  Mo"", Nb") complexes which have shown 
cytostatic activity against various tumour cell lines [27]. Titanocene dichloride and 
Bodotitane (see Figure 1.2) have been shown to be potent agents against various solid 
tumour models and colon carcinomas whereas they are only marginally effective 
against leukaemias [28]. In contrast to cisplatin, titanocene dichloride exhibits side 
effects in the liver when used in therapeutically necessary doses [29]. 
The metallocene diacido complexes are "bent sandwich" compounds. The 
central metal is in a distorted tetrahedral coordination geometry with two it-bonded 
Cp ligands and two other ligands bound in a cis configuration (Figure 1.2). In a 
molecular orbital description, the electronic structure of bent metallocene can be 
n. 
I ,%%t%0 Et Ti 
OEt 
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understood by distorting a D5h molecular structure. Contracting angle of Cp-M-Cp 
below 1800  rehybridizes three of the five metal d orbitals such that the frontier 
orbitals are directed to the open side of the Cp 2 "wedge" [30] and depending on the 
d electron count, the Cp 2M moiety exhibits variable acid-base reactivity. For 
example, group 4 Cp 2MC12 complexes ( M = Ti, Zr, Hf) have an empty central 
frontier orbital that renders the complexes Lewis acidic, while the group 6 (M = Cr, 
Mo, W) complexes have a filled orbital and frequently display Lewis basic character. 
This explains the dramatic difference in the coordination chemistry of the group 4 and 
group 6 metallocenes wherein the former tend to bind to it-basic ligands such as R0 
while the latter tend to bind to it-acceptor ligands such as ethylene [30]. The 
fundamental differences in the coordination chemistry of these two classes of 





Figure 1.2 Structural drawings of titanocene dichloride (left) and Budotitane (right) 
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Bis(cyclopentadienyl) metal(IV) diacido complexes Cp 2MX2 with M = 
titanium, vanadium, niobium, or molybdenum as central metal atom were the first 
early transition metal compounds for which antitumour activity was detected. They 
had pronounced antineoplastic activity against various tumour cell lines [31]. 
Some ionic derivatives of metallocene compounds, such as titanocene 
acetonitrile tetracloroferrate [Cp2Tir"Cl(NCCH3)11FeCl41 -, the niobocene and 
molybdenocene fluoroantimonates [Cp 2Nb"CI21[SbF6] - and [Cp2Mo"Cl2][SbF6] 2 , 
rhenocene trichloride [Cp 2Re"C12]Cl, and rhenocene hexafluoroarsenate 
[Cp2Re"Cl21[AsF6] -, also exhibit antitumour activity against the Ehrlich ascites 
tumour in vivo [32]. 
The bis(-diketonato)-Ti"' complexes are octahedral, coordinated by the four 
oxygen atoms from the two diketonato units and two other donor atoms from the two 
cis-X ligands. Ti" here is basically a hard Lewis acid and the bis(3-diketonato)-Ti"' 
complexes are very susceptible to hydrolysis. On the other hand, the bis(-
diketonato)-Ti"' complexes that have been investigated so far are difficult to dissolve 
in water. They are usually formulated as a co-precipitate, containing Cremophor EL®, 
1,2-propylene glycol in ethanol, and the drug in a ratio of 9:1:1 and dissolved in water 
[33,34]. 
1.2.3 Antitumour Activity of Ti" Complexes 
Titanium(IV) complexes show impressive in vivo and in vitro carcinostatic 
activities against breast, lung and intestinal (colon) cancer tissue [31,32,35]. At 
8 
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optimal doses, titanocene diacido complexes and their vanadium, niobium, 
molybdenum analogues Cp 2MX2 where M = Ti(IV), V(IV), Nd(IV) and Mo(IV) show 
cyctostatic activity against fluid and solid Ehrlich ascites tumours 
[36,37,38,39,40,41], fluid and solid sarcoma 180 [42,43,44], B16 melanoma 
[42,43,44], Lewis lung carcinoma [45], mouse mammary tumour TA3Ha [46] and 
colon 38 adenocarcinoma [44,47], and markedly inhibit the growth of xenografted 
human carcinomas of the lung, breast, and gastrointestinal tract [48,49,50,5 1 ]. These 
results are noteworthy in view of previous clinical and experimental experience that 
human adenocarcinomas of the stomach and colon are generally rather insensitive to 
known cytostatic agents, and thus indicate possible clinical activity of metallocene 
complexes against human gastrointestinal carcinomas. In most experiments, 
titanocene dichloride Cp 2TiCl2 was the most active metallocene complex, followed by 
vanadocene dichloride Cp 2VC12. Moreover, titanocene complexes -were shown to be 
antiviral agents and potent anti-inflammatory compounds comparable to 
phenylbutazone [31]. 
Ionic derivatives of Cp 2MC12 have greater water solubility and also exhibit 
pronounced antitumour activity against Ehrlich ascites and several other experimental 
solid tumour systems in vivo [52,53,54,55]. Moreover, the titanocene acetonitrile 
tetrachloroferrate complex inhibited the growth of the solid tumours B 16 melanoma, 
Lewis lung carcinoma, and broad spectrum of xenografted human colon, lung, and 
breast carcinomas [32]. The antitumour efficacy of the ionic titanocene 
tetrachioroferrate complex was at least as pronounced as that of titanocene dichioride. 
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In contrast, the Zr and Hf metallocene dichiorides have negligible tumour-
inhibiting properties in terms of prolonging the survival of mice infected with Ehrlich 
ascite tumours cells [39]. Furthermore, free cyclopentadiene and dicyclopentadiene 
do not effect the same systemic antitumour activity as the metallocene complexes 
[56]. Neither hydrocarbon significantly inhibits tumour growth in mice bearing solid 
Ehrlich ascites tumour even at 10 times the metallocene dichloride dosages [56]. 
Bis(f3-diketonato)-Ti" complexes have significant antitumour activity against 
the animal Ehrlich ascites tumour, Stockholm ascitic tumour, sarcoma 180 ascitic 
tumour, and solid tumour models Walker 256 carcinosarcoma, MAC 15A colon 
carcinoma and induced colorectal tumours in animals [17,34,57], whereas the 
leukaemias P388 and L1210 responded only marginally [58]. Among these 
complexes, cis-[Ti"(bzac)2(CH3CH2O)2]  (Budotitane) and cis-[Ti"(bzac)2C12],  where 
bzac = 1 -phenylbutane- 1 ,3-diketonate, were the most 'active compounds against the 
mentioned animal tumours and the chemically-induced autochthonous colon 
adenocarcinoma in rats [59]. Budotitane entered clinical trials in 1989. The dimeric 
complexes, 1u-0-cis-[Ti"(bzac)2X2]  are also active [60]. The analogous zirconium 
and hafnium compounds are also active but are less effective than the titanium 
compounds [58,59]. 
1.2.4 Toxicological Properties 
Pharmacokinetic studies uncovered a main accumulation of titanium in the 
liver and the intestine, whereas low amounts were found in the kidneys and lungs 
[31]. No titanium-containing metabolites appeared to enter the brain or pass across 
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the placental barrier during organogenesis and early fetal period [31]. The clearance 
of titanium from the blood is characterised by a biphasic pattern with a rapid-phase 
half-time of about 5 h and a slow-phase half-time of several days [31]. 
Toxicological studies with mice after application of titanocene dichloride 
showed a different pattern of organ toxicity in comparison to organic antitumour 
agents and platinum cytostatic drugs [61,62,63,64]. Dose-limiting toxicity was due to 
hepatoxicity manifested by significant increases of the serum levels of typical liver 
enzymes and by fatty degeneration and necrotization of liver papenchyma cells. No 
functional and structural alterations of the kidneys were detectable even after 
application of toxic doses of titanocene or vanadocene dichioride. Bone marrow 
function was only slightly impaired, the thrombocytes being the only cells for which 
the number decreased after treatment with titanocene dichloride [311. 
Budotitane shows a similar toxicological pattern as titanocene dichloride [28]. 
1.2.5 Structure-activity Relationships 
Concerning the structure-activity relationships for cyclopentadienyl metal 
complexes, the following conclusions can be drawn [31]. 
Different metals can be present in cyclopentadienyl metal compounds and possess 
antitumour activity. The metals range from first-row, second-row and third-row 
transition metals of the Periodic Table. 
Within titanocene complexes Cp 2TiX2 and ferricenium salts [Cp 2Fe]X, the acido 
group can be varied widely. 
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(3) Modification of the cyclopentadienyl rings in metallocene diacido and 
metallicenium complexes by monosubstitution, 1,1' -disubstitution, or 
decasubstitution with alkyl groups, or exchange of one cyclopentadienyl ring by 
an additional acido ligand, results in distinct reduction in the antitumour activity. 
These results indicate a significant role of the unsubstituted, nonbulky 
cyclopentadienyl ring ligands for achievement of the antitumour action of 
cyclopentadienyl early transition metal and metallicenium complexes. 
1.2.6 Mechanism of Action 
1.2.6.1 General Information 
Most biological experiments performed so far suggest that nucleic acids, 
especially nuclear DNA, are the probable primary intracellular target for titanocene 
complexes [20,31]. 
Incorporation studies [65,66] with tritium-labelled, specific precursors of the 
DNA, RNA and protein syntheses revealed pronounced and persistent inhibitions of 
nucleic acid synthesis following in vivo and vitro application of titanocene dichloride 
or vanadocene dichioride (see Figure 1.3). DNA synthesis was especially suppressed 
in a significant and long-lasting manner, while RNA and protein synthesis is only 
slightly and reversibly inhibited. Interestingly, UV spectroscopic studies also suggest 
an interaction between aqueous Cp 2TiC12 and Cp2VC12 with nucleic acids that 
manifests itself as an alteration in secondary structure of the DNA [67,68,69]. 
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In a study using inductively coupled plasma (ICP) spectrometry, DNA-metal 
binding by metallocene dichiorides was examined in more detail [70]. It was shown 
that Cp2Ti-DNA adducts are formed at pH 53, whereas, at pH 7.0, CpTi-DNA 
adducts occur. Similar findings were observed with niobocene dichioride, 
zirconocene dichioride, although the latter has no antitumour activity. In contrast, 
vanadocene dichioride exhibits similar antiproliferative properties as titanocene 
dichioride, but fails to bind DNA covalently [70]. 
In vivo treatment with 
(C5 H5)2 TI Cl 2 
80 DNA 
0 40 	 0 0----------- 
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0 	
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Figure 1.3 Incorporation rates, as a percentage of untreated controls (100%), for 
[methyl- 3H]thymidine, [5-3H]uridine, and L- [4,5,-3H]leucine as a measure of the 
DNA, RNA, and protein synthesis activities in Ehrlich ascites tumour cells after in 
vivo treatment with 90 mg titanocene dichloride/kg at time 0 [65]. 
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Electron energy loss-spectroscopic studies reveal that the central metal atoms 
titanium and vanadium are mainly accumulated in those cellular regions which are 
rich in nucleic acids after in vivo treatment with titanocene dichlonde [7 1,72,73]. In 
addition, titanium-DNA adducts have been detected in A2780 cells treated with 
titanocene dichloride using atomic absorption spectrometry [74], suggesting that DNA 
may be a target for this drug. Cytokinetic investigations have revealed the appearance 
of a G2 block and the immigration of inflammatory cells belonging to the host 
defensive system in vivo, cell arrests at GuS boundary and G2 were induced [75,76]. 
However, apoptotic cell death occurred from any phase of cell cycle [74]. 
1.2.6.2 Model Complexes and Aqueous Solution Coordination Chemistry with 
Nucleotides 
Following detection of the antitumour properties of titanium and metallocene 
complexes, several groups have tried to synthesize model compounds of these 
species with nucleic acid components to elucidate the molecular mode of action, 
possibly involving direct coordination to the metal-containing moiety to DNA or 
RNA donor sites [77-84]. Many of these experiments have been planned and 
performed by analogy with those done relate for cisplatin, which apparently induces 
cytostatic activity by primary attack upon DNA and formation of bifunctional 
intrastrand cross-links between two adjacent guanine bases [85,86,87]. They were 
initially stimulated by observation that a dissociable cis or cis-like dichlorometal 
moiety of comparable non-bonding Cl"Cl distance ("bite") is present in both cisplatin 
and the cytostatically active metallocene dichlorides. 
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Unfortunately, the synthesis of model complexes of titanocene system with 
nucleic acid components as ligands has turned out to be difficult under physiological 
conditions, i.e. in aqueous solutions, because of hydrolytic side-reactions. Since 
1984, model compounds have been prepared successfully in organic media using as 
starting materials not only titanocene dichioride but also the low-valent titanium(ffl) 
and titanium(ll) species [Cp 2TiCl] 2 or Cp2Ti(CO)2. Monofunctional bonding of a 
chlorobis(cyclopentadienyl)titanium(IV) to N9 of the purinato ligand, as well as 
bifunctional chelation of bis(cyclopentadienyl)titanium(ffl) units to the N7, 06 atoms 
of the theophyllinato ligand have been observed (X-ray crystal structures) [77-80]. 
However, the use of nonaqueous methods of preparing these complexes and their 
hydrolytic instability, raises doubts about whether they are accurate representations of 
titanocene nucleobase/nucleotide/DNA interactions under physiological conditions. 
Quite another kind of binding was pointed out by Marks and co-workers who 
investigated the interaction of Cp2MoC12 and paramagnetic Cp 2VC12 with 
mononucleotides in aqueous solution near physiological pH by NMR and ESR 
methods as well as X-ray crystallographic techniques [82,83]. They observed 
selective, labile outer-sphere complexation of vanadocene to the nucleotide phosphate 
groups, and found that nucleotide-nucleotide Watson-Crick base-pairing was not 
disturbed by Cp2VC12 . 
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Figure 1.4 Crystal structure of the dimer [Cp 2Mo(dGMP)} 2 [83]. 
In contrast to the labile interaction between Cp 2VC12(aq) and nucleotides, the 
"softer" Mo(JV) centre of Cp2MoCl2 forms relatively nonlabile bonds with donor 
atomic sites of nucleotides and nucleobases [83,88]. 'H- and 31 P-NMR studies of 
Cp2MoC12-nucleotide interactions at physiological pH (pH 7.4) show that Cp 2Mo2 
coordinates in a covalent fashion to the base nitrogen sites and phosphate oxygen sites 
of mono-nucleotides. This kind of binding was further confirmed by the X-ray crystal 
structure of a Cp 2Mo-dGMP dimer (see Figure 1.4) [83] which was isolated from 
aqueous media at physiological pH (pH 7.4) under an argon atmosphere. In the 
crystal state, Cp 2Mo2 is simultaneously covalently bound to N7 of the guanine base 
and phosphate oxygen of different nucleotides. 'H NMR studies show that 
Cp2MoCl 2(aq) exhibits little or no coordinative nucleotide selectivity, and causes, as 
in the case of Cp 2VC1 2(aq), little or no disruption in the Watson-Crick base pairing. 
Furthermore, the covalent bonding in the Cp 2Mo-nucleotide complex is weak as it can 
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be disrupted by the presence of other free nucleotides. However, these results 
obtained under anaerobic conditions may not be readily applicable to physiological 
systems which are aerobic. In the presence of oygen, the reactivity may be different 
from that in anaerobic conditions [89]. A recent NMR study showed that stable 
molybdocene-oligonucleotide (d(ATGGTA) or dCpG) adducts were not formed at pD 
7.0, but formed at only low pD (Ca 3.0) values [90]. 
Relatively less is known about the aqueous coordination between nucleotides 
and Cp2TiCl2  or Budotitane, the antitumour agents which are in clinical development. 
Preliminary NMR studies with Cp2TiCl2 and Cp2NbC12 [91,92]suggest that 
complexation of Cp 2TiCl2 to nucleotides is weak in water and the binding modes 
might be similar to those of Cp 2MoCl2, but the binding sites have not been 
determined. No interaction between Cp 2NbCl 2 and nucleotides or amino acids has 
been observed [91]. Moreover, at pH > 6, little or no complexation of Cp 2TiCl2(aq) to 
nucleotides or nucleobases is observed [92,93]. These results do not explain the 
formation of CpTi-DNA adducts at pH 7.0, nor the anticancer activity of Cp 2TiCl2 
and Cp2NbC12 . However, at pH 5, the dimethylsubstituted derivatives (MeCp) 2TiX2 
(X = Cl, 02CCH2NH3C1) form complexes with purine nucleotides which were stable 
for 24 h [93]. This suggests that formation of stable chelates between (MeCp) 2TiX2 
and nucleic constituents in vivo is possible [93]. 
Solid state FT-IR and high-resolution 'H and 31 P NMR studies in wet DMSO 
[84,94,95] suggest that Cp 2Ti2 binds to nucleotides by N donors on the base rings 
and 0 donors of the phosphate groups. Moreover, A-T Watson-Crick base pairing is 
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disturbed by Cp 2TiC12 in DMSO [94]. This is quite different from Cp 2VC12 and 
Cp2MoC12 which have no effect on the A-T or G-C Waston-Crick base pairing 
[82,83]. By using an osmium dihydrogen compJex, [trans-Os en20-H2)] 2 as an 'H-
NMR probe [96], Cp2TiC12(aq) and Cp2MoC12 (aq) have been shown to bind to both 
the phosphate and N7 sites of dGMP, while Cp 2ZrC12(aq) binds only to the phosphate 
group [20,69,97]. 
The crystallographic and NMR results for Cp 2MoC12(aq) clearly show that 
Cp2Mo2 can bind covalently to mononucleotides via both base N-donors and 0-
donors from phosphomonoester groups, but not phosphodiesters [83]. NMR studies 
[98] with the oligo-nucleotide d(ApGpGpCpCpT) show that only minor changes 
occur upon addition of Cp 2MoC12(aq). Only the 5'-terminal adenosine binds to 
Cp2MoC12(aq) via its N7 and phosphate groups. These results suggest that binding of 
Cp2MoCl2(aq) is through the phosphate-base and not through base-base coordination 
(e.g., to N7 sites of adjacent guanosines) as is found for cisplatin. Consistent with this 
is the observation that Cp 2MoC12(aq) has no effect on the electrophoretic mobility of 
supercoiled DNA plasmids [98]. This is again in contrast with the results of 
analogous experiments performed with cisplatin, where binding to DNA induces 
unwinding and consequently a reduction in the electrophoretic mobility of DNA 
plasmids. 
The reason for the difference in Cp 2M2 and cis(NH3)Pt2tDNA coordination 
modes is due in part to the steric interactions involving the respective nonchloride 
ligands. Platinum(ll) complexes are square-planar, whereas the metallocenes are 
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pseudotetrahedral; with respect to binding to the DNA duplex, one is flat with small 
amine ligands that are directed away from the binding site whereas the other 
possesses transversely-oriented ligands of considerable steric bulk. Molecular 
graphics studies (see Figure 1.5) [83,98] show that the planar platinum complexes 
can be readily accommodated within the DNA major grove in an orientation that 
facilitates binding to adjacent nucleobases. However, the same is not true for 
pseudotetrahedral metallocene complexes. The sterically more demanding Cp ligands 
of metallocenes appear to preclude this mode of binding to DNA; metallocenes are 
simply too large to fit into the major groove. 
Little is known about the mechanism of action of Budotitane. There have 
been few reported investigations of its cellular or molecular mechanism of action or 
its metabolism in man or animals. In vitro studies reveal that the diaqua complex 
binds strongly to DNA [99], and suggest that the mechanism of action of Budotitane 






Figure 1.5 Comparison of Cp2Mo2 and cis-(NH3)2Pt2 bonding to two adjacent purine 
nucleobases in DNA via the two N7 sites [83]. 
1.2.6.3 Interaction with Proteins 
Chapter 1 Introduction 
From the above results, it seems unlikely that the metallocene dichiorides 
disrupt cellular function by binding to DNA in a mode analogous to that of cisplatin. 
Unlike cisplatin, the titanium complexes do not affect cellular function by blocking 
DNA-processing enzymes such as polymerase and restriction endonucleases [98]. 
Therefore, it appears that the carcinostatic activity of the titanium complexes does not 
originate predominantly from DNA binding. So alternative biomolecular targets for 
titanium complexes have been sought. The first characterised Ti-protein complex, 
titanium-transferrin has been reported recently by Sadler's group [100]. Ti"-citrate 
and titanocene citrate bind strongly to the blood plasma iron transport protein, apo-
transferrin, which could deliver titanium drugs to cells. 
1.2.7 Aqueous Dissociation and Hydrolysis Reactions 
In aqueous solution, the titanium anticancer complexes currently on trial are 
not stable, but undergo dissociation, aquation and hydrolysis reactions. Both alkyl 
ligands and chloride ligands can dissociate from the metal centre, depending on pH 
and concentration [101,106]. Substitution of dichioride by water in Cp 2MCI2 can be 
modelled as shown in Scheme 1.1. Table 1.1 shows the pKa values for aqua species 
of some metallo anticancer agents. 
Cp2MC1 2 + 21­120 
- [Cp2MCl(OH2)] + Cl + H20 
- [Cp2M(OH2)2] 2 + 2C1 
PKai 
[Cp2M(OH)(OH2)] + H + 2C1 
pKa2 
Cp2M(OH)2 +2W + 20F 
Scheme 1.1 
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Table 1.1 PKa data for [Cp2M(H20)2] 2 , [Me2Sn(H20)2] 2 and cis-
[Pt(NH3 )2(H20)2] 2 complexes 
Complex pKai pKa2 Temp Ionic strength Ref 
[Cp2Ti(H20)2] 2 3.5 4.4 37 °C 0.318 M KNO3 103 
[Cp2Mo(H20)2] 2 5.5 8.5 37 °C 0.318 M KNO3 83 
[Cp2V(H20)2 ] 2 4.7 5.2 1 37 °C 1 0.318 M KNO3 103 
[Me2Sn(H20)2] 2 3.2 1 5.2 125 °C 10. 1 M NaNO3 107 
cis- [Pt(NH3)2(H20)2] 2 5.6 17.4 125 °C 10. 1 M NaClO4 108 
So the metallocene dichlorides are more stable in acidic or saline solutions 
than in water. Moreover, neutral oxo-bridged binuclear and by hydrolytic cleavage 
of cyclopentadienyl rings, oligonuclear species, e.g. Cp 2C1Ti-O-TiClCp2 , 
Cp2(H20)Ti-O-Ti(H 20)Cp2 and [CpTiC1O] 3 , are also formed in the course of 
hydrolysis reactions [104,105]. Detailed information of the aqueous chemistry of 
titanocene dichloride can be found in a review [105]. 
In a detailed kinetic study on metalocene dichlorides [83,103], the order of 
decreasing hydrolytic stability of M-Cp bonds of metallocene dichiorides in un-
buffered aqueous solution was determined to be Cp 2MoC12 > Cp2VC12 > Cp2TiC1 2 >> 
Cp2ZrCl2 >Cp2HfC12. The antitumour-active compounds Cp 2MoC12, Cp2VC12 and 
Cp2TiC1 2 are expected to have stable M-Cp bonds over a period of days in 
unbuffered aqueous solutions, whereas Cp 2ZrC12 and Cp2HfC12 undergo rapid ring 
protonolysis. At pH values near physiological, Cp 2TiC12 ring loss is also extensive. 
with formation of a precipitate formulated as "Ti(C 5115)
0
. 3100 . 30(OH)"[103]. 
However, some anions in blood plasma, such as phosphate and citric, can markedly 
retard Cp ring dissociation from Ti(IV) at neutral pH [20]. 
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Budotitane also undergoes hydrolytic reactions in aqueous media. Hydrolysis 
of the ethoxy groups in water proceeds with a half-life of about 20 s, followed by 
condensation of the hydrolysed species, probably by fonnation of -oxo or - 
hydroxy bonds, to yield oligomeric complexes with the formulation [Ti(bzac) 20}. 
The diketonate moieties also hydrolyse but with a half-life of the order of hours 
[109]. 
1.2.8 Clinical Results 
Two titanium(IV) complexes, titanocene dichloride and Budotitane, have 
undergone clinical studies after showing promising antitumour activity in 
experimental colon tumour models. Phase I clinical trials with Budotitane (in 1986) 
indicate it to be fairly well tolerated by patients with the doses-limiting side effect 
being cardiac arrhythmia [110]. The maximum tolerable dose is 230 mg/rn 2 on a 
biweekly schedule, with 180 mg/rn 2 being suggested for any future studies. Higher 
doses lead to liver toxicity, kidney toxicity, and a reversible loss of taste [111]. 
Titanocene dichioride entered phase I clinical trial in Germany in December of 
1991 [112]. It has been given to patients in single intravenous doses, starting with a 
dose of 15 mg/rn 2  and increasing thereafter according to a modified Fibonacci 
procedure up to 560 mg/rn 2 (about 14.5 mg/kg). The maximum tolerated dose was 
determined to be 315 mg/rn 2 [113]. Two minor responses (bladder carcinoma and 
non-small cell lung cancer) were reported [113]. The main toxic effect was 
nephrotoxicity, in the form of a pronounced increase in serum creatinine 
concentration; two patients developed WHO grade 1 liver toxicity at doses of 240 and 
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420 mg/rn 2 . Some patients treated with doses higher than 134 mg/rn 2 reported a 
reversible metallic taste immediately after administration, and one patient reported 
transient loss of taste. The mechanism of this adverse effect, which has also been 
observed with budotitane and gallium(Ill) nitrate, is not known. The maximum-
tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of a weekly schedule of 
titanocene dichloride was determined to be 140 mg/m 2, with cumulative, but 
reversible creatinine and bilirubin elevation being the DLTs [114]. Most of the 
titanium (70-80%) was bound to plasma protein after intravenous administration of 
titanocene dichioride [113]. 
In some patients, transient and reversible reduction of blood glucose levels and 
hypoglycemia have been observed, independent of the dose of titanocene dichioride; 
short-lasting hypoglycemia had already been observed in animals [112]. 
Phase II trials with titanocene dichloride have been carried in Germany since 
1997. A recent report of phase H trial in patients with metastatic breast cancer by 
given patients at a dose of 240-270 mg/rn 2 , show only minor remission in 2 of the 12 
patients [115]. 
The biological features described above confirm that metallocene complexes 
are an independent group of non-platinum-group metal antitumour agents 
characterised by high anticancer activity against experimental models and low 
toxicity. The molecular mechanism of action may be quite different from that of 
cisplatin and is in need of further investigation. 
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1.3 Transferrin as a Metal Ion Mediator 
1.3.1 Transferrins 
Transferrin is the iron-carrying protein in the serum component of vertebrates 
[116,117,11 8]. It is a single-chain glycoprotein containing about 670-700 amino acid 
residues with a molecular weight of about 80 kDa. In human serum the concentration 
of transferrin is about 2.5 mg/mi (35 .tM) [118]. The iron-free transferrin (apo-
transferrin) can bind to two equivalents of Fe" reversibly, one in each of the two 
lobes (N- and C-terminal lobes) of the protein. The main function of transferrin is 
iron(III) transport. It ferries iron between very different cell types, such as the 
intestinal epithelium, where iron enters the body from the diet, the liver, where it is 
stored as ferritin, the developing erythroid cells, which require it for haemoglobin 
synthesis, and cells which need iron for cell growth, including tumour cells. Besides 
serum transferrins (TF) in blood, there are similar proteins in the transferrin family 
including ovotransferrins (oTF) found in egg white, lactoferrins (LF) found in 
secretory fluids such as milk, tears, saliva, bile and other secretions, as well as 
melanotransferrins (p97) found on the cell membrane of melanomas [119]. 
Transferrin is synthesised in liver in quantities of 1.2-2.0 g per day. 
1.3.2 Receptor-mediated Endocytosis and the Transferrin Cycle 
Receptor-mediated endocytosis is a natural process which cells utilise for the 
uptake of proteins or peptides such as low-density lipoprotein, asialoglycoprotein, 
epidermal growth factor, transferrin, insulin, and small vitamins such as folic acid 
[120]. The first step of this process involves binding of the protein to its specific cell- 
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surface receptors, receptor clustering and internalisation through coated vesicles into 
endosomal acidic compartments. The following steps are strongly dependent on the 
type of protein/receptor pair; the low endosomal pH may or may not trigger 
dissociation of receptor and protein, and sorting processes may lead to degradative 
lysosomal compartments. 
Iron-bound diferric transferrin gains entry to cells via receptor-mediated 
endocytosis (see Figure 1.6). Firstly, diferric transferrin binds strongly to a specific 
cell surface receptor (transferrin receptor) and is taken up. After internalisation, 
diferric transferrin is held as a receptor adduct in membrane-bound vesicles 
(endosomes) where the pH is lowered from the extracellular value of 7.4 to about 
5-5.5, and Fe" is released [121]. Apo-transferrin remains bound to its receptor at 
acidic pH. The apo-transferrin-receptor complex is sorted into exocytic vesicles and 
is recycled back to the surface of the cell. Only holo- but not apo-transferrin binds 
strongly to the receptor at cell surface [121]. At extracellular pH, apo-transferrin 
dissociates from its receptor due to its low affinity at pH 7.4, is released into the 
circulation, and reused [122,123]. Inside cells, intracellular chelates, such as ATP, 
might then be involved in the further uptake and transport of iron within the cell 
[124,125]. After Fe" is released from transferrin in endosomes, it is likely to bind to 
some small chelators such as ATP or citrate. ATP is known to be a metal 
macrochelator and a major intracellular iron carrier (126). It plays a major role in the 
transport of Fe" to the nucleus, and the 7-phosphate of ATP is hydrolysed during Fe 
transport (127). The entire transferrin cycle may take only 4-5 mm (as shown in 
K562 cells with ca 150,000 transferrin receptors per cell) with a mean transit time of 
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ca 10 min and avoids lysosomal compartments [128]. The rapid recycling leads to 
very high turnover numbers on the order of 2x10 4 transferrin molecules internalised 
per minute per cell [120]. A second, minor pathway with a longer transit time has 
also been identified as routing to the trans-Golgi and then back to the plasma 
membrane [129]. 
Uptake and release of Fe(lll) by cells 
pH 7.4 





Figure 1.6 Diagram showing the pathway of cellular uptake of iron from transferrin 
by cells via a receptor. 
1.3.3 Structures 
X-ray crystal structures show that transferrins are bilobal with two structurally 
similar lobes, the N-lobe (1- ca 330 residues) and C-lobe (last ca 330 residues), each 
of ca 40 kDa, joined by a short peptide [130-134]. The polypeptides share a very 
similar folding motif among all the proteins in the transferrin family. This is 
attributed to their high sequence identity (ca 40%). Each lobe is further divided into 
two domains (NI, N2 and Cl, C2) of similar size which have alternating a-helical 
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and n-sheet segments, a common feature for binding proteins of the 'Venus fly-trap' 
family [135]. Each lobe contains a distorted octahedral Fe 3 binding site consisting of 
two oxygens from two Tyr, one nitrogen from His, one oxygen from Asp and two 
oxygens from a bidentate carbonate synergistic anion [132] (Figure 1.7). 
Figure 1.7 Left, X-ray crystal structure of human serum Fe-transferrin at 2.6 A 
[133]. The C-lobe, with Fe 3 bound, is shown in a closed form (green) and the the N-
lobe with no metal bound, is in an open form (yellow). Right, coordination site of 
Fe3 (shown as a red ball) in the recombient N-lobe half molecule at 1.6 A [136]. 
Residue numbers are for the N-lobe site, with C-lobe analogues in brackets. 
The ligands are from four different parts of the protein, Asp63 from domain 1, 
Tyr188 from domain 2, the other two residues (Tyr95 and His249) are from the two 
polypeptide strands which cross over between the two domains at the back of the iron 
27 
Chapter 1 Introduction 
site. The domains are functionally important since the cleft separating the two 
domains of each lobe houses the metal binding site. Thus the domains can move 
apart, allowing iron release. 
One of the most important structural features of transferrins is that it 
undergoes large conformational changes during Fe 3 uptake and release. Both X-ray 
crystallographic studies and X-ray solution scattering studies have shown that the 
binding of iron and carbonate causes the protein to change its conformation from 
fully-opened to lobe-closed forms [132,137,138,139]. The metal-induced 
conformational changes in the N-lobe upon Fe 3 binding are shown in Figure 1.8. 
The conformational changes involve a large rigid body domain movement of 63° of 
the N2 domain relative to the Ni domain, to give an open binding cleft [138]. In 
addition to this rigid-body movement, several local changes in the. iron-binding cleft 
also occurred, i.e., two iron ligands, His249 and Asp63, change conformation to form 
salt bridges with G1u83 and Lys296 in the apo-form, respectively. Both salt bridges 
do not exist in the holo-form. [138]. Lactoferrin also undergoes similar open-to-
closed conformational changes upon iron binding [134]. The C-lobe is believed to 
undergo similar conformational changes as well but to a less extent since the 
additional -S-S- bridge will not allow such a big movement in C-lobe. The structures 
of duck [140,141,] and hen [142,143] apo and holo-overtransferrin show that iron also 
induces a C-lobe change conformation from wide-open to closed form but the extent 
of lobe opening in the C-lobe (rotation 35°) is less than that in the N-lobe (rotation 
53°) [142]. Other metals such as Cu2 , In 31  or even the large metal ion Sm 3 (ionic 
radius 0.96 A) also induce a similar overall conformational change in the protein as 
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Fe3 binding although the local changes around the metal binding site are different 
[139,144J45]. The conformational changes are functionally important because they 
may be crucial for receptor recognition. 
Figure 1.8 X-ray crystal structures of open (left) and closed (right) forms of the 
recombinent N-lobe of human transferrin (hTF/2N) [136,138]. The side-chains of the 
binding amino acids are shown in green, iron and carbonate are shown in red. 
1.3.4 Receptor Recognition 
Iron is transported into cells by transferrin via receptor-mediated endocytosis. 
The receptor imports iron-loaded transferrin and recycles apo-transferrin after 
discharge of iron in the endosome. Only holo- but not apo-hTF binds strongly to the 
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the receptor in the endosome (pH ca 5.5), suggesting that conformational changes in 
transferrin are crucial for receptor recognition. 
- 





Figure 1.9 Structure of the etodomain of the transferrin receptor [adapted from ref 
147]. (A) Domain organisation of the transferrin receptor polypeptide chain. The 
cytoplasmic domain is shown in white, the transmembrane segment is shown in black, 
the stalk is shown in grey, the protease-like, apical and helical domains are shown in 
red, green, and yellow, respectively. Numbers indicate residues at domain 
boundaries. (B) Ribbon diagram of the transferrin receptor dimer depicted in its 
likely orientation with respect to the plasma membrane. Pink spheres indicate the 
Sm3 ions soaked into the crystal during crystallisation. 
The transferrin receptor is a disufide-linked homodimeric trans-membrane 
protein with each subunit of molecular mass 90 kDa [146]. Each monomer has a 
short, NIH2-terminal cytoplasmic region (residues 1-67) containing the internalisation 
motif, a single transmembrane pass region (residues 66-88), and a large extracellular 
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region (ectodomain, residues 89-760) containing a transferrin binding site. The 
crystal structure of the ectodomain of the human transferrin receptor dimer has been 
solved recently at 3.2 A [147] (see Figure 1.9). The receptor dimer has a butterfly-
like shape with each monomer containing three distinct domains, a protease-like 
domain (residues 122-188 and 384-606), an apical domain (residues 189-383) and a 
helical domain (resiudes 607-760). 
Figure 1.10 Proposed model for binding of transferrin (rabbit) to the transferrin 
receptor [147] showing recognition contacts between the two proteins. The surface of 
the receptor dimer is rendered predominantly in white, with elements of the lateral 
cleft that are in contact with the docked transferrin coloured according to the domain 
as in Figure 1.9. The structure of rabbit transferrin is shown as a worm with lobe and 
domains indicated. It is clearly seen that most of the contacts on the transferrin are on 
the C-lobe with minor contacts on the N-lobe, with all the three domains of the 
receptor involved the interaction. 
One transferrin receptor dimer binds two transferrin molecules. Studies with 
proteolytically derived or recombinant N- and C-lobe of transferrin show that both 
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lobes of transferrin interact with receptor but the C-lobe binds more strongly 
[148,149,150]. The primary receptor recognition site in transferrin has been localised 
to the C-lobe [149]. There is apparent surface complementarity between transferrin 
and the lateral clefts of the transferrin receptor, which has allowed a model to be build 
by docking the two molecules, followed by a rigid body refinement [147] (see Figure 
1.10). This model suggested that the major contact sites on transferrin are in the C-
lobe, and particularly involve the Cl domain, with minor contributions from the N-
lobe (Ni domain). It is interesting that the glycosylation sites on transferrin are 
pointed away from the receptor and not involved in transferrin-receptor interaction. 
This may suggest that the carbohydrate has no role in receptor recognition as 
evidenced by the observation that nonglycosylated recombinant transferrin bound to 
HeLa S3 cells with the same avidity and to the same extent as the glycosylated protein 
[151]. 
Besides diferric transferrin, gallium-transferrin complexes have also been 
reported to interact with the transferrin receptor and are taken up into cells via 
receptor-mediated endocytosis [152,153,154]. 
1.3.5 Transferrin Mediated Delivery of Metallo Drugs to Tumour Cells 
Transferrins are mainly iron-carriers, but in human serum, transferrin is only 
30% saturated with iron, so there is potential capacity for carrying other metal ions 
which enter the body. Indeed more than 30 metal ions have already been reported to 
bind human serum transferrin reversibly. Moreover, transferrin is thought to play an 
important role in the transport and delivery of diagnostic radioisotopes such as 67Ga3 
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[155] and "th 3 [156,157], toxic metal ions such as A1 3 [158], and therapeutic metal 
ions such as Ru3 [159] and Pt2 [160]. 
The natural transferrin cycle for the delivery of iron to cells offers a potential 
strategy for metallo drug targeting to tumour cells. Four features of tumour biology 
and transferrin chemistry point to the possibility that transferrin could deliver 
antitumour metal complexes to cancer cells. First, it is known that malignant cells 
have a high iron requirement and consequently express a greatly elevated level of 
transferrin receptors (161). The transferrin receptor levels in proliferating malignant 
cells have often been found to be far higher than in the corresponding normal cells. 
The increased receptor levels result from changes in both proliferation and 
differentiation: i.e., transferrin receptor numbers in transformed cells are far higher 
than in non-proliferating cells and may be more than twice as high as in the 
corresponding normal cells even when proliferating at the same rate [162]. An 
enhanced rate of transferrin endocytosis is observed in malignant cells [120]. For 
these reasons, the transferrin receptor has been proposed as a target for cancer 
therapy [163]. Second, tumours in animals and man show a high "parasitic" uptake 
of Fe" when they are fast growing [164]. Fast-growing tumour cells show a much 
higher uptake of transferrin than the normal surrounding tissue of the affected organ. 
This uptake, which is directly related to the degree of differentiation of the tumour, 
can be two- to eight fold higher than in the normal surrounding tissue in tumour-
bearing mice or rats. Third, measurements of pH in viva have shown that the 
microenvironment of tumours is more acidic than in normal tissue [165], which may 
facilitate metal release in tumour tissues. Fourth, although Fe 11' is the natural metal 
ion bound by transferrins, many other metal ions can also bind at the same specific 
sites [166]. In blood plasma, less than 30% of the iron sites in human transferrin are 
occupied by iron, and the vacant sites could be used to transport other metal ions as 
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well. Indeed, transferrin has already been shown to be responsible for the selective 
delivery of 67Ga complexes to tumour cells [167]. 
Recently, 	Sadler's group has found that Ti(IV)-citrate forms strong 
complexes with human serum transferrin by binding to the specific Fe 3 binding sites 
in this protein [100]. Investigation of transferrin as a potential carrier of titanium(IV) 
anticancer agents to tumour cells may therefore aid understanding of their 
mechanisms of action as well as the mechanisms of toxicity. Moreover, considering 
the high uptake of iron-transferrin in rapidly multiplying tumour cells and the vital 
role which iron bound to transferrin plays in controlling cell division, replacement of 
the iron by titanium, which when released in the tumour cell can still disrupt the cell 
division process, seems to be a promising strategy. 
1.4 Pathogenic Ferric-iron binding Proteins as Potential Targets for 
Titanium(IV) 
1.4.1 Iron in Biological Systems 
Iron is an essential element for nearly all organisms (except for a lactobacillus 
that appears to maintain high concentrations of manganese instead of iron) and plays 
crucial roles in many biological systems [168]. It serves as a cofactor in key 
metabolic processes, such as DNA biosynthesis (ribonucleotide reductase), energy 
production (respiration), energy conversion (photosynthesis), nitrogen reduction, 
oxygen transport (respiration, muscle contraction), and oxygenation (e.g., steroid 
synthesis, solubilization, and detoxification of aromatic compounds) [169]. 
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At neutral pH and aerobic conditions of most physiological fluids, the 
predominant oxidation state of iron is Fe(ffl) (ferric). In this form iron readily 
undergoes hydrolysis and polymerisation, resulting precipitates as ferric hydroxide 
which is extreme low solubility (K101 = 1038  M). On the other hand, free iron(IH) is 
toxic due to it catalyze the homolytic fission of hydrogen peroxide (H 202) to liberate 
the hydroxyl free radical (OH.). This highly reactive and aggressive radical can 
interact with almost all kind of molecules in living cells, inflicting enormous damage 
on biological systems. Organisms have evolved specific systems for iron 
sequestering, transport and storage [170]. In biological fluids, such as serum and 
secretion, free extracellular iron is tightly bound by the iron-binding glycoprotein 
transferrin (TF) and lactoferrin (LF) which ensure that all extracellular iron is both 
efficiently sequestered from pathogenic invaders and mobilised for transport to host 
tissues [171]. Inside cells, most iron is bound to heme (as an Fe-porphyrin complex) 
in hemoglobin (Hb) and to other iron-enzymes. Excess iron within cells is stored in 
the protein ferritin as Fe(llI) [170]. The concentration of free iron that remains in 
equilibrium with host proteins is about 10.18  M, twelve orders of magnitude lower 
than the concentration of Fe 3 required by bacteria for iron sufficiency [172,173]. 
To overcome the problem of iron scarcity, pathogenic bacteria have envolved 
efficient high-affinity systems for procuring iron from their host by extracting the 
metal from eukaryotic proteins such as TF, LF and Hb [173]. Iron acquisition plays a 
significant factor in the colonisation of pathogenic bacteria and the presence of an 
efficient iron-acquisition system in the organism is correlated with its ability to cause 
disease [174]. 
1.4.2 Iron Acquisition Systems in the Pathogenic Neisseria 
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Neisseria gonorrhoeae and Neisseria meningitidis are pathogenic bacteria 
which cause a range of diseases including gonorrhea, otitis media, meningitis and 
septicemia [174]. They are two Gram-negative bacteria whose membranes 
organisation comprising an outer membrane (OM), a cytoplasmic membrane (CM), 
and the intervening periplasmic space. Like numerous pathogenic microbes, 
pathogenic Neisseria has the ability to use iron from host-derived compounds. They 
utilize highly efficient specific iron-transport proteins other than small molecule 
siderophores pathway [175,176] to transport free iron to the cytosol [177,178]. 
CM= 
= Periplasm 
Figure 1.11 Transport of iron by pathogenic Neisseria is initiated by binding human 
transferrin (hTF) to the cell surface using the hTF binding proteins (TbpA and TbpB). 
Iron is removed and transported across the outer membrane (OM) using energy 
supplied by TonB. Free Fe(III) is bound to FbpA in the periplasm where it is 
transported across the cytoplasm membrane (CM) by a classic ABC transporter, 
encoded by FbpB (a putative cytoplasmic permease) and FbpC (a putative nucleotide 
binding protein) (from ref. 174). 
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At the outer membrane surface of pathogenic Neisseria, specific proteins 
(receptors) initiate acquisition of iron from host in vivo: ThpA and TbpB (transferrin-
binding proteins), LbpA and LbpB (lactoferrin-binding proteins), HmbR 
(haemoglobin receptor), HpuA and HpuB (haemoglobinlhaptoglobin utilization 
proteins) [179]. All N. gonorrhoeae and N. meningitidis strains produce TbpAIB, 
which is crucial for bacterial colonization and initial of infection [180], while a small 
number produce LbpAIB, HpuAIB and/or HmbR. These receptor proteins have 
surface-exposed epitopes that bind their cognate iron-containing proteins, remove iron 
from the protein and transport it across the outer membrane into the periplasmic 
space, presumably by an energy-dependent TonB-mediated process, involving gated-
porin properties of the outer membrane receptor [181]. The result is deposition of 
free iron within the periplasm, where it is separated from the cytosol (its eventual 
destination), by the cytoplasmic membrane. Transport of free iron from the 
periplasmic space into the cytoplasm is by an active transport process involving a 
periplasmic ferric-binding protein (FBP or FbpA), shuttling Fe(IH) across the 
periplasmic space and cytoplasmic membrane, a specific cytoplasmic permease 
(FbpB) and an energy-supplying nucleotide-binding protein (FbpC). Figure 1.11 
shows the possible process of free iron transport in pathogenic Neisseria. The exact 
details of how iron is captured from outside the bacterial cell (e.g. from transferrin) 
and transported across two membranes into the cytoplasm are still unclear. 
The chromosomal loci encoding N. gonorrhoeae and N. meningitidis TbpA 
and TbpB have been well characterized [182, 183]. In both bacteria, the transcription 
of the tbpBA operon is regulated by the Neisseria Fur (ferric uptake regulator) 
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homologue [184,185]. At high iron levels, Fur binds upstream of tbpB and prevents 
transcription of thpBA. When iron level is low, Fur binding is abolished and tbpBA is 
expressed at high level [186]. The predominantly hydrophilic lipoprotein ThpB binds 
the outer membrane with its lipid tail. While ThpA is an integral outer membrane 
protein whose periplasmic region are thought to interact with TonB to facilitate iron 
transport across the outer membrane into the periplasmic space. Iron is then shuttled 
into the cytosol by the FbpABC transporter. 
FbpABC is an operon which encodes three open reading frames: JbpA, JbpB 
and JbpC. FbpA functions as a periplasmic iron binding protein (FBP) with the 
binding of Fe([ll) occurring in a manner highly analogous to one-lobe of the 
transferrins [187]. The second gene of this operon, JbpB is predicted to encode a 
cytoplasmic permease that removes Fe(llI) from FbpA and transports this cation 
across the inner membrane. The third gene, JbpC, encodes a putative nucleotide 
binding protein that supplies the energy for transport of Fe(ffl) to the cytoplasmic 
permease using energy derived from the hydrolysis of a phosphate bond. The 
proposed functions of FbpB and FbpC have not been explored biochemically. This 
transport process must involve protein–protein interactions among these protein 
components. These interactions may be dependent upon conformational changes in 
any of the proteins involved in the transport iron process [188]. 
1.4.3 The Major Iron Regulate Protein—Ferric-iron Binding Protein (FBP) 
FBP, encoded by jbpA gene, plays a central role in iron transport in the 
pathogenic Neisseria. It appears to be the sole protein responsible for transport of 
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free Fe 3 across the periplasmic space and is conserved in all species of pathogenic 
Neisseria. The FBP of N. gonorrhoeae (gonorrhoea) and N. meningilidis 
(meningococcal meningitis) (nFBP) is about 37-kDa protein, which appears pink 
colour in the purified form [189]. FBPs have been found in other pathogenic bacteria 
such as Haeinophilus influenzae (hFBP) (Haemophilus meningitis, otitis media) 
[190], Serratia marcescens (sFBP) (urinary tract infection, septicaemia) [191], and 
more recently in Yersinia enterocolitica (gastroenteritis) [192], Pasteurella 
haemolytica (pFBP) (bovine shipping fever) [193], Actinobacillus pleuropneumoniae 
(souse of porcine pleuropneumonia) [194] and A ctinobacillus actinomycetemcomitans 
(aFBP) (human periodontal disease) [195,196]. 
Figure 1.12 X-ray crystal structure of ferric binding protein from Haemophilus 
influenzae at 1.6 A reveals its 3-D structure and Fe(1II) coordination. (PDB code 
1MRP, see Ref 197) 
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FBP from Haemophilus influenzae (hFBP) is the first iron—transporter ferric-
binding protein which has had its crystal structure solved and well characterised 
(Figure 1.12) [197]. The structure data of hFBP reveals that the 3-D fold of FBP 
resembles one-lobe of transferrin with Fe(III) bound at the cleft between the two 
domains although the iron site in FBP is much more solvent exposed. The iron(1H) 
ligands include side chains of two Tyr residues (Tyr195 and Tyr196), 1 His (His9) 
and iGlu residue (G107), a water molecule and a synergistic anion phosphate. 
These are almost identical to those in transferrins (two Tyr, 1 His and 1 Asp) but with 
a bidentate carbonate as synergistic anion. Whether FBP will also accommodate 
carbonate remains to be determined [170]. However, the source of these ligands in 
FBP is from completely different parts of the protein fold, compared with their 
counterparts in transferrins, only the carboxylate ligand (G1u57 in FBP, Asp63 in 
hTF) comes from a spatially equivalent position in the two proteins. 
Despite the structural homology between FBP and transferrins, the sequence 
identity between them is very low (ca. 10% between N-lobe transferrin and hFBP). 
However, amino acid sequence alignments have revealed that nFBP, hFBP, aFBP, 
sFBP and yFBP share extremely high sequence homology [190,198,199] with 
possible similar iron binding residues, while FBPs from P. haemolytica and A. 
pleuropneumoniae show only low level of sequence homology [193] with other FBPs 
and the latter may have different iron binding residues. 
1.4.4 Ferric-iron Binding Proteins (FBPs) as Targets for Ti(IV)? 
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FBP-mediated high-affinity Fe(Ill) transport is a specific and efficient 
mechanism of iron acquisition, which, in combination with other factors, allows 
pathogenic Neisseria to aggressively multiply within the human host. The vigorous 
host response to the bacterial invasion causes the pathology associated with these 
organisms, thus FBPs play a critical role in gonococcal, menigicoccal and a wide 
range of diseases [200,201]. The recently reported whole genome sequence of 
Neisseria meningiridis suggests that gene sequences coding for iron regulating 
proteins including FbpA are highly conserved and important for virulence of these 
pathogens [202,203]. Much of our knowledge of bacterial iron acquisition derives 
from studies of surface components that initiate the transport of iron across the OM 
(outer membrane). However, the basic biochemistry of the iron transport process is 
still unknown. 
It is clear that FbpA is a key molecule in iron uptake systems in pathogenic 
Neisseria species and that it is homologous to those found in other bacteria. It is 
hoped that a biochemical study of FBP will lead to a greater understanding of the 
mechanism of iron binding and transport with a possible view to future industrial 
manipulation, or selective drug design. The necessity for virulence makes FBP an 
ideal drug target. Blocking of FBP iron binding or release could inhibit the invasion 
of these pathogenic bacteria and thus could provide a route for developing novel 
antibiotics against a wide range of serious diseases. 
The X-ray crystal structure reveals that hFBP shares similar 3-D structures and 
similar iron binding residues with transferrin and lactoferrins [197]. This could be 
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true for other FBPs because of their high sequence homology. Since titanium(IV) can 
bind strongly to transferrin, it is of interest to investigate experimentally whether Ti 
and other metal ions can also bind strongly to FBPs and subsequently block its Fe(IH) 
binding, in the view of exploring novel inhibitors of this pathogenic bacterial protein. 
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Chapter 2 
Experimental Techniques 
In this chapter, some specific techniques used in this study are briefly 
described, in particular techniques of molecular biology and protein chemistry. 
2.1 General Strategies for Gene Expression in E. coli 
The general approach used to express foreign genes in E. coli begins with 
insertion of the gene into an expression vector, usually a plasmid, and then involves 
transforming a suitable E. coli host strain with the plasmid. Transformed cells are 
then subjected to evaluation of plasmid stability and foreign protein expression 
following induction of the controllable transcriptional promoter present in the 
expression vector. The next step is small-scale shaker flask expression experiments, 
once successful expression systems have been identified. The transformed E. coli 
strain can be grown in large-scale shaker flasks or fermentation systems, which can be 
designed to produce recombinant proteins with altered amino acids (e.g., 
selenomethionine in place of methionine) or stable isotope labels to facilitate 
structural studies [1]. Protein production is followed by protein purification and 
characterisation. 
2.2 Over-expression of Proteins in E.coli 
2.2.1 General Equipment 
Electrophoresis for protein samples was carried out using a Biorad Protean II 
minigel system, while using a Gibco BRL H5 system for DNA samples. Denley 
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BR40I, Sorvall RC-5B and Dupont Microspin 12 centrifuges were used for 
centrifugations. Pharmacia FPLC systems and various columns were used for 
chromatographic separations of proteins. 
2.2.2 General Regents, Solutions and Buffers 
All the materials, chemicals and solvents were of appropriate quality and were 
purchased from Fisher, Aldrich, Sigma, Acros, Pharmacia, Promega, Biorad, Gibco 
BRL, Amicon, New England Biolabs, Waters Millipore or Invitrogen unless 
otherwise stated. 
Ampicillin - a stock solution (100 mg/mI) was made and sterilised by filtration (0.45 
jiM filter) and stored at 4 °C. A final concentration of 100 .tg/m1 was used. 
Ethidium bromide - a stock solution (10 mg/mi) was made and stored at 4 °C in a 
dark bottle. A final concentration of 5 jig/mI was used in the DNA gel. 
IPTG - a stock solution of isopropyl-f3-D-thiogalactopyranoside (100 mM) was 
sterilised by filtration (0.45 pM filter) and stored at 4 °C. 
TAE - Tris-HC1 (40 mM, pH 8.0), acetic acid (57.1 ml), EDTA (0.5 M, pH 8.0, 100 
ml). 
SDS sample buffer - Tris-HC1 (0.5 M, pH 6.8, 1.0 ml), Glycerol (2.0 ml), SDS 
(10%(w/v), 1.6 ml), 2-3-meraptoethanol (0.4 ml), bromophenol (0.05% (w/v), 2.0 
ml). 
SDS running buffer - Tris-HC1 (25 mM, pH 8.3), glycine (192 mM), SDS (l%(w/v). 
Transformation buffer (TB) - Calcium chloride (50 mM), Tris-HCI (10 mM, pH 
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2.2.3 Media 
Agar plates - bacto-agar (15 gIl) was added to specified media to prepare agar plates. 
MRS modified - proteose peptone (15 g), yeast extract (5 g), sodium acetate (5 g), 
ammonium citrate (2 g), tween 80 (1 ml), K2HPO 4 (2.4 g), MnSO4 (0.02 g), pH was 
adjusted to 6.4 with acetic acid, made upto 900 ml and then autoclaved (121 °C, 15 
psi, 15 mm). Glucose (20 g) was dissolved in water (100 ml) and filter sterilised into 
the medium once it had cooled. 
Resuspension medium - 12% reconstituted milk solution (5 ml), MRS modified 
medium (2.5 ml) and glycerol (2.5 ml). This medium was then autoclaved (121 °C, 
15 psi, 15 mm). 
2YT - bacto-tryptone (16 g), bacto-yeast extract (10 g), NaCl (5 g) were dissolved in 
distilled water (11) and then adjusted to pH 7.5 with NaOH. 
Luria Bertani (LB) - bacto-tryptone (10 g), bacto-yeast extract (5 g), NaC1 (10 g) 
were dissolved in distilled water (11) and then adjusted to pH 7.5 with NaOH. 
Minimal medium (M9) - Na2HPO4 (6 g), KH2PO4 (3 g), NaCl (0.5 g), NH4CI 0 g). 
This was adjusted to pH 7.4, made upto 1 litre distilled water and autoclaved (121 °C, 
15 psi, 15 mm). The medium was allowed to cool and then the following filtered 
(0.45 tiM) solution were added: Mg50 4 0 M, 2 ml), glucose (20%, 10 ml) and CaC12 
(1M, 0.1 ml). 
Modified M9 medium [2,3] - (recipe for 1 litre of growth medium) K2HPO 4 (10.0 
g), KH2PO4 (13.0 g), NaCl (0.5 g), Na2HPO4(9.0 g), Na2SO 4 (1.74 g). This was made 
up to 970 ml distilled water and autoclaved (121 °C, 15 psi, 15 mm). The media was 
allowed to cool and then the following filtered (0.45 p.M) solution were added: 1 M 
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MgCl2 (10 ml), thiamine (10 ml, 5 mg/mi), ampicillin (1 ml, 100 mg/mi), glucose (5 
g), 10% yeast extract (10 p.1), and 10 ml trace element solution (recipe as below). 
Trace element solution- (recipe for 100 ml) FeSO 4•7H20 (0.60 g), CaC1 2•21-120 
(0.60 g), MnC12'41-120 (0.12 g), CoC12•61-120 (0.08 g), ZnSO4•7H20 (0.07 g), 
CuC12•2H20 (0.03 g), H31303 (2 mg), (NH4)6M07024•4H20 (25 mg), Na2EDTA (0.50 
g). This was made up to 100 ml distilled water and stirred overnight to give a green 
solution and filtered (0.45 p.m). 
2.2.4 Bacterial Cell Lines and Storage of Bacterial Stocks 
E.coli cell lines DH5ctF', JM109 and TOP1OTM  were used for the storage of 
genes and also for the initial transformation of ligation gene products. DH5ctF' and 
TOP 10TM  were used to overexpress proteins as well as mutant proteins. 
Table 2.1 Genetypes of some plasmids used in these studies 
Cell Line Genetype 
DH5aF' F/endAl hsdRl7 (rk mk)  supE44 thil recAl gyrA (Nal t) 
relAlA91acIZYA-argF) u169 deoR (80dlacA (lacZ) MiS) 
Top 10TM 
F'mcrA D(mrr-hsdRMS-mcrBC) (801acZAM15 AlacX74 deoR 
recA 1 araD 139 A(ara-leu)7679 gal/U gal/K rpsL endA I nupG 
JM109 F traD36 lac' A(lacZ) M15 proA B /e14 (McrA) A(lac- 
proAB) thi gyrA96 (Nalr)  endAl hsdRl7 (rk mk)  relAl supE44 
recAl 
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LB or 2YT medium containing the appropriate antibiotics were used for the 
short-term storage of E.coli cells. Colonies of bacteria were stored on inverted 
parafilm sealed agar plates at 4°C for up to four weeks. For long term storage strains 
were frozen at -80°C in LB or 2YT media containing glycerol (15%). 
2.2.5 DNA Vectors and plasmids 
The vector pUC 1 8/RB S was used for the initial cloning, mutation and storage 
of genes. pUC18IRBS is a derivative of pUC18 that contains a NcoI site. The plasmid 
used for the cloning and overexpression of proteins was pTRC 99A, and pUC 18 was 
used for overexpression of mutant proteins. 
The plasmid pTRc99A with the FBP gene (from Nesseria gonorrhoeae) 
inserted (pTRc99AIFBP_NG, see Figure 2.1) was supplied by Professor R.T.A. 
MacGillivray (University of British Columbia, Vancouver, Canada). The plasmid 
pUC 1 8IRBS/FBP (see Figure 2.1) was constructed by digestion pTRc99AIFBP_NG 
with NcoI and HindJll followed by isolation the FBP gene from an agarose gel, the 
gene was subsequently insert into pUC18IRBS digested by the same enzymes 
2.2.6 Transformation of E.coli Competent Cells with Recombinant DNA 
The competent cells were gently resuspended and 100 ll of the suspension 
was transferred to a sterile Eppendorf tube. This was then left on ice for 15 min and 
DNA was added (up to 40 ng). The tube was tapped gently and left on ice for 30 mm. 
The cells were then heat shocked at 37°C for 5 mm, and warm LB (37°C) was added. 
The tube was then incubated at 37°C for 1 h, centrifuged (15,000 rpm, 15 mm, RT) to 
57 
Chapter 2 Experimental Techniques 





p HI (447) 
Bsp HI (552) 
Apr 
OR 	 Bsp HI(1560) 
'NG 
f-End ffl(1261) 
9sp HI (1733) 
Bsp HI (2741) 
Figure 2.1 Plasmid map of pTRc99A/FBP_NG (left) and pUCI 8/FBP_NG (right) 
showing the main restriction sites and those used in cloning. Constructed using the 
Vector Nti program. 
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pellet the cells. The supernatant was discarded and the pellet was resuspended in LB 
(50 pi). The suspension was spread to dryness on selective agar plates and incubated 
(37°C, 16 h). Ready-made competent cells weretransformed according to the 
manufacturer's instructions. 
2.2.7 Handling DNA 
Preparation of plasmid DNA. This was prepared from the pellet of E.coli 
containing the target plasmid DNA by using the Promega Wizard Tm Plus Minipreps 
DNA purification system (Promega). 
Purification of DNA from gel. DNA was purified from either agarose or 
from solution using the Prep A Gene®  kit from Biorad. 
Digestion of DNA with restriction endonucleases. Typically the required 
amount of DNA (0.5-1 p.g) was treated with the appropriate amount of enzyme and 
buffer and the sample was then placed at the appropriate temperature for the required 
amount of time (according to the manufacturer's suggestion). Blue/orange loading 
dye (Promega), typically 2 p110 p.1 of incubation mixtute was added and the samples 
were subjected to electrophoresis on agarose gel. The gels were then viewed and 
photographed under ultraviolet light. 
Electrophoresis of DNA. The required amount of agarose was added to TAE 
buffer and heated at 100°C until it dissolved. The solution was allowed to cool to 
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55°C and ethidium bromide was added to a final concentration of 0.5 .tg/ml. The gel 
was then poured into the casting mould and allowed to set at room temperature. 
2.2.8 Cloning DNA Fragment intoplasmid Vectors 
The DNA fragment (or PCR product) cut with suitable restriction enzymes (13 
pi), the host vector cut with suitable restriction enzymes (3 p1), lOxT4 DNA ligase 
buffer (2 tl) were placed in an Eppendorf tube. A control with water (13 jtl) instead 
of the gene or PCR product was also set up. The reaction was left at room 
temperature for 24 - 48 h and then transformed into a suitable cell line (as section 
2.1.7). 
2.2.9 Over-expression of Proteins 
Mini induction of proteins. A single colony from a freshly transformed plate 
was placed in LB or 2YT (2m1 - 10 ml) containing ampicillin. The cells were grown 
to an 0D600  = 1.0 and divided equally into two aliquots. One sample was induced 
with IPTG (1 mlvi) while the other served as a control. Both samples were then 
allowed to grow for a further 3 h prior to being centrifuged (13000 rpm, 30 s). The 
supernatants were discarded and the pellets were resuspended in SDS sample buffer 
(100 p1), boiled (5 mm) and loaded (15 1.11) onto SDS gel (15%). 
Large scale preparation of FBP from E. coli. Transformant Top 1OJDH5a 
was grown in 10 - 30 ml of 2 YT containing ampicillin (100 jig/mI) overnight. These 
were used to inoculate 1 - 3 litres 2YT containing ampicillin (100 jig/mi) for 28 h. 
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The cells were harvested and pelleted by centrifuge at 10,000 rpm for 15 mm. The 
pink pellet was collected and frozen at -20°C for protein extraction and purification. 
2.3 Purification of Ferric-iron Binding Protein (FBP) 
Wild-type FBP was purified by a modification of the method previously 
described by Berish et al. [4]. The pink pellet (ca. 5 g) was defrosted at room 
temperature and was resuspended in 50 ml of 1 M Tris (pH 8.0) and 50 ml of 2% 
CTAB was added followed by shaking overnight at 37 °C. The white insoluble 
materials were removed by centrifugation (10000 g for 15 min at 4 °C). The 
supernatant (cell free extraction) was diluted to a final volume of 1 litre by adding of 
distilled water and filtered with Whatmann no. 4 paper (Fisher). The cell free extract 
was applied to a RESOURCE ®S cation exchange column (1 ml or 6 ml, Pharmacia), 
washed according to the manufacturer's instructions and equilibrated with 10 mlvi 
Tris buffer (pH 8.0). The filtered CTAB extract was loaded to the column at a flow 
rate of 4 ml/min and then eluted with NaCl gradient of low to high-salt (0 to I M 
NaCl) in 10 mM Tris buffer at a rate of 4 mI/mm. Pink fractions (at Ca. 16% NaC1 
gradient, 4°C) were collected and were analysed by SDS-PAGE. The concentrated 
protein was made by dialysis or ultrafiltration (amicon concentrator 10, 10 kDa cut-
off). 
2.4 Protein Characterisation 
2.4.1 UV-Vis Spectroscopy 
The near—UV (250-350 nm) absorbance spectrum of a protein is almost 
entirely generated from its aromatic amino acids (tryptophan, E280 5559 M 1 cm 1 ; 
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tyrosine, E280  1197 M 1 cm 1 ; and phenylalanine, E280  0.7 M'cm', E257  Ca. 195 M'cm' 
[5]), also small contribution from disulfide bonds. Because each protein has a unique 
amino acid sequence, the particular aromatic acid content of each protein results in a 
unique spectrum in the near-UV region. A small inflection point on the declining 
shoulder of the main peak around 290 nm originates from Trp residues. The sharper 
the inflection point, the more homogeneous and apolar the average microenviroment 
of these side chains. 
Protein concentrations can be calculated using the spectral intensity at 280 nm. 
c= A280/cI 
where c is the protein concentration (M), £ is the molar extinction coefficient 
(Mcm') at 280 nm, 1 is the path length (cm). 
For a protein with known amino acid components, c can be calculated using 
the numbers of Trp (Nim),  Tyr (NT 1), and disulfide bonds (N) in the protein as 
follows [6]: 
C2805540NT+ 1480NTyr + 134N 
Besides absorption in the UV region, many metalloproteins exhibit d-d 
transitions from the metal centre and charge-transfer absorption in the visible region. 
Most of the charge-transfer transitions involve a metal ion which serves as an electron 
acceptor, and side-chains from proteins which serve as electron donors. An example 
is Fe2-transferrin which has a ligand-metal-charge-transfer (LMCT) band at Ca. 465 
nm, arising from charge-transfer from Tyr to Fe(IH)[7]. This provides a convenient 
way to detect specific metal-protein binding and release by UV-Vis spectroscopy. 
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2.4.2 Bicinchinoic Acid (BCA) Assay for Quantitation of Total Protein 
The bicinchinoic acid (BCA) assay for total protein is a spectophotometric 
assay based on the alkaline reduction of the Cu(ll) ion to the Cu(I) ion by the protein, 
followed by chelation and colour development by the BCA reagent [8].  If interfering 
compounds (reducing sugars and ammonium ions) are eliminated, the BCA assay has 
a good combination of sensitivity and simplicity, and it has some advantages over 
Lowry technique [1]. Bovine serum albumin (BSA) was used as calibration standard 
and absorbance at 562 nm (A562) was measured to calculate protein concentrations 
2.4.3 ICP-AES 
Inductively coupled plasma atomic emission spectroscopy (ICP-AES) was 
used for metal and phosphorus analyses. The R.F. power was 1150 watts, the 
netubilizer flow was 30 psi, the pump rate was 100 rpm and the purge time was 90 s. 
fron, titanium, phosphorus atomic absorption standard solutions (Aldrich) were used 
as standards. The final protein solution was diluted with ultrapure water, and metal or 
phosphorus contents were measured without digestion of the sample. All data were 
interpreted using thermospec/CID software. 
2.4.4 Mass Spectrometry 
Electrospray mass spectrometry was used to determine the molecular weight 
of the proteins. Mass spectra were obtained on a Micromass Platform H quadrupole 
mass spectrometer equipped with an electrospray ion source. The purified holo- or 
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apo-protein samples (in 10 mM Hepes, pH 7.2) were diluted with MeOHIH 20 (1:1, 
vlv) to a final concentration of 20 .tM (20 pmol/jtl), CH 3COOH (final concentration 
0.5%) was added to the samples before measurement. The final pH of the protein 
samples was ca. 3.7. The mass spectrometer was scanned at intervals of 0.1 s, the 
scans accumulated, the spectra combined, and average molecular mass determined 
using the MaxEnt and Transform algorithms of massLynx software. 
2.4.5 NMR Spectroscopy 
Details of basic theory and concepts of NMR are given in textbooks such as 
Mason [9] and Roberts [10]. The nuclei used in this study and their magnetic 
properties are given in Table 2.2. 
NMR spectra for biomolecules are normally recorded in aqueous media, such as 
D20 (99.96%) or H 20/1320 (90%: 10%, v/v). Special techniques are needed to 
suppress the large HOD signal. "Presaturation" and "WATERGATE (WATER 
supression by GrAdient Tailored Excitation)" were used in this study. The former 
method is applied by irradiation at frequency of the HOD resonance during the 
relaxation delay between pulses, before the observe pulse in an experiment. The 
disadvantage is that exchangable NH protons can also be saturated resulting in loss of 
intensity. The WATERGATE method uses a selective 180° pulse field gradients to 
select different coherence pathways [11], yielding a superior water suppression. 
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Table 2.2 Magnetic properties of the nuclei used in this study 
Property/nuclei 1 H 31P 13c 15N 
Nuclear spin ½ ½ ½ ½ 
Frequency (MHz) at 11.74 T 500.0 202.4 125.7 50.7 
Natural abundance % 99.98 100 1.108 0.37 
Relative sensitivity 1.00 6.63x 1 02 1 .59x 1 02 1 .04x 1 0 
Two-dimensional NMR (21) NMR) 
Homonuclear Correlated NMR Spectroscopy (COSY)[ 12,13] COSY is the 
simplest 2D experiment that can be used to identify pairs of protons. that have a 
mutual scalar coupling. Through-bond connectivities between protons separated by 
two or three bonds can be established by COSY experiments. The basis of COSY 
experiments is the process of coherence transfer in which magnetization is transferred 
between coupled spins. It is very useful for peptides and proteins for which cross-
peaks can be observed within a specific spin system (amino acid residue). However, 
the sensitivity is poor for macromolecules and extremely harsh weighting functions 
must be used to give spectra with usable lineshapes, and this in turn gives further 
reduction in sensitivity. More favourable lineshapes can be obtained by using double-
quantum filtered COSY (DQF-COSY) [14], in which the diagonal peaks and the 
cross-peaks all show the same antiphase absorption fine-structure. 
Nuclear Overhauser Enhancement Spectroscopy (NOESY) [15,16] The 
NOESY experiment is usually used to identify pairs of protons that are undergoing 
cross-relaxation. Through-space connectivities between protons close in space can be 
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established by NOESY experiments. It is an essential method for determination of 
peptide conformations and 3D structures of proteins. The NOESY correlation signals 
are caused by dipolar cross-relaxation between nuclei (e.g. 'H-'H) in a close spatial 
relationship. The intensities of the cross-peaks are related the distances between them 
(proportional to the inverse sixth power of the distance between protons i and j, oc 
/rij The cross-peaks are generated by magnetization transfer that takes place 
during the mixing time so the length of this delay must be chosen according to the rate 
of transfer process. For small molecules, the mixing time is usually chosen as the 
order of 1 to 5 sec whereas for macromolecules such as proteins it is of the order of 50 
to 200 ms. Both the cross-peaks and diagonal peaks in NOESY spectra can be 
obtained with absorption-mode lineshapes. 
Total Correlation Spectroscopy (TOCSY) or Homonuclear Hartmann-Hahn 
Spectroscopy (HOHAHA) [17,18] TOCSY can be thought of as an alternative 
version of COSY. Through-bond connectivities between protons, not restricted to 
two or three bonds, but extending, under favourable conditions, through a spin system 
such as amino acid side chain or an oligosaccharides can be established by TOCSY 
experiments. In this experiment magnetization is transferred coherently from one spin 
to another belonging to the same scalar-coupled spin system during an extended spin-
lock period. In TOCSY, the cross-peaks have the same phase and both cross-peaks 
and diagonal peaks have absorption-mode lineshapes. 
Heteronuclear multiple quantum correlation (HMQC) and Heteronuclear 
single quantum correlation (HSQC) HMQC and HSQC use inverse or indirect 
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detection techniques in which an INEPT sequence is used to transfer 'H 
magnetisation into antiphase 1 5N or 13C magnetisation. 'H decoupling during t, 
(evolution time) is accomplished by the application of a 1800  pulse at the midpoint of 
t,. A subsequent INEPT transfer reconverts the 15N or 13C magnetisation into 
observable 'H magnetisation. Connectivities between proton resonances and those of 
directly bonded heteronuclei (e.g., 13C or 15N) can be detected. The main advantage of 
this technique is the enhanced sensitivity, a theoretical maximum of [I YH I A Yx 11 5/2  (32 
for ' 3 C and 306 for 15N, y is the magnetogyric ratio of the nuclei) compared to direct 
detection and relatively short repetition time due to polarization transfer [19]. In 
addition, the resolution in the 'H dimension is also improved via inverse detection. It 
is, therefore, possible to detect species at concentrations of biological relevance (mM 
or M) in D20 and aqueous solution where no substitution of dueterium occurs, and 
thus NH protons can be observed [20]. This technique is very useful for study 
proteins labelled with 13C or 
Transverse Relaxation-Optimized Spectroscopy (TROSY) [21,22,23]. The 
size of protein structures that can be studied by NMR is limited by fast transverse 
relaxation in amide 15N- 1 H groups by dipole-dipole coupling and chemical shift 
anisotropy modulated by rotational molecular motions. TROSY is designed to reduce 
1'2 relaxation based on the fact that cross-related relaxation caused by interference of 
dipole-dipole coupling and chemical shift anisotropy gives rise to different relaxation 
rates of the individual multiplet components in a system of two coupled spins 1/2, 
such as 15N-'H fragments in 15N-uniformally labelled proteins. In principle, at 
frequencies near 1000 MHz, highly efficient cancellation of transverse relaxation 
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effects within the 15N- 1 H fragment can be achieved for one of the four multiplet 
components [21]. TROSY observes exclusively this narrow component, for which the 
residual linewidth is mainly due to dipole-dipole interactions with remote protons in 
the protein. As TROSY yields greatly improved sensitivity for multidimensional 
NMR experiments in proteins. The TROSY improvement in signal-to-noise relative 
to corresponding conventional NMR experiments increases with increasing molecular 
size and can be further significantly enhanced by combined use of the 'H and 13C 
steady-state magnetizations [22]. 
2.5 Site-directed Mutagenesis 
The polymerase chain reaction (PCR) can be used as a quick and efficient 
method for introducing sequence change into the DNA of interest. In this study, 
synthetic oligonucleotides (primers) are designed to incorporate a point mutation in 
the FBP gene. 
Amplification of DNA. PCR and sequencing reactions were done using a 
Perkin Elmer 480 thermal cycle. The following were placed in a PCR tube (0.5 ml): 2 
Ready to Go PCRTM  beads (Pharmacia), DNA template (1 p1), primer 1 (forward) (5 
p1), primer 2 (reverse) (5 p.1) and distilled water (39 p1). There were then overlayed 
with one drop of PCR oil and cycled 30 times at 95°C (1 mm), 54 or 58°C (1 mm) 
and 72°C ( 2 mm). After the cycles, heating at 72°C for 5 min terminated the 
reaction. The PCR product was then subjected to agarose gel electrophoresis and the 
required band was excised and the DNA was purified as described in section 2.2.7. 
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Site-directed mutagenesis of DNA (FBP/Y195F and FBPIY196F). The 
mutant genes for FBP/Y195F and FBP/Y196F are made by PCR megaprimer method 
[24]. For the tyrosine to phenylalanine mutants,. CCT was used as the mutant codon 
to change the CTA encoding tyrosine to phenylalanine. Synthetic oligonucleotides 
5' -CTCATCAACAACTTCTACTGGCAC-3' and 5 1 -
ATCAACAACTAç[CTGGCACGCT-3' (Genosys Biotechnologies) were used as 
mutant primers for making the FBPIY195F and FBP/Y196F mutants, respectively. 
The mutagenic PCR reactions containing two PCR steps: PCR 1, pUC 1 8/FBP was 
used as template, mutant primer as forward primer and M13 (5'-
CGCCAGGGTTTTCCCAGTCACG-3') as reverse primer; the PCR products were 
applied on a DNA gel and the band containing the target PCR1 product was collected 
and purified; PCR2, pUC18IFBP was used as template, NR (5'-
GTTGTGTGGAATTGTGAGCGG-3') was used as forward primer and the resulting 
PCR 1 product (megaprimer) was used as reverse primer. The PCR2 products were 
applied on a DNA gel and the band containing PCR2 product of interest (mutated 
genes) was collected and purified. If necessary, NR and M13 were used as primers to 
amplify PCR2 adducts of interest. 
The mutated genes were then ligated and subcloned into pUC18/RBS. The 
pUCI 8IRBS containing the mutated gene was used to transform Top 10 E.coli cells 
and the positive colonies were used to purify plasmid DNA for sequencing and 
produce mutant proteins. 
2.6 In vivo 15N-labelling of Protein 
M. 
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Uniform incorporation of stable isotopes in recombinant proteins is of great 
interest since it can greatly facilitate protein structure-function studies by NMR 
spectroscopy. The labelling methods require the use of semi-defined or minimal 
medium containing salts, trace elements, and yeast extract. Cells are supplied with 
15N-labelleci NH4C1 (or (NH4)2SO 4, amino acids), 13C-labelled glucose (or glycerol, 
acetate, amino acids), andlor D20, and are induced to synthesise recombinant protein 
labelled with 15N, 13C, and/or 2H. The three labels can be used individually or in 
combination. The yield of a recombinant protein usually depends critically on the 
medium used. 
A modified M9 minimal medium [see section 2.2.3] was used to produce 15N-
labelled FBP. ToplO cells (transformed with either pTRC99AIFBP pUC18IF'BP) do 
not produce much FBP in this medium, while DH5aF cells (transformed with either 
pTRC99AIFBP or pUC 1 8IFBP) produced reasonable amounts of protein in this 
medium, pTRC99AJFBP being the best. The DH5aF cell strain transformed with 
pTRC99A/FBP was chosen to produce labelled protein with the following protocol: 
E. coli (DH5(xF transformed with pTRC99A/FBP) was grown in 5 ml 2YT 
medium overnight in an incubator shaker (37 °C, 200 rpm) (about 108  cell/mI, 
0D600 ~! 1.0). 
The cells were pelleted and resuspended them in complete minimal medium. 
Cells were transferred to a 250 ml Ferbach flask filled with 100 ml of the 
modified minimal medium (with 15NH4C1). 
Cells were grown in an incubator shaker (37 °C, 200 r.p.m.) for 28 - 30 h. 
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Cells were pelleted by centrifugation (10 000 rpm, 15 mm), stored at - 20°C. 
The cell suspension were thawed and the labelled protein purified as for wild type 
protein using FPLC with a cation exchange column. About 37 mg purified FBP 
per litre culture was obtained from minimal medium (unlabelled) and 54 mg 
purified 15N-labelled FBP was obtained from two litres of culture. 
2.7 Crystallisation of Proteins 
The hanging drop vapour-diffusion method [25] was used to crystallise wild 
type holo-, apo-FBP and Ti-FBP. Purified protein samples were filtered (0.22 j.tM) 
and centrifuged at 13000 rpm for 5 min before use. Concentrated protein samples (2 
- 5 mg/ml, 5 tI) and precipitant well solution (5 .il) (15- 30% PEG 4000, 0.2 M 
NaCl, 0.4 M malate/imidazole buffer, pH 6.2 - 7.8) were placed on a silicanised 
cover-slip which was then placed upside down over a parrafin wax coated well lip in a 
drop fashion. The droplets were equilibrated against 0.9 ml of the precipitant solution 
at 17°C. Needle and trunk crystals suitable for X-ray diffraction studies were 
obtained between 2 weeks and 2 months. Efforts using sodium citrate (0.25 M) buffer 
failed to produce crystals and MalicIKOH (0.4 M) gave rise to only small needle 
crystals. 
2.8 Sequence Alignments 
Swissprot (http://www.expasy.ch/sprot) and the Genomes Representation 
Organisation (http://www.ncbi.nim.nih.gov/En trezJGenome/org.htm) database were used to 
search for amino acid sequences which were then aligned using Expasy 
(http://www.cxpasy.ch/)  Clustal W (http://www2.ebi.ac.uk/clustalw/)  and Alscript. 
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Chapter 3 
Model complexes of Ti(IV)-transferrin - stereoselective 
formation of seven-coordinate Ti(IV) monomer and dimer 
complexes of ethylenebis(o-hydroxyphenyl)glycine 
Synopsis. 
Reactions between the antitumour agent titanocene dichioride (Cp 2TiC12) and the 
hexadentate ligand N,N'-ethylene-bis-(o-hydroxyphenylglycine) (H 4ehpg) in aqueous 
solution afford two seven-coordinate pentagonal-bipyramindal Ti" complexes. The 
racemic ligands selectively form crystals containing the monomer [Ti(ehpg)(H 20)] 
(1), while the meso ligand selectively forms crystals containing the oxygen-bridged 
dimer [{ Ti(Hehpg)(H 20) } 20] (2). All previously-reported crystalline metal.-
EHPG(rac) complexes contain N(S,S)C(R,R), or N(R,R)C(S,S), whereas 1 
unexpectedly contains the N(S,S)C(S,S) and N(R,R)C(R,R) form. Complexes 1 and 2 
exhibit phenolate-to-Ti" charge transfer bands near 387 nm, and 2D NMR studies 
indicate that 1 and 2 have similar structures in solution to those in the solid state. 
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3.1 Abstract 
Reactions between the antitumour agent titanocene dichloride (Cp 2TiC12) and the 
hexadentate ligand N,N '-ethylene-bis-(o-hydroxj'phenylglycine) (H 4ehpg), have been 
investigated in aqueous solution and the solid state. The racemic ligands give crystals 
of the monomer [Ti(ehpg)(H20)]1 1/3H 20 (1), while the meso ligand gives the oxo-
bridged dimer [{Ti(Hehpg)(H20)}20]. 1 3H20 (2). Complex 1 crystallizes in the 
monoclinic space group C21c with a = 24.149(4) A, b = 14.143(3)A, c = 19.487(3) A, 
a=90°, 13 = 105.371(13)°,y=90°, V = 6417.7(19) A3, Z = 12, R(F) = 0.027 for 5662 
independent reflections having I> 4c(Io), and contains seven-coordinate pentagonal-
bipyramidal Ti"' with two axial phenolate ligands (Ti-O, 1.869(2) A). The pentagonal 
plane contains the two N at 2.210(2) A, two carboxylate 0 at 2.061(2) A, and a water 
molecule (Ti-OH2, 2.091(3) A). Complex 2 crystallizes as an oxygen-bridged dimer in 
the triclinic space group P1 with a = 12.25 1(6) A, b = 14.085(7) A, c = 16.635(8) A, 
a = 80.93(2)°, 13 = 69.23(2)°, y = 64.33(2)°, V= 2419(2) A3 , Z = 4, R(F) = 0.0589 for 
5956 independent reflections having I> 2(I). Each seven-coordinate, pentagonal-
bipyramidal Ti" has a bridging oxide and a phenolate as axial ligands. The pentagonal 
plane donors are H 20, two carboxylate 0, and two NH groups, which form H-bonds 
to 0-atoms both in the same half molecule (O ... N, 2.93-3.13 A) and in the other half 
molecule (0 N, 2.73-2.75 A); the second phenoxyl group of each Hehpg ligand is 
protonated and not coordinated to Ti'v, but H-bonds to a nearby amine proton (0.. 
2.73 - 2.75A) from the same ligand and to a nearby H 2O (0.. •O, 2.68 A). In contrast to 
all previously-reported crystalline metal-EHPG complexes containing racemic 
ligands, in which the N(S,S)C(R,R) or N(R,R)C(S,S) form is present, complex 1 
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unexpectedly contains the N(S,S)C(S,S) and N(R,R)C(R,R) forms. This is attributed to 
the presence of ring strain in seven coordinate Ti" complexes. Moreover, the rac 
ligands selectively form crystals of monomeric 1, while the meso ligand selectively 
forms crystals of the dimer 2 (N(R,R)C(R,S) or N(S,S)C(S,R)). Complexes 1 and 2 
exhibit phenolate-to-Ti"" charge transfer bands near 387 nm, and 2D NMR studies 
indicate that the structures of 1 and 2 in solution are similar to those in the solid state. 
Complex 1 is stable over the pH range 1.0-7.0, while 2 is stable only between pH 2.5-
5.5. CP2TiC12  reacts with EHPG at pH*  7.0 to give complex 1 with a t112 ca 50 mm 
(298 K) but complex 2 was not formed at this pH*  value. At pH*  3.7, the reaction is 
very slow: 1 forms with a half-life ca 2.5 d, and 2 after Ca. 1 week at ambient 
temperature. The relevance of these data to the possible role of serum transferrin as a 
mediator for the delivery of Ti" to tumor cells is discussed. 
3.2 Introduction 
Biscyclopentadienyl Ti' v complexes and bis(f-diketonato)-Ti" complexes have 
been shown to exhibit low toxicity and high antitumour activities against a wide range 
of murine and human tumours [1,2]. Two of them, titanocene dichioride (Cp 2TiC12) 
and Budotitane [Ti(bzac) 2(OEt)2] (Hbzac = 1 -phenylbutane- 1 ,3-dione) [3] are 
currently on clinical trial. The initial results with Cp 2TiC12 suggest a lack of cross-
reactivity with cisplatin and patterns of antitumour activity different from those 
produced by platinum based anticancer drugs [4]. Recent reports [5] have shown that 
Cp2TiC1 2 significantly overcomes cisplatin resistance in ovarian carcinoma cell lines. 
The potent antitumor activity and low toxicity of this compound, supported by the 
encouraging results from two recent phase I clinical trials [6] (one in Germany, one in 
76 
Chapter 3 Ti(JV)-EHPG model complexes 
UK) suggest that titanocene dichioride could be a promising novel chemotherapeutic 
agent [5].  In addition, titanocene dichioride exhibits pronounced antiviral, 
antiinflammatory and insecticidal activities [7]. Additional medical interest in 
titanium arises from the recent use of 45Ti in radiopharmaceuticals [8].  However, in 
contrast to platinum-based anticancer drugs [9], very little is known about the 
biological chemistry of titanium compounds. The cytotoxic action of titanium 
complexes, and their vanadium and molybdenum analogues, may involve mechanisms 
different from those of cisplatin [2,10-13]. Formation of Ti"-DNA complexes is 
thought to be important for the antitumour properties of Cp 2TiC12, which inhibits 
DNA synthesis rather than RNA and protein synthesis, and from which titanium 
accumulates in nucleic-acid-rich regions of tumour cells after in vivo or in vitro 
administration [14-16]. However, unlike cisplatin, Cp 2TiCl2 does not bind to DNA 
bases strongly at physiological pH, but forms strong complexes with nucleotides only 
at low pH [17]. Also, there is no evidence for stable complexes of the V or Mo 
analogues with nucleotides or DNA under physiological conditions [1 Oa, 1 3c]. This 
raises doubts about DNA as the predominant target [10a,13c]. EffOrts to identify the 
biologically active Ti species have been largely unsuccessful due to the rapid 
hydrolysis of the titanium(IV) complexes at neutral pH, which results in precipitation 
of uncharacterised polymeric hydrolysis products [2, 11 a]. 
Transferrin is an 80 kDa iron-transport protein present in the serum of 
vertebrates at a concentration of about 35 pM [18]. It carries iron(ffl) in blood at pH 
7.4, delivers it to cells via receptor-mediated endocytosis, and releases it at pH Ca. 5-
5.5 in endosomes [19]. In human serum, only 30% of the transferrin sites are 
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saturated with iron. Many other metal ions have been reported to bind reversibly to 
human serum transferrin [18]. Moreover, transferrin has been implicated in transport 
and delivery of therapeutic metal ions such as 67,Ga and Ru IU to cancer cells [20,2 1]. 
Since it has been found recently in this laboratory that Ti" forms a strong complex 
with human serum transferrin (hTF) by binding to the specific Fe u, binding sites [22], 
a detailed study of the binding of Ti"' to the phenolic ligand ethylenebis(o-
hydroxyphenylglycine) (EHPG) was carried out. The EHPG ligand itself contains 
donor groups similar to those of transferrin (2Tyr, His, Asp and C0 3 2 ) and has long 
been used to model metal-transferrin binding. Metal-EHPG complexes have been 
shown to model not only many of the physical properties of metal-transferrin 
complexes but also a number of other iron-phenolate proteins [23-34]. In addition, 
EHPG has been suggested as a potential radiopharmaceutial carrier for positron 
emission tomography [33]. The interaction of EHPG with titanocene dichioride and 
Ti"-citrate in aqueous solution over a wide range of pH values have been studied, 
and here describe the NMR studies and X-ray crystal structures of two novel Ti-
EHPG complexes. The structures reveal a unique stereoselective recognition of the 
EHPG ligands by Ti" 
3.3 Experimental 
Materials. The ligand (H4ehpg, see Figure 3.1) was purchased from Sigma 
Chemical Co. and purified as described previously [26]. No attempt was made to 
separate the racemic R,RJS,S and mesomeric R,S isomers of the ligand, which are 
present in an unspecified mixture in commercial preparations (subsequently 
determined to be Ca. 1:1 in our samples). Cp2TiC1 2 was purchased from the Arcos 
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Chemical Co, and monosodium citrate from the Aldrich Chemical Co. Ti"-citrate 
was prepared as described previously [22]. All other chemicals were A.R. grade and 
were used as received. 
	
OOC a NH2 	H2N a COO 
HOL 6 
5 	3 	3 	
5 
4 	 4 
H4ehpg 
Figure 3.1 Schematic drawing of N,N'-ethylenebis[(o-hydroxyphenyl)glycine] 
(H4ehpg). The asterisks indicate the chiral a carbons. The labelling scheme indicated 
is used for protons in NMR spectra. For complex 2, a dash is used to label atoms on 
the uncoordinated phenol (H3', H4' etc.). 
NMR spectroscopy. 'H (500 MHz or 600 MHz) NMR spectra were recorded in 
D20 on Bruker DMX 500 or Varian 600 NMR spectrometers. 'H chemical shifts were 
referenced to 1 ,4-dioxane (internal). The 2D COSY, 2D DQFCOSY and 2D NOESY 
data were obtained using standard techniques. All spectra were recorded at 298 K 
unless otherwise stated. The water resonance was suppressed by presaturation or via 
the WATERGATE pulsed-field-gradient sequence [35]. 
pH measurements. The pH values were determined using a Corning 240 pH meter 
equipped with an Aldrich micro combination electrode, calibrated with Aldrich buffer 
solutions at pH 4, 7 and 10. The pH-meter readings for D 20 solutions are recorded as 
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pH* values, i.e. uncorrected for the effects of deuterium on the glass electrode. 
Adjustments of pH were made with HC1 or NaOH (DC1 or NaOD for samples in 
D20). 
UV-vis and FT-JR spectra. UV-vis spectra at different pH values were recorded in 
0.1 M NaCl solution on a Shimadzu UV-2501PC spectrophotometer at 298K, using 1 
cm path length cells. Concentrations of complexes 1 and 2 were determined by 
measuring the Ti content using ICP-AES technique. The FT-IR spectra were recorded 
on a Perkin-Elmer Paragon 1000 spectrometer using KBr pellets. 
Synthesis of [Ti(ehpg)(H20)]1113H 20 (1). Cp2TiC1 2 (124.5 mg, 0.5 mmol) was 
dissolved in boiling distilled water (10 mL) and H 4ehpg (180 mg, 0.5 mmol) was 
added slowly with stirring. The mixture was stirred for 30 min with addition of drops 
of cold water to keep the volume approximately the same. The resulting deep red-
orange solution was filtered while hot to remove traces of unreacted ligand. After 
cooling to ambient temperature, the pH of the solution was Ca. 1.7. One day later, 
regular rhombic orange crystals were obtained which were suitable for X-ray 
crystallography. The crystals were filtered and washed 3x with cold water. Yield 
73.6% (82.56 mg, based on EHPG rac, or 36.8% based on Ti). Calc. for 
[Ti(C18H 1 6N206)(H2O)] 5H20, C18H18N207Ti•5H20: C, 42.20; H, 5.50; N, 5.47. 
Found: C, 42.00; H, 5.32; N, 5.28. FT-JR data (cm 1 ) 3423br, 1637vs, 1597s, 1478m, 
1452m, 1340m, 1250vs, 1188w, 1072w, 1032w, 963w, 901s, 829m, 779m, 761m, 
730w, 69 1w, 646s, 501m, 447w, 428m. 
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Synthesis of [(Ti(Hehp9)(H20))20]13H 20 (2). The pH of a solution of 200 mL 
titanocene dichloride (249.5 mg, 1.0 mmol) containing 1.0 equiv of H 4ehpg was 
adjusted to 3.7 and left at ambient temperature. A week later, large thin orange 
rectangular plate crystals were obtained, which were suitable for X-ray 
crystallography. The crystals were fitered and washed 3x with cold water. Yield 
47.4% (117 mg, based on EHPG meso, or 23.7% based on Ti). Calc. for 
C36H38N2O 15Ti2 •9H20: C, 42.21; H, 5.50; N, 5.47. Found: C, 42.53; H, 5.35; N, 5.44. 
FT-JR data (cm 1 ) 3422br, 3211br, 1638vs, 1597s, 1480m, 1458m, 1353m, 1294w, 
1267m, 1187w, 1106w, 1062w, 1053w, 1006w, 966w, 902w, 790m, 760m, 738m, 
702s, 616s, 500m, 434m. 
Similar crystals of pure 2 were also obtainable in very low yield from solutions of 
the same concentration as above at pH 1.9 or at pH 5.0 after about a week at ambient 
temperature. 
X-ray Crystallography'. X-ray crystallographic studies of 1 and 2 were carried out 
on a Stadi-4 diffractometer equipped with Oxford Cryosystems low-temperature 
devices. Single crystals were mounted at ambient temperature on the ends of quartz 
fibers in Paratone N oil, and data were collected at 220 K with Mo-K u radiation for 1 
and Cu-Ku 2, using a 0/co scan mode. Psi-scan data showed no significant intensity. 
variation, and so no absorption correction was applied. The crystal structures were 
solved by Patterson methods (DIRDIF) (1) and by direct methods (SHELXS) (2). H- 
The X-ray crystal structures for complexes 1 and 2 are solved by Dr. Robert 0. Gould and Dr. Simon 
Parsons (Edinburgh). 
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atoms attached to C and N were placed in calculated positions, while those attached to 
0 were located in difference Fourier maps; all were allowed to ride on their parent 
atoms during subsequent refinement. Both structures were refined by full-matrix least-
squares against 172 (SHELXL). All non-H-atoms were modelled with anisotropic 
displacement parameters (adps). The final difference map max. and mm. were +0.75 
and -0.38 (1) and +0.82 and -0.78 ek 3(2). Further crystallographic information is 
summarized in Table 1. 
Table 1. Crystal Structure Data for Complexes 1 and 2 
1 	 2 
formula 	[Ti(C 1 8H 1 6N206)(H20)]. 11 I3HO [Ti20(C 18H 1 7N206)2(H20)2]. 1 3H20 
fw 488.30 1096.47 
colour deep orange deep orange 
crystal system Monoclinic Triclinic 
space group C2/c P 1 
a (A) 24.149(4) 12.251(6) 
b (A) 14.143(3) 14.085(7) 
(A) 19.487(3) 16.635(8) 
a (°) 90 80.93(2) 
18(0) 105.371(13) 69.23(2) 
y(°) 90 64.33(2) 
V(A) 6417.7(19) 2419(2) 
Z 12 4 
T (K) 220(2) 220(2) 
pca1cd(gcm) 1.5 16 1.506 
iucajcd(mm) 0.462 3.661 
F(000) 3056 1152 
Orange(°) 2.56-25.03 2.84-73.16 
refi. collected/unique 9463/5662 8694/8070 
refi. with I> 2cy(I) 4428 5956 
parameters 434 729 
Ri (F0>2cy(Fo)) 0.0499 0.0588 
wR2 (all data) 0.1340 	- 0.1664 
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Kinetic studies of reactions in solution. These were carried out at pH*  values of 
7.0 and PH*  3.7 in D20. An aliquot of Cp2TiC12 (aq.) was introduced to a 5-mm NMR 
tube charged with EHPG solution (pH* 8.5 or 7.4, respectively) to give a final 
concentration of 5 mlvi of each reactant. The pH*  values fell to 5.7 or 3.7, 
respectively, and were readjusted with concentrated NaOD. 'H NMR spectra were 
recorded immediately, and then subsequently at various time intervals thereafter. 
There was no measurable change in pH*  during the reaction. Similar experiments 
were performed using Ti"-citrate instead of Cp 2TiC1 2. For kinetic analysis of NMR 
spectra, relative concentrations of each species were calculated at each time point 
from peak integrals. 
.3.4 Results 
3.4.1 Preparations of [Ti(ehpg)(H20)].1 1/3H20 (1) and [{Ti(Hehpg)(H20)}20] 
13H20 (2). 
The reaction of Cp2TiC12(aq) with commercial EHPG ligand (1 molequiv) in 
water afforded orange crystals containing both monomeric [Ti(ehpg)(H 20)] (1) and 
the oxygen-bridged dimer [{Ti(Hehpg)(H 20)}20] (2), containing the rac and meso 
isomers of the ligand, respectively (vide infra). The yields of 1 or 2 depended on the 
pH, the concentrations of the reactants and reaction times. Complex 1 has a higher 
solubility in water (ca. 5 mM) and was stable at low pH (near pH 1), so a good yield 
of complex 1 was achieved by carrying out the reaction near boiling temperature for 
0.5 h at higher concentrations (ca. 50 mM reactants) at pH Ca. 1.7. Then crystals 
formed after overnight standing of the reaction solution at ambient temperature. The 
crude crystals obtained under these conditions sometimes contained trace amounts of 
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the dimer 2, but this was readily removed by washing the crystals with cold water 
during filtration. Pure crystals of 1 were also obtained from reactions at higher pH (ca 
6.1), using Cp 2TiC12 orTi"-citrate as starting materials, but the yields were quite low. 
Complex 2 is stable only over the pH range ca 2.5-5.5. It is less soluble (< 1 mM) in 
water at low pH, but dissolves readily at neutral pH forming a colourless solution. 
This implies that 2 decomposes at neutral pH. The reaction giving crystals of 2 was 
quite slow, a good yield being achieved after a week at ambient temperature with low 
concentrations of reactants (ca. 5 mM) at pH 3.7. Crystals of pure dimer 2 were 
obtainable without contamination by 1. Pure crystals of 2 were also obtainable at pH 
ca 1.9 or 5.0 with the same concentrations of reactants but with very low yields. 
3.4.2 X-ray Structure of [Ti(ehpg)(H 20)]11/3 1120 (1). 
Two independent molecules (la and ib) and their enantiomers ( N(S,S)C(S,S) 
and N(R,R)C(R,R) ) are present in the unit cell. Molecule la lies on a crystallographic 
2-fold axis while lb is in a general position. They differ slightly in their bond lengths 
and bond angles (Figure 3.2, and Table 2). Both contain the racemic isomer of EHPG 
(R,R and S,S). Ti" exhibits sevenfold coordination with a distorted pentagonal 
bipyramidal geometry. In la, the two phenolate oxygen atoms are in the axial 
positions (O-Ti-O angle 171.32°, Ti-O, 1.869(2) A), while the two nitrogen atoms 
from the two amine groups (Ti-N, 2.210(2) A), the two oxygen atoms from the two 
carboxylate groups (Ti-O, 2.061(2) A) and an additional oxygen atom from a water 
molecule (Ti-O, 2.09 1(3) A) are nearly equally distributed around the equatorial 
pentagonal plane of Ti'". Selected bond lengths and bond angles are given in Table 2. 
The Ti-N bonds are much longer while the short phenolate Ti-O bond lengths are 
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comparable to those reported previously for Ti' v-phenoxo complexes [36] The 
coordinated water molecule is further away, with a bond length similar to those in 
[Ti"(EDTA)(H 20)] (Ti-OH2, 2.082(2) A) [37a] and Co (EDTA)(H 20)] (Co-OH2 , 
2.073(2) A) [37b]. It fonns H-bonds with each of the nearby coordinated carboxylate 
oxygens (OH ... O distance 2.20 A). The coordination sphere in lb is slightly more 









Figure 3.2 The molecular structure and atom-labelling scheme complex la (left) and 
complex lb (right). 
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Figure 3.3 The molecular structure and atom-labelling scheme for one of the mirror 
isomers of complex 2. 
In the crystal of complex 2, two molecules, a pair of mirror isomers, appear in 
the unit cell, and both of them contain only the meso isomer of EHPG. In each of the 
enantiomers (N(R,R)C(R,S) in both {Ti(Hehpg)(H 20)} units in one molecule or 
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N(S,S)C(S,R) in both {Ti(Hehpg)(H 20) } units in the other molecule, one of them is 
shown in Figure 3.3), two {Ti(Hehpg)(H 20)} units are linked by a t-O bridge. The 
atoms are also seven-coordinate with a more distorted pentagonal bipyramidal 
geometry than that in complex 1, bound to the bridging oxide, one phenolate group, 
two nitrogens, two carboxylates and a water molecule. The other phenol group is 
protonated and uncoordinated, but forms a hydrogen bond with the nearest amine 
proton (N•• •O distance 2.73 - 2.75 A) and a nearby water molecule (O•• .0 distance 
2.68 A). The coordinated phenolate oxygen and the bridging .i-O atom are located in 
the axial positions (0-Ti-0 angles = 164.3° and 167.10).  The other five coordinated 
atoms are located in the equatorial plane. The bridging oxygen forms short Ti-O 
bonds of 1.843(3) A and 1.820(3) A, and the Ti-0-Ti angle is slightly bent (159.9°). 
The existence of a nearly linear Ti-O-Ti fragment is also indicated by the strong 
vibration band [37c] at 702 cm 1 in the FF-IR spectrum of 2. The other bond lengths 
are comparable to those of 1. There is extensive hydrogen bonding between the 
complex and solvent water molecules in the unit cells of both 1 and 2. 
Table 3.2 Selected bond lengths (A) and bond angles (deg) for complexes 1 and 2 
Complex la Complex lb 
Distances (A) 
Ti(1 1)-0(1 1) 1.869(2) Ti(22)-N(92) 2.197(3) 	Ti(22)-N(122) 	2.231(3) 
Ti(1 1)-0(1W1) 2.091(3) Ti(22 Ti(22)-0(12) 1.866(2) 	Ti(22)-0(202) 	1.879(2) 
Ti(1 1)-0(821) 2.061(2) Ti(22)-0(822) 2.056(2) 	Ti(22)-0(1332) 	2.059(2) 
Ti(1 1)-N(91) 2.210(2) Ti)-0(2W2) 2.077(2) 
Angles (deg) 
0(1 1)-Ti(1 1)-0(1 1#) 171.22(14) 0(12)-Ti(22)-0(202) 168.24(10) 
0(11 )-Ti( 11 )-0(82 1) 91.64(9) 0(1 2)-Ti(22)-0(822) 93.18(10) 	0(202)-Ti(22)-0( 1332) 	91.74(10) 
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0(11 )-Ti( 11 )-0(82 1#) 90.91(9) 0(1 2)-Ti(22)-0( 1332) 90.51(10) 0(202)-Ti(22)-0(822) 	91.41(10) 
0(11 )-Ti(1 1 )-N(9 1) 82.74(10) 0(1 2)-Ti(22)-N(92) 82.22(10) 0(202)-Ti(22)-N( 122) 	81.60(10) 
0(11 )-Ti( 11 )-N(9 1#) 90.14(10) 0(1 2)-Ti(22)-N( 122) 88.25(10) 0(202)-Ti(22)-N(92) 	89.03(10) 
0(1 1)-Ti(1 1)-0(1W1) 94.39(7) 0(12)-Ti(22)-0(2W2) 95.89(11) 0(202)-Ti(22)-0(2W2) 	95.81(11) 
0(821 )-Ti( 11 )-0(82 1#) 146.24(12) 0(822)-Ti(22)-0( 1332) 145.92(9) 
0(821 )-Ti( 11 )-N(9 1) 71.16(8) 0(822)-Ti(22)-N(92) 71.31(9) 0(1 332)-Ti(22)-N( 122) 	70.80(9) 
0(821 )-Ti( 11 )-N(9 1#) 142.47(9) 0(822)-Ti(22)N( 122) 143.13(9) 0(1 332)-Ti(22)-N(92) 	142.67(10) 
0(821 )-Ti( 11 )-0( 1W 1) 73.12(6) 0(822)-Ti(22)-0(2W2) 72.59(9) 0(1 332)-Ti(22)-0(2W2) 	73.33(9) 
N(9 1 )-Ti( 11 )-N(9 1#) 71.91(12) N(92)-Ti(22)-N( 122) 72.41(9) 
N(9 1 )-Ti( 11 )-0( 1W 1) 144.05(6) N(92)-Ti(22)-0(2W2) 143.67(10) N( 1 22)-Ti(22)-0(2W2) 143.91(9) 
Complex 2 
Distances (A) 
Ti( 1 )-0( 1) 1.853(3) Ti(2)-0(21) 1.944(3) 
Ti( 1 )-0( 1 B) 1.874(3) Ti(2)-0(1B) 1.803(3) 
Ti(1)-0(4) 2.025(3) Ti(2)-0(24) 2.045(3) 
Ti( 1 )-0(3) 2.093(3) Ti(2)-0(23) 2.097(3) 
Ti( 1 )-0( 1 T) 2.084(3) Ti(2)-0(2T) 2.095(3) 
Ti( 1 )-N(2) 2.226(3) Ti(2)-N(22) 2.222(3) 
Ti( 1 )-N( 1) 2.241(3) Ti(2)-N(21) 2.233(3) 
Angles (deg) 
0(1 )-Ti( 1 )-0(3) 91.59(12) 0(21 )-Ti(2)-0(23) 87.53(12) 
0(1 )-Ti( I )-0(4) 99.40(12) 0(21 )-Ti(2)-0(24) 91.51(12) 
0(1 )-Ti( 1 )-0( 1B) 164.59(12) 0(21 )-Ti(2)-0(1B) 167.36(12) 
0(1 )-Ti( 1 )-0( 1 T) 93.69(12) 0(21 )-Ti(2)-0(2T) 93.77(12) 
0(1 )-Ti( 1 )-N( 1) 80.70(12) 0(21 )-Ti(2)-N(2 1) 82.73(12) 
0(1 )-Ti( 1 )-N(2) 85.73(12) 0(21 )-Ti(2)-N(22) 86.20(12) 
0(3)-Ti( 1 )-0(4) 142.98(10) 0(23)-Ti(2)-0(24) 144.09(11) 
0(3)-Ti( 1 )-0( 1B) 88.24(12) 0(23)-Ti(2)-0(1B) 91.27(12) 
0(3)-Ti( I )-0( iT) 71.56(11) 0(23)-Ti(2)-0(2T) 72.33(11) 
0(3)-Ti(1)-N(1) 71.32(11) 0(23)-Ti(2)-N(21) 70.53(11) 
0(3)-Ti( I )-N(2) 144.25(11) 0(23)-Ti(2)-N(22) 143.41(12) 
0(4)-Ti( I )-0( I B) 90.92(11) 0(24)-Ti(2)-0( 1B) 97.79(12) 
0(4)-Ti(1)-0(1T) 72.19(11) 0(24)-Ti(2)-0(2T) 71.92(11) 
0(4)-Ti( I )-N( 1) 145.40(11) 0(24)-Ti(2)-N(21) 144.88(11) 
0(4)-Ti( I )-N(2) 72.37(11) 0(24)-Ti(2)-N(22) 72.14(11) 
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0(1 B)-Ti( I )-0( 1 T) 100.86(11) 0(1 B)-Ti(2)-0(2T) 97.85(12) 
0(1B)-Ti(1)-N(1) 84.65(12) 0(1B)-Ti(2)-N(21) 85.01(12) 
0(1 B)-Ti( I )-N(2) 84.43(12) 0(1 B)-Ti(2)-N(22) 87.30(12) 
0( IT)-Ti( 1 )-N( 1) 142.33(12) 0(2T)-Ti(2)-N(21) 142.81(12) 
0(1 T)-Ti( 1 )-N(2) 144.07(12) 0(2T)-Ti(2)-N(22) 144.04(12) 
N( 1 )-Ti( 1 )-N(2) 73.07(12) N(2 1 )-Ti(2)-N(22) 72.93(12) 
Ti(1)-0(1B)-Ti(2) 160.22(16) 
3.4.4 UV-vis Spectra 
The optical spectra of complexes 1 and 2 over the pH range 0.7 to 8.0 in 0.1 M 
NaCl are shown in Figure 3.4. They both exhibit two bands at acidic pH, one below 
and one above 300 nm. The higher energy band is due to internal ligand transitions, 
whereas the band centred at 386 nm for 1 and at Ca. 388 nm for 2 (the origin of the 
orange colour of the complexes) can be assigned as a ligand-to-metal charge transfer 
band (LMCT). As can be seen from the LMCT bands in Figure 34, complexes 1 and 
2 are both more stable at low pH than at high pH. Complex 1 is stable between pH 
1.0 and 6.5. At pH 7.0, Ca. 40% of the absorbance at 386 nm is lost, and by pH> 8.0, 
the LMCT band has nearly disappeared, corresponding to the loss of Ti"-phenolate 
bonding. Complex 2 was less stable than 1. The LMCT band was observable only 
between pH 2.5-6.0. At pH > 7.0, this band disappeared completely. While the 
absorbance maximum of the rac-EHPG complexes is constant at 386 nm throughout 
the pH range 1.0-6.4, the absorbance maximum of the meso-EHPG complex 2 shifted 
from 388 nm to a slightly higher wavelength as the pH was lowered (401 nm at pH 
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Figure 3.4 The UV-vis spectra of complexes 1 and 2 showing the LMCT bands at 
various pH values. (A) Complex 1, pH 0.73-4.12; (B) complex 1, pH 4.12-8.06; (C) 
complex 2, pH 0.70-3.37; (D) complex 2 pH 4.30-8.03. Concentration: 1, 3.08 x 10 
M, 386 = 9,600 M'cm, pH 4.1; 2, 1.86 x 10 5 M, 9388 = 9,500 M'cm, pH 4.3 (298 
K, t = 0.1 M, 0.1 M NaCl). 
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3.4.5 NMR of Ligands 
Commercially available EHPG ligand consists of a mixture of meso and rac 
isomers. Since it was possible to prepare Ti" complexes containing either the pure 
meso or rac ligand, individual isomers of the ligand could be characterised by NMR. 
The NMR spectra of free meso or rac EHPG ligands were obtained by acidifying the 
corresponding Ti"'' complex until a colourless solution was obtained. During this 
process, tiny amounts of white precipitate, presumably polymeric titanium hydroxide, 
was formed and subsequently filtered off. Since the 1 11 NMR spectra are in agreement 
with formation of the free ligand, as can be seen by comparison with the commercial 
ligand at low pH (Figure 3.5), no further attempt was made to remove the metal. 1D 
'H NMR data on the EHPG isomers at alkaline pH have been published [27,32], but 
only the a-protons of the isomers gave distinguishable signals under these analysis 
conditions. In addition, resonances for the phenyl ring protons of the isomers were 
unassigned. At pH*  values below 2, resonances for all the protons of the isomers of 
EHPG are well resolved. The 'H NMR spectrum of the commercial ligand is 
reproduced exactly by combining the spectra of the individual meso and rac isomers. 
Unambiguous assignments were established by 2D ['H,'H] COSY and NOESY NMR 
experiments (Figure 3.6) and the chemical shifts are listed in Table 3.3. 
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Figure 33 500 MHz 'H NMR spectra of commercial EHPG and its rac and meso 
isomers at acidic pH*  values in D20. 
Table 3.3 Comparison of the 'H NMR chemical shifts (ö) of complexes 1 and 2 and 
the rac and meso isomers of EHPG in D 20 at various pH values, at 298K. For atom 
labels see Figure 3.1. 
EHPG (rac) EHPG (meso) Complex 1 (rac) Complex 2 (meso) 
pH* 1.38 1.33 1.37 3.41 
czH 5.08(s) 5.11(s) 4.86(s) 4 .94(s) , 4 . 81(s )c 
methylene 3.43(m), 3.33(m) 3.01(d), 3.55(t), 3.32(d) 
3.21(m) 2.66(d) 2.90(d), 2.65(t) 
phenol H3a [H3]b 6.96(d) 6.98(d) 6.73(d) 6.66(d), [6.93(d)] 
H4 [H4'] 7.41(t) 7.43(t) 7.40(t) 7.36(t), 	[7.34(t)] 
H5 [H5'] 7.00(t) 7.02(t) 7.08(t) 7.02(t), 	[6.99(t)] 
H6 [H6'] 7.28(d) 7.27(d) 7.40(d) 7.39(d), [7.34(d)] 
a closed phenolate ring. b  uncoordinated phenol. C  at 308 K. 
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Figure 3.6 500 MHz [ 1 H,'H] COSY(left) and NOESY(right) (mixing time 1.2 s) 
spectra of EHPG rac isomer in D20 at 310K, which establish the NMR resonance 
assignments. 
3.4.6 NMR of Complexes 
Solution state 'H NMR studies of the diamagnetic Ti" complexes 1 and 2 
allowed comparison of some of their structural features with those in the solid-state. 
Peak assignments were established by 2D NMR techniques. The 2D COSY and 2D 
NOESY NMR spectra of 1 and 2 in acidic solution are shown in Figures 3.7 and 
Figure 3.8. The chemical shifts and assignments are shown in Table 3.3, together 
with data for the meso and rac isomers of the EHPG ligand. Both upfield (low 
frequency) and downfield (high frequency) shifted signals were observed for the 
complexes compared with the corresponding ligands. The phenolate-Ti r" 
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and 0.3 ppm for meso isomer), but downfield shifts for H6 (Ca. 0.17 ppm for rac, and 
0.10 ppm for meso), whereas H5 and H4 peaks are only slightly shifted (<0.08 ppm). 
Resonances for the uncoordinated phenol ring in the dimer complex 2 were assigned 
with the aid of 2D DQFCOSY and 2D NOESY NMR data. 
H6,H4 	
ref -CH2CH2-- 	H6,H4 	 aH HOD 	
-CH2CH2- 
Figure 3.7 2D COSY and 2D NOESY(800 ms mixing time) spectra of the monomer 
complex 1 in D20 at 308 K, which established the NMR resonance assignments. 
Strong NOE peaks are observed for the phenyl protons, NCH 2CH2N protons and for 
aH to NCH2CH2N and for aH to H6. For labelling system, see Fig. 3.1; a, axial 
protons; e, equatorial protons. 
The a-Hs of monomeric complex 1 gave rise to a peak at 4.86 ppm, which was 
not affected by pH over the range 1.0-7.0, in contrast to the large chemical shift 
changes of the a-Hs of the free ligands. As expected, only one single peak was 
observed for the monomer 1, indicating that the two a-Hs are magnetically equivalent. 
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Figure 3.8 2D DQFCOSY 'H NMR spectrum (top, 500 MHz, 298 K), and 2D 
NOESY spectrum (bottom, 500 ms mixing time, 308 K) of the dimer complex 2 in 
D20, establishing the NMR resonance assignments. Strong NOE peaks are observed 
for the phenyl protons, for the geminal NCH 2CH2N protons (a/b and c/d, see insert) 
and for aH to H6 for the ring-closed but not for the ring-opened side of the ligand. For 
labelling system, see Figure 3.1. 
of 
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The ethylenediamine protons for the monomer gave rise to two deceptive quasi-
quartets at 3.01 and 2.66 ppm representing an A 2B2 system. This indicates a gauche 
conformation of the ethylenediamine portion of the EHPG ligand, similar to that 
observed in the solid state. The resonances for the axial protons are 0.45 ppm to 
higher field than those for the equatorial protons, perhaps due to differences in 
magnetic shielding by the phenyl rings and the diamagnetic anisotropic C-N bonds. 
For the dimer 2, two single peaks (one for each of the (x-H connected to the 
unbound phenolate and the bound phenolate) were expected for the four a-Hs. 
However, we observed only one a-H peak (2H) at 4.94 ppm at 298 K. The other peak 
is under the water signal at this temperature. Upon raising the temperature > 308 K, 
the other a-H peak (2H, 4.81 ppm at 308 K) was readily observed. 2D NOESY NMR 
experiments revealed connectivities between the a-H at 4.94 ppm and the bound 
phenolate. The ethylenediamine region of the spectrum of the dimer showed two 
triplets at 3.55 and 2.65 ppm, and two doublets at 3.32 and 2.90 ppm, each of which is 
further split into fine doublets, representing an AA'BB' system. This indicates that the 
HNCH2CH2NH groups are also fixed in a gauche conformation in solution. The 
assignment of the NMR peaks is shown in Figure 3.7. The chemical shifts of 
complexes 1 and 2 were unchanged over the pH ranges studied (7.5-1.0 and 6.0-1.4, 
respectively). 
3.4.7 pH Stability of Complexes 1 and 2 
The stability of complexes 1 and 2 at different pH values was further 
investigated by 'H NMR. Complex 1 is stable over the range pH*  1.0 to 7.0, but 
all 
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Figure 3.8 'H NMR spectra of (top) complex 1 and (bottom) complex 2 at different 
pH* values. 
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below pH* 1.0, disassociation occurred slowly, the 'H NMR spectrum being 
consistent with the appearance of the free ligand. However, at pH ~! 7.5, many new 
peaks appeared, indicating that 1 decomposes at alkaline pH (Figure 3.8A). Complex 
2 is less stable than 1, and only over the range pH 2.5 to 5.5. At pH> 5.5, many new 
'H NMR resonances appeared (Figure 3.813), indicating the decomposition of complex 
2. No attempt was made to identify all the decomposition products. 
3.4.8 Reactions in Solution 
phenyl 	 ref 	-CH2CH2- 
free 
1 1 iCp 	 1 1 	28h 
£ 	 m 	1 	 ii 
1 1 1 	 mr 




Figure 3.9 Kinetics of the reactions between Cp 2TiC12(aq) and EHPG in D20 at pH* 
7.0 and 298 K followed by 'H NMR, showing the gradual release of the Cp ligands 
and formation of complex 1. Peak labels: Cp, cyclopentadiene; m and r, meso and 
racemic forms of free ligand H4ehpg. 
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Figure 3.10 Kinetics of the reactions between Cp 2TiC12(aq) and EHPG in D20 at 
pH* 3.7 followed by 'H NMR, , showing the slow reaction with the formation of both 
complex 1 and complex 2. 
The interaction between Cp 2TiC12 and EHPG was followed by 1 H NMR in D20 
at two pH*  values,  pH*  7.0 and 3.7. At pH*  7.0, the Cp ligands were readily released 
as can be seen from the decrease in intensity of the 1 H NMR peak for TiRbound  Cp 
at 6.42 ppm, and the appearance of peaks at 6.64 and 6.57 ppm assignable to free 
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cyclopentadiene (Figure 3.9) [1 la]. Both of the isomers of EHPG bind to Ti" but the 
rac ligand binds faster than the meso isomer as can be seen from the rate of decrease 
of the aH NMR peaks. The increase in intensity of the two deceptive quasi-quartets at 
2.99 and 2.64 ppm (NCH 2CH2N), the doublet at 6.72 ppm (H3), the triplet at 7.06 
ppm (H5) and the multiplet at 7.39 ppm (H4 and H6) are indicative of the gradual 
formation of the rac complex 1 with a t112 of ca 50 mm. However, no NMR peaks 
characteristic of the meso complex 2 were observed during the reaction, suggesting 
that species containing the meso ligand were other than complex 2 at this pH value. 
At pH*  3.7, Cp2TiC12 reacted very slowly with both of the EHPG isomers, as can 
be seen from the NMR spectra (Figure 3.10). The reaction leading to the formation of 
the rac complex 1 required about one week for completion 41,2 ca 2.5 d), and weak 
NMR peaks characteristic of the meso dimer, complex 2, did not appear until 7 d later. 
Deep orange crystals were isolated from the solution after 8 d at ambient temperature. 
3.5 Discussion 
The yield of monomeric complex [Ti(ehpg)(H 20)]•11/3H20 1 or dimeric complex 
[(Ti(ehpg)(H 20)} 20].13H20 2 depends on pH, concentrations, and the reaction time. 
Complex 1 has higher solubility in water (ca. 5 mM) than complex 2 (< 1mM) and, 
can tolerate low pH conditions. Hence a good yield of complex 1 was achieved by 
reacting high concentrations (ca. 50 mM) of reactants at close to boiling temperature 
for 0.5 h and a pH of ca 1.7. Crystals of 1 then formed after standing overnight at 
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ambient temperature. Crude crystals obtained under these conditions sometimes 
contained trace amounts of dimer crystals of 2, but these were readily removed by 
washing with cold water during filtration. Pure crystals of 1 were also obtained from 
reactions at higher pH (ca 6.1) using Cp2T1Cl2 or Ti"-citrate as starting material, but 
the yields were quite low. Complex 2 is stable only between pH ca 2.5-5.5. It is less 
soluble (< 1 mM) in acidic solutions, but it readily dissolves at neutral pH forming a 
colourless solution, which implies that 2 decomposes at neutral pH. The reaction 
leading to crystals of 2 is quite slow. A good yield of product was achieved after a 
week of reaction at ambient temperature using low concentrations (ca. 5 mM) and pH 
3.68. This gave only dimer 2 without contamination by any crystals of the monomer 1. 
Pure crystals of 2 were also obtained at pH ca 1.9 or 5.0 using the same 
concentrations of reactants but with very low yields. 
Both complexes 1 and 2 exhibit strong visible absorption bands near 387 nm. The 
visible bands for Fe'-EHPG and VO-EHPG have been recognised as L-3M charge 
transfer bands involving a pt orbital on the phenolate oxygen and half-filled d orbitals 
of iron or empty d orbitals of vanadium(V), respectively [22,31,38]. Similar bands 
have also been observed for other phenoxo Ti" complexes, and assigned to ligand-to-
metal charge-transfer transitions [38]. The visible bands for 1 and 2 can therefore be 
attributed to L->M charge transfer from a pt orbital of the phenolate oxygen to an • 
empty titanium d orbital. We have observed a similar broad band at 300 to 400 nm for 
Ti"'-transferrin [22]. The CT band of the meso isomer is slightly red-shifted 
compared with the rac isomer, as is also the case for Fe"-EHPG complexes. 
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The NMR spectra of the ligands at acidic pH have not been reported previously, 
probably because of the poor solubility of the ligand at low pH values [31, 32]. 
However, the commercial EHPG ligand readily dissolves in D 20 at pH*  values below 
2, which may be due to the protonation of the carboxylate groups of the ligand. 
Resonances for all the protons of the rac and meso isomers of EHPG were well 
resolved and have been unambiguously assigned for the first time in this work. 
The Ti fl' complexes of both the rac and meso EHPG ligand are seven coordinate 
with a water molecule as a co-ligand (Figure 3.11). In the crystal structure of 2, one 
of the phenol groups of the Hehpg ligand is not coordinated and is present in an ring-
opened form. The only reported ring-opened metallo-EHPG complex [39] is the 
octahedral vanadyl complex [VO(Hehpg)], containing one ring-opened phenol. 
Similar to 2, the vanadyl complex is stable only under weakly acidic conditions. In 
transferrin, Fe" is coordinated to two deprotonated phenolates (Tyr residues), but 
intermediates with just one bound Tyr may be formed during metal uptake and 
release. The detection of ring-opened model complexes is therefore of significance. 
Ti" has empty 3d orbitals and an ionic radius of ca 0.68 A [40]. Similar to its 4d° 
and 5d° analogues Zr" and Hf"' [40], Ti' v is readily isolated in solvated form with the 
metal achieving seven-coordination, and several X-ray structures of 7-coordinate 
complexes have been reported [37a,41,42]. It has been suggested [37a] that a 
spherically symmetric charge distribution favours pentagonal-bipyramid geometry if 
the central metal ion is of sufficient size to tolerate a coordination number higher than 
6, or if the ligand-field splitting does not greatly favour an octahedral arrangement. 
DYA  
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Figure 3.11 The intramolecular hydrogen bonds in complexes 1 and 2. 
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With its relatively large size, and a spherically symmetric charge distribution, Ti" can 
adopt coordination numbers from 2 to 11. An examination of a number of X-ray 
crystal structures in the Cambridge Structure Datbase (Ca. 1000) suggested that the 
most common coordination number is 4 (ca 45%), followed by 6 (Ca 18%) and 5 (ca 
16%) with about 2.5% having a coordination number of 7. 
Stezowski et al. have pointed out [42] that for metal-EDTA complexes, as the 
size of the central ion increases and the M-N bond lengths increase, seven-
coordination becomes favourable via the binding of a water molecule to fill the 
"hole" created by expansion of O-M-O bond angles trans to M-N bonds. This seems 
to be the case for metal-EHPG complexes. Table 3.4 compares data for available X-
ray crystal structures of metal-EHPG complexes. It can be seen that Ti"' has a 
relatively large ionic radius (0.68 A), and that Ti"'-EHPG complexes have the longest 
M-N bonds ( >2.2 A), and therefore the smallest N-M-N angles. Modelling studies 
reveal that increases in the M-N bond lengths lead to movement of the trans oxygen 
atoms connected to the nitrogens by chelate rings and to concomitant opening of the 
corresponding O-M-O bond angles trans to the M-N bonds. In the case of Ti 1"-
EHPG complexes, the M-N bond lengths are long and the N-M-N angles are small 
(71-73°). Concomitant opening of the O-M-O bond angles trans to the M-N bonds is 
large enough (>143.5°) to encourage the coordination of a water molecule in the large 
hole thus formed. Therefore, it is understandable that Ti"' becomes 7-coordinate in 
these circumstances. 
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Table 3.4 Comparison of data for metal-EHPG complexes 
metal(M) 	d 	radius a  CN geom b  M-O C  M-N C  ZNMN d ZoMoe Ligand 	Complex chirality 	 ref 
Ti" (2) 0 0.68 7 pent 1.976 2.229 72.94 143.50 meso N(R,R)C(R,S) or N(S,S)C(S,R) this work 
Ti1" (lb) 0 0.68 7 pent 1.987 2.214 72.41 145.92 rac N(R,R)C(R,R) or N(S,S)C(S,S) this work 
Ti"(la) 0 0.68 7 pent 1.990 2.210 71.91 146.24 rac N(R,R)C(R,R) orN(S,S)C(S,S) this work 
VIV 1 0.63 6 Oct 1.894 2.208 78.20 103.24 rac N(R,R)C(S,S) or N(S,S)C(R,R) 39 
Fe 5(hs) 0.64 6 Oct 1.977 2.166 79.86 105.51 rac N(R,R)C(S,S) orN(S,S)C(R,R) 43 
Fe 5(hs) 0.64 6 Oct 1.967 2.151 80.61 107.17 rac N(R,R)C(S,S) orN(S,S)C(R,R) 43 
Fe11' 5(hs) 0.64 6 Oct 1.967 2.157 79.17 112.66 meso N(R,R)C(R,S) or N(S,S)C(S,R) 43 
Ga" 10 0.62 6 Oct 1.949 2.090 82.96 96.53 rac N(R,R)C(S,S) or N(S,S)C(R,R) 28 
Cu" 9 0.72 6 Oct 2.187 2.005 85.94 91.55 rac N(R,R)C(S,S) or N(S,S)C(R,R) 28 
Cotm 6(ls) 0.63 6 Oct 1.907 1.938 86.59 87.14 rac N(R,R)C(S,S) or N(S,S)C(R,R) 28 
a  ionic radius (A). b  Key: pen, pentagonal bipyramid; Oct, octahedral. 
Average bond distance (A). d  NMN angle 	e  the OMO angle trans to NMN angle (°) 
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The VLVEHPG  complex also has long V-N bonds, but V(IV) has a smaller ionic 
radius (0.63 A) and one of the oxygen ligands (V=O) in the trans O-V-O unit is not 
connected by a chelate ring (one of the phenolates is not coordinated to V" in this 
complex), and the O-V-O angle is only 103°, not large enough to accommodate a 
water molecule. 
A similar analysis may also apply to the spherically symmetric high-spin d 5 Few-
EHPG complexes, which also have relatively long Fe-N bond lengths (ca. 2.16 A) and 
a medium ionic radius for Fe (0.64 A). Although they are six-coordinate in the 
crystal lattice with O-Fe-O angles of 105-112°, optical spectroscopic properties 
suggest that Fe' 11-EHPG may be seven-coordinate in aqueous solution with an 
additional bound water ligand [28]. 
The most distinguishing feature of these Ti' v-EHPG structures is their 
stereochemistry. The EHPG ligand itself contains two chiral carbon atoms, so it has 
two diastereomeric forms, a pair of enantiomers (R,R and S,S) and a meso form (R,S 
or S,R). However, the EHPG ligand contains two pro-chiral nitrogen atoms, and so 
the two amine nitrogens become chiral when bound to a metal. Thus there are four 
chiral atoms in metal-EHPG complexes, resulting in a total of 16 possible 
configurations. 
Another consideration is the conformation about the C-C bond in the N-CH 2 
CH2-N group. As discussed earlier [34], while either a gauche or cis conformation is 
conceivable, modelling and previous studies [29] confirm that the cis conformation 
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will cause severe strain in the molecule, only a gauche conformation for the 
NCH 2CH2N group in the metal complexes is possible. The restriction of NCH 2CH2N 
to a gauche conformation imposes a correlatipn between the two chiral nitrogen 
atoms: they will both assume either the R or S configuration, i.e., R,R or S,S. This 
constraint also eliminates the possibility of mirror symmetry in the molecule, thus 
reducing the original 16 possible conformers to only 8. 
In the four conformers with nitrogen atoms in the N(S,S) configuration, the 
chiral carbon atoms can be labelled as C(R,R), C(S,S), C(S,R) and C(R,S). The last 
two are the same since C(S,R) and C(R,S) are related by a 2-fold axis. So only three 
conformers are possible. if the nitrogen atoms is in the N(S,S) configuration, a similar 
arguments hold since they are the mirror images of the three N(R,R) conformers. 
These factors reduce the original 16 possible conformers to only 6. 
In the three conformers with nitrogen atoms in the N(S,S) configuration, the 
chiral carbon atoms can be labelled as C(R,R), C(S,S), and C(R,S). if the nitrogen 
atoms are in the N(R,R) form, a similar argument holds, since they are mirror images 
of the three N(S,S) conformers. The complex with absolute chirality of N(S,S)C(R,R), 
which has been designated as (R,R) rac [34] or ARR [28] in some previous reports, 
and its mirror image isomer N(R,R)C(S,S), AS [28], have the six-membered phenolate 
chelate rings in the equatorial positions and five-membered carboxylate chelate rings 
in axial sites. One of the mirror isomers with N(S,5)C(R,R) configuration is shown in 
Figure 3.12A. The complex with N(S,S)C(S,S), which has been designated as (S,S) 
rac [34] or ARR [28], in the literature, and its mirror isomer N(R,R)C(R,R), both have 
108 
Chapter 3 Ti(!V)-EHPG model complexes 
the six-membered chelate phenolate rings in axial sites. One of the mirror isomers 
with N(S,S)C(S,S) configuration is shown in Figure 3.12B. The N(S,S)C(R,S) meso 
isomer, which has been designated as (R,S) meso in the literature, and its mirror 
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Figure 3.12 Schematic drawing of octahedral M-EHPG isomers, the asterisks indicate 
chiral atoms. 
Although X-ray crystal structures containing the N(S,S)C(R,R) and N(R,R)C(S,S) 
((R,R) rac, ARR and ASS) conformers of Fe(ffl), Co(ffl), Ga(ffl), Cu(II), V(IV) and the 
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(R,S) meso conformer of Fe(IH) are available, the crystal structure of a complex 
containing the corresponding N(S,S)C(S,S) or N(R,R)C(R,R) ((S,S) rac, ASS or ARR) 
conformer has not yet been reported, as far as I am aware. The absence of the 
N(S,S)C(S,S) or N(R,R)C(R,R) ((S,S) rac, ASS or LIRR) conformers in crystals has 
previously been ascribed to unfavourable crystal packing [43] or to the inherent 
instability of the (S,S) rac conformer [19]. Molecular mechanics studies [34] of Fe' 11-
EHPG complexes show that the most stable conformers are the N(S,S)C(R,R) and 
N(R,R)C(S,S) ((R,R) rac, ARR and ESS) both in vacuo and in aqueous solution, while 
the least stable is the N(S,S)C(S,S) or N(R,R)C(R,R) ((S,S) rac, ASS or IIRR) 
conformer. Stability constants for the (R,R) rac and (R,S) meso complexes of EHPG 
with a few metal ions (Fe", Ni", Zn", Cu", Ga' 11 and In) have been determined [33], 
and the results show that all the (R,R) rac conformers are more stable by 2-3 kcal/mol 
than the (R,S) meso conformer for all the metal ions studied. Thus the presence of the 
(S,S) rac conformers (N(S,S)C(S,S) and its mirror isomer N(R,R)C(R,R) as pairs in the 
unit cell) in crystals of 1 was unexpected. In crystals of the dimer 2, both Ti''-EHPG 
units are in the (R,S) meso form (N(R,R)C(R,S) for both EHPG ligands with its mirror 
isomer N(S,S)C(S,R) also present in the unit cell). None of the preparations gave rise 
to TiWEHPG  N(S,S)C(R,R) or N(R,R)C(S,S) ((R,R) rac, ARR and ASS) isomers, 
which have always been observed for other metals studied so far. 
For octahedral metal-EHPG complexes, greater stability has been proposed [33,34] 
for (R,R) rac isomers due to the geometric selectivity in the placement of both six-
membered chelate rings in the equatorial plane defined by the ethylenediamine ring. In 
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the (S,S) rac conformer, both of the six-membered chelate rings are in the axial 
position, which is a very strained arrangement. In the case of the (R,S) meso isomer, 
the only possible arrangement is the one with all coordinating groups cis to one 
another, that is, one axial phenyl and one equatorial phenyl. This structure is 
intermediate between the highly strained (S,S) rac arrangement and the most 
favourable (R,R) rac arrangement. 
The unusual N(S,S)C(S,S) or N(R,R)C(R,R) ((S,S) rac, ASS or ARR) chirality of 
TiWEHPG in 1 can be understood by considering the factors leading to metal 
complex stability. The two major factors are ligand basicity and coordination 
geometry [33]. Experimental results have suggested that the two isomers of EHPG 
have the same basicities (rac 38.0 and meso 37.9) [33]. Therefore the coordination 
geometry is likely to play a major role. Since the bite angle of a six-membered chelate 
ring [28,44] is about 90-95° and substantially greater than that of a five-membered 
chelate ring (Ca. 70-80°) [28,44], more satisfactory octahedral coordination is 
achieved with both six-membered rings bound to the metal in the equatorial plane that 
contains the five-membered ethylenediamine group. This is the case for (R,R) rac 
conformation in most of the reported metal-EHPG complexes. For the Ti-EHPG 
complexes, Ti'" is seven-coordinate with pentagonal bipyrimidal geometry, which will 
be very strained if any of the six-membered chelate rings bound to the metal is in the 
pentagonal plane. More satisfactory pentagonal bipyrimidal coordination is achieved 
with the six-membered chelate rings in the axial position, which results in the ring-
closed monomer [Ti(ehpg)(H 20)].1 l/3H20 (1) crystallizing as the N(S,S)C(S,S) and 
Ill 
Chapter 3 Ti(JV)-EHPG model complexes 
N(R,R)C(R,R) ((S,S) rac, ASS or iXRR) isomer, and the (R,S) meso ligands forming the 
ring-opened oxo-bridged dimer [{ Ti(Hehpg)(H 20) } 20F 1 3H20 (2). 
Titanium(IV) readily forms complexes with EHPG (rac), a chelating amino acid 
derivative, at neutral pH. This has implications for the mechanism of action of 
titanium anticancer drugs. Ti" is very "hard" and readily hydrolyses to form insoluble 
polymeric species at neutral pH. Both titanocene dichioride and Budotitane undergo 
rapid and complete hydrolysis to form insoluble polymers at physiological pH [2,1 la]. 
However, biological experiments reveal that titanium is accumulated in the cellular 
nucleic acid-rich regions (mainly the nucleus) after in vivo application of titanium 
drugs [7]. Therefore biomolecules must be involved in the stabilisation of Ti" and its 
transport. The present work shows that Ti"' can bind to EHPG (rac) at neutral pH, and 
is thought to bind in a similar manner to transferrin [22]. Both Ti"'-citrate and 
Cp2TiC1 2(aq) can transfer Ti"' to the specific Fe" sites of human apotransferrin at pH 
7.4. Transferrin may therefore serve to deliver Ti"' from the antitumour drug 
Cp2TiCl 2  or Budotitane to cancer cells, which are known to have a higher density of 
transferrin receptors than normal cells [45] and may release the metal in endosomes 
inside cells. This may allow these drugs to target biomolecules such as nucleic acids at 
low pH, or subsequently to bind to other phenolate proteins. Either of these routes 
could result in Ti"' inhibition of DNA synthesis and mitotic activity. Recently, Marks 
and coworkers also suggested that enzymes could also be targets for metallocene 
anticancer drugs [lOa]. Further biological investigations of titanium transferrin or 
other proteins containing Tyr residues are therefore warranted. 
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Chapter 4 
Competitive binding of titanocene dichioride to N,N'-
ethylene-bis-(o-hydroxyphenylglycine) and adenosine 
triphosphate: a model for Ti 1" uptake and release by 
transferrin 
4.1 Abstract 
1 H and 31 P NMR studies show that in aqueous solution the anticancer agent 
titanocene dichioride (Cp 2TiC12) binds selectively to N,N'-ethylene-bis-(o-
hydroxyphenyiglycine) (H 4ehpg) at neutral pH, but preferentially to adenosine 
triphosphate (ATP) at pH*  values below 5.1; intermolecular Ti" transfer from 
[Ti"(ehpg)(H20)] to ATP occurs at acidic pH values. 
4.2 Introduction 
Ti" complexes are of current medicinal interest owing to the pronounced 
antitumour properties and low toxic side-effects of two Ti" complexes, titanocene 
dichioride (Cp2TiC12) and Budotitane [Ti(bzac) 2(OEt)2] (Hbzac = 1 -phenylbutane-
1,3-dione), which are currently in phase II clinical trials [1,2]: Cp 2TiC1 2 also 
exhibits pronounced antiviral, antiinflammatory and insecticidal activities [1]. Some 
Ti" complexes have recently been shown to exhibit antibacterial activity [3,4]. The 
significant effectiveness of Cp 2TiC12 against cisplatin-resistant tumour cell lines 
indicates that it has a different mechanism of action to cisplatin.[2] However, in 
contrast to platinum-based anticancer drugs [5], very little is known about the 
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biological chemistry of titanium and its mechanism of action as an anticancer agent 
is poorly understood [6].  Attack on cellular nucleic acids is believed to be a key 
process for the antitumor activity of Cp 2TiC12, which inhibits DNA synthesis rather 
than RNA and protein synthesis, and titanium accumulates in nucleic-acid-rich 
regions in tumor cells after in vivo or in vitro administration [7,8]. However, unlike 
cisplatin, Ti" does not bind strongly to DNA bases at physiological pH, but forms 
strong complexes with nucleotides only at pH values below 5 [9]. Also, there is no 
evidence for stable complexes of the V or Mo analogues with nucleotides or DNA 
under physiological conditions [6,10]. This raises doubts that nucleic acids are the 
major target [10,11]. Efforts to identify the active Ti" species in biological media 
have been largely unsuccessful due to the rapid hydrolysis of Ti" complexes at 
neutral pH and precipitation of inactive polymeric hydrolysis products [12]. 
It was found recently in this laboratory that Ti"-citrate and Cp 2TiCl2 bind 
strongly to the specific Fe ln sites of human serum transferrin (hTF) and that Ti' s' is 
released from Ti 2-hTF at low pH, which may provide a transport mechanism for Ti" 
[13,14]. Transferrin is the 80 kDa iron-transport protein in the blood serum of 
vertebrates present at a concentration of about 35 pM [15]. It takes up Fe In from 
blood plasma at pH 7.4 and delivers it to cells via receptor-mediated endocytosis. Fe 111 
is released from transferrin in cell compartments called endosomes at pH ca 5.5 [15]. 
The metal binding properties of transferrin have long been mimicked by using the 
chelating agent N,N '-ethylene-bis-(o-hydroxyphenylglycine) (I-Lehpg) [16]. This 
ligand contains donor groups similar to the metal binding sites of transferrin (2Tyr, 
His, Asp and C0 32 ). In particular the two tyrosinate ligands are thought to play a 
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dominant role in determining the strength of metal binding to transferrin [17]. 
Recently I found that, in contrast to its rapid hydrolysis at neutral pH in the absence of 
chelator ligand, Cp 2TiCl2 reacts readily with H4ehpg (rac) at pH*  7 and forms a 
seven-coordinate Ti" complex [Ti(ehpg)(H 20)] (1) [18]. In this chapter, the pH-
dependent competitive binding of Cp 2TiC1 2 to H4ehpg and ATP and the 
intermolecular transfer of Ti" from the EHPG complex to ATP at low pH have been 
investigated. ATP is a potential acceptor ligand for metals released from transferrin 
in cells and also a purine nucleotide present in DNA (as a phosphate monoester). 
These results suggest that novel routes could exist for the transfer of Ti"' onto DNA 
in vivo. 
4.3 Experimental 
Materials. The ligand (H4ehpg, see Figure 4.1) was purchased from Sigma 
Chemical Co. and purified as described previously [19]. No attempt was made to 
separate the racemic R,R/S,S and mesomeric R,S isomers of the ligand, which are 
present in an unspecified mixture in commercial preparations (subsequently 
determined to be Ca. 1:1 in our samples). Cp2TiC12 was purchased from the Arcos 
Chemical Co, and 5'-Adenosine triphosphate disodium salt (ATP) was obtained from 
Aldrich Chemical Co. and used as a freshly prepared aqueous solution. The purity 
was verified by 'H and 31 P NMR spectroscopy. Ti(ehpg)(H 20) (rac) complex was 
synthesised as described in Chapter 1. 
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Figure 4.1 Schematic drawings of ethylenebis[(o-hydroxyphenyl)glycine] (H 4ehpg), 
Cp2TiC1 2 and ATP. 
NMR spectroscopy. 'H (500 MHz or 600 MHz) NMR spectra were recorded 
in D20 on Bruker DMX 500 or Varian 600 NMR spectrometers. 'H chemical shifts 
were referenced to 1 ,4-dioxane (internal). The water resonance was suppressed by 
presaturation. 
Proton-decoupled 31 P NMR spectra were recorded on a Bruker DMX 500 
spectrometer operating at 202 MHz. The reference for 31 P was external 85% H3PO4 . 
The spectra were processed using exponential functions (line-broadening of 1-5 Hz). 
pH measurements. The pH values were determined using a Corning 240 pH 
meter equipped with an Aldrich micro combination electrode, calibrated with Aldrich 
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buffer solutions at pH 4, 7 and 10. The pH-meter readings for D 20 solutions are 
recorded as pH t values, i.e. uncorrected for the effects of deuterium on the glass 
electrode. Adjustments of pH were made with HC1 or NaOH (DC1 or NaOD for 
samples in D20). 
4.4 Results 
4.4.1 pH-dependent Binding of Cp 2TiC12(aq) for EHPG and ATP 
Solution 'H and 31 P{ 'H) NMR experiments were carried out to probe the 
competitive reaction of Cp 2TiCl2(aq) with H4ehpg (rac + meso, ca 1:1) and ATP 
(1:1:1 mol ratio, 5 mM), at different pH*  values in D 20. The 'H NMR spectra 
(purine region and methylene region) and 31 P1 'H) NMR spectra recorded after 6.5 h 
of reaction at 298 K are shown in Figure 4.2. 
At pH*  7.0, peaks due to free EHPG' [6 3.12 and 3.03 ppm, methylene] and 
bound Cp ligand [6 6.42 ppm] nearly disappeared, and new peaks characteristic of 
Ti"'-EHPG complexes [6 2.62 (d) and 2.97 (d) ppm, -CH 2CH2-; 6.72 (d), 7.05 (t) and 
7.40 (m) ppm, phenyl ring] appeared in the 'H NMR spectrum. None of the ATP 
reacted, as indicated by both the 'H and 31 P NMR spectra. At pH* = 5.1, peaks for 
both free H4ehpg and free ATP decreased in intensity and new peaks characteristic of 
Ti''-EHPG and Ti"-ATP complexes [upfield shifted broad peaks for H8 and H2 at 
8.43 and 8.20 ppm, respectively; broad 31 P{ 'H) peak at -24.43 ppm for f3 phosphate, 
broad shoulder at -10.85 ppm for a or/and y  phosphate) emerged in both 'H and 
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31 P( 'H} NMR spectra. Integration of 1 H NMR peaks indicated that Ca. 30% of the 
Cp2TiC12(aq) formed complexes with EHPG and about 36% of Cp 2TiC12(aq) formed 
complexes with ATP. However, at pH* _< 4.6, the free peaks for EHPG remained 
unchanged and no peaks for Ti"-bound EHPG were detected, suggesting that Ti"-
EHPG complexes were not formed. In contrast, new peaks assignable to Ti"-bound 
ATP dominated both the 'H and 31 P NMR spectra, e.g. the broad upfield-shifted H8, 
H2 peaks for ATP, and new upfield-shifted broad peaks for the a, 3 and 7 phosphates 
of ATP. This indicates that Cp 2TiC12(aq) forms complexes with ATP only at these 
lower pH*  values. The broad upfield shifts of H8 and H2 suggest coordination of Ti" 
to N7 [20], (downfield shifts of H8 and H2 are more common for Pt-N7 coordination, 
however, upfield shifts have been established for Cp 2Mo-N7 coordination [20]), and 
the upfield shifts of the new 31 P peaks indicate phosphate coordination. 
The 'H NMR assignments for free EHPG (rac and meso) ligands and Ti"-
EHPG complexes have been established by 2D NMR techniques and their solid-state 
structures have been determined by X-ray crystallography [18]. They are 7-
coordinate with a hexadentate EHPG ligand and an additional water ligand. 
However, efforts to crystallise Ti"-ATP complexes were not successful and their 
structures can not be established from the NMR data alone, although it is evident that 
both N7 and phosphate groups (f3 and y) are involved in Ti" coordination. 
1  EHPG represents the H 4ehpg ligand without designation of the state of protonation. 
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Figure 4.2 1 H (top) 31 P( 'H) (bottom) NMR spectra of reactions of Cp 2TiC12(aq), 
EHPG and ATP (5mM) in D20 at different pH*  values, 298K, after 6.5 h, showing 
that Ti-EHPG complexes are formed at pH* >— 5.1 while Ti-ATP complexes are 
formed at pH* —< 5.1. 
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At pH*  2.6, new 31 P peaks emerged at ca. 0.70 and 0.81 ppm. These can be 
assigned to inorganic phosphate and AMP, respectively, indicating that the phospho-
diester bonds of ATP are cleaved by reaction with titanocene dichloride [9].  These 
results suggest that the affinity of Cp 2TiC12(aq) for EHPG or ATP is pH-dependent. 
At neutral pH, Ti"' is more strongly bound to EHPG, while at acidic pH, it has a 
higher affinity for ATP. The cross-over point is at pH*  ca 5.1, which is comparable to 
the pH value inside the endosome (pH 5.0-5.5) where iron is released from 
transferrin. 
4.4.2 Intermolecular Transfer of Ti(IV) from Ti 1"-EHPG Complex to ATP 
The Ti-EHPG (rac) complex, [Ti(ehpg)(H 20)] (1), is very stable between pH* 
7 to 1 [18], however, unexpectedly, in the presence of ATP, it becomes labile and Ti" 
transfers from the hexadentate ligand to ATP. Figure 4.3 shows the time course of 
the reaction between 1 and ATP monitored by 'H and 31 P NMR at 310K and pH* 
2.80. In the presence of 1 mol equiv of ATP, 'H NMR peaks for 1 [6 2.76 (d) and 
3.12 (d) (methylene), 6 6.82 (d), 7.19 (t) and 7.50 (m) (phenyl ring)] decreased in 
intensity, while, simultaneously, new peaks characteristic of free EHPG [6 3.40(m) 
and 3.56(m) (methylene), 6 7.05(d), 7.10(t), 7.35(d), 7.46(t) (phenyl ring)] appeared 
and increased in intensity with time. This indicates that Ti" dissociates from the 
EHPG ligand. At the same time, the H8, H2 peaks for free ATP decreased in 
intensity, while new H8 and H2 peaks appeared upfield and continued to increase in 
intensity. Also new 31 P peaks emerged in the 3 1  P NMR spectrum (6 0.95, 0.82, -10.00, 
124 












7.5 	7.0 	3.5 3.0 2.5 
1 H(ppm) 







Figure 4.3 Time course of the reaction between Ti(ehpg)(H20) (1) and ATP (1:1) at 
310 K, pH*  2.80 followed by 'H (top) and 31 P{'H} (bottom) NMR, showing the 
gradual dissociation of complex 1 accompanied by formation of Ti-ATP complexes, 
indicating intermolecular Ti'" transfer. 
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-10.47) and increased in intensity with time. These new peaks may be due to the 
species produced from the cleavage of ATP induced by Ti"(such as ADP, AMP and 
inorganic phosphate). Therefore Ti' v is transferred from EHPG to ATP. 
4.4.3 Ti(IV) Transfer at Physiologically Relevant pH Values 
To investigate if intermolecular Ti" transfer can occur at physiologically 
relevant pH values, and the effect of ATP concentration, separate experiments were 
carried out in D 20 at 310 K, using 1:ATP mol ratios of 1:1 or 1:10, at pH*  2.8, 4.4 
and 6.2. The simultaneous decrease in intensity of 'H NMR resonances for 1 and free 
ATP, and increase in intensity of resonances for free EHPG and Ti-ATP adducts, 
confirm that Ti" transfer does occur under these conditions. Figure 4.4 shows the 
time course of Ti"' transfer, as determined by integration of 'H NMR peaks. In the 
presence of I mol equiv of ATP at pH*  2.8, 38% of the Ti" was transferred in 2 d; at 
pH* 4.4, 25% Ti" was transferred, while at pH*  6.2, little Ti" transfer was detected 
over a 2 d period. In the presence of 10 mol equiv of ATP, Ti" transfer was more 
complete and even occurred at pH*  6.2. In 2 d, 83% Ti(IV) was transferred at pH* 
2.8, 41% at pH*  4.4, and 21% at pH*  6.2. A similar reaction was also carried out 
using 5'-GMP instead of ATP at pH*  2.9. Ti'v transfer also occurred, though to a lower 
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Figure 4.4 Time course of intermolecular Ti" transfer from complex 1 to ATP in the 
presence of 1 mol equiv ATP (A) or (B) 10 mol equiv ATP at different pH*  values. 
The data show that both pH and ATP concentration affect the rate of Ti"' transfer. 
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4.5 Discussion 
Titanium transfer reactions to nucleotides mediated by EHPG, a chelator and 
amino acid derivative, may be relevant to the mechanism of action of titanium 
anticancer drugs. In terms of "HSAB" theory [21], Ti"' is a "hard" Lewis acid and 
readily hydrolyses to form insoluble polymeric species at neutral pH values. Both 
titanocene dichloride and Budotitane undergo rapid and complete hydrolysis to form 
anticancer-inactive insoluble polymers at physiological pH values [1]. However, 
biological experiments reveal that titanium is accumulated in the cellular nucleic-acid-
rich regions (mainly the nucleus) after in vivo application of titanium drugs [7,8]. 
Hence Ti"' must be stabilised for transport by binding to biomolecules. Transferrin is 
a likely candidate for Ti" transport from blood plasma to cells [13,14]. The current 
work shows that at neutral pH, Cp 2TiCl2 has a higher affinity for the transferrin model 
ligand EHPG than for ATP while at pH*  values below 5.1 the affinity for the 
nucleotide chelator ATP is higher. Intermolecular Ti n' transfer from Ti"-EHPG 
complexes to nucleotides occurs at low pH or high ATP concentrations. Ti" transfer 
from human transferrin (Ti 2-hTF) to ATP also occurs at low pH[14]. Extra-cellular 
ATP levels are low, but intracellular concentrations of ATP are as high as 3-5 mM 
[22]. Inside cells, ATP is a major metal macrochelator and intracellular iron carrier. 
It plays a major role in transport of Fe IH to the nucleus, and the y-phosphate of ATP is 
hydrolysed during Fe 11' transport [23]. Therefore ATP could also facilitate the 
intracellular transport of Ti"" and allow it to target polynucleotides which are 
condensed in the nucleus. DNA in the nucleus has a high negative charge and 
potentially a markedly lower pH value near its surface (up to 3 pH units lower than the 
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bulk pH [241). Cp2Ti-DNA adducts have been detected in vitro at pH 5.3 [25], and 
Ti-DNA adducts in tumour cells treated with Cp 2TiC12 [2]. 
Metal anticancer agents are often electrophilic and can react with many 
biomolecules, such as amino acids, polyphosphates, proteins and nucleic acids. 
However, these biomolecules are located in different extracellular and intracellular 
compartments, and there are carrier molecules (e.g. proteins such as albumin and 
transferrin, or small molecules such ATP, citrate, and GSH) which communicate 
between them. The substrate binding properties (such as uptake and release) are finely 
controlled by natural gradients which exist in different tissues or cellular 
compartments (e.g. pH, ATP or ionic gradients). The gradients could also alter the 
relative affinity of drug molecules for different cellular components and facilitate drug 
binding to its target. "Hard" Ti" may be transported into the cell by transferrin and 
subsequently bind to DNA at both the negatively-charged phosphates on the backbone 
and base N-donors [6b,26]. The high DNA concentration in the cell nucleus and 
potentially low pH close to the surface of DNA may favour DNA as a target for Ti" 
binding under these conditions. Further work is needed to establish this. 
Ip 
Chapter4 Ti'1' transfer 
4.6 References 
[1](a) Kopf-Maier P, Köpf H, in Metal Compounds in Cancer Therapy,. Fricker SP, 
ed., Chapman & Hall: London, 1994, p. 109. (b). Keppler BK, Friesen C, 
Vongerichten H, Vogel E, in Metal Complexes in Cancer Chemotherapy, Keppler BK, 
ed., VCH, Weinhein, 1993, p. 297. 
[2]Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR, Kerr DJ, 
British J. Cancer, 1998, 77, 2088. 
[3]Schwietert CW, McCue JP, Coord. Chem Rev., 1999, 184, 67. 
[4]Tornieporth-Oetting IC, White PS, Organometallics, 1995, 14, 1632. 
(a) Jamieson EJ, and Lippard SJ, Chem. Rev., 1999, 99, 2467; (b) Reedijk J, 
Chem. Commun., 1996, 801; (c) Reedijk J, Chem. Rev., 1999, 99, 2499; (d) Z. Guo 
and P. J. Sadler, Angew. Chem. mt. Ed. Engi., 1999, 38, 4001 and references therein. 
(a) Kuo LY, Liu AH, Marks TJ, Metal Ions Biol. Sys., 1996, 33, 53; (b) Yang P 
and Guo ML, Coord. Chem. Rev., 1999, 185-186, 189, and references therein. 
Kopf-Maier P and Martin R, Virch. Arch. B Cell Pathol., 1989, 57, 213. 
Kopf-Maier P, J. Struct. Biol., 1990, 105, 35. 
Guo ML, Chapter 6 in this thesis. 
Harding MM, Mokdsi G, Mackay JP, Prodigalidad M, and Lucas SW, Inorg. 
Chem., 1998, 37, 2432. 
Clarke MJ, Zhu F, Frasca DR, Chem. Rev., 1999, 99, 2511. 
Toney JH and Marks TJ, J. Am. Chem. Soc., 1985, 107, 947. 
Sun H, Li H, Weir R, and Sadler PJ, Angew. Chem. mt. Ed., 1998, 37, 1577. 
Guo ML, Sun H, and Sadler PJ, J. Inorg. Biochem., 1999, 154, 150. 
Sun H, Li H, and Sadler PJ, Chem. Rev., 1999, 99, 2817 and references therein. 
(a) Pecoraro VL, Harris WR, Carrano CJ, Raymond KN, Biochemistry, 1981, 20, 
7033; (b) Lin W, Welsh WJ, Harris WR, Inorg. Chem., 1994, 33, 884. 
Li H, Sadler PJ, Sun H, Eur. J. Biochem., 1996, 242, 387. 
Guo M, Sun H, Bihari S, Parkinson JA, Gould RO, Parsons 5, and Sadler PJ, 
Inorg. Chem., 2000, 39, 206-2 15. 
130 
Chapter4 Ti's' transfer 
Pecoraro VL, Harris WR, Carrano CJ, Raymond KN, Biochemistry 1981, 20, 
7033. 
(a) Kuo LY, Kanatzidis MG, and Marks TJ, J. Am. Chem. Soc., 1987, 109, 7207; 
(b) Kuo LY, Kanatzidis MG, Sabat M, Tipton AL, and Marks TJ, J. Am. Chem. Soc., 
1991, 113,9027. 
Pearson RG, in Survey of Progress in Chemistry, Scott A ed., Academic Press, 
New York, 1969, ch. 1. 
Mathews CK, and van Holde KE, in Biochemistry, Benjamin/Cummings Pub. 
Co. Inc., Redwood City, USA, 1990, pp 410. 
(a) Aisen P, Adv. Exp. Med. Biol., 1994, 356, 31; (b) Gurgueira SA, and 
Meneghini R, J. Biol. Chem., 1996, 271, 13616. 
[24]Lamm G and Pack GR, Proc. Nati. Acad. Sci. U.S.A., 1990, 87, 9033. 
[25]McLaughlin ML, Cronan JM Jr, Schaller TR, Sneller RD, J. Am. Chem. Soc., 
1990, 112, 8949. 
[26](a) Guo ML, Yang P, Yang B, Zhang Z, Chinese Sci. Bull. 1996, 41, 1098; (b) 
Yang P and Guo ML, Metal-Based Drugs, 1998, 5, 41. 
131 
Chapter 5 Titanium-transferrin 
Chapter 5 
TiW Uptake and Release by Human Serum Transferrin 
and Recognition of Ti"-transferrin by Cancer Cells: 
Understanding the Mechanism of Action of the Anticancer 
Drug Titanocene Dichloride 
5.1 Abstract: 
The organometallic anticancer agent titanocene dichloride, Cp 2TiCl2 , is now 
on phase H clinical trials as an anticancer drug, but its mechanism of action is 
poorly understood. We show here that the interactions of Cp 2TiC12 with human 
serum transferrin (hTF) and that of Ti 2-hTF with adenosine triphosphate (ATP) 
have characteristics which could allow transferrin to act as a mediator for titanium 
delivery to tumor cells. Such reactions may therefore be important to the anticancer 
activity of this new class of drugs. Cp 2TiCl2 reacts rapidly with human apo-
transferrin under physiological conditions (100 mM NaCl, 25 mM bicarbonate, 4 
mM phosphate, pH 7.4) with carbonate as a synergistic anion. The Cp ligands are 
released from the drug. Two-dimensional ['H, ' 3C] NMR studies of E- [ 13C]Met-
hTF show that Ti" loads the C-lobe first followed by the N-lobe, and binds in the 
specific Fe11' sites. The protein conformational changes induced by Ti" appear to be 
similar to those induced by Fe w. Carbonate can act as a synergistic anion in Ti 2-
hTF but does not appear to be essential. A specific Ti"-hTF adduct is formed even 
in the absence of bicarbonate. When the pH of Ti 2-hTF solution is lowered, no Ti"' 
is released at the endosomal pH of Ca. 5.0-5.5, but one Ti"' dissociates between pH 
4.5-2.0. In contrast, in the presence of 1 mM ATP, all Ti r" is readily released from 
both lobes when the pH is lowered from 7.0 to 4.5. Moreover, Felu displaces Ti" 
rapidly from the C-lobe of Ti 2-hTF (< 5 mm), but only slowly (days) from the N- 
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lobe. Thus the species FeCTiN-hTF  might also provide a route for Ti" entry into 
tumor cells via the transferrin receptor,Ti 2-hTF effectively blocked cell uptake of 
radio-labelled 59Fe-hTF into BeWo,-x.611s, a human placental choriocarcinoma cell 
line in culture. These results imply that titanium transferrin might be recognized by 
the transferrin receptor and taken up into cancer cells. 
5.2 Introduction 
Two classes of Ti'v complexes, organometallic biscyclopentadienyl 
titaniuml'V complexes and bis(13-diketonato)-Ti 1" complexes, have been shown to 
exhibit high antitumor activities against a wide range of murine and human tumors, 
with less toxic side-effects than cisplatin [1,2]. Titanocene dichloride (Cp 2TiC12 , 
Cp = 1 5-05H5) is currently on phase II clinical trials as an anticancer agent [3-5. 
Titanocene dichloride significantly overcomes cisplatin resistance in ovarian 
carcinoma cell lines [6] and also exhibits pronounced antiviral, anti-inflammatory 
and insecticidal activities [7]. In addition, some Ti 1" complexes show pronounced 
anti-bacterial activity [8-10] and 45Ti is potentially useful as a radiopharmaceutial 
[11]. However, in contrast to platinum-based anticancer drugs [12], the biological 
chemistry and mechanism of action of titanium compounds are poorly understood 
[1,2,13]. Attack on cellular nucleic acids is believed to be crucial for the antitumor 
activity of Cp2TiCl2, which inhibits DNA synthesis rather than RNA and protein 
synthesis, and titanium accumulates in nucleic-acid-rich regions of tumor cells after 
in vivo or in vitro administration [7,14,15]. However, unlike cisplatin, Ti'v does not 
bind strongly to DNA bases at physiological pH, but forms strong complexes with 
nucleotides only at pH values below 5 [16]. This and the finding that the vanadium 
and molybdenum analogues fail to form stable complexes with DNA under 
physiological conditions, raise doubts that nucleic acids are the predominant target 
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[13,17,18]. Efforts to identify the biologically-active species have been largely 
unsuccessful due to the rapid hydrolysis of Ti" complexes at neutral pH and 
precipitation of polymeric hydrolysis products [2,19]. 
Recently, a preliminary finding that Ti" binds strongly to the serum 
transport protein transferrin has been reported by this laboratory [20,21]. This was 
subsequently confirmed by other workers [22], and suggests that transferrin may 
mediate the uptake of Ti from the anticancer drug into cells. Transferrin is an 80 
kDa glycoprotein present in blood plasma at a concentration of ca 35 .tM. It has 
two specific Fe' 11 binding sites, one in the N-lobe and one in the C-lobe, each 
providing approximately octahedral coordination from two Tyr, His, Asp and 
bidentate carbonate (synergistic anion) ligands (see Figure 5.1). The major receptor 
recognition sites on hTF are thought to be localized on the C-lobe [23-26], 
supported by the recent X-ray crystal structure of the human transferrin receptor 
[25]. Transferrin in human serum is only 30% saturated with iron and the vacant 
sites can bind other metal ions [35,36]. It has been suggested that transferrin can act 
as a natural carrier for anticancer metal ions [36] as well as other chemotherapeutic 
drugs [26], since there are high levels of transferrin receptors on the surface of 
tumor cells [27-30], possibly due to their increased requirement of iron for 
metabolism, growth and development. Indeed, it has been suggested that 
transferrin is responsible for the transport and delivery of metal ions such as 67Ga']' 
and Ru to cancer cells [31,32]. Transferrin takes up Fe m at pH 7.4 and delivers it 
to cells via receptor-mediated endocytosis [33]. The general features of this process 
are now well understood [34-36]. First, Fe m binds to apo-hTF and induces a major 
conformational change of the protein, from lobe-open to lobe-closed form. Then, 
the iron-saturated holo-hTF binds to the specific transferrin receptors on the cell 
surface and is internalized by clathrin-coated vesicles into endosomes. Here the pH 
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is mildly acidic (pH ca 5.0-5.5) and Fe is released from the transferrin. ATP is a 
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Figure 5.1 Schematic drawing of the structures of ATP, Cp 2TiC12 and Fe(Ill) 
binding sites in hTF. 
A detailed study was carried out here on the uptake of Ti" from the 
anticancer agent Cp 2TiC1 2 by human transferrin at blood plasma pH values, release 
of bound Ti'v to ATP at cellular endosomal pH values, displacement of Ti" by 
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Fe11 , as well as the uptake of Ti 2-hTF into BeWo placental cancer cells. These 
studies may shed light on how titanium anticancer complexes are activated in vivo, 
as well as on the rational design of more active and less toxic metallo-drugs. 
5.3 Materials and Methods 
Materials. Apo-hTF was purchased from Sigma (catalogue no: T0519) and 
washed three times with 0.1 M KC1 to remove low molecular mass impurities using 
Centricon 30 ultrafilters (Amicon). Titanocene dichloride was purchased from 
Arcos Chemical Co. and was used in all the experiments as a freshly prepared 
DMSO/saline (0.1 M NaCl; 1/9,v/v) solution at 277 K, as in reported in vivo 
experiments [14,15]. This stock solution was ca. 10-20 mM and was used within 5 
h. 5'-Adenosine triphosphate disodium salt (ATP) was obtained from Aldrich 
Chemical Co. and used as a freshly prepared aqueous solution. The purity was 
verified by 'H and 31 P NMR spectroscopy. NaHCO3 (Aldrich), nitrilotriacetic acid 
(H3NTA, Aldrich), Hepes (Aldrich), NaH' 3CO3 (MSD isotopes, >99% enriched) 
and 59FeC13 (Amersham, in 0.1 M HC1) were used as received. 59Fe-hTF was 
prepared by incubating apo-hTF with 59FeCl3 in the presence of NaHCO 3 . 
Recombinant -[13CH3]Met-hTF  was supplied by Professor R.C. Woodworth and 
Dr. A. B. Mason (University of Vermont) and was prepared as previously described 
[38,39]. All other chemicals were reagent grade and were used as received. For all 
the UV experiments, a freshly prepared physiological buffer was used with final 
concentrations of 4 mM NaH2PO4, 100 mM NaCl and 25 mM NaHCO3 (pH 7.4). 
A solution of [Fe(NTA) 2] was prepared from the iron atomic absorption 
standard solution and 2 mol equiv of H 3NTA. The pH was slowly raised to 5.5 with 




UV-Vis Spectroscopy. Apo-hTF solutions were prepared by diluting aliquots 
of a stock apo-hTF solution to Ca. 2.5x10 5 M with physiological buffer, pH 7.4. 
The hTF concentrations were determined spectrophotometrically using c280 93,000 
M'cm [40]. UV difference spectra after addition of Cp 2TiC12 to apo-hTF were 
recorded immediately and at different time intervals. For titration experiments, 
aliquots of Cp 2TiC12 (0.5-10 M 1  ) were added and the solution was left to equilibrate 
at 298 K for 30 mm. The binding or release of Ti n' was monitored by the increase 
or decrease in absorbance at 321 nm. All the UV experiments were performed with 
1 cm cuvettes on a computer-controlled Shimadzu UV-1000 spectrometer with 
temperature control at 298 K or 310 K. 
NMR Spectroscopy. Apo-transferrin was dissolved in 0.1 M KC1 in 
D201H20 (10%/90%) containing 10 mM NaHCO3 . The pH was adjusted to 7.4 ± 
0.1, when necessary, using NaOH and HC1 (0.1 M). The pH*  values (meter 
readings) of NMR solutions were recorded before and after NMR measurements. 
'H NMR spectra were recorded on a Bruker DMX 500 spectrometer at 500 
MHz, using 0.6 ml of hTF solution (Ca 0.8 mM) in 5-mm tubes at 298 K, using Ca. 
1000 transients, 6 lis (50°) pulses, 1.8 s recycle time, 16,384 data points, and water 
suppression via presaturation. The chemical shift reference for 'H was sodium 
trimethylsilyl-d4-propionate (TSP) via endogenous formate (8.465 ppm, pH*>  7) 
Resolution enhancement of the spectra was achieved by processing the free 
induction decays with a combination of unshifted sine-bell and exponential 
functions (line broadening of 1.5-20 Hz) on a Silicon Graphics computer using 
XWIN-NMR software. 
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Proton-decoupled 13C and 31 P NMR spectra were recorded on a Bruker 
DMX 500 spectrometer operating at 125 and 202 MHz, respectively. Typically, 
30,000 and 1000-2000 transients were collected using a pulsewidth of 6 J.LS (500), 
relaxation delay 2 s, and 16,384 data points. The 1 3C reference was external TSP, 
and for 31 P was external 85% H3PO4 . The spectra were processed using exponential 
functions (line-broadening of 5-20 Hz). 
NMR samples of E-[13C]Met-hTF  (Ca. 0.26 mM) were prepared in 0.1 M 
KC1 in D20/H20 (30%/70%), and pH values were adjusted to 7.4 ± 0.1 using 
NaOH or HC1. Sodium bicarbonate in D 20 (0.25 M) was added to transferrin 
solutions to give a concentration of 10 mM. After addition of Cp 2TiCl2 to protein 
samples to give drug: protein mol ratios of up to 2:1, the pH was readjusted to 7.4 ± 
0.1, and the samples were left 30 min at 298 K for equilibration. 
2D ['H, 13C] HSQC spectra [41] were acquired on a Bruker DMX 500 
spectrometer at 298 K. The sequence was optimized for 'J('H-' 3C) = 136 Hz, and 
16-32 transients were acquired using 2,048 data points in the f2 dimension ('H), 
32-64 increments of t,, 13C frequency width of 3,000 Hz (swi), and relaxation 
delay of 1.6 s, giving a total of ca. 30 min to 1 h for the acquisition of each 
spectrum. The GARP-1 sequence [42] was used to decouple 13C. After zero-filling 
to 2,048 x 512 points, unshifted-Gaussian functions were used for processing. The 
residual water signal was suppressed by a combination of presaturation and pulsed-
field gradients. Peaks were referenced to TSP via the c-CH 3 peak of L-methionine 
(external, 15.14 ppm) for 13C, and via formate (8.465 ppm, present as a minor 
impurity) for 'H. 
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Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES). 
This was performed on a Thermo Jarrell Ash IRIS spectrometer using standard 
methods. Metal-loaded protein was purified by using Centricon 30 (Amicon) 
ultrafilters and washing three times with ultra-purity water followed by 
ultrafiltration after each washing. The final protein solution was diluted with ultra-
purity water, and titanium and iron contents were measured without digestion of the 
sample. 
pH Measurements. The pH values of the solutions were adjusted with HCl 
or NaOH (DC1 or NaOD for samples in D 20 solution) and determined using a 
Corning 240 pH meter equipped with an Aldrich micro combination electrode, 
calibrated with Aldrich buffer solutions at pH 4, 7 and 10. The pH-meter readings 
for D20 solutions are recorded as pH*  values, i.e. uncorrected for effect of 
deuterium. 
Bicarbonate-free Experiments. All the solutions were freshly prepared using 
ultra-pure water and were bubbled thoroughly with high-purity helium to remove 
residual CO2 . Anaerobic UV cuvettes were used to prevent CO 2 contamination 
from the air. Similar experiments in the presence of NaHCO3 were also carried out 
for comparison. 
Cell Culture Experiments. BeWo cells were cultured to 80% confluence in 
Ham's F12 medium plus 10% fetal calf serum, with glutamine, penicillin and 
streptomycin. The cells were washed three times with balanced salt solution (BSS, 
136 mM NaCl, 5 mM KCI, 1 mM CaCl 2, 1 mM M902, 18 mM Hepes, pH 7.4.) and 
incubated in balanced salt solution containing 0.5 l.LM 59Fe-hTF for 1 h at 310 K in 
the presence or absence of competing metal transferrin complexes, at increasing 
139 
Chapter 5 Titanium-transferrin 
molar ratios. Following incubation, the cells were washed three times with balanced 
salt solution and incubated with Pronase (1 mglmL) for 30 min at 277 K. They were 
aspirated from the plate into Eppendorf tubes, and centrifuged at 14,000 g for 1 mm. 
The supernatant was removed and counted, representing surface-bound 59Fe. The 
pellet was resuspended in 1 mL BSS, sonicated and 100 jiL was removed for DNA 
analysis. The remaining 900 pL was counted representing intracellular 59Fe [43]. 
All values were calculated as cpm/p.g DNA and are the mean ±SEM of four 
experiments, each performed in triplicate. DNA was analysed using Hoechst dye as 
previously described [43]. 
5.4 Results 
5.4.1 Uptake of Ti" by apo-hTF 
Reactions of human serum transferrin, recombinant isotopically-labelled 
human transferrin (-[ 13C]Met-hTF with > 95% c-' 3CH3 enrichment at all nine Met 
residues) with the anticancer complex Cp 2TiCl2
. 
TiI'V  release to ATP, and 
displacement of Ti" by Fe ln were studied by UV-Vis spectroscopy, ICP-AES 
spectrometry and one-dimensional 'H, 13C, 31 P and 2D ['H, 13C] NMR 
spectroscopy under physiologically-relevant conditions. 
Uptake of TiIV  by apo-hTF from Anticancer Drug Cp 2 TiC12 under 
Physiologically Relevant Conditions Reactions of the anticancer drug Cp 2TiCl2 
with human serum apo-transferrin in physiological buffer (100 mM NaCl, 4 mM 
phosphate, 25 mM bicarbonate, pH 7.4) were studied initially using UV-Vis 
spectroscopy. When 2 mol equiv of Cp 2TiC12 was added to an aqueous solution of 
apo-hTF (2.4 x 10 M) at 310 K, two new sharp bands at 242 and 295 nm and a 
new broad band at 321 nm appeared immediately in the difference spectrum, and 
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increased in intensity over a period of 5 mm. There was little further change in the 
spectrum over a period of 24 h. 
A titration to investigate the stoichiometry of Ti" binding was performed 
under similar conditions, but at 298 K. Selected UV difference spectra at 
equilibrium are shown in Figure 5.2. A plot of AA32 1 against the molar ratio (r) of 
Cp2TiC12 to apo-hTF is shown in Figure 5.3. It can be seen that with the increase 
of r, the three UV bands near 242, 295 and 321 nm increase in intensity and reach a 
plateau at r = 2, which suggests that two Ti"" ions bind strongly to transferrin (i.e. 
one in each lobe). The value of the extinction coefficient for the broad band at 321 
nm is 4,830 M'cm' based on protein concentration. The resulting yellow Ti 2-hTF 
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Figure 5.2. Reaction of Cp 2TiC12 with apo-hTF gives rise to new bands in the UV 
difference spectrum after addition of various mol equiv of Cp 2TiC12. Conditions: 
25 MM apo-hTF in 100 mM NaCl, 25 mM HCO3, 4 mM NaH2PO4, pH 7.4, 298 K. 
Ratio (TiIhTF) from bottom to top: 0.41, 0.82, 1.27, 1.64 and 2.05. 
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Figure 5.3. Titration curve for the reaction of Cp 2TiC12 with apo-hTF. The increase 
in intensity of the LMCT band at ca 321 nm is plotted against the ratio [Ti]/[hTF] 
(r). Conditions: as Fig. 5.2. 
'H NMR studies were carried out to investigate the structural changes in 
hTF induced by reactions with Cp 2TiC12. Aliquots of a solution of Cp 2TiC12 (0-2 
mol equiv, freshly prepared in DMSO-d/saline, 1/9, v/v) were added to a solution 
of apo-hTF in 0.1 M KC1 (D 20/H20, 10%/90%) containing 10 mM bicarbonate, pH 
7.4. 'H NMR spectra of hTF are complicated by the overlap of a large number of 
resonances from this large molecule (80 kDa). However, some regions of the 'H 
NMR spectrum are sensitive to metal binding to the specific iron sites of the 
protein [44]. The region near 2 ppm contains resonances due to the N-acetyl 
groups of the NAcGlc and NAcNeu residues in each of the two biantennary glycan 
chains attached to Asn-413 and Asn-611 in the C-lobe of the protein [39,45,46]. 
The high-field region (0.5 to —1 ppm) consists mainly of ring-current shifted 
resonances, including those from groups in hydrophobic patches near the specific 
metal binding sites in both the N-lobe and the C-lobe of the protein [47]. The 500 
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MHz 'H NMR spectrum of the N-acetyl region is shown in Figure 5.4. After 
addition of the first mol equiv of Cp2TiC12, two new sharp peaks appeared at 2.07 
and 2.03 ppm, together with a broad weak peals at 2.10 ppm. No further changes 
occurred in this region on addition of the second equivalent of Cp 2TiC12. The 
changes which occurred in the high-field region of the 500 MHz 'H NMR spectrum 
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Figure 5.4 Resolution-enhanced 500-MHz 'H NMR spectra of hTF showing the 
effect of Cp 2TiC12 on the N-acetyl region. Bottom, 0.8 mM apo-hTF in 0.1 M KC1, 
10 mM bicarbonate, pH 7.4; middle, after addition of 1.0 mol equiv; and top, after 
addition of 2.0 mol equiv of Cp2TiC12(aq). 
'H NMR studies were also carried out to investigate whether the Cp ligands 
are displaced during reaction of Cp 2TiC12 with hTF. Ti"-bound Cp exhibits a 
singlet at 6.42 ppm at neutral pH, while released Cp (CpH) shows two multiplets at 
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6.57, 6.62 ppm and a weak multiplet at 2.95 ppm [19]. 500 MHz 'H NMR spectra 
recorded over the period 10-40 min during reaction of 1 mol equiv of Cp 2TiC12 with 
apo-hTF in the presence of 10 mM bicarbonate at pH 7.4, 298 K, are shown in 
Figure 5.5. It can be clearly seen that a strong singlet for Ti"-bound Cp at 6.42 
ppm is present after 10 mm, and that two broad peaks at 6.57 and 6.62 ppm are 
already discernible. The latter peaks continued to increase in intensity at the 
expense of the peak at 6.42 ppm. After 30 mm, the peak at 6.42 ppm had nearly 
disappeared and the peaks at 6.57 and 6.62 ppm had attained their maximum 
intensities. With addition of a second mol equiv of Cp 2TiC121  similar changes in 
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Figure 5.5 500 MHz 'H NMR showing the displacement of Cp from Cp 2TiC12 
during reaction with apo-hTF. Time dependence spectra of 0.8 mlvi apo-hTF in 0.1 
M KC1, 10 mM bicarbonate, pH 7.4 after addition of 1.0 mol equiv of 
Cp2TiC12(aq). 
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Figure 5.6 Detection of carbonate binding as synergistic anion during reaction of 
apo-hTF with Cp 2TiCl2
. 13C NMR (125 MHz) spectra of (A) apo-hTF (1.0 mM, 4 
mM 13C-bicarbonate in 0.1 M KC1, pH 7.2); (B) after addition of 2.0 mol equiv of 
Cp2TiC12(aq). 
13C NMR studies were carried out to investigate whether the binding of Ti" 
to hTF also involved concomitant binding of carbonate as synergistic anion. The 
carbonyl region of a 125 MHz 13C NMR spectrum of apo-hTF in the presence of 4 
mol equiv of H' 3CO3 (4 mM, enriched to > 99% in 13C), and after addition of two 
mol equiv of Cp2TiC12 is shown in Figure 5.6. In the absence of Cp 2TiC12, a sharp 
peak at 161.1 ppm due to H' 3CO3 was observed, together with a broad envelope at 
173-183 ppm corresponding to the backbone and side-chain carbonyls of apo-hTF 
(natural abundance 13C) [48]. In the presence of Cp 2TiC12, the peak due to free 
H' 3CO3 decreased in intensity markedly, and a new peak assignable to Ti-0O 3-hTF 
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appeared at 166.5 ppm. This peak is weak and has a chemical shift comparable with 
.3-,- that for hTF loaded with other diamagnetic metals (such as Ga3-,-  , Bi , CO3- ), and 
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Figure 5.7. Time dependence of UV difference spectra of reaction of Ti 2-hTF 
(formed in the absence of carbonate) with NaHCO 3 . Conditions: 5 mM (final 
concentration) was added to 45 j.iM Ti2-hTF (formed in the absence of carbonate) in 
10 mM Hepes, pH 7.3, 298 K. Time from top to bottom: 0, 1, 5, 10, 20, 30, 60 miii 
and 16 h. 
Ti" binding to apo-hTF under bicarbonate-free conditions. To investigate 
whether carbonate as synergistic anion is essential for Ti 11' binding to apo-hTF. 
comparative UV-Vis and 'H NMR experiments were performed in the absence or 
presence of bicarbonate. In the absence of bicarbonate, the reaction of 2.0 mol equiv 
of Cp2TiCl2 with apo-hTF (30 tM) in 10 mM Hepes buffer, pH 7.4, 298 K, give 
rise to three new bands in the UV-Vis difference spectrum at Ca. 242, 295 and 315 
nm, which increased in intensity over a period of I h. Similar UV-Vis changes were 
observed in the presence of 5 mM bicarbonate and at the same apo-hTF 
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concentration, but the reaction was faster (0.5 h) and the intensities of the bands 
were lower at equilibrium (Ca. 26% lower at 315 nm). However, when NaHCO 3 (5 
mM final) was introduced into the Ti 2-hTF solutions formed under bicarbonate-free 
conditions, the bands decreased in intensity markedly over a period of 4 h (see 
Figure 5.7), and the final UV-Vis difference spectrum was nearly identical to that 
for Ti 2-hTF formed in the presence of bicarbonate. 
To investigate possible structural differences between Ti 2-hTF adducts 
formed in the absence and in the presence of bicarbonate, 'H NMR experiments 
were performed. When Cp 2TiC12 was added into the apo-hTF solution (0.7 mM), a 
yellow color developed. However, the changes in NMR peaks in the absence of 
bicarbonate were quite different from those in the presence of bicarbonate (vide 
infrã). In the glycan N-acetyl region near 2 ppm, there was little change when 1.0 
or 2.0 mol equiv of Cp2TiC12 was added in the absence of bicarbonate, in contrast 
to the marked changes in the presence of bicarbonate (see Figure 5.4). These peaks 
remained unchanged even when 10 mM NaHCO 3 was introduced into the solution. 
In the high field region (see Figure 5.8), the changes to peaks in the absence of 
bicarbonate were also different from those in the presence of bicarbonate when 1.0 
or 2.0 mol equiv of Cp2TiCl2 was added to the apo-hTF solution. When 10 mM of 
bicarbonate ( 13C enriched) was introduced after the reaction of Cp 2TiC12 and apo-
hTF in the absence of bicarbonate, some peak changes in the high field region 
occurred slowly but the final spectrum was not identical to that for Ti 2-hTF formed 
in the presence of bicarbonate (Figure 5.8). A 13C NMR spectrum recorded after 
introducing NaH' 3CO3 , contained a small peak at 166.5 ppm, but this disappeared 4 
days later. 
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Figure 5.8 A comparison of the effects of Cp 2TiC12 on the high field region of 
resolution-enhanced 500-MHz 'H NMR spectra of hTF in the presence and in the 
absence of bicarbonate. 
5.4.2 Order of lobe loading of apo-hTF with Ti". 
2D ['H, "Cl NMR spectra of recombinant non-glycosylated human 
transferrin with > 95% -' 3CH3 enrichment at all nine Met residues (for locations, 
see Figure 5.9) were obtained using inverse detection techniques [49,50]. 
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Figure 5.9 The locations of the nine Met residues in hTF (coordinates from the 
crystal structure of hTF with Fe(HI) in C-lobe and N-lobe no metal; Zuccola HJ, 
PhD thesis, Georgia Institute of Technology, Atlanta, GA, 1993) 
When 0.65 mol equiv of Cp2 TiC12 was added to recombinant apo-hTF at pH 
7.4 in the presence of 10 mM Nal-1CO 3 , the cross-peak for Met-464 in the C-lobe 
of the protein decreased markedly in intensity (Figure 5.10), and a new strong peak 
shifted ca. 2 ppm downfield in the ' 3C dimension and ca. 0.2 ppm upfield in the 'H 
dimension appeared concomitantly. The cross-peak for C-lobe Met-499 (1.86/15.65 
ppm) split into two peaks with the new peak appearing slightly to low field in both 
' 3C and 'H dimensions. With 1.0 mol equiv of Cp 2TiC12 present, the original cross-
peaks for Met-464 and Met-499 had disappeared almost completely and the new 
peaks at 1.12/18.32 ppm and 1.89/15.68 ppm had increased in intensity; similarly, 
the cross-peak for Met-499 had almost completely shifted to its new position. Also, 
a cross-peak assignable to Met-389, which was not observed for the apo-protein, 
appeared after addition of 1.0 eq of Cp 2TiCl2 (Fig. 5.10). When the second mol 
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C-lobe Met residues, but shifts were observed for the cross-peaks of the N-lobe 
residues Met-26, Met-309 and Met-313. 
ppm 
' S c 16 
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Figure 5.10. Detection of the order of lobe loading of hTF with Ti'. 2D [ 1 H,' 3C] 
HSQC spectra of -' 3CH3-Met-hTF (0.26 mM in 0.1 M KC1, 10 mM bicarbonate, 
pH* 7.4) and after addition of 0.65, 1.0 and 2.0 mol equiv of Cp2TiC12. The solid 
boxes indicate initial peaks and dotted boxes show new peaks. There are specific 
shifts of cross-peaks for the C-lobe residues Met-464 and Met-499 on binding to 
the first equiv of Cp 2T1C12 and N-lobe residues Met-309 and Met-3 13 on binding 
the second equiv of Cp2TiC12. The assignments are based on refs 39 and 50. 
5.4.3 Ti" Release from Ti 2-hTF 
pH-induced Ti'1' Release from Ti 2-hTF. The pH-dependent properties of 
Ti 2-hTF (obtained from the reactions of Cp 2T1C12 with apo-hTF in physiological 
buffer) were investigated over the pH range of 2 to 10 by introducing aliquots of 
HCl or NaOH (0.5-3.0 M), and the absorbance at 321 nm (ligand-to-metal-charge-
transfer LMCT band) was then measured after incubation at 298 K for I h. No 
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absorbance change at 321 nm was evident over the pH range of 5.0 to 9.5 (see 
Figure 5.11), suggesting that Ti 2-hTF is stable over this pH range. Below pH 5, the 
absorbance at 321 nm decreased and plateaued to Ca. 53% of its initial value by pH 
2, implying cleavage of Ti 1"-tyrosinate bonds in the protein. Ti 2-hTF was stable at 
alkaline pH with a small decrease in A321 only at pH> 9.5 (Figure 5.11). 
Tifl' Release from Ti 2-hTF in the Presence of ATP. In the presence of 1 mM 
ATP, the A321 value for Ti2-hTF decreased sharply over the pH range 7.4 to 5.0, 
and by pH 4.5 was the same as that of apo-hTF in the presence of the same 
concentration of ATP (Figure 5.11). This suggests that Ti" is completely released 
from Ti 2-hTF under these conditions. This contrasted with the partial release of Ti" 
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Figure 5.11 pH dependent profile of Ti" release from Ti 2-hTF and the effect of 
ATP. Conditions: 20 pM Ti2-hTF in 100 mM NaCl, 25 mM HCO3 , 4 mM 
NaH2PO4, 298 K, in the absence (open circles) or presence (closed circles) of 1 
mM ATP, as monitored by the Ti"-tyrosinate charge-transfer band at 321 nm. 
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Figure 5.12. Effect of Ti 2-hTF on the 202 MIEIz 31 P{'H} NMR spectra of ATP at 
different pH values. Conditions: ATP:Ti 2-hTF = 2:1, 1.0 mM Ti2-hTF in 0.1 M 
KC1, 70% H20/30% D20, spectra recorded after equilibration at 298 K for 0.5 h. 
A 31 P {'H} NIvIR pH titration was carried out to investigate further the role 
of ATP (see Figure 5.12) in facilitating Ti" release from T1 2-hTF. A solution of 
purified T1 2-hTF in the presence of 2 mol equiv of ATP was titrated over the pH 
range 7.5 to 4.5 in ca. 0.5 pH unit steps, each equilibrated at 298 K for ca. 30 mm 
before the 31 P{'H} spectrum was recorded. A similar pH titration of ATP at the 
same concentration but in the absence of Ti 2-hTF was also studied for comparison. 
The 31 P NMR spectrum of ATP alone at pH 7.0 shows doublets at -6.97 ppm and 
-10.38 ppm and a triplet at -21.20 ppm, assignable to.the y,  a and 13  phosphate 
groups, respectively [51]. These shifts changed only slightly over the pH range of 
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8.0 to 4.0 and no hydrolysis was observed. However, in the presence of Ti 2-hTF, a 
new 31 P{ 'H} peak assignable to inorganic phosphate [16] appeared at 2.72 ppm 
even at pH 7.5, as shown in Figure 5.12. This peak continued to increase in 
intensity and shift to higher field as the pH was lowered. Also, at pH 6.0, a new 
31 P{ 'H} doublet appeared to high field of the y  phosphate signal and continued to 
increase in intensity at the expense of the y phosphate signal as the pH was lowered. 
However, there was little change in the a phosphate peak. In the 1 H NMR 
spectrum, peaks for H8, H2 and Hi' of ATP gradually lost intensity when the pH 
was lowered and had almost disappeared by pH*  4.5. 
5.4.4 Fe" Displacement of Ti" from Ti 2-hTF. 
When 2.5 mol equiv of Fe(NTA) 2 was added to a solution of Ti 2.hTF 
(physiological buffer, pH 7.4, 298 K), a new broad band in the visible region 
centered at ca. 465 nm appeared in the difference spectrum and gradually increased 
in intensity over a period of about 30 h (Figure 5.13). The reaction appeared to 
proceed in two phases: a first fast phase lasting about 7 min and accounting for ca 
50% of the total increase in intensity at 465 nm, and a second slower phase lasting 
for about 30 h, which accounted for the remaining 50% increase in intensity at 465 
nm. The second phase itself appeared to consist of two steps with the initial stage 
lasting from 7 min to ca. I h. Increases in intensity at > 438 nm were accompanied 
by decreases in intensity at < 438 nm. An isobestic point was observed at 438 nm 
during this period, indicating a two-state mechanism. The second step lasted for up 
to 30 hours with increases in intensity around 472 nm. Also the absorption 
maximum at 465 nm which was seen during the first phase, shifted to 472 nm 
during the second phase. 
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Figure 5.13 The dependence of the difference absorption spectrum of Ti 2-hTF on 
time after addition of 2.5 mol equiv of Fe(NTA) 2. Conditions: 19.4 pM Ti 2-hTF in 
100 mM NaCl, 25 mM HCO3 , 4 mM NaH2PO4 , pH 7.4, 298 K. The appearance of 
new band centred ca 465 nm is indicative of Ti'Y displacement by Fe 11' at the 
specific metal sites in transferrin. 
The order of displacement of Tn from the two lobes by Feul was 
established by 2D ['H, ' 3C] HSQC NMR studies using g-' 3CH3-Met labelled 
recombinant human transferrin. In order to fully load the protein with Ti", 2.5 mol 
equiv of Cp 2TiC12 was added to the labelled apo-protein in the presence of 10 mM 
of NaHCO 3 . A yellow color developed quickly, and the 2D ['H, 13C] HSQC NMR 
spectrum was identical to that in Figure 5.10, indicating formation of Ti 2-hTF. 
Aliquots of Fe"(NTA) 2 solution were added to the Ti 2-hTF solution at pH 
7.4 to give Fe: hTF mol ratios of 0.5: 1 to 2.0: 1 (in steps of 0.5 mol equiv, with 
equilibration for 30 min at 298 K before recording the spectrum). The color of the 
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Figure 5.14, the addition of the first 0.5 mol equiv of Fern  to Ti2-hTF led to a 
dramatic decrease in intensity of the cross-peaks for Met-464 and Met-499 of Ti 2-
hTF, and was accompanied by the appearance of two new peaks at slightly lower 
field in the 'H dimension. With 1.0 mol equiv of Fern  present, the original cross-
peaks for Met-464 and Met-499 of Ti 2-hl'F completely disappeared as did the 
cross-peak for Met-389. No shifts were observed for the cross-peaks of the Met 
residues in the N-lobe although the peaks Met-309 and Met-3 13, which are in the 
interlobe contact region, decreased in intensity (Figure 5.14). With 1.5 and 2.0 
mol equiv of Fe" present, no further changes to these C-lobe peaks was observed, 
but shifts of the cross-peaks for Met residues in the N-lobe, Met-109, Met-309 and 
Met-3 13 developed over a period of several hours: a 2D HSQC NMR spectrum 
recorded 0.5 h after addition of 1.5 equiv of Fe(NTA)2 revealed that Met 313 had 
split into two peaks but there was little change in the other cross-peaks (data not 
shown). However, 2 h after addition of 2.0 mol equiv of Fe(NTA) 2, new-cross 
peaks were observed for Met-309 and Met-109, shifted to slightly lower field in the 
'H dimension (Fig. 5.14). The above sample (with 2.0 mol equiv of Fe" present) 
was left at ambient temperature for 3 d, at which time some white precipitate was 
visible in the solution. The 2D ['H, 13C] HSQC NMR spectrum at this time was 
almost identical to that observed for Fe 2-hTF [49]. An interesting feature in Figure 
5.14 is the presence of an additional 'H/' 3C cross peak at 1.72/16.03 ppm (marked 
by *) which is not present in the spectra of either Ti 2-hTF or the final protein Fe 2-
hTF. It was most intense during the addition of the first equiv of Fern  and had 
disappeared by the time the final spectrum was recorded. 
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Figure 5.14. Determination of the order of displacement of Ti" from the N- and C-
lobes of Ti2-hTF by Fe'11 . 2D ['H,' 3C] HSQC spectra of c-[' 3CH3]Met-Ti2-hTF 
(0.26 mM in 0.1 M KC1, 10 mM bicarbonate, pH 7.4) after addition of 0.5 (0.5 h), 
1.0 (0.5 h), 2.0 (2 h) and 2.0 (3 d) mol equiv of Fe(NTA) 2 (equilibrated for the 
periods specified). The solid boxes indicate initial peaks and dotted boxes show 
new peaks. The spectrum of Ti 2-hTF alone is shown in Fig. 5.10. The specific 
shifts of cross-peaks for the C-lobe residues Met-464 and Met-499 on binding to 
the first mol equiv of Fern,  and N-lobe residues Met-309 and Met-109 on binding 
the second mol equiv of Fe' 11 are notable. An additional cross-peak marked with an 
asterisk (*) also appeared during the course of the titration but had disappeared by 
the time the final spectrum was recorded. 
5.4.5 ICP-AES Studies. 
In order to further confirm the displacement of Ti" by Fern,  the metal 
content of hTF at various stages of the titration of Ti 2-hTF (19.4 1.tM) with 
Fe(NTA)2 (2.5 mol equiv) in physiological buffer (pH 7.4) was determined by 
inductively coupled plasma atomic emission spectrometry (ICP-AES). After 
incubation at ambient temperature (Ca. 293 K) for various times, the sample was 
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ultrafiltered and the protein was purified by washing three times with ultra-pure 
water followed by ultrafiltration (Centncon 30). The metal (Ti and Fe) content was 
measured without digestion of the protein. The results are shown in Figure 5.15. 
For Ti2-hTF without added Fe(NTA)2, the TiIhTF ratio was determined to be 2.03, 
and FeIhTF ratio 0.03. After 5 min of reaction of Fern  with Ti2-hTF, the TiJhTF 
ratio was 1.08 and Fe/hTF ratio 0.94, i.e., nearly half of the protein-bound Ti n' had 
been displaced by Fern.  One hour later, the Ti/hTF ratio was 0.94 and Fe/hTF ratio 
1.02; 18 h later, the Ti/hTF ratio was 0.77 and Fe/hTF 1.17, confirming a slow 
displacement of TiW  by  Fern  during the second phase. One-week later, a small 
amount of white precipitate developed, and only the supernatant was used for metal 
determinations. This gave a TiJhTF ratio 0.04 and Fe/hTF 1 93, indicating that Ti" 
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Figure 5.15. Time dependence of the displacement of Ti"' from Ti 2-hTF by Fe111 . 
Metal contents were measured by ICP-AES. Note the rapid displacement of one 
Ti" by Fern  followed by a much slower displacement of the second Ti". 
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5.4.6 Cell Uptake Studiest. 
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Figure 5.16. The effect of increasing concentration of metal transferrins on uptake 
of 59Fe from 59Fe-hTF by BeWo cells. Cells were incubated with 0.5 jtM 59Fe-hTF 
in the presence or absence of 0.1 pivI, 1 j.iM or. 10 j.tM metal-transferrins (Fe 2-hTF, 
Ga2-hTF, Ti2-hTF, Bi2-hTF) and apo-hTF. Data are expressed as a percentage of 
untreated control cells (100%). (a), Membrane-bound 59Fe; (b), intracellular 59Fe. 
In order to investigate whether Ti 2-hTF can be recognized by transferrin 
receptors and subsequently taken up into cells, Ti 2-hTF was incubated with 
placental BeWo cells in competition with 59Fe radiolabelled Fe2-hTF. 
Competitions between 59Fe-hTF and Bi 2-hTF, Ga2-hTF, Fe2-hTF, and apo-hTF 
were also studied for comparison. Cell-membrane-bound 5917e and intracellular 
5917e were measured as described in the experimental section. The results are shown 
in Figure 5.16. As expected, Fe2-hTF was a strong inhibitor of 5917e binding and 
uptake, as was Ga2-hTF, in agreement with previous reports [52]. Both Ti2-hTF and 
In collaboration with Dr. Harry J. McArdle and Dr. Lorraine Gambling (Aberdeen) 
who carried out the cell experiments. 
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Bi2-hTF also showed marked dose-dependent inhibitory effects (Figure 5.16), 
whereas apo-hTF was the least effective. 
5.5 Discussion 
The natural transferrin cycle for the delivery of iron to cells offers a 
potential strategy for drug targeting to tumor cells. Three features of transferrin 
chemistry point to the possibility that transferrin could deliver antitumor metal 
complexes to cancer cells. First, it is known that malignant cells have a high iron 
requirement and consequently express a greatly elevated level of transferrin 
receptors [27-30,53]. Second, measurements of pH in vivo have shown that the 
microenvironment of tumors is more acidic than in normal tissue [54], which may 
facilitate Ti 1" release in tumor tissues. Third, although iron(ffl)is the natural metal 
ion bound by transferrins, many other metal ions can also bind at the same specific 
sites [34,35,55]. In blood plasma, less than 30% of the iron sites in human 
transferrin are occupied by iron, and the vacant sites could be used to transport 
other metal ions as well. Indeed, transferrin has already been shown to be 
responsible for the selective delivery of 67Ga'11 complexes to tumor cells [56], and it 
is possible that the specific delivery of antitumor Ti" complexes can be achieved 
by a similar process. 
Complexation of metal ions to the phenolic oxygen of the tyrosine residues 
in the specific metal-binding sites of apo-hTF (Figure 5.1), perturbs the 7t7t* 
transitions of the aromatic rings and leads to the production of two new absorption 
bands near 241 and 295 nm [35,36]. These new bands are readily apparent in the 
difference UV spectra of metal-hTF and apo-hTF. Specific binding by some metal 
ions, such as Fe 111, Ce"', and Cu 11, also gives rise to LMCT bands in the visible 
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region [35,36]. This provides a convenient way to detect specific metal-hTF 
binding and release by UV-Vis spectroscopy. 
The changes in the UV spectrum of hTF on reaction with Cp 2TiC12 are very 
similar to those observed previously for the binding of other metal ions to the 
specific FeW  sites [35,36]. The two sharp new bands near 242 and 295 nm are 
typical of phenolate groups (1tm*  transitions) generated by binding of metal ions to 
Tyr residues in the specific iron binding sites. The third broad band centred near 
321 nm, lies in the range typical of LMCT transitions of Ti"' with phenolate ligands 
[57,58]. For example, we have observed similar bands for Ti"-EHPG (EHPG, 
N,N'-ethylenebis(o-hydroxyphenyl)glycine) model complexes with known X-ray 
crystal structures [57]. The magnitude of the change in extinction coefficient of 
this LMCT band (c321  = 4830 M'cm') in physiological buffer is similar to those 
for Fe'112-hTF (AE465= 4950 M' cm') [59] and Ce"-hLF (A& 2= 4640 M' cm') 
[60]. The titration curve obtained by monitoring the absorbance.change at 321 nm 
gave a sharp break at a ratio of Ti: hTF of 2:1. The same ratio was also obtained by 
ICP-AES measurement of bound metal (data not shown), suggesting that Ti" binds 
to the specific metal binding sites in both the N-lobe and C-lobe of the protein, and 
that two tyrosines are involved in binding Ti r" in both lobes (Tyr-95/Tyr- 188 in the 
N-lobe, and Tyr-426/Try-517 in the C-lobe) as is the case for Fe' 11 [35,36]. 
Moreover, the displacement of Ti"' from transferrin by Fe 11' provides further 
evidence for specific binding of Ti"' to the two lobes of the protein. 
The rapid uptake of Ti"' from the anticancer agent Cp 2TiCl2 by human 
transferrin under physiological conditions (within 5 min in physiological buffer at 
25 gM hTF, 310 K) may be relevant to its anticancer activity. Other Ti" complexes 
such as Ti"'-citrate can also donate Ti"' to hTF, but very slowly (> 10 h for 
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completion under similar conditions) [20], while Ti"-NTA is not able to denote 
Ti" to transferrin [22]. 
'H NMR spectroscopy shows that the cyclopentadienyl ligands are 
displaced from Ti" after reaction of Cp 2TiCl2 with hTF (Figure 5.5). It is known 
that the chloride ligands are readily displaced from Cp 2TiCl2 in aqueous solution 
(e.g., by H20/OH on hydrolysis in water) [7,13,19], and therefore only the Ti" ion 
from the drug is taken up by the protein. It had been suggested that the active 
antitumour species could be the cyclopentadiene released during the decomposition 
of titanocene compounds [61]. However, subsequent in vivo experiments have 
shown that neither cyclopentadiene (C 5H6) nor its dimer are the active 
antiproliferative agents [62]. The active component must be Ti" itself. The role of 
the Cp ligands may be to stabilize Ti" and prevent rapid hydrolysis to give inactive 
polymeric species. Thus it may not be surprising that structurally distinct Ti' v 
species, such as titanocene dichloride and Budotitane share similar patterns of 
antitumor activity and organ toxicity [4,5]. 
The structural changes in hTF induced by Ti"' binding were monitored by 
'H NMR. Resonances for apo-hTF and Ti-hTF are in slow exchange on the NMR 
time scale, indicative of strong Ti"' binding. Resonances in the glycan region (2.0-
2.1 ppm) were perturbed only on the addition of the first mol equiv of Cp 2TiC1 2 , 
suggesting that preferential binding of Ti" occurs to the C-lobe of hTF since the 
glycan chains are present only in the C-lobe. This conclusion was further confirmed 
by 2D HSQC NMR data using c-' 3C-Met labelled protein. A similar NMR behavior 
has been observed for Ga, M in and Bi'11 binding to hTF with bicarbonate as the 
synergistic anion [46,47,63]. 
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The ' 3 C NMR studies showed a decrease in intensity of the peak for free 
(bi)carbonate and gradual increase in intensity of the new signal at 166.5 ppm after 
addition of the first and second mol equiv of cp2TiC12. This suggests that Ti" 
binds to both the N- and C-lobes of hTF concomitantly with carbonate as 
synergistic anion. The chemical shift of this bound anion is close to that observed 
previously for other metallo-transferrins, e.g. 166.0/166.2 ppm for Tim  [64], 165.4 
ppm for Al", 166.5 ppm for Ga [48], 166.8/167.2 ppm for Sc m [65], and 165.8 
ppm for Bi" [46], suggesting a similar mode of carbonate binding, probably as a 
bidentate carbonate ion. 
The weakness and gradual disappearance of the peak for bound carbonate 
suggests that Ti" binding does not require carbonate as an obligatory synergistic 
anion. Such a binding mode is known for V0 2 [66]. The UV-Vis and NMR 
experiments carried out in the absence of bicarbonate reveal that Ti" can still bind 
to hTF at the Fe" sites but in a slightly different manner. in the absence of 
bicarbonate, the structural changes in hTF induced by Ti" are different from those 
in the presence of bicarbonate, as evidenced by the 'H NMR data. Chemical 
exchange effects could give rise to the broadening which decreases the intensity of 
the 13C peak for bound carbonate. Such effects could arise from multiple 
conformations of bound carbonate as suggested from the X-ray crystal structure of 
recombinant N-lobe of transferrin [67]. TiW bound to transferrin could adopt a 7-
coordinate geometry. This is favored, for example, in model complexes of Ti" 
with the model ligand EHPG, in which Ti" has pentagonal bipyramidal geometry 
with axial phenolate ligands, two amine nitrogens, two carboxylate oxygens, and an 
additional H20 ligand in the equatorial plane [57]. 
162 
Chapter 5 Titanium-transferrin 
The 2D ['H, 13C] HSQC NMR experiments on E-[ 13CH3]Met-hTF show that 
Ti" preferentially loads the C-lobe, followed by the N-lobe. A similar preference 
has been observed previously for reactions of hTF with NTA complexes of F ern, 
Sc", and Bm  with bicarbonate as synergistic anion [49]. This preference can 
sometimes be switched by changing the initial ligands on the loading metal, but the 
factors which determine the preference are not well understood. The overall 
changes in chemical shifts for the nine Met CH 3 cross peaks induced by Ti" are 
similar to those induced by Fe" binding (added as Fe(NTA) 2), suggesting the Ti"-
induced conformational changes in hTF are similar to those induced by Fe in  
binding. This could be important for the recognition of the protein by the 
transferrin receptor on cell membranes and the subsequent uptake of transferrin into 
cells. It is known that only holo-hTF but not apo-hTF binds strongly to the receptor 
and is taken up into cells [72]. 
In terms of "HSAB (hard-soft-acid-base)" theory [68],. Ti"' is a "hard" 
Lewis acid similar to Fe", and readily hydrolyses to form insoluble polymeric 
species at neutral pH values. Both Cp 2TiCl2 and Budotitane undergo rapid 
hydrolysis to give anticancer inactive polymeric species at neutral pH [1,2,17]. 
Hence, it is likely that Ti" is stabilized by binding to certain biomolecules and is 
transported to the nucleus inside tumor cells. Transferrin is a strong candidate to 
act as mediator for the uptake of Ti" from Cp 2TiCl2 in blood plasma and transport 
it to tumor cells. Both in vivo (rat) and in vitro studies using radio-labeled 45Ti"-
DTPA (DTPA, diethylene-triaminepentaacetic acid) have also suggested that 45Ti" 
is mainly associated with transferrin in blood plasma, and 45Ti is transferred into 
tumor tissue over a period of 3 to 6 h postinjection in tumor-bearing rats [11]. 
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Whether Ti" can be released from Ti 2-hTF under physiologically relevant 
conditions were investigated. The UV-Vis experiments showed that Ti 2-hTF is 
stable over the pH range of 5.0-9.5 in 100 mM NaCl, 25 mM NaHCO3 , 4 mM 
NaH2PO4, conditions which mimic extracellular ones. Only 53% of bound Ti"' 
was released from transferrin even at pH 2 over a period of 1 h at 298 K. In 
contrast, more than 80% of Fe 11' is released from Fe2-hTF over the pH range 6.0 to 
4.0 in the absence of chelators (35,60). Protonation of carbonate (synergistic anion) 
may therefore trigger Fe release, but not Ti" release. However, upon introduction 
of ATP (at a concentration of 1 mM, a 40-fold molar excess over hTF), Ti"' was 
readily released over the pH range of 7.0 to 5.0, with 50% Ti"' release at pH 6.3, 
and almost complete release by pH 4.5. Extracellular ATP levels are low but 
intracellular concentrations of ATP are as high as 3-5 mM [69,70]. Inside 
endosomes, where Fern  is released, the pH is as low as 5.0-5.5 [33,34]. Therefore, 
the release of Ti r" after cellular uptake may be favoured inside there. The 31 P NMR 
studies suggested that the y-phosphate group of ATP was hydrolyzed after 
interaction of ATP with Ti 2-hTF, a reaction which is also observable for Ti"'-ATP 
alone [16], suggesting that the released Ti r*" binds to the chelator ATP. Ti"' transfer 
from the model ligand EHPG to ATP readily occurs at low pH or high ATP 
concentrations [71]. Fern  is likely to bind to ATP after it is released from 
transferrin in endosomes [37]. ATP is known to be a metal macrochelator and a 
major intracellular iron carrier [72,73]. It plays a major role in the transport of Fe" 1 
to the nucleus, and the y-phosphate of ATP is hydrolyzed during Fe m transport [73]. 
Therefore ATP could also facilitate, the intracellular transport of Ti"' and allow it to 
target polynucleotides, which are condensed in the nucleus. DNA in the nucleus has 
a high negative charge and potentially a markedly lower pH value near its surface 
(up to 3 pH units lower than the bulk pH) [74]. These factors may favor Ti"' 
binding. The results with nucleotides reveal that Ti"' has a high affinity for 0-sites 
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of the phosphate groups and N-sites of bases at low pH [16]. Ti-DNA adducts have 
been detected recently in vitro and in tumor cells treated with Cp2TiC1 2 [6,75]. 
Köpf and coworkers have shown that Ti" accumulates mainly in nucleic acid-rich 
regions of tumor cells, especially the nucleus, after both in vivo and in vitro 
administration of Cp2TiC12 [14,15]. 
The UV-visible, ICP-AES and 2D HSQC NMR data show that Fe" can 
displace Ti" from Ti2-hTF and that displacement of Ti" occurs preferentially and 
more rapidly from the C-lobe than from the N-lobe. Early studies also noted that 
Feul displaced one of the two Cr' 11 ions from bound transferrin or lactoferrin much 
more readily [76,77], but the lobe preference was not determined. There are few 
other reported data on lobe-selective metal displacement from hTF with which to 
compare, but it is interesting to note that the C-lobe is less flexible (can open only 
to about 75% of the N-lobe) due to the presence of an extra disulfide bridge 
[35,36], and metal in the N-lobe is normally more exposed and accessible [35]. 
The preferential displacement of Ti"' from the C-lobe of Ti 2-hTF was therefore 
unexpected. This could suggest that the C-site is better optimized for binding 
specifically to Fe w. The Fein loaded C-lobe appears to be responsible for receptor 
recognition [23,24,34]. The cross peaks for the N-lobe Met residues were affected 
by addition of the second mol equiv of Fe w. The displacement of Ti" from the N-
lobe was very slow but Fe 2-hTF was finally formed after 3 d (Figure 5.14). A new 
cross-peak for an unassigned Met residue appeared during substitution of the C-
lobe Ti'v by Few, a peak not present in spectra of Ti 2-hTF or Fe2-hTF (peak marked 
by * in Figure 5.14). This may represent an intermediate in which the C-lobe/N-
lobe interface is perturbed. Additional evidence for this mechanism was provided 
by the shift of the Fe"-hTF LMCT band (ca 470 nm for Fe 2-hTF, an average for N-
and C-lobes, and 473 nm for the N-lobe alone [35,78] during the two-phase of Fe 
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displacement Ti"' from Ti 2-hTF (Figure 5.13). The absorption maximum of the 
LMCT band shifted from 465 nm in the first fast phase to 472 nm in the second 
slow phase suggesting that metal displacement occurs in the C-lobe first followed 
by the N-lobe. The two-phase displacement was further confirmed by ICP-AES 
measurement of protein metal content during the reaction course (Figure 5.15). 
The two-phase displacement implies that Fe CTiN-hTF could survive for a long time 
(days) under physiological conditions. Because the primary receptor recognition 
sites on human transferrin appear to be in the C-lobe [23-25,35], hTF with Fern  in 
the C-lobe and Ti n' in the N-lobe (Fe CTiN-hTF) may be recognised by the 
transferrin receptor and taken up into cells. Therefore the formation of both Ti 2-
hTF and FeCTiN-hTF may provide routes for entry of Ti"' into cells. 
The cell uptake experiments show that Ti 2-hTF competes with Fe 2-hTF for 
membrane binding and uptake into BeWo cells, although it is slightly less effective 
than Ga2-hTF which has previously shown to enter cells via the transferrin receptor 
[79]. Bi2-hTF also appears to be recognised by the transferrin receptor. Ti", Bi 
and Fe" binding appear to induce similar conformational changes in hTF, as judged 
from the 'H and ' 3C NMR shift data [46]. A recent X-ray crystal structure of S17112-
lactoferrin has revealed that the large metal ion Sm 3 induces the same overall 
structural changes in this protein, as Fe 3 , although different structural changes 
occur at the metal binding sites [80]. Therefore both chemical and biochemical 
experiments suggest that Ti" can be taken up and released inside cells via 
transferrin mediated routes. 
Metal anticancer agents can react with various biomolecules in vivo including 
carriers such as albumin, transferrin, ATP, citrate, and OSH), which communicate 
between extracellular and intracellular, and between various intracellular 
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compartments. Substrate binding is finely controlled by natural gradients which 
exist in different tissues or cellular compartments (e.g. pH, ATP and ionic 
gradients). These gradients may alter the relative affinity of drug molecules for 
different cellular components and facilitate drug transport to their targets. "Hard" 
Ti"' may be transported into tumor cells by transferrin and subsequently bind to 
DNA at both the negatively-charged phosphates on the backbone and base N-donors 
[13b,81]. The high DNA concentration in the cell nucleus, the much lower 
dielectric constant [82], and potentially low pH close to the surface of DNA may 
favor DNA as a target for Ti". 
5.6 Conclusions 
Ti"' from the antitumor drug Cp 2TiC12 is readily taken up into the two 
specific iron sites of human transferrin under physiological conditions, in the 
presence of carbonate as synergistic anion. Both Cp ligands are displaced during 
Ti1r*" uptake. Ti 1"' is preferentially taken up into the C-lobe, followed by the N-lobe 
as indicated by NMR spectroscopy. Binding of Ti" appears to induce similar 
conformational changes in hTF to those induced by Fe ln binding in the presence of 
bicarbonate. Ti" can also bind to apo-hTF in the absence of bicarbonate but 
induces different structural changes from those in the presence of bicarbonate. 
Bicarbonate is readily displaced from Ti 2-hTF. ATP facilitates the release of Ti"' 
from transferrin complexes. Unexpectedly Fe" displaces Ti"' from the C-lobe more 
rapidly than from the N-lobe. FeCTiN-hTF  may be a significant species under 
physiological conditions and be recognized by transferrin receptors and taken up 
into cells. Ti2-hTF blocked both membrane binding and cellular uptake of 59Fe-hTF 
into BeWo placental cancer cells. The rapid and strong interaction of the anticancer 
drug titanocene dichloride with transferrin may be relevant to its low toxicity and 
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high activity. It would be of interest to investigate whether transferrin can enhance 




(a) Kopf-Maier P, and Kopf H, Chem. Rev., 1987, 87, 1137-1153 and references 
therein. (b) Kopf-Maier P, and Köpf H, Drugs Future, 1986,11, 297-3 19 and 
references therein. (c) Kopf-Maier P, and Kopf H, in Metal Compounds in Cancer 
Therapy, Fricker SP, Ed., Chapman & Hall, London, 1994, pp  109-146. 
Keppler BK; Friesen C, Vongerichten H, and Vogel E, in Metal Complexes in 
Cancer Chemotherapy (Keppler, B. K., Ed.), VCH, Weinhein, 1993, pp  297-323,. 
(a) Sadler PJ, Adv. Jnorg. Chem., 1991, 36, 1-48. (b) Guo Z, and Sadler PJ, Adv. 
Inorg. Chem., 1999, 49, 183-305. 
Kopf-Maier P, Eur. J. Clin. Phannacol., 1994, 47, 1-14. 
Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, 
Eliopoulos AG, Hale K, Baumgart J, Sass G, and Kerr DJ, J. Clin. Oncology, 1998, 
16, 2761-2769. 
Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR, and Kerr 
Di, Br. J. Cancer, 1998, 77, 2088-2097. 
Kopf-Maier P. and Kopf H, Struct. Bonding, 1988, 70, 105-185. 
Duffy B, Schwietert C, France A, Mann N, Culbertson K, Harmon B, and 
McCue JP, Biol. Trace. Element Res., 1998, 64, 197-2 13. 
Schwietert C, and McCue PJ, Coord. Chem. Rev., 1999, 184, 67-89. 
Tornieporth-Oetting IC, and White PS, Organometallics, 1995, 14, 1632-
1636. 
Ishiwata K, Ido T, Monma M, Murakami H, Fukuda M, Kammeyama K, 
Yamada K, Endo 5, Yoshioka S, Sato T, and Matsuzawa T, Appl. Radiat. Isot., 
1991, 42, 707-7 12. 
(a) iamieson, EJ, and Lippard SJ, Chem. Rev., 1999, 99, 2467-2498. (b) Reedijk 
i, C/tern. Rev., 1999, 99, 2499-2510. (c) Guo Z, and Sadler PJ, Angew. Chem. mt. 
Ed., 1999, 38, 4001-4019 and references therein. 
(a) Kuo LY, Liu AH, and Marks TJ, Metal Ions Biol. Sys., 1996, 33, 53-85. (b) 
Yang P, and Guo ML, Coord. Chem. Rev., 1999, 186, 189-211 and references 
therein. 
Kopf-Maier P. and Martin R, Virch. Arch. B Cell Pathol., 1989, 57, 213-222. 
169 
Chapter 5 Titanium-transferrin 
Kopf-Maier P, J. Struct. Biol., 1990, 105, 35-45. 
Guo ML, Chapter 6 in this thesis. 
Toney JH, Brock CP, and Marks TJ, J. Am. Chem. Soc., 1986, 108, 7263-7274. 
Harding MM, Mokdsi G, Mackay JP, Prodigalidad M, and Lucas, SW, Inorg. 
Chem., 1998, 37, 2432-2437. 
Toney JH, and Marks TJ, J. Am. Chem. Soc., 1985, 107, 947-953. 
Sun H, Li H, Weir R, and Sadler PJ, Angew. Chem. mt. Ed., 1998, 37, 1577-
1579. 
Guo ML, Sun H, and Sadler PJ, J. Jnorg. Biochem., 1999, 154, 150. 
Messori L, Orioli P, Banhoizer V, Pals I, and Zatta P, FEBS Lett., 1999, 442, 
157-16 1. 
(a) Bali PK, and Aisen P, Biochemistry, 1991, 30, 9947. (b) Zak 0, Trinder D, 
and Aisen P, J. Biol. Chem., 1994, 269, 7110-7114. 
Mason AB, Tam BM, Woodworth RC, Oliver RWA, Green BN, Lin LN, 
Brandts JF, Savage KJ, Lineback JA, and MacGillivray, RTA, Biochem. J., 1997, 
326, 77-85. 
Lawrence CM, Ray 5, Babyonyshev M, Galluser R, Borhani DW, and Harrison 
SC, Science, 1999, 286, 779-782. 
Wagner E, Curiel D, and Cotten M, Adv. Drug. Deliv. Rev., 1994, 14, 113 and 
references therein. 
Flulk WP, Hsi BL, and Stevens PJ, Lancet, 1980, 2, 390-392. 
Yeh CJG, Taylor, CG, and Faulk WP, Vox Sanguinis, 1984, 46, 2 17-223. 
Panaccio M, Zalcberg JR, Thompson CH, Leyden Mi, Sullivan JR, 
Lichtenstein M, and McKenzie IF, Immumol. Cell Biol., 1987, 65, 46 1-472. 
Seymour GJ, Walsh MD, Lavin MF, Strutton G, and Gardiner RA, Urol. Res., 
1987, 15, 341-344. 
Chitambar CR, Matthaeus WG, Antholine WE, Graff K, and O'Brien WJ, 
Blood, 1988, 72, 1930-1938. 
Kratz F, Hartmann M, Keppler BK, and Messori L, J. Biol. Chem., 1994, 269, 
2581-2588. 
(a) Klausner RD, Ashwell G, Harford JB, and Bridges KR, Proc. Nati. Acad. 
170 
Chapter 5 Titanium-transferrin 
Sci. U.S.A., 1983, 80, 2263-2266. (b) Klausner, RD, van Renswoude J, Ashwell G, 
Kempf C, Schechter AN, Dean A, and Bridges KR, J. Biol. Chem., 1983, 258, 47 15-
4724. (c) Dautry-Varsat A, Ciechanover A, and Lodish HF, Proc. NatI. Acad. Sci. 
U.S.A. 1983, 80, 2263-2266. (d) Ciechanover A, Schwartz AL, Dautry-Varsat A, and 
Lodish HF, J. Biol. Chem., 1983, 258, 9681-9689. (e) Hopkins CR., and 
Trowbridge IS, J. Cell Biol. Chem., 1983, 97, 506-52 1. 
Aisen P, Metal Ions Biol. Sys., 1998, 35, 585-631 and references therein. 
Baker EN, Adv. Inorg. Chem., 1994, 41, 389-463 and references therein. 
Sun H, Li H, and Sadler PJ, Chem. Rev., 1999, 99, 28 17-2842 and references 
therein. 
(a) Weaver J, and Pollack 5, Biochem. J., 1989, 261, 789-792. (b) Weaver J, 
Zhan H, and Pollack S, Br. J. Haematol., 1993, 83, 138-144. 
Mason AB, Miller, MK, Funk WD, Banfield DK, Savage KL, Oliver RWA, 
Green BN, MacGillivray RTA, and Woodworth RC, Biochemistry 1993, 32, 5472-
5479. 
Beatty EJ, Cox MC, Frenkiel TA, Tam BM, Mason AB, MacGillivray RTA, 
Sadler PJ, and Woodworth RC, Biochemistry, 1996, 35, 7635-7642. 
Chasteen ND, White LK, and Campbell RF, Biochemistry, 1977, 16, 363-368. 
Bax A, Griffey RH, and Hawkins BL, J. Magn. Reson., 1983, 55, 301-3 15. 
Shaka AJ, Barker PB, and Freeman R, J. Magn. Reson., 1985, 64, 547-522. 
McArdle HJ, Douglas AJ, Bowen BJ, and Morgan EH, J. Cell Physiology, 
1985, 124, 446-450. 
Sun H, Cox MC, Li H, and Sadler PJ, Struct. Bonding, 1997, 88, 71-102. 
Lu J, and van Halbeek H, Carbohydrate Res., 1996, 296, 1-21. 
(a) Li H, Sadler PJ, Sun H, J. Biol. Chem., 1996, 271, 9483-9489. (b) Sun H, Li 
H, Mason AB, Woodworth RC, and Sadler PJ, Biochem. J. 1999, 337, 105-111. 
Kubal G, Mason AB, Sadler PJ, Tucker A, and Woodworth RC, Biochem. J., 
1992, 285, 711-714. 
Bertini I, Luchinat C, Messori L, Scozzafava A, Pellacani GC, and Sola M, 
Inorg. Chem., 1986, 25, 1782-1786. 
171 
Chapter 5 Titanium-transferrin 
Sun H, Cox MC, Li H, Mason AB, Woodworth RC, and Sadler PJ, FEBS Lett., 
1998, 22, 3 15-320. 
He QY, Mason AB, Tam BM, MacGillivray RTA, and Woodworth RC, 
Biochem. J., 1999, 344, 88 1-887. 
Korn S, and Sheidrick WS, J. Chem. Soc., Dalton Trans., 1997, 2191-2199. 
Chitambar CR, and Narasimhan J, Pathobiology, 1991, 59, 3-10. 
Cazzola M, Bergamaschi G, Dezza L, and Arosio P, Blood, 1990, 75, 1903-
1919. 
Yamagata M, and Tannock IF, Brit. J. Cancer, 1996, 73, 1328-1334. 
Smith CA, Sutherland-Smith AJ, Keppler BK, Kratz F, and Baker EN, J. Biol. 
Inorg. Chem., 1996, 1, 424-431. 
Ward 5G, Taylor RC, in Metal-based Antitumour Drugs (Gielen, MF, Ed.), 
1988, pp  1-54, Freund, London. 
Guo, ML, Sun H, Bihari S, Parkinson JA, Gould RO, Parsons 5, and Sadler PJ, 
Inorg. Chem., 2000, 39. 206-2 15. 
Harrod, JF, and Taylor KR, Inorg. Chem., 1975,14, 1541-1545. 
Bali PK, and Harris WR, Arch. Biochem. Biophys., 1990, 281, 25 1-256. 
Smith CA, Ainscough EW, Baker HM, Brodie AM, and Baker EN, J. Am. 
Chem. Soc., 1994, 116, 7889-7890. 
Doppert K, J. Organomet. Chem., 1987, 319, 351-354. 
Kopf-Maier P, and Kopf H, J. Organomet. Chem., 1988, 342, 167-176. 
Beatty EJ, Recognition of Metal Ions and Anions by the N-lobe of Human 
Serum Transferrin, Ph. D. thesis, 1995,University of London. 
Aramini JM, Krygaman PH, and Vogel HJ, Biochemistry, 1994, 33, 3304-
3311. 
Aramini JM, and Vogel HJ, J. Am. Chem. Soc. 1994, 116, 1988-1993. 
Saponja JA, and Vogel HJ, J. Inorg. Biochem., 1996, 62, 253-270. 
MacGillivray, RTA, Moore, SA, Chen J, Anderson BF, Baker H, Luo Y, 
Bewey MC, Smith CA, Murphy MEP, Mason AB, Woodworth, RC, Brayer, GD, 
and Baker EN, Biochemistry, 1998, 37, 79 19-7928. 
Pearson RG, in Survey of Progress in Chemistry (Scott, A., Ed.), 1969, ch. 1, 
172 
Chapter 5 Titanium-transferrin 
Academic Press, New York. 
Mathews CK, and van Holde KE, in Biochemistry, 1990, pp 410, 
Benjamin/Cummings Pub. Co. Inc., Redwood City, USA. 
Hatakeyama K, Harada T, and Kagamiyama H, J. Biol. Chem., 1992,267, 
20734-20739. 
Guo ML, and Sadler PJ, J. Chem. Soc., Dalton Trans., 2000, 7-9. 
Aisen P, Adv. Exp. Med. Biol. 1994, 356, 31-40. 
Gurgueira SA, and Meneghini R, J. Biol. Chem., 1996, 271, 13616-13620. 
Lamm G, and Pack GR, Proc. Nati. Acad. Sci. U.S.A., 1990, 87, 9033-9036. 
McLaughlin ML, Cronan JM Jr, Schaller TR, and Sneller RD, J. Am. Chem. 
Soc., 1990, 112, 8949-8952. 
Aisen P. Aasa R, and Redfield AG, J. Biol. Chem., 1969, 244, 4628-4633. 
Ainscough EW, Brodie AM, Plowman JE, Bloor SJ, Loehr JS, and Loehr TM,) 
Biochemistry, 1980, 19, 4072. 
Woodworth RC, Mason AB, Funk WD, and MacGillivary RTA, Biochemistry, 
1991, 30, 10824-10829. 
Clarke MJ, Zhu F, and Frasca DR, Chem. Rev., 1999, 99, 2511-2533 
Sharma AK, and Singh TP, Acta Crystallogr. D, 1999, 55, 1799-1804. 
(a) Guo ML, Yang P, Yang BS, and Zhang ZZ, Chin. Sci. Bull., 1996, 41, 1098-
1102. (b) Yang P, and Guo ML, Metal-Based Drugs, 1998, 5, 4 1-58. 
(a) Lamm G, and Pack GR, J. Phys. Chem. B, 1997, 101, 959-965. (b) Jin R, 
and Breslauer KJ, Proc. Nazi. Acad. Sci. U.S.A., 1988, 85, 8939-8942. (c ) Barawkar 
DA, and Ganesh KN, Nucleic Acids Res. 1995, 23, 159-164. (d) Yang L, 
Weerasinghe S, Smith PE, and Pettitt BM, Biophys. J., 1995, 69, 15 19-1527. 
173 
Chapter 6 Titanium-nucleotides interactions 
Chapter .6 
Ti(IV) targets phosphoesters on nucleotides: implications for 
the mechanism of action of the anticancer drug titanocene 
dichioride 
6.1 Abstract 
Reactions between the anticancer drug titanocene dichioride and various 
nucleotides and their constituents in aqueous solution or N,Ndimethylformamide 
(DMF) have been investigated by 'H and 31 P NMR spectroscopy and in the solid state 
by infrared spectroscopy. In aqueous solution over the pH*(pH  meter reading in 
D20) range 2.3 to 6.5, CMP forms one new species with Ti(IV) bound only to the 
phosphate group. In acidic media at pH*  <4.6, three species containing titanocene 
bound to the phosphate group of dGMP, AMP, dTMP and UMP are formed rapidly in 
each case. The bases also appear to influence titanocene binding. Only one of these 
Ti(IV)-bound species can be detected in the pH*  range of 4.6 - 6.5 in each case. The 
order of reactivity towards Cp 2TiC12(aq) at pH*  Ca. 3 is: GMP > TMP z AMP > 
CMP. At pH* > 7.0, hydrolysis of titanocene dichloride predominated and little 
reaction with the nucleotides was observed. Binding of deoxyribose 5'-phosphate and 
4'-nitro-phenyl phosphate to Cp 2TiC12(aq) via their phosphate groups was detected by 
31 P NMR spectroscopy, but no reaction between Cp 2TiC1 2(aq) and deoxyguanosine, 9-
ethylguanine or deoxy-D-ribose was observed in aqueous solution. The nucleoside 
phosphodiesters 3',5'-cyclic GMP and 2',3'-cyclic CMP did not react with 
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Cp2TiC1 2(aq) in aqueous solution, but in the less poiar solvent DMF, 3', 5'-cyclic 
GMP coordination to {Cp 2Ti} 2 via its phosphodiester group was readily observed by 
31 P NMR spectroscopy. Binding of titanocene to the phosphodiester group of the 
dinucleotide GpC was also observed in DMF by 31 P NMR. The nucleoside 
triphosphates ATP and GTP reacted more extensively with Cp 2TiCl2(aq) than their 
monophosphates; complexes involving both phosphate groups binding were formed in 
acidic media as well as at neutral pH, although to a lesser extent at neutral pH. 
Cleavage of phosphate bonds in ATP (and GTP) by Cp 2TiC12(aq) to form inorganic 
phosphate, AMP (or GMP) and ADP (or GDP) was observed in aqueous solutions. In 
addition, titanocene-ATP binding was not inhibited by Mg(II) but the ternary 
complex titanocene-ATP-Mg appeared to form. These reactions contrast markedly 
with those of the drug cisplatin which binds predominantly to the base nitrogen atoms 
of nucleotides and only weakly to the phosphate groups. The high affinity of Ti(IV) 
for phosphate groups may be important for its biological activity. 
6.2 Introduction 
The dichiorometallocene (Cp 2MC12) complexes, where M=Ti(IV), V(IV), 
Nb(IV) and Mo(IV), have been shown exhibit promising antitumour properties and 
low toxic side-effects [1]. Titanocene dichloride (Cp 2TiC1 2, Cp = 1 5-05H5 ) is one the 
best candidates and is currently in phase H clinical trials as an anticancer drug [2,3]. It 
also significantly overcomes platinum-resistance in carcinoma cell lines [4], and has 
been suggested as a new therapeutic option against ovarian cancer [5,6]. 
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Most biological experiments performed so far suggest that nuclear DNA is the 
primary cellular target of Cp 2TiCl2, which interactions with DNA as a hydrolysed 
species [1,7,8]. Electron energy loss spectroscopy and electron spectroscopic imaging 
studies show that Ti is mainly accumulated in the cellular nucleic-acid-rich regions, 
especially in the nucleic chromatin after in vivo treatment with Cp 2TiC12 [9]. Ti-DNA 
adducts have been detected by inductively coupled plasma emission spectrometry in 
tumour cells in vitro [4], and Cp-Ti-DNA adducts are formed at pH 7.0 in DNA 
solutions treated with Cp 2TiC12 [10]. Marks and co-workers have shown that the 
molybdenum analogue Cp2MoC12(aq) reacts with both the base nitrogen sites and 
phosphate groups of mononucleotides and binds as {Cp 2Mo} 2 , while Cp2VC12(aq) 
can form only labile outer-sphere complexes with the phosphate group but not the 
base sites of mono-nucleotides [11,12]. However, in aqueous solution, little is known 
about the coordination of nucleotides to Cp 2TiCl 2 . Initial NMR work has suggested 
that Cp2TiC12(aq) binds to mono-nucleotides at pD 6.5-7.5 (pD = pH* + 0.4, where 
pH* = pH meter reading in D 20 solution [13]) in a similar coordination mode as 
Cp2MoCl2(aq) [14], based on 'H NMR shifts. Harding et al. subsequently reported 
that at pH > 5, stable adducts between nucleotides and Cp 2TiX2 are not formed [15] 
and no interactions between Cp 2NbCl2(aq) and nucleotides or amino acids occur in 
aqueous solution [16]. Cp 2MoC12(aq) also fails to form complexes with 
oligonucleotides at pH > 5 [17,18]. These findings do not explain the formation of 
Cp-Ti-DNA adducts at pH 7.0 and raise doubts as to whether the anticancer activity 
involves binding to nucleic acids at all [17,18]. Moreover, no evidence for metal-
coordination to phosphodiesters which form the DNA backbone has so far been 
demonstrated for metallocenes [11,17,18]. 
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Prompted by recent findings that Ti(IV) is likely to be transported into tumour 
cells by the blood plasma protein transferrin, and that titanium can be released from 
the protein and bind to nucleotides such as ATP under conditions close to those in the 
cell [19-23], we have investigated reactions of Cp 2TiCl2 with DNA subunits and 
precursor nucleotide triphosphates at various pH values in aqueous solution and in the 
less polar solvent N,N-dimethylformamide (DMF). 
6.3 Materials and methods 
Materials. Cp2TiCl2 (TDC) was purchased from Arcos Co. The nucleotides 
5'-GMP, 3'-GMP, 5'-ATP and 5'-GTP were purchased from Aldrich Co., while, 5'-
dGMP, 5'-AMP, 5'-CMP, 5'-dTMP, 5'-UMP, 3', 5'-cyclic GMP (all as sodium salts), 
2', 3'-cyclic CMP (free acid), GpC (guanylyl-3'-5'-cytidine, free acid), deoxy-D-
ribose, 4'-nitro-phenyl phosphate, deoxyribose 5 '-phosphate, 9-ethylguanine and 
deoxyguanosine were purchased from Sigma Co. The purity was checked by 'H and 
31 P NMR spectroscopy. N,N-Dimethylformamide (DMF-d 7 , 99.5%) and D20 
(99.96%) were obtained from Aldrich Co. 
Preparation of NMR samples. The nucleotide solutions (50 mM) were 
typically prepared freshly by dissolving the nucleotides in D 20. A freshly prepared 
solution of titanocene dichloride (10-50 mM in D20) was added dropwise to the 
nucleotide solutions (2-10 mM). This resulted in a clear solution with a pH of 
approximately 2 to 3. The pH*  was adjusted by dropwise addition of deuterated DC1 
or NaOD. 
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NMR Spectroscopy. 'H (500 MHz) and proton-decoupled 31 P (202 MHz) 
NMR spectra were recorded on a Bruker DMX 500 NMR spectrometer in D20. 
Proton chemical shifts are referenced to dioxane as internal standard, and 31 P 
chemical shifts are referred to 85% H3PO4 as external standard. The 2D ['H, 'H] 
NOESY experiments were performed using standard techniques (mixing time 500 
ms) 
Infrared Spectroscopy. FT-JR spectra were acquired from KBr pellets on a 
Perkin-Elmer Paragon 1000 spectrometer. 
pH measurements. These were recorded using a Corning 240 pH meter 
equipped with an Aldrich microcombination electrode calibrated with Aldrich pH 
buffers at pH 4, 7 and 10. DCI and NaOD (0.05 - 1.0 M) were used to adjust the pH*. 
All reported pH*  values in D20 are pH meter readings without correction for 
deuterium isotope effects. pH titrations were performed by adding NaOH or HCl 
(0.05 - 1.0 M) to the sample until the required pH was reached. pK a values were 
calculated using the program KALEIDAGRAPH [24] on a Macintosh computer. 
6.4 Results and Discussion 
6.4.1 Reactions of Cp 2T1C12 with Nucleoside Monophosphates 
Upon dissolution in D20, Cp2TiCl2(aq) gives an acidic solution (10 mM, pH* 
Ca. 2.2) due to the rapid hydrolysis of the chloride ligands and subsequent 
deprotonation of coordinated water molecules (PK a 1 = 3.5, pKa 4.4 [12]). At pH* 
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values between I to 3.5, two major species were present in aqueous solution with 
singlet Cp 'H NMR resonances at 6.62 and 6.51 ppm (integral ratios Ca. 1.4:1). These 
can be assigned as monomer [Cp 2Ti(OH2)(OH)] and p.-O bridged dimer 
[Cp2(OH2)Ti-O-Ti(OH2)Cp2 } 2 respectively [25,26]. These two species undergo 
further hydrolysis at higher pH*  with release of Cp ligand (multiplets at 6.64, 6.57, 
2.91 ppm) and formation of unidentified precipitates, and a soluble species (singlet, 
6.42 ppm) assignable to the trimer [(CpTiC1O) 3] [ 11]. At basic pH, a white 
precipitate (presumably Ti0 2) formed and Ti-bound Cp species disappeared. The 
hydrolysis of Cp 2TiCl 2 in water can result in up to 17 possible species containing 
Ti(IV)-bound Cp, depending on pH and concentration [26]; we observed only the 
above mentioned three species in solution (10 mM, 298 K) over the pH*  range 1.8 to 
11. 
Reactions of titanocene dichloride (aq) with each of the five nucleoside (or 2'-
deoxy-nucleoside) 5'-monophosphates, 5'-dGMP, 5'-GMP, 5'-AMP, 5'-CMP, 5'-
dTMP and 5'-UMP (for structures see Figure 6.1), were monitored by 'H NMR and 
31 P NMR spectroscopy in aqueous solution. Cp 2TiCl2 (aq, 1.0 mol equiv) was added 
to each nucleotide solution (sodium salt, pH* Ca. 7 - 8, 4 mM), and the pH*  values 
were lowered to 2 - 4. 'H NMR and 3 'P NMR spectra of the clear orange solutions 
were recorded immediately and then every 30 min for 20 h. A small amount of 
orange precipitate formed at the bottom of the NMR tube in the case of 5'-dGMP, 5'-
AMP 5'-UMP and 5'-dTMP, but not in the case of 5'-CMP, after the overnight 
measurement, and there was no pH*  change. 'H NMR and 31 P NMR spectra revealed 
marked changes compared with those of the free nucleotides at similar pH values. 
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Figure 6.1 Structures and atom numbering of nucleotides and their subunits. 
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Figure 6.2 (A) 500 MHz 'H NMR spectra of the H8 region of 5'-dGMP (5 mM) on reaction 
with Cp2TiC1 2(aq)(TDC) in D 20 at pH*  2.9, 288 K; (B) 202 MHz 31 P NMR spectrum of 5'-
dGMP with 1.0 equiv Cp 2TiCl2(aq, 5 mM) in D20 at pH*  2.9, 288 K. Assignments: peak a, 
free dGMP, peaks b, c and d, Ti(W)-dGMP adducts. 
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recorded subsequently, suggesting that the reactions between Cp 2TiCl2(aq) and 
nucleotides were rapid. The changes in both 'H NMR and 31 P NMR spectra were 
similar for the interaction with 5'-dGMP, 5'-GMP, 5'-AMP, 5'-UMP or 5'-dTMP, but 
5'-CMP showed a different much simpler behaviour. For the former, new 'H NMR 
peaks for sugar, base and Cp protons appeared and new peaks for the phosphate group 
appeared in the 31 P NMR spectra. The peaks for base protons and phosphate groups 
were well separated in the NMR spectra and were analysed further. 'H NMR (H8 
region) and 31 P NMR spectra of 5'-dGMP in the presence of 1.0 mol eq of 
Cp2TiC12(aq) are shown in Figure 6.2. Four H8 peaks appeared in the 'H NMR 
spectrum and four phosphate peaks appeared in the 31 P NMR spectrum (a, b, c and d 
in Figure 6.2) and are labelled according to their relative intensities (relative 
integrals: a:b:c:d = 51: 8 : 16 : 25 (for 'H), 49 : 9 : 14 : 27 (for 3 'P)). The slow 
exchange behavior of these peaks on the NMR time scale suggests strong binding of 
5'-dGMP to Ti(IV) in aqueous solution. Peak a has similar chemical shifts as free 5'-
dGMP at a similar pH*  value. Thus, up to three new 5'-dGMP adducts may be 
formed by reactions with of Cp 2TiC12 (aq). A titration with Cp 2TiCl2(aq) was 
performed with the pH*  value controlled at 2.9. Peaks b, c and d increased intensity 
at the expense of peak a on addition of further Cp 2TiC12(aq). With the ratio Ti15'-
dGMP <0.2, only peaks a and b were observed. This suggests that peak a is due to 
free 5'-dGMP, and peak b corresponds to the major Ti-adduct at low Ti/5'-dGMP 
ratios. 
There were marked changes in Cp 'H NMR resonances upon reaction of 
Cp2TiC1 2(aq) with nucleotides at pH*  ca. 3. The Cp resonance corresponding to the 
monomer [Cp2Ti(0H2)(OH)] decreased in intensity markedly and discrete new Cp 
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resonances appeared in the 'H NMR spectra but little change was observed for the Cp 
resonances corresponding to the dimer [Cp2(0H 2)Ti-O-Ti(0H2)Cp2] 21 . This 
suggested that the monomer is much more reactive than the dimer. In reactions with 
deoxyribose 5'-phosphate, 4'-nitro-phenyl phosphate, 3'-GMP or the pyrimidine 
nucleotides 5'-dTMP, 5'-CMP and 5'-UMP, downfield-shifted new Cp resonances 
appeared, while with the purine nucleotides 5'-dGMP and 5'-AMP, upfield-shifted 
new Cp resonances appeared. The upfield shifts may be due to ring current effect of 
the purine ring shielding the Cp protons in the titanocene-dGMP or titanocene-AMP 
complexes. The pyrimidine ring would be expected to be less effective in shielding 
the Cp protons in the complexes. Efforts to correlate the intensities of the new Cp 
resonances with the new nucleotide resonances were not successful. 
6.4.2 pH Dependent Interactions between Titanocene Dichioride with Nucleoside 
Monophosphates 
The pH dependence of interactions between Cp 2TiC12(aq) and 5'-dGMP was 
examined further at various pH*  values and monitored by 'H and 31 P NMR (see 
Figure 6.3). At pH*  values below 4.6, adducts c and d are the major products and the 
adduct b is minor. Above pH*  4.6, little of c and d were formed but the peaks for 
adduct b increased greatly in intensity. Moreover, two broad peaks at ö 6.57, 6.64 for 
free cyclopentadiene appeared at pH* > 5, indicating that the loss of Cp ligands from 
Ti occurs at these pH*  values [12]. When the pH*  was raised above 7, even the peaks 
for the adduct b nearly disappeared and peaks for free dGMP dominated the spectra. 
The major reaction at this pH is the hydrolysis of titanocene dichioride since Ti-bound 
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Cp 'H NMR signals had completely disappeared and a white precipitate (possibly 
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Figure 6.3 'H and 31 P NMR spectra for reactions of the Cp 2TiC12(aq)-dGMP (1:1, 5 mM) at 
different pH values, 288 K. Peak assignment: a, free dGMP, b, c, d, Ti-dGMP adducts. 
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To identify Ti(IV) binding sites on 5'-dGMP, a pH titration was performed 
for reactions of Cp 2TiCl2(aq) and 5'-dGMP and was monitored by both 'H NMR and 
31 P NMR spectroscopy. A pH titration for free 5'-dGMP was also obtained as a 
reference. The plots are shown in Figure 6.4. The S-shaped curves shown in Figure 
6.4B reveal the effects of protonation/deprotonation at the phosphate group, while the 
sigmoidal curves shown in Figure 6.4A reveal the effects of protonation/depronation 
at the guanine N7 site. Protonation of the heterocyclic nitrogens or the phosphate 
group of dGMP are known to have a strong influence on the NMR chemical shift of 
the H8 proton or the phosphate 31 P peak [27]. The downfield shifts of H8 in the low 
pH range reflect protonation at N7, while the upfield shifts of the 31 P NMR signal of 
the phosphate group at low pH reflect protonation at one oxygen site of the phosphate 
group. The presence of metal bound to a particular nitrogen atom or phosphate 
prevents the protonation and can also lower the PK a values of distant protonatable 
sites, so, by analysis of NMR spectra, obtained at different pH values, the metal 
binding sites can be determined [28]. 
The 'H and 31 P pH titration behaviour of peak a is identical to that of free dGMP 
(Figure 6.4). 31 P peak b, is shifted downfield from the peak for free dGMP, but there 
is little change in its chemical shift between pH*  5.0-7.4, in contrast to the large 
downfield shift observed for free dGMP due to deprotonation of phosphate. This 
indicates that deprotonation of phosphate in species b is blocked, suggesting that the 
phosphate is bound to Ti(IV). Its associated H8 'H peak is shifted to higher field 
compared to free dGMP at pH*  values below 5 (.ö = 0.29 ppm at pH * 2.9). 
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However, the pH titration curve monitored by the changes in chemical shifts of H8 
'H NMR peaks (Fig. 6.4A) shows that N7 site in species b can still be titrated but at a 
lowered pH*  value (fitted apparent PK a Ca. 1.3) compared to free dGMP (fitted PK a 
2.8 ). This suggests that Ti(IV) is not directly coordinated to N7. A 2D-NOESY 
experiment (mixing time 500 ms, data not shown) revealed exchange cross-peaks 
between signals a and b, suggesting a bound lifetime of the order of seconds. The 
species corresponding to peaks c and d are formed below pH*  5.5. Their 31 P 
chemical resonances are upfield shifted compared to free dGMP ( A5 Ca. 1.6 and 2.0 
ppm, respectively, relative to free dGMP at pH*  2.9). This also suggests that 
phosphate may be involved in Ti(IV) binding. pH titrations did not confirm Ti-
phosphate binding for species c and d because they disappeared from solution at pH* 
values above 5.5 (see Figure 6.3 and Figure 6.4B). Their H8 chemical shift behaviors 
are similar to species b, i.e. upfield 'H chemical shifts (A6 ca. 0.48, 0.50 ppm, 
respectively, relative to free dGMP at pH*  2.9). Their pH titration curves (Figure 
6.4A) suggest that the N7 sites were also titrated but at lower pH*  values (with 
apparent pKa values lowered by ca. 0.32 and 0.60 compared to free dGMP under these 
conditions). Therefore, N7 is not directly coordinated to Ti(IV) in species c and d. 
At pH*  values below 2, peaks c and d decrease intensity markedly but peak a (free 
dGMP) increased in intensity, suggesting that dGMP dissociated from Ti(IV) in these 
species at low pH*. 
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Figure 6.4 pH titration curves for dGMP-Cp 2TiC12(aq, 1:1). (A) Plot of H8 1 H chemical 
shift vs pH*;  (B) plot of 31 P chemical shifts of dGMP phosphate vs pH*.  The titration 
curve for free dGMP (v')  is shown for comparison and is identical to that for species a. 
The peak assignments are as Fig.2. The fitted pK a values (Hill coefficients in brackets) 
are a 2.77 (n = 0.9), b 1.31 (n = 0.6), c 2.49 (n = 1.9), d 2.21 (n = 1.1). 
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The upfield H8 shifts and lowed PK a (N7) for Ti-dGMP adducts suggest that 
interactions occur between titanocene and the guanine ring of dGMP. Recent studies 
have shown that (i 5-05H5 )- or  (116-C6H6)-metal  complexes cause upfield shifts of H8 
or H2 in their complexes with GMP or AMP [11,29,30,31]. The upfield shifts of H8 
or H2 have been assigned to the diamagnetic anisotropy of the Cp or arene ring 
shielding the H8 position of the nucleotides [11]. This effect may also contribute to 
the H8 upfield shifts in titanocene-dGMP adducts. It is interesting to notice that 
upfield shifted Cp peaks were also observed in titanocene-dGMP adducts and 
titanocene-AMP adducts. This supports the suggestion that the Cp ring and purine 
ring are spacially close in these adducts and their ring current affect 'H shifts each 
other. Another possible reason for the upshift of H8 peaks is that the Ti(IV) 
coordination promotes self-association of dGMP, e.g., base stacking. Base stacking in 
aqueous solutions of nucleotides is well known and upfield shifts of 'H NMR peaks 
for base ring protons due to aromatic ring current effects resulting from base stacking 
are well documented [32]. Metal ions can markedly promote self-association by 
reducing the charge repulsion by coordination at the phosphate group or more 
effectively by forming an intermolecular coordinative link between the phosphate 
group of one nucleotide and the base residue of the next which can enhance the 
stability of the dimeric form [32]. Low pH can also promote self-stacking [33]. 
These effects could also affect protonation at the N7 site, giving rise to 
lowered apparent pKa values in titanocene-dGMP adducts. However, the possibility 
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that Ti(IV) coordinates to guanine sites such as 06, or Ti(IV) bound water binds to 
06 or N7 via H-bonds can not be excluded. 
Similar experiments were performed with AMP, CMP, dTMP, UMP instead 
of 5'-dGMP. Among them, AMP, dTMP and UMP showed analogous NMR changes 
to 5'-dGMP (see Figure 6.5) when they were mixed with Cp 2TiC12(aq), e.g. new 'H 
peaks for H8 and H2 shifted to higher field together with new peaks for phosphate in 
both higher and lower field regions for the AMP-Cp 2TiC12(aq) system, new peaks for 
H6 and the methyl group at higher field together with new peaks for phosphate in 
both higher and lower field regions for the dTMP-Cp 2TiC12(aq) system, new peaks for 
H6 in the higher field region together with new peaks for phosphate in both higher 
and lower field regions for the UMP-Cp 2TiCl2(aq) system. On the basis of pH 
titration experiments (Figure 6.6), the peak marked a can be assigned to the free 
nucleotide in each case. The 31 P pH titration curves (data shown in Fig.6.6B, D, F, H) 
the deprotonationlprotonation processes (near pH*  6.2) are blocked in all the adducts 
labelled b, suggesting Ti(IV)-phosphate binding. In the case of AMP, the 'H pH 
titration curve of the adduct peak b shows a lowered pK a value (ca. 2.8) compared to 
free AMP (a, pKa 3.8 (Ni)). This could be due to the influence of Ti(IV)-phosphate 
binding or interactions of titanocene with the adenine ring. dTMP, UMP do not have 
titratable base N sites between pH 2 to 7, but their titanocene adducts exhibit 'H and 
31 P NMR shift changes analogous to the adducts in the 5'-dGMP-Cp 2TiCl2(aq) and 
AMP-Cp2TiCl2(aq) systems (see Fig.6.5), suggesting a similar modes of binding. 
However, in the case of CMP, only a small amount of one new product was formed 
with the 'H NMR peak for H6 shifted slightly downfield and 31 P peak shifted 
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Figure 6.5 'H and 31 P NMR spectra of 5 mM AMP, CMP, dTMP or UMP with 2.0 equiv of 
Cp2TiC12(aq) in D20 at 298 K. 
(A)'H NMR of AMP-Cp2TiC12 at pH*  2.2, (B) 31 P NMR of AMP-Cp2TiC12 at pH*  3.0; (C) 'H 
NMR of CMP-Cp2TiC12 (1:1) at pH*  3.9, (D) 31 P NMR of CMP-Cp2TiC12 (1:1) at pH*  3.9; (E)'H 
NMR of dTMP-Cp2TiC12 at pH*  2.9; (F) 31 P NMR of dTMP-Cp2TiC12 at pH*  2.9; (G) 'H NMR of 
UMP-Cp2TiCl 2 at pH*  2.2, (H) 31 P NMR of UMP-Cp2TiCl2 at pH*  3.2. 
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Figure 6.6 'H and 31 P NMR pH titration curves for (A,B) AMP-Cp 2TiC1 2(aq, 1:1), (C,D) 
CMP-Cp2TiC12(aq, 1:1), (E,F) dTMP-Cp2TiC1 2(aq, 1:1), (G,H) UMP- Cp2TiC12(aq, 1:1). Left, 
plot of 'H chemical shift of H8 (or H6) vs pH*;  Right, plot of 31 P chemical shifts of nucleotide 
phosphate vs pH*.  Peak assignments are as Fig. 6.5. 
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downfield (see Fig. 6.5C,D). The 'H pH titration curve of the adduct (b) shows a 
similar behaviour to free CMP (a) between pH*  3.0 to 5.6 (Fig. 6.6C), suggesting that 
N3 (PKa 4.4) is not involved in Ti(IV) binding. However, the 31 P pH titration curve of 
b (Fig. 6.6D) suggests that the phosphate is coordinated to Ti(IV). The pH titration 
curves give little information about the binding mode for products corresponding to 
peaks c and d (for AMP, dTMP, UMP systems) because they disappeared at pH*> 
4.5. However, they show similar behaviour as products c and d in the dGMP-
titanocene system, and it is likely that they have similar modes of binding. 
6.4.3 Competitive Reactions of dAMP, dGMP, dCMP, TMP with Titanocene 
Dichioride 
These were performed by mixing two of the four nucleotides in a 1:1 mol ratio 
to give all 6 possible combinations (i.e. A+T, A+G, A+C, G+C, G+T, C+T). 
Cp2TiCl 2(aq) was then added into each of the mixtures and 'H and 31 P NMR spectra 
were recorded after 1 h incubation at 298 K. The amounts of the free nucleotides and 
the formation of Ti-bound nucleotide were determined by peak integration. The order 
of reactivity of Cp2TiCl 2(aq) at pH* Ca. 3 was determined to be GMP > TMP AMP 
> CTP. 
6.4.4 Interactions with dGMP Constituents 
All three constituents of nucleotides, the base ring, phosphate group and the 
sugar moiety, may contribute to nucleotide-metal ion binding [34]. To investigate 
further which part of 5'-dGMP plays the major role in titanocene binding, the 
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interaction of titanocene dichioride with 9-ethylguanine, 2'-deoxy-D-ribose, 2'-
deoxy-D-ribose -5'-phosphate and deoxyguanosine was investigated by 'H and 31 P 
NMR spectroscopy. To detect any reactiqns between Cp2TiCl2(aq) and the 
phosphate group, reactions with 4'-nitro-phenyl phosphate were also studied. 
For 2'-deoxy-D-ribose, 9-ethylguanine, deoxyguanosine, addition of 1 or 2 
mol equiv of Cp2TiCl2(aq) resulted in neither new resonances nor shifts in the 'H 
NMR spectra (data not shown) over a period of 24 h at 298 K and pH*  3, indicating 
that no complexion between Cp 2TiC1 2(aq) and the sugar or guanine rings occurred in 
aqueous solution. In contrast, addition of 1 mol equiv. Cp 2TiC12(aq) to either deoxy-
ribose-phosphate (dRP) or 4'-nitro-phenyl phosphate (NPP), resulted in the 
appearance of a new downfield-shifted 31 P resonance (5 1.0 at pH*  2.8 vs dRP 8 0.9, 
-3.2 at pH*  3.3 vs NPP 5 -4.2) as well as downfield-shifted new Cp 'H resonances 
in each case. This suggests that the phosphate group is a binding site for 
Cp2TiC1 2(aq) in aqueous solution. However, the amount of these adducts is much 
less compared with dGMP-Ti adducts formed under similar conditions. This implies 
that both the phosphate and base of 5'-dGMP are crucial for strong binding of Ti(IV). 
6.4.5 Interactions with Nucleoside Phosphodiesters in Aqueous Solution 
In order to probe possible modes of interaction of Cp 2TiC12(aq) with the 
phosphodiester backbone of DNA, complexation with cyclic nucleotides containing a 
phosphodiester group was investigated. 3',5'-Cyclic GMP and 2',3'-Cyclic CMP were 
used and both contain a phosphodiester group and a base moiety as potential 
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coordination sites. However, the mixing of Cp 2TiCl2(aq) and cGMP or cCMP (1:1, at 
pH* 2.8 and 6.2, 298 K for 24 h) resulted in no NMR changes ('H and 31 P NMR, data 
not shown) at all, indicating that no reaction occurs. This implies that interactions 
between Cp2TiC12(aq) and phosphodiesters are rather weak under these conditions. 
6.4.6 Binding to Nucleoside Phosphodiesters in N,N-dimethylformamide (DMF) 
Failure to detect any coordination of Cp 2TiC12(aq) to phosphodiesters in 
aqueous solution seems to imply that Ti(IV) is unlikely to bind to the DNA backbone 
under cellular conditions since the phosphate moieties in DNA are phosphodiester 
bonds and not phosphomonoester bonds. However, bulk water does not mimic 
cellular conditions. In the densely packed cell nucleus, the dielectric screening is 
expected to deviate from that in bulk water [35]. In addition, both experiments and 
calculations have recently revealed that macrobiomolecules such as proteins and 
nucleic acids and active-site cavities of enzymes can maintain a medium with a much 
lowered local dielectric constant near their surfaces compared to the bulk solvent [36-
39], due to the presence of aliphatic and aromatic residues at the macrobiomolecule-
water interface. The dielectric constant of water in the minor groove of poly[d(A•T)] 
has been determined to be about 20 [37] and that in the major grove of a dodecamer 
DNA is 55 [38], compared with a value of near 80 for the aqueous environment. The 
results of calculations on the B form of DNA agree with these measurements [36]. 
Decreasing solvent polarity may considerably enhance the affinity of metal ions for 
negative-charged phosphodiester groups [34]. Therefore studies using a polar solvent 
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with lower dielectric constant, such as N,N-dimethylformamide (CDMF = 38.25, 293.2 
K [40]) may be relevant to the local dielectric conditions near DNA. 
Figure 6.7A shows the effect of Cp 2TiC12 on the 31 P NMR spectrum of cGMP 
in DMF-d7 . The decrease in intensity of the cGMP 31 P peak and the appearance and 
increase in intensity of new 31 P NMR peaks in the upfield region (shifted by up to 12 
ppm) suggest direct coordination of Ti(IV) to phosphodiesters under these conditions. 
The slow exchange on the NMR timescale suggests strong binding. Figure 6.7B 
shows the changes in the 'H NMR spectra. Addition of Cp2TiC12 to cGMP resulted in 
the appearance of two broad peaks at 13.1 ppm and 9.5 ppm, and splitting of the NH 
peak (11.0 ppm), the H8 peak (7.8 ppm), the NH 2 peak (6.8 ppm), and peaks for the 
sugar protons as well as for the Cp rings. The two broad 'H peaks at 13.1 ppm and 
9.5 ppm have shifts typical of NH• •N and NH 2 • • O hydrogen bonding systems, 
respectively, between base rings of nucleotides [41-44]. This suggests that hydrogen 
bonding (GG base pairing) is induced by the presence of Cp 2TiC12 . Titration studies 
revealed that 1.0 mol equiv of Cp 2TiC12 induced the maximum NMR shift changes. 
Similar experiments were also performed with the dinucleotide GpC. Addition 
of 0.5 mol equiv Cp2TiC12 caused the 31 P NMR peak of GpC to shift upfield from 2.1 
ppm to —1.6 ppm (Figure 6.8), again suggesting that Ti(IV) coordinates to the 
phosphodiester group of GpC. Addition of 1.0 mol eq or higher amounts of Cp 2T1C12 
resulted in the disappearance of the 31 P NMR signal. This may be due to chemical 
exchange. 
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Figure 6.7 Titration of 3',5'-cyclic GMP (6 mM) with Cp 2TiC12 in DMF, 298 K as monitored 
by 500 MHz 'H and 31 P NMR spectroscopy. The new peaks in the 31 P NMR spectrum are 
indicative of Ti(IV) binding to the phosphodiester group of cGMP. The two new peaks at 13.1 
ppm and 9.5 ppm in the 'H NMR spectra are indicative of GG base pairing. 
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Figure 6.8 3  1 P NMR spectra of GpC (bottom) and in the presence of 0.5 mol equiv of 
Cp2T1C12 (top) in DMF at 298 K. The upfield shift is indicative of Ti(IV) binding to 
the phosphodiester group of GpC. 
6.4.7 pH Dependent Interactions between Titanocene Dichioride and Nucleoside 
Triphosphates 
The weak binding of titanocene dichioride to base nitrogen sites but relatively 
stronger binding to negatively charged phosphate groups of nucleoside 
monophosphates at biologically relevant pH values suggested that it would be 
worthwhile to study the reactions between titanocene dichioride and nucleoside 
triphosphates. Nucleoside triphosphates potentially provide much stronger binding 
sites for metal ions than nucleoside monophosphates because of larger negative 
charges on the triphosphate groups, and the possibility of the formation of six-
membered chelate rings between the metal ion and the phosphate groups [34]. In 
addition, nucleoside triphosphates are precursors for DNA synthesis and one of them, 
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ATP, has a high intracellular concentration of 3 to 5 mM [45]. Inside cells, ATP is a 
major metal macrochelator and intracellular iron carrier [46]. The interactions of 
Cp2TiC1 2(aq) with 5'-GTP and 5'-ATP were investigated in aqueous solution at 
various pH values. No precipitation occurred throughout the whole pH range studied 
(pH* 2.4-7.4) and even at higher concentrations (10 mM each). 
Due to 31 P-31 P coupling, two doublets and a triplet are present in the 31 P NMR 
spectra of ATP and GTP [31]. The y-phosphate 31 P signals shift upfield with 
decreasing pH, due to protonation of the phosphate oxygens (PKai,  6.3, 298 K [471). 
New 31 P signals shifted upfield relative to the resonances of free ATP or GTP 
appeared immediately upon introduction of Cp 2TiC12(aq) into ATP or GTP solutions, 
suggesting Ti-phosphate coordination. Selected 'H and 3 1  P NMR spectra for the 
aqueous ATP-Cp 2TiC12(aq) system (1:1 molar ratio) at various pH values are 
presented in Figure 6.9. After introduction of Cp 2TiCl2(aq), free ATP peaks 
decreased in intensity and new broad H8, H2, Hi' 'H NMR peaks appeared in the 
upfield region of the 'H spectra, and new broad peaks for n-phosphate, y-phosphate in 
the upfield region of the 31 P NMR spectra, but little change to the a-phosphate signal. 
This suggests that both the n-phosphate and the y-phosphate are coordinated to 
Ti(IV). At pH* > 5.5, with the increase of pH*  values, the intensity of the peak for 
bound Cp decreased markedly, indicating the loss of Cp ligands from Ti(IV). Also 
peaks for Ti-ATP adducts decreased in intensity while peaks for free ATP increased 
in intensity. At pH*  values higher than 7, complexation still occurred but to a much 
lowered extent. Reactions of GTP followed a similar course to those of AlP: new 
broad H8 and H I ' 'H NMR peaks appeared in the upfield region and new 3 'P NMR 
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Figure 6.9 (A) 'H and (B) 31 P NMR spectra for the solution containing 1.0 mol equiv of 
Cp2TiC12(aq) in ATP (5mM) in D20 at different pH values, 298 K. The peaks marked with an 
asterisk (*) are new peaks which form after addition of Cp2TiC12(aq), and are indicative of 
formation of Ti(IV)-ATP adducts. The extent of the reaction increases with decreasing pH*. 
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peaks for n-phosphate, y-phosphate in the upfield region. Again this suggests that the 
n-phosphate and the y-phosphate are coordinated to Ti(IV). The pH dependence of 
the GTP reactions was also similar to that of ATP. 
6.4.8 Cleavage of ATP Phospho-ester Bonds by Titanocene Dichloride 
Additional peaks due to neither Ti-bound nor free nucleoside triphosphates 
were observed in both the ATP-Cp 2TiC12(aq) and the GTP-Cp 2TiC12(aq) systems after.  
12 h of incubation at pH*  5.5 and 310 K. In the 31 P NMR spectra, two singlets at Ca. 
0.8 and 1.0 ppm appeared 12 h after mixing and grew with time over a period of two 
weeks, indicating the formation of inorganic phosphate or nucleoside 
monophosphates. Also, the triplets for the f'-phosphates decreased in intensity and 
new doublets appeared in the 7-phosphate and the a phosphate region (shifted slightly 
downfield, Es6 ca 0.15 ppm), suggesting the removal of the terminal phosphate group 
from ATP or GTP. In the 'H NMR spectra, two sets of new peaks for H8 (8.61, 8.57 
ppm; 8.63 ppm for ATP), H2, and sugar protons appeared. By comparing the spectra 
with those of free AMP, ADP and ATP under similar conditions, it was confirmed 
that the new peaks are due to the formation of AMP and ADP. Similar changes 
occurred with GTP but the cleavage was more efficient than for ATP. No such new 
peaks were observed for solutions of ATP in the absence of Cp 2TiCl2(aq) over 1 d 
under similar conditions. The cleavage reactions were much faster at lower pH 
values. At pH*  2.3, cleavage was observed within 30 min at 298 K, and after 53 h 
ATP was almost completely converted to AMP and inorganic phosphate. Similar 
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experiments were performed with Cp 2M0C12(aq) and cleavage reactions were also 
observed. Cleavage of phosphoester bonds by Cp 2MoC12(aq) has been reported 
recently [48]. 
6.4.9 The Titanocene-ATP-Mg Ternary System 
It is well known that Mg2 plays an important role in many cellular activities. 
It can bind to all the three phosphate groups of ATP, and such binding plays an 
important role for the biological activity of Mg 2 [49]. The strong binding of 
titanocene to ATP raises the question as to whether it might affect Mg-ATP binding. 
Addition of Mg2 to ATP solutions induced broadening of the three phosphate 31 P 
NMR peaks and downfield shifts of the n-phosphate and y-phosphate peaks of ATP, 
but had little affect on the 'H NMR peaks. Two mol equiv of Mg 2 induced the 
maximum NMR changes. A precipitate formed immediately upon addition of one 
mol equiv of Cp2TiC12(aq, 5mM) to M92-ATP, or vice versa. Even at lower 
concentrations ( <2 mM), a precipitate formed several hours after the introduction of 
1.0 mol equiv of Cp 2TiCl2(aq) to M92-ATP. The 'H NMR spectra showed similar 
upfield peaks for H8, H2, and Hi' (see Fig. 6.10A) as for the ATP-Cp 2TiCl2 binary 
system, suggesting that Ti(IV) is still bound to ATP in the presence of Mg 2t Upfield 
31 P signals are expected if Mg 2 is displaced by Ti(IV). However, in contrast, further 
downfield shifts of 31 P signals of both n-phosphate and y-phosphate signals were 
observed (see Fig. 6.10B). This behavior is quite distinct from that for the binary 
systems. These results suggest that ternary complexes, CpTi-Mg-ATP, are formed. 
No further characterization of these was made. 
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Figure 6.10 Effect of Cp 2TiC12 on the binding of Mg 2 to ATP (2 mM) in D20 at pH*  5.6, 
298 K, as monitored by 'H and 31 P NMR spectroscopy. The peaks marked with an asterisk (*) 
are new peaks formed after addition of Cp 2TiC1 2(aq), and are indicative of Ti(IV) still bound 
to ATP. The further downfield shifts of the f3- and y-phosphate peaks after addition of 
Cp2TiC12(aq), suggest the formation of Ti(IV)-ATP-Mg ternary adducts. 
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6.4.10 Solid state Investigation of Coordination between GMP and Titanocene 
Dichioride 
FT-JR spectroscopy was also used to investigate the solid products from 
reaction of titanocene dichioride and 5'-GMP. The solid titanocene-GMP adducts 
obtained from dry CH 30H were insoluble in water as well as in common organic 
solvents and efforts to obtain crystals for X-ray studies failed. FT-IR spectra provides 
information about the solid state coordination between titanocene and 5'-GMP. 
Characteristic band shifts due to metal -N7(5'-GMP) binding and metal-PO 4 binding 
were observed in the titanocene-GMP adducts. The band at 1491.7 cm 1 for 5'-
GMPNa2 assigned to the N7-C8 stretching and C8-H bending vibration [50], shifted 
to 1482.5 cm'for the Cp2Ti-GMP adduct. The shift (5 - 14 cm') of this band is 
attributable to a metal-guanine interaction [50]. The pyrimidine and imidazole bands 
of free GMPNa2 at 1537.8 cm 1 shifted to 1533.8 cm 1 in the adducts, also supporting 
a Ti-guanine interaction. Two strong antisymmetric and symmetric R0P0 32 
stretching vibrations (1084.1 and 980.8 cm') [51] for free 5'-GMPNa 2 broadened 
greatly and shifted to 1079.4 and 1019.6 cm t in the Cp2Ti-GMP adducts. The band 
shift of nearly 40 cm indicates that the phosphate group is coordinated to Ti(JV). 
6.4.11 Relevance to the Mode of Action of Titanocene Dichloride 
In terms of "HSAB (hard-soft acid-base) theory", both hard oxygen atoms of 
the phosphate group and the sugar ring and soft nitrogen atoms of the aromatic purine 
and pyrimidine ring in nucleotides are potential donor ligands for metal ions [34,52]. 
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The hard-soft matching between metal ions and DNA or their constituents can play an 
important role for their selective recognition [53].  It is well known that the soft Pt(H) 
preferably binds to the N7 of guanine and adenine residues on DNA, while hard metal 
ions such as Mg(ll) show a preference for phosphate groups [34,54]. For borderline 
metal ions such as Cu(H) and Mo(IV), simultaneous coordination to both N7 and 
phosphate group of GMP have been revealed by X-ray crystallographic studies 
[11,56]. Ti(IV) is essentially a hard metal ion in the "HSAB" classification. It is 
expected to have a high affinity for phosphate groups but most mechanism of action 
studies on titanocene dichloride have concentrated on the similarity of its 
configuration to that of cisplatin (similar Cl• . •Cl bite) and possible similar mode of 
action [1]. Ti-O-P bonds are well known and titanium phosphates (R0P0 32 ), 
phosphonate (RP0 3 2 ) and phosphinate (R 2P02 ) adducts have been well characterised 
recently [57, 58]. Crystal structures for complexes of bidentate phosphinate and 
tridentate phosphonate Ti(IV) have been published [58]. 
The high affinity of Ti(IV) for phosphate groups may play a significant role in 
its biological activity. Nucleotide phosphate-metal ion interactions play crucial roles 
in biological systems [59]. Mg2t or Mn2tphosphate  binding is crucial for DNA 
replication, transcription to RNA and translation to protein. Also metal-phosphate 
interactions affect the secondary and tertiary structures, stability, and conformational 
states of DNA and RNA [60]. Metal-phosphate interactions may be more important 
in vivo compared to metal-nucleobase and metal-sugar moiety interactions [60]. 
Ti(IV) has a similar ionic radius (Pauling's value 0.68 A, or six-coordinate 0.74 A) to 
Mg(H) (Pauling's value 0.65 A, or six-coordinate 0.86 A) [61] but a higher positive 
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charge, and would be expected to have a higher affinity for the negatively-charged 
phosphate groups of DNA or nucleotides. There is evidence from the experiments 
reported here that Ti(IV) still binds to ATP in the presence of 4 mol equiv of Mg(H) 
and moreover ternary complexes are formed. This could affect the functions of 
Mg(II) ion in vivo. In the nucleus, DNA is packed in chromatin which consists of 
nucleosomes with a histone core surrounded by DNA coils. The DNA backbone is 
highly negatively-charged and in spite of its association with positively-charged 
histones, is water-accessible [62,63]. The first observation of Ti(IV)-phosphodiester 
binding in DMF reported here may shed light on the possible Ti(IV)-DNA backbone 
binding in vivo because of the low dielectric constant near the surface of DNA. It is 
interesting that mechanistic studies on organotin(IV) anticancer complexes also reveal 
strong Sn(IV)-phosphate binding rather than Sn(IV)-nucleobase binding [64-66]. 
Even for platinum drugs, Pt(ll) binding to phosphate of dinucleotides has also 
recently been observed in DMF [35], and it has been suggested [67] that Pt(ll)-
phosphate binding may be the first step in Pt(ll)-DNA interactions. 
Ti(IV)-phosphate binding in vivo has been suggested by Kopf-Maier on the 
basis of the in vivo result that Ti(IV) is mainly associated with nuclear DNA inside 
tumour cells after application of titanocene dichloride. Where Ti is detected, extra 
phosphate is also accumulated in the same region at high concentrations inside cells 
[7,9]. Such binding could block DNA replication. Cytokinetic investigations have 
shown that titanocene dichloride arrests tumour cells at the G,/S boundary (pre DNA 
synthesis phase) and the premitotic G 2 phase of the cell cycle, and results in apoptosis 
of tumour cells [7]. In addition, Ti-phosphate binding could provide an intracellular 
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transport pathway for Ti(IV), otherwise it will hydrolyse and form inactive species at 
cellular pH values (Ca. pH 7). Also phosphates may play a role in the clearance of Ti 
from nuclei since in vivo studies have also revealed that Ti(IV) is subsequently 
extruded out of nuclei and is incorporated into cytoplasmic digestion compartments, 
lysosomes, with phosphorus becoming simultaneously enriched in the same region 
The binding of Ti(IV) to nucleotides is weak at neutral pH, but much stronger 
at lower pH values. This is of biological significance because there are acidic 
domains around the DNA duplex and the pH close to the surface of DNA is much 
lower than in bulk solution. In the minor grove of DNA, it may be as low as 4.5 
compared to 7.5 in the bulk solution [68]. It is known that Ti(IV) binds strongly to 
the blood protein transferrin at pH 7.4 and Ti(IV) can be transferred to nucleotides at 
low pH since low pH can invert their relative affinities [19, 21, 23]. The high DNA 
concentration in the cell nucleus, its high negative charge, low electric constant and 
low pH near its surface may enhance Ti(IV) binding. 
6.5 Conclusions 
The anticancer drug Cp 2TiC12 binds strongly to the phosphate groups of 
nucleotides in aqueous solution. Binding is weak at neutral pH but stronger at low pH 
with the formation phosphate-bound adducts in acidic solution. In DMF, Ti(IV) 
binding to phosphodiesters was observed. This behavior contrasts with that of the 
anticancer drug cisplatin which binds predominately to nitrogen atoms of nucleobases 
even at neutral pH, and may account for the intracellular localisation behavior of the 
Ti(IV) drugs. 
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Chapter 7 
Ferric-iron binding protein (FBP) 
- over-expression, biochemical characterision, 
crystallisation, site-directed mutagenesis, N-15 
labelling, synergistic anion binding and metal 
binding studies 
7.1 Abstract 
Ferric-iron binding protein (FBP) is a periplasmic iron transport protein 
expressed by some pathogenic bacteria. Recombinant FBP from Neisseria 
gonorrheae has been overexpressed in E. coli. with yields ca. 100-200 mg/litre of cell 
culture. The recombinant protein has been purified and characterised by UV-vis, 
NMR, ICP-AES and ESI-Mass spectrometry. The protein is ca. 34 kDa with both 
Fe(llI) and phosphate (synergistic anion) bound in the active site and shows a 
characteristic absorption band at 481 nm. The bound phosphate can be displaced by 
at higher concentrations of carbonate to form a FBP-carbonate complex which shows 
a characteristic band at 459 nm. Besides phosphate and carbonate, a number of other 
anions such as, oxalate, pyrophosphate and ATP but not sulphate or perchlorate can 
also serve as synergistic anions. FBP binds Fe(ffl) less strongly compared to human 
transferrin (hTF) and Fe(ffl) from FBP can be transferred to hTF under physiological 
conditions in vitro. fron can be removed from FBP together with the synergistic 
anion phosphate at low pH in the presence of the chelator citrate. Apo-FBP shows no 
band near 481 nm and different 'H NMR shifts. It is less soluble and less stable, 
which suggests a different conformation. Apo-FBP binds strongly to Fe(III) but binds 
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weakly to other metal ions such as Ga(IIT) and Bi(llI) and not to Co(ffl), ions which 
have all been shown to bind strongly to transferrin. Both holo- and apo-FBP were 
crystallised and single crystals of apo-FBP diffracted X-ray to 3.0 A. N-15 globally 
labelled FBP was also expressed in E. coli and purified. 2D and 3D NMR spectra of 
the labelled protein were obtained. 
7.2 Introduction 
Iron is an essential nutrient absolutely required for all organisms with the 
possible exception of lactobacilli [1]. Iron is abundant in the environment but it is 
highly insoluble and tends to precipitate as ferric hydroxide under aerobic aqueous 
conditions at neutral pH, where the concentration of free Fe 3 is 108  M, 12 orders of 
magnitude lower than that required for bacteria to grow [2,3]. In human and other 
mammals, iron is sequestered and transported by transferrins and lactoferrins, and 
stored in ferritin [4]. The tight binding of iron by these proteins leads to a very low 
level of free iron in the host which acts as an antibacterial defence mechanism. 
However, some pathogenic bacteria, such as Neisseria meningitidis, Nesseria 
gonorrhoeae, Haemophilus influenzae, Actinobacillus pleuropneumoniae and 
Pasteurella haemolytica, have developed a highly efficient iron-uptake system 
including specific iron-binding proteins (FBPs) to sequester iron from hosts [5,6]. 
Iron is transported in the periplasm of the pathogens by FBP, which is a highly 
conserved periplasmic protein and are required for virulence [6-1 1]. Therefore 
structural functional studies of FBP are important for understanding the iron uptake 
mechanism in these pathogens and could shed lights on design of novel bacteriostatic 
agents targeted on this protein. 
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FBP has been called "bacterial transferrin" because of its remarkable 
similarity to transferrin in its iron-binding properties. A recent crystal structure of 
FBP from Haemophilus influenzae (hFBP) reveals that it is also structurally 
homologous to one lobe of transferrin or lactoferrin but without sequence homology 
[7]. The crystallographic data reveal that the Fe(ffl) binding site in the protein 
resembles the two Fe 3 binding sites in transferrin, binding to two cis tyrosine ligands, 
one histidine ligand, but with glutamate instead of the aspartate found in transferrins. 
A major and striking difference is that hFBP has monodentate tetrahedral anion 
phosphate bound to Fe(IH) as a synergistic anion together with a water ligand [7], 
whereas transferrins use bidentate carbonate as synergistic anion bound to Fe(III). 
Transferrin can use other carboxylates as synergistic anions but cannot use phosphate 
or sulphate anions [12]. The fundamental nature of the synergistic anion binding 
properties in transferrins, such as its role in metal binding and release, has been well 
documented [13, 14,15]. Little is known about the synergistic anion binding 
properties of bacterial FBP apart from the X-ray crystallographic data [7]. The FBP 
from Neisseria gonorrhoeae has been biochemically characterised [16] and 
subsequently expressed in E. coli [17,18]. The native synergistic anion for this 
protein has not been identified. It has been reported that a large excess of NaHCO 3 
increases the iron-binding capacity to apo-FBP [19], but whether the bacterial FBP 
can also accommodate carbonate is still to be determined [4]. 
In this Chapter, extensive biochemical techniques including UV-vis, ICP-
AES, ESI-MS, multinuclear NMR spectroscopy, EXAFS, molecular modelling and 
site-directed mutagenesis have been used to characterise the recombinant FBP from 
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Neisseria gonorrhoeae. Particular efforts were aslo performed to investigate the 
synergistic anion binding properties. These studies are important for understanding 
the iron transport mechanism in this pathogenic bacterial protein. 
7.3 Experimental 
Materials. Apo-hTF was purchased from Sigma (catalogue no: T05 19) and 
washed three times with 0.1 M KC1 to remove low molecular mass impurities using 
Centricon 30 ultrafilters (Amicon). 5'-Adenosine triphosphate disodium salt (ATP) 
was obtained from Aldrich Chemical Co. and used as a freshly prepared aqueous 
solution. The purity was verified by 'H and 31 P NMR spectroscopy. Monosodium 
citrate (Aldrich), NaHCO 3 (Aldrich), nitrilotriacetic acid (H 3NTA, Aldrich), 
NaH2PO4 and Na2HPO4 (BDH), tetresodium pyrophosphate (Strem) Hepes 
(Aldrich), Tris (Aldrich), NaH 13CO3 (MSD isotopes, >99% enriched) and were used 
as received. Iron, phosphorus, gallium, bismuth, cobalt atomic absorption standard 
solutions were purchased from Aldrich. All other chemicals were reagent grade. A 
freshly prepared physiological buffer was used with final concentrations of 4 mM 
NaH2PO4, 100 mlvi NaCl and 25 mM NaHCO3 (pH 7.4). 
Stock solutions of [Fe ... (NTA) 2], [Ga"(NTA)2], [Bi111(NTA)] were prepared 
from the iron, gallium, bismuth atomic absorption standard solutions and H 3NTA. 
The pH values were slowly raised to ca. 5.5 with microlitre amounts of NaOH (I M). 
Diluted solutions were used where necessary. Aqua Co" ions are unstable under 
normal conditions so Na 3Co"(CO3)3 was prepared by published procedures [20,21] 
and the purity was confirmed by elemental analysis and ICP-AES. A stock solution 
of Na3Co'11(CO3 ) 3 was prepared in 1 M NaHCO 3 according to published methods 
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[22]. This complex has been used successfully to load Co(IH) into human transferrin 
[22]. 
Electrophoresis was carried out using a Bio-Rad protean II minigel system 
(protein) and a Life Technologies, Inc., H5 system (DNA). Primers were purchased 
from Life Technologies, Inc., and Ready to Go PCRTM  beads from Amersham 
Pharmacia Biotech. PCR and sequencing reactions were carried out on a Perkin-
Elmer 480 thermal cycler, and automated DNA sequencing was done using an ABI 
prism 377 DNA sequencer. An Amersham Pharmacia Biotech FPLC system and 
columns were used for chromatographic separations of proteins. Electrospray mass 
spectrometry (ESI-MS) was performed on a Micromass Platform H quadrupole mass 
spectrometer. 
E. co/i Strains and FBP Plasmid Constructs. The E. coli DH5aF' strain 
containing the plasmid pTRc99A with the FBP gene (from Neisseria gonorrhoeae) 
inserted was supplied by Professor R.T.A. MacGillivray (University of British 
Columbia, Vancouver, Canada). However, this strain was unable to express any 
FBP in our laboratory. Fortunately FBP was expressed after transformation of the 
plasmid (pTRc99AIFBP) into E. coli strain Top 10 cells. The E. coil strain ToplO 
One ShotTM  cells (F'mcrA D(mrr-hsdRMS-mcrBC) F801acZDM15 DlacX74 deoR 
recAl araD 139 A(ara-leu)7679 galU galK rpsL endAl nupG, Invitrogen) were used 
for the maintenance of plasmids and also for the initial transformation of ligation 
products. The Top 10 cells containing the plasmid pTRc99AJFBP were used to over-
express the protein FBP. An E. coii DH5cF' strain transformed by pTRc99AIFBP 
was also constructed and used for over-expression of the protein FBP. 
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Overexpression of FBP. FBP was overexpressed in E.coli Top 10 strain or 
DH5aF' strain transformed by pTRc99A/FBP. Briefly, a single colony from an 
overnight growth of bacteria on LB agar containing 100 p.g/ml ampicillin was used 
to inoculate 5 ml of 2YT broth (see Chapter 2.2.3) containing 100 pg/mi ampicillin 
in a sterile 10 ml white top tube. This culture was shaken overnight at 37 °C and 
used to inoculate 1 litre of 2YT with 100 pg/mI ampicillin in sterile 500 ml flask. 
After the flask was shaken overnight at 310 K (37 °C), a pink pellet of cells was 
isolated by centrifugation (10000 g for 15 min at 4 °C) and stored at —20 °C. 
Purification of FBP. FBP was purified by a modification of the method 
previously described by Berish et al. [18]. The pink pellet (ca. 5 g) was defrosted at 
room temperature and was resuspended in 50 ml of 1 M Tris (pH 8.0). Then 50 ml of 
2% CTAB (cetyltrimethylammonium bromide) was added, followed by stirring 
slowly overnight at 310 K (37 °C). The white insoluble material was removed by 
centrifugation (10 000 g for 15 min at 4 °C). The supernatant (cell free extraction) 
was diluted to a final volume of 1 litre by adding distilled water and then filtered 
using Whatmann no. 4 paper (Fisher). The cell free extract was applied to a 
RESOURCE®S cation exchange column (1 ml or 6 ml, Pharmacia) connected to an 
FPLC system (Pharmacia), washed according to the manufacturer's instructions and 
equilibrated with 10 mM Tris buffer (pH 8.0). The filtered CTAB extract was 
loaded onto the column at a flow rate of 4 ml/min and then eluted with an NaCl 
gradient of low to high-salt (0 to I M NaCl) in 10 mM Tris buffer at a rate of 4 
mi/mm. Pink fractions were collected and were analysed by SDS-PAGE. The 
protein was concentrated by dialysis or ultrafiltration (Amicon concentrator). The 
concentrations of purified protein were determined by the BCA method using bovine 
serum albumin as a reference [23]. 
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Preparing apo-FBP Apo-FBP was prepared by treatment of holo-FBP 
solutions in a Centricon 10 microconcentrator (Amicon) with 250 mM sodium 
citrate, pH 4.5 at least 4 times, until no pink colour was observed. The apo-FBP was 
then sequentially washed 4 times with 2 ml of 0.1 M KC1. At this point the 
colourless protein, still in the Centricon, was exhaustively exchanged into the buffer 
to be used in different experiments. 
UV-Vis Spectroscopy. All the UV experiments were performed with 1 cm 
cuvettes on a computer-controlled Shimadzu UV- 1000 spectrometer with 
temperature control at 298 K or 310 K. UV difference spectra after addition of metal 
complex to apo-FBP were recorded immediately and at different time intervals. For 
titration experiments, aliquots of metal complex (0.5-10 p1) were added and the 
solution was left to equilibrate at 298 K for 30 mm. The binding or release of Fe 
was monitored by the increase or decrease in absorbance at 481 nm. 
NMR Spectroscopy. FBP samples were dissolved in 0.1 M KC1 in D 20/H20 
(10%/90%). The pH was adjusted to 7.4 ± 0.1, when necessary, using NaOH and 
HCI (0.1 M). The pH*  values (meter readings) of NMR solutions were recorded 
before and after NMR measurements. 
'H NMR spectra were recorded on a Bruker DMX 500 spectrometer at 500 
MHz, using 0.6 ml of FBP solution (ca 1 mM) in 5-mm tubes at 298 K, using ca. 
1000 transients, 6 ps (50 °) pulses, 1.8 s recycle time, 16,384 data points, and water 
suppression via presaturation. The chemical shift reference for 'H was sodium 
trimethylsilyl-d4-propionate (TSP). Resolution enhancement of the spectra was 
achieved by processing the free induction decays with a combination of unshifted 
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sine-bell and exponential functions (line broadening of 1.5-20 Hz) on a Silicon 
Graphics computer using XWIN-NMR software. 
Proton-decoupled 31 P NMR spectra were recorded on a Bruker DMX 500 
spectrometer operating at 202 MHz. Typically 3000-10 000 transients were 
collected using a pulsewidth of 6 ts (500),  relaxation delay 2 s, and 16,384 data 
points. The 31 P reference was external 85% H3PO4. The spectra were processed 
using exponential functions (line-broadening of 2-10 Hz). 
2D ['H, 'H], NOESY (mixing time 100 ms), TOCSY spectra (mixing time 50 
ms) [24,25) were acquired on a Bruker DMX 500 spectrometer at 298 K, using 
4,096 data points in the f2 dimension ('H), 32-64 increments of t,, acquisition time 
0.2 s, 96 scans and 512 increments in the fi dimension in a total time of ca 21 h. 
Qsine functions were used in both dimensions for processing data using XWINNMR 
2.0 software. 2D ['H, ' 5N] HSQC (26),2D ['H, 15N] TROSY [27] and 3D ['H, 15N] 
HSQC-NOESY (mixing time 100 ms), HSQC-TOCSY(mixing time 50 ms) spectra 
[28,29,30] for ' 5N-labelled FBP were recorded on a Varian Unity 600 spectrometer 
at 310 K. The pulse sequences combine the 2D ['H,' 5N] HSQC sequence with a 
NOESY or TOCSY sequence added at the end. These experiments were set-up with 
the assistance of Dr. John Parkinson. Qsine functions were used for processing 
using Varian VNMR 4.3 software. The residual water signal was suppressed by 
presaturation or pulsed-field gradients. Peaks were referenced to water or sodium 3-
(trimethylsilyl)-propionate-2,2,3,3-d4 (TSP) (ö 0.00). 
Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES). This 
was performed on a Thermo Jarrell Ash IRIS spectrometer using standard methods. 
Metal-loaded- and apo-proteins were purified by using Centricon 10 (Amicon) 
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ultrafilters and washing three times with ultra-purity water followed by ultrafiltration 
after each washing. The final protein solution was diluted with Tris buffer (10 mM), 
and phosphorus and iron contents were measured without digestion of the sample. 
pH Measurements. The pH values of the solutions were adjusted with HCl or 
NaOH (DC1 or NaOD for samples in D20 solution) and determined using a Corning 
240 pH meter equipped with an Aldrich micro combination electrode, calibrated 
with Aldrich buffer solutions at pH 4, 7 and 10. The pH-meter readings for D 20 
solutions are recorded as PH*  values, i.e. uncorrected for effect of deuterium. 
X-ray Absorption Spectroscopy—X-ray spectra were recorded at the iron K 
edge on EXAFS station 9.3 at Daresbury Laboratory Synchrotron Radiation Source 
with the assistance of Dr. Ian Harvey. Data for native FBP and the apo-FBP loaded 
with Fe3 in the presence of bicarbonate rather than phosphate were collected at 20 K 
(using a liquid helium cryostat) in fluorescence mode using a 13-element solid state 
germanium detector. Samples were prepared as follows. Purified native FBP was 
concentrated by ultrafiltration (Centricon 10) and washed three times with 0.1 M KCI. 
FBP-Fe-0O3 complex was made by loading apo-FBP with 1.2 mol eq. of Fe(NTA) 2 
in Hepes buffer (pH 7.4) in the presence of 10 mM of sodium bicarbonate. The 
excess of Fe(NTA) 2 was removed from the yellowish pink solution by ultrafiltration 
(Centricon 10) washing four times with 0.1 M KCI. Data were processed by Dr Ian 
Harvey using EXCALIB, EXBACK [31] and/or SPLINE(modified for use with 
EXCURV) [32], and analysed using the Rehr-Albers approximation [33] in 
EXCURV98 [34]. 
Homology Modelling. This was carried out with the assistance of Dr John 
Parkinson (Edinburgh) on a Silicon Graphics computer using the molecular modelling 
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program Sybyl version 6.3 (Tripos Inc.). The X-ray crystal structure coordinates of 
Haemophilus influenzae FBP (hFBP, PDB code 1MRP [7]) with water molecules 
deleted was used as the starting model since its sequence is highly homologous to the 
FBP of Neisseria gonorrhoeae (72% identity). The identical amino acid residues 
were kept and the different residues were replaced by the residues from the sequences 
of the N. gonorrhoeae FBP (supplied by Prof. R.T.A. MacGillivray and our DNA 
sequencing results); this was followed by energy minimisation calculations. 
Site-directed Muta genesis (FBP/Y195F and FBP/Y196F). The mutant genes 
for FBP/Y195F and FBP/Y196F were made by the PCR megaprimer method [35]. 
CTT was used as the mutant codon to change the CTA encoding tyrosine to 
phenylalanine. Synthetic oligonucleotides 5' -CTCATCAACAAçjCTACTGGCAC 
-3' and 5'-ATCAACAACTAjCTGGCACGCT-3' (Genosys Biotechnologies) 
were used as mutant primers for making the FBP/Y195F and FBP/Y196F mutants, 
respectively. The Mega primers were made by PCR reactions using pUC 1 8/FBP as 
template, mutant primer as forward primer and M13 (5'-CGCCAGGGTTTTCCCAG 
TCACG -3' as reverse primer. The resulting mega primer was used as reverse primer 
together with NR (5'-GTTGTGTGGAATTGTGAGCGG-3') as forward primer and 
pUC 1 8IFBP as template to make the mutant genes by PCR reactions. The 
HindIllJNcoI fragment of the mutation genes were then ligated and subcloned into the 
identical site in the pUC 1 8IRBS background. Successful ligations were selected upon 
transformation of E.coli Top 10 cells and the positive colonies were used to purify 
plasmid DNA for sequencing and produce mutant proteins. 
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Crystallization of FBP. Crystals of holo-FBP and apo-FBP were grown at 
17 °C by hanging drop vapour diffusion from 10 p.1 drops containing 2-5 mg/mi, of 
holo-FBP, 10 mM Tris, pH 8.0, 10 mM NaCl or apo-FBP, 0.1 M KCI. The drops 
were equilibrated against 1 ml reservoir containing 15- 30% PEG 4000, 0.2 M NaCl, 
0.4 M malate/imidazole buffer, pH 6.2-7.8, or sodium citrate buffer (0.25 M, pH 6.4-
7.6) or malic acidIKOH (0.4 M, pH 6.4-8.0). Diffractable quality crystals grew 
between two weeks to two months. 
7.4 Results 
7.4.1 Cloning and Over-expression of FBP Gene in E. coli 
Cloning and overexpression of fbp in E. coli. The vector pTRC99A and 
pUC I 8IRBS (a modified version of pUC 18 which contains a ribosome binding site 
and a NcoI site) were used for cloning of the Jbp gene. An NcoI /HindllI fragment 
(1.3 kb) of the plasmid pTrc99A containing the Jbp gene was cloned into 
pUC 1 8IRBS and thus resulted in new plasmid named pUC 1 8IRBSIFBP (see Chapter 
2, Figure 2.1) 
Wild-type FBP was overexpressed in both ToplO and DH5aF' E.coli cell lines 
transformed with pTRc99AJFBP or pUC 1 8IFBP. The pink pellet is indicative of the 
overexpression of FBP. Expression levels were similar in 2YT for both cell lines but 
cells containing pTRC99A give deeper pink pellet and was used for large scale 
protein expression. In minimal media, DH5aF' cells containing pTRc99AIFBP gave 
a much better expression level than ToplO cells containing the same plasmid. IPTG 
did not induce better expression. Optimal yields of protein were obtained by aerobic 
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cell growth in 2YT at 37°C for 28-30 h. From I litre cell culture purified protein 
(100 - 200 mg) was normally obtained. 
7.4.2 Purjfication of FBP 
The overexpressed protein is located in the periplasmic space of E. coli 
because theJbp gene contains a leading sequence directing it to the periplasmic space. 
Cationic detergent cetyltrimethylammonium bromide (CTAB) was used to make the 
cell free extraction. The method of Berish et al [18] (4% CTAB extraction for 1 h at 
3 7°C) still gave a pink pellet after centrifugation. This suggests that the extraction 
was not complete. After using 2% CTAB with extraction overnight, a white pellet 
with red supernatant was obtained after centrifugation., indicating that a complete 
extraction had been achieved. 
FBP Marker 







Figure 7.1 SDS-PAGE profile of purified FBP showing a clear band at Ca. 34 kDa. 
Low molecular weight protein markers were used. 
Then the cell-free extraction was applied to a cation exchange column and 
eluted with I M NaCl gradient, pink fractions were eluted at 0.16 M salt and were 
collected. After dialysis and ultrafilteration, pink-coloured high purity FBP was 
221 
Chapter 7 Ferric-iron binding protein (FBP) 
obtained and the SDS-PAGE gel shows a major band at ca 34 Wa (see Figure 7.1). 
Crystals trials produced crystals and confirmed the high purity of the protein. 
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Figure 7.2 ESI-mass spectrum of holo-FBP shows a major peak at 33,643 Da, 
indicating the molecular weight of the protein. The additional peaks at 33,662 Da and 
33,690 Da are likely a Ne adduct and a K adduct of the protein, respectively. 
Mass spectrometry The molecular masses of both holo- and apo-FBP were 
investigated by ESI-MS spectrometry. When the pink holo-FBP solution was added 
into the mass spectrometry buffer containing 50% organic solvent (CH 3CN or.  
CH30H), a red precipitate formed which dissolved after gentle shaking giving rise to 
a colourless solution. However, no precipitate formed with the apo-FBP sample. The 
holo-FBP had an apparent molecular mass of 33 643 Da (see Figure 7.2), in 
agreement with the amino acid sequence (309 aa, without iron or phosphate, 
% 
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theoretical mass 33 639.39 Da). The apo-FBP had an apparent molecular mass of 33 
648 Da, very close to that of the holo-FBP as well as to the theoretical data. This 
suggests that under the conditions of mass spectrometry, both holo- and apo-FBP 
have neither iron nor synergestic anion bound in the protein. 
ICP-AES Studies. The iron and phosphorus contents for both holo- and apo-
FBP ICP-AES were determined by inductively coupled plasma atomic emission 
spectrometry. The protein concentrations (holo-FBP, 5.83 mg/mi; apo-FBP, 5.64 
mg/mI) were measured by the BCA method using bovine serum albumin as standard 
[23] (see Chapter 2), and they were converted into molar concentrations (holo-FBP, 
1.72 x 10 M; apo-FBP, 1.67 x 10 M) according to their calculated molecular 
masses (holo-FBP, 33 811 Da; apo-FBP, 33 639 Da). The samples were used to 10 
times dilution as for the sample for ICP-AES analysis and 3 repeat measurements 
were made. The iron and phosphorus contents of the proteins are shown in Table 7.1. 
These data suggest that the holo-FBP contains one iron and one phosphorus 
(probably the synergistic anion phosphate), while the apo-FBP contains neither iron 
nor phosphorus. 
Table 7.1 ICP-AES iron and phosphous analysis of holo- and apo-FBP 
Protein FefProtein molar ratio P/Protein molar ratio 
Holo-FBP 1.04 0.98 
Apo-FBP 0 0.05 
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Figure 7.3 UV-vis spectra of holo-FBP and apo-FBP in 0.1 M KC1, 33.1 j.tM each, 
pH7.4. 
UV-vis studies. The UV-vis spectra of holo- and apo-FBP are shown in 
Figure 7.3. Both holo-FBP and apo-FBP exhibit a band near 280 nm, with 
maximum at 279 nm and a shoulder near 290 nm indicative of the presence of Trp 
residues. The molar coefficients at 280 nm was determined as 44 200 M'cm' for 
apo-FBP and 48 900 Mcm for holo-FBP (protein concentrations were determined 
as described in ICP-AES studies section). Apo-FBP has no band in the visible region 
while holo-FBP exhibits a broad band centred near 481 nm which gives rise to the 
pink colour of the protein. The molar coefficient at 481 nm (E481) was determined to 
be 2440 M'cm'. 
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NMR Spectroscopic Studies. Holo-FBP is highly soluble in 0.1 M KC1 (>7 
mM) and the solution is stable at 4 °C as well as at room temperature. However, apo-
FBP is much less soluble (<2 mM) and less stable at 4 °C but more stable at room 
temperature. Precipitation occurred in apo-FBP solutions a few days after 
preparation, even at 0.2 mM. 
31 P NMR investigations revealed no 31 P signal for both apo- and holo-FBP. 
This was expected for apo-FBP since ICP-AES studies revealed no phosphorus 
associated with the apo-protein. However ICP-AES detected one phosphorus in the 
holo-protein, so the disappearance of 31 P NMR signal suggests that this phosphorus 
atom must be very spacially very close the paramagnetic Fe(ffi) centre, which greatly 
broadens the 31 P signal into the baseline. 
'H NMR spectra for both holo- and apo-FBP are shown in Figure 74. Major 
'H NMR differences exist between the apo- and the holo-forms. The sharp peaks a, b 
and c, which disappeared from the spectra of holo-form, are probably aromatic CH 
peaks from the residues near the Fe(ffl) centre. The peaks d, e and f, which are in the 
high-field region, are probably from methyl groups below or above some side chain 
aromatic rings in the protein (ring current shifts), and are greatly broadened and 
decreased in intensity in the holo-form, suggesting that they might be near the Fe(HI) 
centre. 
The 2D TOCSY and 2D NOESY spectra of apo-FBP and holo-FBP contain 
many overlapping peaks (see Figure 7.5) due to the large size of the protein. More 
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NOESY connectivities can be seen for apo-FBP than for holo-FBP, especially in the 
region between 5 to 6.6 ppm. This may due to the existance of the paramagnetic 
Fe(ffl) centre in the holo-FBP, and also different forms of the protein might exist in 
different conformations. The TOCSY spectra of apo-FBP revealed only one pair of 
cross peaks for peak f, which suggests that is is likely to arise from the methyl group 
of Ala residues (see Figure 7.5C, in box). The 2D NOESY spectrum revealed their 
connectivities to resonances at low field region (6.5 ppm, 7.2 ppm, typically for 
resonances from side chain aromatic rings in the protein, see Figure 7.5 in boxes). 
Ala 201 (in (x-helix and above Trp 197) and Ala 90 (also in (x-helix and below Trp95) 
are some possible candidates. Although it is difficult to assign these peaks 
unambiguously in such a large protein based on the current data, the great difference 
in 1 H spectra between the apo- and holo-FBP, as well as their different behaviour in 
solution, may suggest that they have different conformations, e.g open and closed 
forms, respectively, as in the cases of transferrins. However, advanced 2D and 3D 
NMR studies are needed to establish this. 
7.4.4 Synergistic Anion Binding Properties of FBP 
Although the FBP from Neisseria gonorrhoeae has been biochemically 
characterised [16] and subsequently expressed in E. coli [17,18], the identity of the 
native synergistic anion for this protein is unsolved and little is known about the 
synergistic anion binding properties of bacteria FBP. Recent X-ray crystallographic 
data for recombinant FBP from Haemophilus influenzae [7] suggest that phosphate is 
the synergistic anion. It is interesting to investigate whether FBP from Neisseria 
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Figure 7.4 Resolution enhanced 'H NMR spectra of apo- and holo-FBP in 0.1 M KCI (10%:90%, D 20:H20), 1 mM each, •.pH*  7.4, 298 
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Figure 7.5 2D NMR spectra of holo- and apo-FBP (Ca. 2 mM each) in 0.1 M KC1, pH 
7.4, 298 K. A, NOESY of holo-FBP (t = 100 ms); B, NOESY of apo-FBP (t = 100 
ms); C, TOCSY of apo-FBP ('r = 50 ms). 
gonorrhoeae also uses phosphate as a synergistic anion. Moreover, as mentioned by 
Aisen et al recently [4], it is still not known whether the bacterial FBP can also 
accommodate carbonate and other anions. 
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Figure 7.6 UV-vis spectra of Fe(Ill) binding to apo-FBP. [Fe(NTA) 2] (0, 0.2, 0.4, 
0.6, 0.8, 1.0, 2.0 mol equiv) was added to 84 jiM apo-FBP in 10 mM Hepes, 5 mM 
NaH2PO4 , pH 7.3, 298 K. 
AA48 
0.0 	0.5 	1.0 	1.5 	2.0 
r [Fe/FBP] 
Figure 7.7 Titration curve for binding of Fe(III) to apo-FBP. Conditions as Fig. 7.6 
UV-vis studies. The above ICP-AES and 31 P NMR studies imply that 
phosphate could be a native synergistic anion in holoFBP with no iron or phosphate 
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present in the apo-FBP. To obtain further evidence regarding iron and synergistic 
anion binding properties, a titration of Fe(III) (as Fe(NTA) 2) against the apo-FBP in 
the presence of 5 mM phosphate (10 mM Hepes buffer, pH 7.4) was performed and 
monitored by UV-vis spectroscopy. As shown in Figure 7.6, when Fe(Ifl) was added 
to a solution containing apo-FBP, a broad band centred at 481 nm appeared 
immediately and increased in intensity after the addition of more Fe(ffl) until I mol 
eq. was reached. A plot of zA 481 against the molar ratio (r) of Fe to apo-FBP is 
shown in Figure 7.7. It can be clearly seen that with the increase of r, the band at 481 
nm increased in intensity and reached a plateau at r = 1, which suggests that one 
Fe(ffi) binds strongly to FBP. 
Similar experiments were performed using other anions (pyrophosphate, ATP, 
(bi)carbonate, oxalate and NTA) instead of phosphate. In all these cases, Fe(III) 
bound strongly to FBP at a 1:1 molar ratio, and a distinctive position of the MLCT 
band was observed as shown in Figure 7.8 and Table 7.2. This suggests that FBP 
can use all these anions (carboxylates and phosphates) as synergistic anions. The 
LMCT band in the presence of phosphate is the same as the band for the native 
protein (481 nm), suggesting that phosphate is the native synergistic anion. A 
titration performed in physiological buffer, (100 mM NaCl, 4 mM phosphate and 25 
mM bicarbonate, pH 7.4) gave rise to a LMCT band at 481 nm which supports this 
idea. This was also confirmed by anion exchange studies (section 7.4.5). 
231 
Chapter 7 Ferric-iron binding protein (FBP) 





400 	500 	600 	700 
Wavelength (nm) 
Figure 7.8 UV-vis spectra of Fe(IH) binding to apo-FBP with different synergistic 
anions. Conditions: 1.0 mol eq of [Fe(NTA) 2] was added to 33 to 84 jiM apo-FBP in 
10 mM Hepes, 5 mM anion, pH 7.3, 298 K. Anions are 1, AlP; 2, pyrophosphate; 3, 
oxalate; 4, carbonate; 5, NTA; 6, phosphate. 
A titration of Fe(NTA) 2 as the Fe(Ill) source with apo-FBP in 0.1 M KC1 but 
in the absence of any added synergistic anion also readily gave rise to a specific band 
at 457 nm. This implies that NTA (nitri lotri acetate) can also act as a synergistic 
anion. NTA is known to be able to act as a synergistic anion in transferrins [36], 
confirmed by a recent 2.1 A resolution X-ray crystal structure of an Fe11 - 
ovetransferrin-NTA ternary complex [37]. Fe 111-hTF-NTA shows a LMCT band at the 
same position as Fe"-hTF-0O 3 , at 465 nm [36]. So it is not strange that the LMCT 
band of Fe-FBP-NTA is at the same position as Fe-FB P-CO 3 (ca. 459 nm). 
However, the contamination of HCO 3 from air cannot be excluded since in aqueous 
solution the [HCO3] in equilibrium with air is 0.14 mM (pH 7.4, 298 K) [38]. 
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Table 7.2 Spectral properties of the LMCT bands of FBP with different synergistic 
an ion S * 
Anion phosphate pyrophosphate ATP carbonate oxalate NTA 
LMCT band 481 
maximum (nm)  
439 472 459 451 457 
E(Mcm 1 ) 2440 1650 1940 2750 3050 2780 
*Conditions :  0 to 2 mol eq of Fe(NTA)2 was added to apo-FBP (33-84 p.M) in the 
presence of 5 mM anions,10 mM Hepes, pH 7.3, 298 K. 
Similar titrations of Fe(NTA) 2 with apo-FBP were also performed by using 
sulphate and perchlorate instead of phosphate to see if they can serve as synergistic 
anions. LMCT bands centred at ca. 458 nm were observed but these are likely to be 
due to NTA (E458 = 2800 M'cm') serving as synergistic anion or the contamination 
of HCO3 from air. Moreover, anion exchange studies monitored by 31 P NMR 
(described below) also do not support sulphate or perchiorate serving as a synergistic 
anion for Fe-FBP. 
7.4.5 Synergistic Anion Exchange Studies 
UV-vis studies. These were initiated following interesting observations of the 
shift of the FBP LMCT band by different anions. An FBP-Fe-0O 3 complex was 
made by mixing 1.0 mol eq. Fe(NTA) 2 with apo-FBP in the presence of a large excess 
of HCO3 (5 mM). A broad band at ca 459 nm is indicative of the formation of the 
FBP-Fe-0O3 complex. Upon addition of phosphate (5 mM, final) to this solution, the 
LMCT band was readily shifted to 481 nm over a period of 30 mm (see Figure 7.7). 
This suggested that the synergistic anion carbonate is readily displaced by phosphate 
and phosphate binds much strongly to FBP. Similar experiments were also performed 
233 
Chapter 7 Ferric-iron binding protein (FBP) 
with FBP-FBP-oxalate (oxalate as synergistic anion). When phosphate (5 mM, final) 
was added into the FBP-oxalate solution, the LMCT band shifted from 452nm to 481 
nm and decreased in intensity over a period of 30 mm, which suggests that the 
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Figure 7.9 UV-vis spectra showing the shift of the LMCT band after adding 5 mM 
NaH2PO4 to 83 iM FBP-Fe-0O3 in 10 mM Hepes, 50 mM KC1, 5 mM NaHCO3 , pH 
7.3 solution at 298 K. 1, FBP-Fe-0O 3 ; 2-6, 1, 10, 20, 30 min and lh after addition of 
5 mM NaH2PO4. The shift of the LMCT band from 460 to 481 nm is indicative of 
displacement of the synergistic anion carbonate by phosphate. 
UV-vis studies were also performed to see if phosphate in native FBP can be 
displaced by carbonate. As shown in Figure 7.10, when a 200-fold molar excess of 
NaHCO3 was added to the native FBP solution (0.11 mM, 0.1 M KCI, pH 8.0), the 
LMCT band of native FBP gradually shifted from 481 nm to 460 nm and increased in. 
intensity over a period of 5 h. This suggests that the phosphate in FBP has been 
displaced and FBP-Fe-0O3 has formed. 
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Similar experiments were also performed using a 400-fold molar excess of 
sulphate or perchlorate instead of bicarbonate, however, no shifts of the LMCT band 
of the native FBP were observed. 
0.4-i 	460 nm 	+ NaHCO 3 
5.5 
0.3 1 
A 0.2 	-' 	481 nm 
ho Ic-F B P 
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Figure 7.10 UV-vis spectra of holo-FBP (0.11 mM) and 0.5, 2.5, 3.5, 5.5 h after 
addition of 20 mM NaHCO3 at 298 K in 0.1 M KCI. pH 8.0. The shift of the LMCT 
band from 481 mu to 460 nm is indicative of the slow substitution of the synergistic 
anion phosphate by carbonate. 
31P NMR studies. To confirm the synergistic anion displacement, 31 P NMR 
studies were carried out. When a fifty-fold molar excess Nal-1CO3 (pH 8.0) was 
added to the native holo-FBP solution (1 mM, pH 8.0, 0.1 M KCI), no 31 P NMR 
peaks appeared after incubation for 12 h at 298 K, suggesting that phosphate binds 
Fe-FBP strongly. However, when a 200-fold NaHCO3 was added, a new 31 P NIMR 
peak appeared at 3.23 ppm and grew to its maximum intensity 24 h later (see Figure 
7.11). This peak, assignable to free inorganic phosphate is within typical chemical 
shift range for free phosphate under similar conditions [39,40]. This confirms that 
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phosphate is the native synergistic anion in FBP and it can be displaced by large 
excess of carbonate. To confirm that the phosphate was displaced and not bound to 
the protein, the sample was ultrafiltered and a colourless filtrate was obtained. 31 P 
NMR measurement of the filtrate gave a peak at 3.23 ppm. 
+ 200 mM HCO 24 h 
+200mM HCO 4h 
40 20 0 —20 ppm 
8 (31 P) 
Figure 7.11 3  1 P NMR spectra of holo-FBP titrated with NaHCO 3 in 0.1 M KC1, pH 
8.0, 298 K. The appearance of the peak at 3.23 ppm after addition of NaHCO 3 is 
indicative of displacement of the synergistic anion phosphate by carbonate. 
Similar experiments were also performed to investigate if sulphate or 
percholate can displace phosphate from native holo-FBP. However, after addition of 
400 molar excess of Na2SO4 or NaC104 into the native FBP solution and incubation 
for 3 d at 298 K, no NMR peak appeared. This, together with the UV studies, 
suggests that sulphate or percholate is unlikely to be acting as a synergistic anion with 
FBP, or if it can, binding is very weak and unlikely to be of biological importance. 
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EXAFS studies. Fe(ffl) K-edge EXAFS studies were carried out to investigate 
the local structural differences between FBP with synergistic anion phosphate (FBP-
Fe-PO4) and carbonate (FBP-Fe-0O 3), in order to link the structures with 
spectroscopic changes in the LMCT band. 
The EXAFS spectra of the two FBP samples, FBP-Fe-PO 4 and FBP-Fe-0O3 
are quite distinct from each other (see Figure 7.12 and Table 7.4). The Fourier 
transforms of FBP-Fe-PO 4 shows two intense, overlapping peaks which can be 
simulated with oxygen/nitrogen back scatters at approx. 1.92 A and 2.09 A 
respectively. These peaks are due to the scattering from the atoms directly 
coordinated to Fe(ffl). The total coordination number refines to 6 (3+3). There is a 
strong peak at 3.23 A arising, presumably at least partially, from scattering by the 
phosphorus atom in the synergistic anion phosphate. When compared to the distances 
obtained from the X-ray crystal structure of FBP from Haemophilus influenzae (PDB 
codelMRP), all but the first (very short) tyrosine distances are similar to the EXAFS 
determined distances. An adequate single-scattering "first" shell fit can be obtained 
from the X-ray (PDB code 1MRP) distances with only Tyr195 changing significantly. 
Tyr195 refines to approx. 1.9 A, which is very similar to that of Tyr196 (and typical 
of iron-tyrosyl systems). The Fourier transform of FBP-Fe-0O 3 is distinctly different, 
with a single first peak in the FT. This refines to 5 donor ligands at 1.98 A. There is 
also a shoulder on this intense peak which identifies a sixth ligand at 2.15 A. There is 
no strong peak at 3.2 A, in contrast to the FBP-Fe-PO 4 data. While this appears to 
confirm that the two FBP samples have different synergistic anions. It must be 
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remembered that in addition to small "rigid" ligands such as phosphate and carbonate, 
the atoms of the cyclic ligands tyrosine and histidine contribute significant multiple 
scattering in the 3-6 A range. Since the ligand bond lengths are different between the 
2 samples, the tyrosine and histidine multiple scattering pattern will also differ. Thus 
it is the different ligand bond length distribution and pattern of peaks in the 3-6 A 
range that supports the notion of different synergistic anions. To prove this notion, a 
full multiple scattering analysis using all atoms of the ligand residues in 3 
dimensional space is required [41]. Such analyses use crystal structure coordinates as 
starting points, are complex and computationally very demanding. Therefore they 
were not attempted. 
Table 7.4 Comparison of the EXAFS data between FBP-Fe-PO 4 and FBP-Fe-0O3 
Sample FBP-Fe-PO 4 FBP-Fe-0O3 
CN 6 6 
fit index 0.00098 0.00089 
Rfactor3 (%) 38.94 41.85 
Ligand distance (A) 2a2 distance (A) 2 2 
His9 2.189 0.003' 2.215 0.005 
Tyr195 1.974 0.003' 1.954 0.0052 
Tyr196 1.884 0.003' 1.954 0.0052 
Glu57 2.104 0.003 2.107 0 .0052 
P041CO3 2.131 0.003' 1.972 0 .0052 
H20 1.986 0.003' 2.012 0 .0052 
phosphorus 3.323 0.005 N/A N/A 
1 refined together as a single parameter 
2 refined together as a single parameter, except histidine 
3 R—factor=>1/cy1(I CXP(k)th(k)I)J00% 
Note The R-factor is not comparable to diffraction R-factor. Typical values are 35-
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Figure 7.12 EXAFS spectra (top), and Fourier transforms (bottom) of the EXAFS spectra of 
FBP-PO4 (A) and FBP-0O 3  (B). Solid line, experimental; dotted line, calculated. 
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By carefully comparing the EXAFS results with the crystal structure of FBP 
from Haemophilus influenzae (1MRP), the difference from the EXAFS spectrum 
could be explained by a small movement of the Fe atom rather than the ligands, or a 
combination of both metal and ligand movement. If Tyr 195, Tyr196 and His9 can be 
thought of as on one side of the Fe, a movement of the metal by approx. 0.09 A away 
from Tyr/His could explain the difference between the FBP-Fe-PO 4 and FBP-Fe-0O3 
data. Such small movements (in this case) have been seen in a few metalloprotein 
crystal structures (I.Harvey, Daresbury Laboratory, unpublished result). The accuracy 
of metal-ligand bond lengths in protein crystal structures are notoriously difficult to 
assess unless diffraction data to atomic resolution (better than 1.2 A) are available. In 
such cases, full matrix inversion can be used to determine directly standard 
uncertainties (previously called estimated standard deviations). When this has been 
done, for example with the copper protein rusticyanin (I. Harvey, Daresbury 
Laboratory, unpublished result), typical results are about 0.05-0.08 A for 1.2 A data. 
These errors increase with decreasing diffraction resolution. Estimates vary for lower 
resolution diffraction, but range around approx. 0.1-0.15 A for 1.5-2.0 A diffraction 
and ~! 0.2 A for > 2 A diffraction. The X-ray structure [7] (PDB code IMRP) was 
determined at 1.6 A, suggesting bond length errors may be of the order of 0.1 A. The 
bond length errors from EXAFS are sample independent, and of the order of 0.02 A. 
Thus this experiment in a good illustration of the complementarity of crystal 
structures and EXAFS for metalloproteins. The crystal structure provides the metal 
site topology and (approximate) metal-ligand bond lengths, while EXAFS "fine 
tunes" these bond lengths to the equivalent of atomic resolution. As a result of such a 
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movement, the Fe(II1)-O(TryI 96) bond is much (0.07 A) longer in FBP-Fe-0O3 than 
FBP-Fe-PO4 while Fe(IIT)-O(Try195) bond is slightly longer (0.02 A) in the latter. 
This makes an average 0.025 A longer Fe(HI)-O(Try) bond length in FBP-Fe-0O3. 
This would change the difference in the energy level between the charge donor (Tyr) 
and acceptor (Fe(III)) and subsequently shift the UV-vis spectra (LMCT band). 
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Figure 7.13 IJV-vis spectra of the reaction of holo-FBP with apo-hTF (1:1) reveals 
Fe(III) transfer from FBP to hTF. Conditions: I mol eq. of apo-hTF was added to 
47.6 M of holo-FBP in 10 mM Hepes, 5 mM NaHCO 3 and 5 mM NaH2PO4, pH 7.4 
and 310 K. 
Human transferrin (hTF) and FBP are both iron transport proteins, in human 
serum and bacterial periplasm, respectively. To investigate which one has the higher 
affmity for Fe, one mol eq. of apo-hTF was added to holo-FBP solution (47.6 tM in 
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10 mM Hepes, 5 mlvi NaHCO3 and 5 mM NaH2PO4 , pH 7.4) and was monitored by 
UV-vis spectroscopy at 310 K. Upon addition of apo-hTF, a slight increase in 
intensity of the LMCT band and a blue shift of the band of FBP at 481 nm (481= 2440 
M'cm') was observed (Figure 7.13). The blue shift of the band was slow and it took 
Ca. 10 h to reach equilibrium and finally stopped at 465 nm with a slightly greater 
intensity (&= 2480 M' cm'), which is the specific LMCT band of hTF with bound 
iron (465= 4950 M' cm for Fe2-hTF) [42]. This suggests that hTF binds Fe(ffl) 
stronger than FBP and Fe(llj) is almost completely transferred slowly from FBP to 
hTF under these conditions. 
7.4.7 Metal Binding Properties of FBP 
Transferrins strongly binds metal ions other than iron, including Ga(III), 
Co(III) Bi(IH) and Ti(IV) in their specific iron sites [46]. Investigations were 
therefore made to determine whether these metal ions also strongly bind to FBP in its 
specific iron site. Metal ion binding to the phenolates groups of the two tryrosine 
residues in the specific iron-sites of apo-TF leads to the production of two new 
absorption bands near 241 and 295 nm, due to the perturbations of the it-it 
transitions of the aromatic ring [43]. This effect has been long used to monitor 
specific metal binding to transferrins by UV-vis difference spectroscopy [12]. This 
procedure should also be applicable to FBP because it shares similar metal-binding 
residues with transferrins, especially the two tyrosine residues in cis configuration 
when they bind to a metal ion. UV difference spectroscopy was used to investigate 
the specific metal ion binding to apo-FBP, including Ga(III), Bi(III), Co(ffl) and 
Ti(IV). 
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Ga(III) binding. Addition of Ga(NTA) 2 to apo-FBP in 10 mM Hepes (pH 7.3) 
solution containing 5 mM phosphate at 298 K resulted in two new absorption bands 
near 245 nm and 298 nm in the UV difference spectrum. The spectra are 
characteristic of metal-tyrosyl coordination and are similar to those reported for Ga-
transferrin complexes [38,43], suggesting that Ga(Ill) binds to the specific iron site in 
apo-FBP. A typical series of UV difference spectra is shown in Figure 7.14. A plot 
of AA245 as a function of r, the molar ratio of total Ga(III) to total FBP, is shown in 
Figure 7.15. The non-linear increase in zA 245 for points below r = I and the 
continued increase in zA 245 for points beyond r = 1 imply that binding of Ga(llI) to 
apo-FBP is rather weak, so that excess Ga(Ill) is needed saturate the site of apo-FBP. 
Apo-FBP was also titrated with Ga(NTA) 2 in 10 mlvi Hepes buffer (pH 7.4) in 
the presence of 5 mM carbonate instead of phosphate. New absorption bands near 
234 nm, 295 nm and a shoulder near 242 nm appeared in the UV difference spectrum. 
This suggests that Ga(III) binds to the specific iron site in apo-FBP. The different 
position of the UV difference bands may due to the different synergistic anion. 
Again, only weak binding was observed (M 242 4690 M 1 cm' by r = 2) similar to 
that in the presence of phosphate (AE245 & 4000 M'cm' by r = 2). The Ac values at 
ca. 242 nm are much weaker than that for Ga 2-transferrin (Ac 242 Ca. 34000 M'cm' 
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Figure 7.14 UV difference spectra for Ga(NTA) 2 binding to apo-FBP. [Ga(NTA) 2] 
(0, 0.2, 0.4, 0.6, 0.8, 1.0, mol equiv) was added to 16.6 j.tM apo-F'BP in 10 mM 
Hepes, 5 mM NaH2PO4, pH 7.3, 298 K. The two absorption bands at 245 and 298 nm 
are indicative of Ga(III) binding to the specific Fe(llI) binding site of FBP. 
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Figure 7.15 Titration curve for Ga(ffl) binding to apo-FBP. Conditions as Fig. 7.14. 
The weak binding of Ga(NTA) 2 to apo-FBP may due to NTA competition 
(Ga(NTA), log KML = 16.20). To test this, apo-FBP was titrated with Ga(NO3)3 (1.43 
mM, prepared by dilution and adding NaOH to gallium AA standard solution until pH 
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= 2.16) under similar conditions in the absence of any chelating ligands. Ga(llI) 
binding to the specific iron site in apo-FBP was observed as evidenced by the 
appearance of two new absorption bands near 245 nm and 295 nm in the UV 
difference spectrum (see Figure 7.16) . The binding is now much stronger as 
evidenced by much stronger bands at 245 and 298 nm (A6245 = 8610 Mcm' by r = 
2). This shows that NTA does compete with apo-FBP for Ga(HI) binding. However, 
the increase in AA245 for points below r = I is still non-linear and still continued to 
increase beyond r = 1. This implies that binding of Ga(III) to apo-FBP is not strong. 
The Ac values are much weaker than those for Ga 2-transferrin (Ac242 ca. 34 000 M' 
cm) and Ga2-lactoferrin (A6242 Ca. 30 000 M'cm') in the absence of chelator agent 
[38,44], implying that the Ga-FBP binding is weaker than Ga-transferrin or Ga-
lactoferrin binding. Such weak binding in the absence of any competing ligand is 
likely related to the hydrolytic properties of the Ga(Ill) ion. In aqueous solution near 
pH 7.4, the major unchelated gallium species is Ga(OH) 4 [45].  The weak binding 
between Ga(III) and apo-FBP may due to the competition between apo-FBP and OH 
(Ga(OH)4 , 340H = 10166 [451), as discussed by Harris and Pecoraro for Ga-
transferrin interactions [38]. 
Co(III) binding. Apo-FBP was titrated with [Co ... (CO 3 )3] 3  in 10 mM Hepes 
buffer (pH 7.4) in the presence of 5 mM carbonate or 5 mM phosphate. However, no 
new bands appeared in the UV difference spettra. This suggested no specific binding 
or that the binding of Co(ffl) to apo-FBP is very weak under these conditions. 
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Figure 7.16 UV difference spectra for Ga(IH) binding to apo-FBP. [Ga(NO 3)3} (0.2, 
0.4, 0.6, 0.8, 1.0, mol equiv) was added to 16.6 j.iM apo-FBP in 10 mM Hepes, 5 mM 
NaH2PO4 , pH 7.3, 298 K. The larger increase in the intensity of the two absorption 
bands at 245 and 298 nm compared to Ga(NTA) 2 indicates that Ga(NO 3)3 is a better 
Ga(ffl) donor to apo-FBP than Ga(NTA) 2 . 
Bi(III) binding. Titration of Bi(NTA) with apo-FBP were performed in 10 
mM Hepes (pH 7.3) in the presence of 5 mM phosphate (see Figure 7.17) or 
carbonate at 298 K. Specific binding was observed as evidenced by the appearance of 
two new absorption bands near 244 nm and 297 nm in the UV difference spectrum. 
However, similar to the case of Ga(III[), the much smaller increase in intensity of the 
bands at 297 nm and 244 nm (A&244  Ca. 4 060 M 1 cm' by r = 1) compared to Bi-
hTF(N-lobe) 0241  ca. 22 000 M'cm' [461) or Bi 2-hTF (C241 Ca. 21 900 M 1 cm 1 per 
Bi [46]) suggests that binding is rather weak. 
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Figure 7.17 UV difference spectra for Bi(NTA) binding to apo-FBP. [Bi(NTA)] 
(0.2, 0.4, 0.6, 0.8, 1.0, mol equiv) was added to 16.6 p.M apo-FBP in 10 mM Hepes, 5 
mM NaH2PO4 , pH 7.3, 298 K. The two absorption bands at 244 and 297 nm are 
indicative of Bi(III) binding to the specific Fe(ffl) binding site of FBP. 
Ti(IV) binding. Apo-FBP was titrated with Ti"-cit or Cp 2TiC12. Unexpectedly, 
strong binding was observed. This will be discussed in detail in the next chapter. 
7.4.8 Homology Model of FBP 
The modelling calculations suggest that the Neisseria gonorrhoeae FBP will 
resemble the Haemophilus influenzae FBP (PDB code 1MRP [8]) in both 
conformation and Fe(IH) coordination residues. Figure 7.18 shows the modelled 
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Figure 7.18 Homology model of N. gonorrhoeae FBP. Left, conformation and 
secondary structure (red, a-helix; blue, 13-sheets, yellow, turns and loops), right. 
Fe(III)-binding ligands (water was deleted from the starting model). 
7.4.9 N-iS Labelling and 2D, 3D NMR Spectra 
15N-Iabelled FBP was obtained by growing DH5a E. co/i cells harboring 
pTRC99A/fbp in modified minimal media containing ' 5NH4CI (2 g/l) as the sole 
nitrogen source, as described in Chapter 2. Using half the NFLC1 concentration 
decreased the yield markedly. The labelled protein was purified on a cation exchange 
column using the same method as purification of the unlabelled FBP. About 5 g ( 5.3 
g and 5.0 g in two batches) of wet cell pellet per litre of minimal media culture was 
obtained. These cells yielded 49.8 mg (24.9 mg/I) of pure ' 5N-labelled FBP in holo- 
form. 
2D ['H, N] HSQC. TROSY, and 3D HSQC-NOESY (mixing time 100 ms), 
3D HSQC-TOCSY (mixing time 50 ms) NMR spectra were obtained with assistance 
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concentration Ca. 0.5 mM in 0.1 M KCI, pH*  7.5, 90% H20-10% D20 solution and at 
310 K. As shown in Figure 7.19 and Figure 7.20, the labelled protein gives a well 
resolved 'H- 15N HSQC and a 1 H-' 5N TROSY spectra. About 150 discrete NH peaks 
can be found in the HSQC spectrum and Ca. 200 in the TROSY spectrum. The peaks 
in the centre region ('H 6.8-9.0 ppm, 15N 110-123 ppm) are markedly overlapped. 
8'Il 	F2 (ppm) 
Figure 7.19 600 MHz ('H, 15N) HSQC spectrum of 15N uniformally labelled holo-
FBP. Conditions: 0.5 mM, 0.1 M KC1, 10%:90% (D 20:H20), pH 7.5, 310 K. 
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Figure 7.20 600 MHz { 'H, ' 5N} TROSY spectrum of 15N uniformally labelled holo-
FBP. Conditions: 0.5 mM, 0.1 M KCI, 10%:90% (D 20:H20), pH 7.5, 310 K. 
Three-dimensional 'H-' 5N HSQC-TOCSY spectrum and 3D 'H-' 5N HSQC-NOESY 
spectrum were also obtained with the 15N-labelled FBP. The 3D spectra can be 
shown as a cube with each dimension represents F1 ('H), F2(' 5N), and F3 ('H). 
Alternatively, it can be shown as a series of 2D spectrum slices at certain chemical 
shifts of the third dimension. The peaks in the 3D spectra are much more resolved 
than the 2D spectra but most of the slices in the 'H(F1)-'H(F3) dimension are still 
severely overlapped. One slice of 'H(F1 )- 1 H(F3 ) dimension at 15N (F2 ) chemical shift 
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Figure 7.21 One selected 'H(F 1)- 1 H(F3) slice of the 600 MHz 3D 'H- 15N HSQC-
TOCSY (A) at 15N chemical shift 128.08 ppm, and one selected 'H(F1)-'H(F3) slice 
of the 3D 'H-' 5N HSQC-NOESY (B) at ' 5N chemical shift 128.08 ppm of the 15N 
uniformally labelled holo-FBP. Conditions: 0.5 mM, 0.1 M KC1, 10%:90% 
(D20:H20), pH 7.5, 310 K. 
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128.08 ppm of each of the 3D HSQC-TOCSY and the 3D HSQC-NOESY spectrum 
is shown in Figure 7.21. The 3D TOCSY spectrum (Figure 7.21A) reveals that the 
NH cross peak at 128.08/10.36 ppm has strong connectivities to the 'H peaks at 7.35. 
6.62 ppm, which suggests that it may be NI-I of a Trp side chain. The 3D NOESY 
spectrum (Figure 7.21 B) reveals its connectivity to a 'H peak at ca 0.25 ppm 
(marked by an arrow in Figure 7.21B), which is probably from a methyl group of an 
Ala residue for which the 2D TOSCY data (Figure 7.5C) revealed only one strong 
cross peak. In the homology model of FBP. Ala 90 is in an a-helix, and is sitting 
above the side chain of Trp 95 at a distance of 3-5 A (see Figure 7.22), and might be 
one of the possible candidates. The other three Typ residues (Trp129, Trp 165 and 
Trp 197) also have methyl groups near their side chains, and are also possible 
candidates. Further analysis is in progress to obtain more assignments. 
Figure 7.22 Ala 90 and its surroundings within 6 A (from homology model. 
Fig.7.18). It can be seen that the methyl, Ca and NH is above the side chain 
of Trp95. 
252 
Chapter 7 Ferric-iron binding protein (FBP) 
7.4.10 Site-directed Mutagenesis Studies 
Multiple sequence alignment of the FBPs from H. influenzae, N. gonorrhoeae, 
A. actinomycetemcomitants reveals that two neighbouring tyrosine residues, Tyr195, 
and Tyr196 are conserved among the proteins and are iron binding residues in FBP 
from H. influenzae as revealed by recently resolved crystal structure [8]. To test if 
they are also iron binding residues in FBP of N. gonorrhoeae and also to investigate if 
they play a crucial role in iron binding, these two tyrosine residues were individually 
mutated to phenylalanine residues. This mutation involves only a small structural 












Figure 7.23 Structures of the tyrosine and phenylalanine. 
Try 195F and Tyrl96F/FBP mutant plasmids were successfully constructed as 
described in Chapter 2 and small scale (10 ml 2YT containing Amp) overexpression 
of mutant FBP/Y195F and FBPIYI96F was performed. After overnight culture, the 
cell pellets appeared white in colour. These pellets were analysised by SDS-PAGE 
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gel and the results are shown in Figure 7.24. DNA sequencing was performed for the 
plasmids isolated from the above cell pellets and the Yl 95F, Y196F mutants were 
confirmed by the gene sequence results at the DNA level. 
1 	2 	3 	4 	M 
Figure 7.24 The SDS-PAGE gel showing the small scale overexpresssion of the 
mutant Y195F and Y196F FBP protein (the strong bands at Ca. 34 kDa). Lanes 1 to 2 
are from Y195 mutant, lanes 3 and 4 are for Y196F mutant. Low molecular weight 
markers (lane M, from top to bottom 94. 66, 43, 30, 20.1, 14.4 kDa) were used. 
From the SDS gels, it is clearly seen that there is a strong band of ca. 34 kDa 
in the pellets of Y195F and Y196F/FBP mutants. This indicates that the above 
mutant proteins were overexpressed. The white colour of the pellets implies that there 
is no iron bound in the mutant proteins. 
Large scale overexpressions were performed for the 2 mutants transformed in 
ToplO or DH5cx E. co/i cells in I litre 2YT resulting ca. 5-6 g wet pellets, which were 
used for purification of mutant proteins using cation exchange FPLC. 
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Much effort was made to purify the mutants Y195F and YI96FIFBP, which 
gave white pellets and showed strong 34 kDa bands on SDS gels. However, these 
mutants proved to be difficult to purify. Unlike the wild-type FBP, the white cell-free 
extraction of Y195F, Y196F precipitated in the cold room and the FPLC elution 
yielded no fractions containing the target protein. The cell-free extract was more 
stable at room temperature so the purification was performed again at room 
temperature. All the Y196F fractions from FPLC were analysed for 0D 280 and the 
fractions containing protein were analysed by SDS-PAGE. The FPLC colourless 
fractions of Y I 96F at 0.13 M NaCl revealed a strong band at 34 kDa, the same 
position as for the wild type FBP. This suggests that the Y196F mutant can bind to 
the cation exchange column but much weaker than the wild type FBP. However, only 
a small amount of purified Y196FIFBP was purified and analysed by UV-vis 
spectroscopy. It showed only one band at 280 nm and no band in the visible region. 
This is similar to apo-FBP, which suggested that there is no iron bound in the mutant 
protein Y196F. The mutant YI95FIFBP behaved similarly to the YI96FIFBP mutant. 
7.4.11 Crystallisation of FBP 
The hanging drop vapour-diffusion method [47] was used to crystallise wild 
type holo-, apo-FBP and FBP-Fe-ATP complex as described in Chapter 2. Efforts the 
use of sodium citrate (0.25 M) buffer and PEG4000 failed to produce crystals while 
using malic acidIKOH (0.4 M) and PEG4000 gave rise to only small needle crystals. 
Fortunately, holo-FBP and apo-FBP gave rise to needle crystals in 0.2 M NaCl, 0.4 
M malate/imidazole buffer. By optimising the conditions, chunky crystals of apo- 
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FBP suitable for X-ray diffraction studies were obtained between 2 weeks to 2 months 
at 291 K(see Figure 7.25). However, FBP-Fe-ATP failed to give any crystals in this 
buffer and precipitation occurred. These crystals diffracted X-rays to Ca. 3.0 A 
resolution and are being analysed in collaboration with Dr. Dmitriy Alexeev of 
I[L1 
Figure 7.25 Crystals of apo-FBP produced by the hanging-drop vapour-diffusion 
method. Protein solution (5 il of 5 mg/mi in 0.1 M KC1) was mixed with an equal 
volume of reservoir solution (0.2 M NaCl, 0.4 M malate/imidazole buffer). Crystals 
were obtained two weeks later in drops of pH 7.0 and 21% PEG 4000. 
7.5 Discussion 
The successful overexpression of FBP in E. co/i and the subsequent highly 
efficient purification by cation exchange column chromatography yielded a large 
amount of recombinant FBP (ca. 100 - 200 mg from 1 litre cell culture). This 
allowed a detailed biochemical characterisation of this protein from a pathogenic 
bacterium. 
Electrospray mass spectra showed essentially the same molecular weight for 
both holo- and apo-FBP (33 643 and 33 648 Da, respectively) which is in agreement 
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with the calculated molecular weight (33 639) based on the amino acid sequence 
using standard residue types. This suggests that no metal or synergistic anion was 
bound to the protein under mass spectrometry conditions, i.e., low pH (<4), in the 
presence of 50% CH30H. The release of metal was also supported by the formation 
of a pink holo-FBP precipitate upon addition of 50% CH30H which subsequently 
redissolved with formation of a colourless solution. Holo-FBP is more soluble than 
apo-FBP in aqueous solutions but the opposite is true for solutions containing organic 
solvents, which suggests that apo-FBP is more hydrophobic than holo-FBP. This 
implies that they have different conformations. Nowalk's preliminary enzyme 
digestion study [48] has suggested that apo- and holo-FBP are in different 
conformations. 
Elemental analysis carried out by ICP-AES revealed that there is no iron nor 
phosphorus present in apo-FBP while one iron and one phosphorus are present in 
holo-FBP. This indicates that the phosphorus is present as an exogenous ligand, 
likely to be the synergistic anion. The presence of phosphate as synergistic anion was 
further conformed by 31 P NMR and EXAFS studies. 
The pink colour of the native FBP, or that which develops when Fe 31  is added 
to the apo-FBP solution, is due to the intense charge-transfer absorption band at 
around 481 nm. The similarity of the visible spectra to those of transferrins [12] and 
metal-phenolate complexes [49] suggested that they arise from tyrosine-metal 
interactions, and the charge-transfer band must be derived from a ligand phenolate (it) 
—p metal (dit*)  transition, as in the case of transferrins [50]. The molar coefficient at 
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481 nm 8481  was determined to be 2440 M'cm', very close to the value reported by 
Nowalk et al [19], and is comparable to half of that of Fe 2-hTF (C5 = 4950 M'cm' 
[511). The molar extinction coefficients at 280,nm for apo-FBP and holo-FBP have 
not been reported and was also determined here as 8280 = 44 200 for apo-FBP and 8280 
= 48 900 for holo-FBP. These values are very useful for protein concentration 
determination by UV spectroscopy. 
The wavelength of maximum absorption is affected by the bound synergistic 
anions, varying from 450 nm to 481 nm from oxalate to phosphate. Different 
synergistic anions may affect the energy levels of Fe(ffi) as well as the Fe-O (Tyr) 
bond length as in the case of carbonate as synergistic anion revealed by the EXAFS 
study. These can subsequently change the difference in the energy levels between the 
charge donor (Tyr) and acceptor (Fe(ffl)) and contribute to the LMCT band shifts in 
UV-vis spectra. 
The synergistic anion exchange studies monitored by electronic absorption 
spectroscopy and 31 P NMR, together with the results from ICP-AES and EXAFS 
studies reveal that the native synergistic anion in FBP is phosphate. This is also the 
case in FBP from Haemophilus influenzae, as revealed by the X-ray crystal structure 
[8]. Besides phosphate, other anions such as carbonate, oxalate, NTA, pyrophosphate 
and even the much larger molecule ATP can serve as synergistic anions with Fe(Ill) 
in FBP. This is quite different from that of transferrins which can use only 
carboxylates as synergistic anions. The failure of phosphate to act as a synergistic 
anion for transferrins is likely to be due to its tetrahedral structure which can not 
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provide the right geometry for the specific metal-anion-transferrin complex, while the 
smaller carboxylates can bind as a bidentate anion the metal ion, leaving no space for 
the attack of water [12]. This could also contribute to the stronger iron binding 
(compared to FBP). FBP can accommodate both phosphates and carboxylates as 
synergistic anions probably because the iron binding cleft in FBP is larger and nearer 
the surface and therefore water accessible. Phosphate can provide more sites than 
carbonate for hydrogen bonding with the protein side chains in the cleft. This may 
contribute to the stronger binding compared to carbonate. Sulphate and perchlorate, 
although isostructural with phosphate, fail to act as synergistic anions. This may due 
to their weaker coordination properties and weaker hydrogen bonding ability, arising 
from the lower polarity of Cl-O and S-O bonds compared with P-O and C-O bonds. 
UV-vis studies revealed that FBP binds iron thermodynamically weaker than 
hTF and iron(III) can transfer from FBP to hTF under physiological conditions in 
vitro. This infers that the presence of transferrin receptors such as TbpA and TbpB is 
crucial for these bacteria to take up iron from transferrin in the host. The importance 
of the transferrin receptor has been proved recently in vivo by making an isogenic 
Tbp-deficient mutant which is avirulent in a human gonococcal infection model, 
while the parent strain is virulent [52]. 
The weaker iron binding of FBP may due to the much greater solvent exposure 
and water accessibility of the iron site in FBP compared to lactoferrin and transferrin, 
as revealed by the crystal structure of FBP from Haemophilus influenzae [8].  In 
transferrin and lactoferrin, the synergistic anion carbonate occupies two coordination 
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site on Fe(HI), leaving no space for the attack of water. In addition, iron uptake and 
release in transferrin and lactoferrin involves domain closing and opening and this 
maybe also the case of FBPs. The overall fo1dng is quite similar between FBP and 
transferrin. Transferrin has disuiphide bridges in each domain, especially a disuiphide 
bridge between the two domains in the C-lobe, which reduce the flexibility of the 
domain movement. However, there is no disuiphide bond in FBP and therefore FBP 
could be more flexible than transferrin. This could give larger change in entropy 
(negative AS °) during iron binding, which may contribute to smaller change in free 
energy (AG°) ((,±tG° = AH° - T(AS°)) and subsequently reduce the binding constant (K 
= e -zlG/RT  or AG° = - RT In K). 
The weaker binding of other metals such as Ga(ffi), Bi(III), Co(IH) to FBP is 
unexpected since they all bind strongly to hTF and lactoferrin. This may also due to 
the much greater solvent exposure and solvent accessible of the iron site in FBP 
compared to lactoferrin and transferrin. There is competition between NTA and apo-
FBP when Ga(NTA) 2 was used as a Ga source. Since FBP binds Fe(III) less strongly 
than transferrins (probably about 2 orders of magnitude weaker), it is likely to bind 
other metals at a weaker level. If the binding constants are at the order of metal-
hydroxide binding, the binding could be greatly affected by the OH level in the 
solution, i.e. pH of solution. 
The successful expression of 15N-labelled FBP in E. coli with high yields (ca. 
25 mg/l) provides a way for high resolution 2D and 3D NMR studies of this protein. 
This would facilitate the structure and ligand binding properties of this protein. 
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My site-directed mutagenesis studies of (Y195F and Y196F) have identified 
Tyr195 and Tyr196 as iron binding residues in this protein. Tyr195 as an iron binding 
residue has been previously identified by making the Tyr1951le null binding mutant 
[48]. Nevertheless, this mutagenesis studies prove that the two tyrosine residues are 
crucial for iron binding. 
Fortunately, apo-FBP crystals suitable for X-ray diffraction studies were 
obtained. Structural studies of FBP will verify its conformation and may lead to a 
better understanding of the iron uptake mechanism in these pathogens which may 
provide insight into drug design to target FBP for antibacterial therapy. 
Aftrer finishing the studies described in this chapter, a crystal structure of 
holo-FBP (PDB code ld9y, McRee DE, et al., unpublished) of Neisseria gonorrhoeae 
and a crystal structure apo-FBP (PDB code ld9v, unpublished) of Haemophilus 
influenzae appeared in the PDB (both released on 17/11/99). As expected, the 
structure of holo-FBP of N. gonorrhoeae resembles the holo-FBP of H. influenzae, 
with Fe(llI) and phosphate bound in the cleft together with Tyr195, Try196, His9, 
G1u57 and a water as the Fe(HI) ligand. The apo-FBP of H. influenzae exhibits a 
large conformational change (domain open form) compared to the holo-FBP [8], no 
iron is bound but with phosphate is present in the cleft. 
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Chapter 8 
Ferric-iron binding protein (FBP) as a target for 
titanium(IV) - spectroscopic, NMR, EXAFS 
and crystallographic studies 
8.1 Abstract 
Ferric-iron binding protein (FBP) is a 34 kDa periplasmic iron transport 
protein expressed by some gram-negative pathogenic bacteria. It displays structural 
and metal-binding properties characteristic of the transferrin family. This makes FBP 
a potential chemotherapeutic target for metallodrugs. The binding of Ti(1V) 
complexes to this pathogenic bacterial protein has been explored using various 
techniques including UV-vis, ICP-AES, 31 P NMR, 1D and 2 D 1 H NMR, EXAFS 
and X-ray crystallography. There is a unique specific strong binding for Ti(IV) on 
FBP (recombinant protein from Neisseria gonorrhoeae) which may allow Ti(IV) 
complexes to act as inhibitors of this protein and as potential antibacterial agents. 
Ti(IV)-citrate and Cp 2TiCl2(aq) react rapidly with apo-FBP under physiological 
conditions (100 mM NaCl, 25 mM bicarbonate, 4 mM phosphate, pH 7.4) to form a 
specific 1:1 complex, which inhibits Fe(ffl) binding. The yellow Ti(IV)-FBP 
complex has a characteristic absorption band centred at 323 nm. 1 H NMR reveals that 
the Cp ligands are displaced from Cp 2TiCl2(aq) on reaction with apo-FBP and that 
Ti(IV) induces specific structural changes in the protein. 31 P NMR reveals that 
phosphate is not bound as a synergistic anion in Ti-FBP. EXAFS studies suggest that 
6 oxygen atoms are directly bound to Ti(IV), one at 1.64 A, two at 1.80, and three at 
1.92 to 1.97 A. There is also a second shell composed of two or three 
oxygens/nitrogens at 2.9 to 3.3 A. The Ti-FBP complex was crystallised with a space 
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group P3 2 12 and the crystals diffracted X-rays to 2.4 A resolution. Preliminary 
refinement of the crystal structure shows that Ti(IV) binds to FBP in the Fe(ffl)-
binding cleft but Ca. 4 A away. from the Fe(Ill) site with no bound phosphate. The 
cleft between the two domains is opened compared to that of the Fe(Ill) protein. 
Ti(IV) is probably bound as a hydrated ion and only Tyr 196 from the protein is 
directly bound to Ti(IV). The other Fe(ffl)-binding residues are not directly bound to 
Ti(IV), but His9 and G1u57 bound ligands for Fe(llI) in Fe-FBP occupy similar 
positions in Ti-FBP and probably interact with Ti(IV)-bound water (or OH, or Ti=O) 
via hydrogen bonds (within 4 A distance from the Ti(IV)), while Tyr195 is shifted 
away from the metal centre. Further refinement is neàessary to confirm this 
preliminary X-ray analysis. Of greater significance is that Ti(IV)-citrate can react 
with holo-FBP and displace Fe(ffi) rapidly under physiological conditions in vitro. 
The displacement occurs with 4 mol equiv of added Ti(IV)-citrate, and with 20 mol 
equiv of Ti(IV)-citrate present, Fe(Ill) is almost completely displaced from FBP. 
These novel findings will encourage the exploration Ti(IV) complexes as potential 
novel anti-bacterial agents. 
8.2 Introduction 
hon is an essential and a limiting resource in most environments, and is 
required for the multiplication of most bacteria. Ferric-iron binding protein (FBP) is a 
periplasmic iron transport protein expressed by some gram-negative pathogenic 
bacteria including Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus 
influenzae, Actinobacillus pleuropneumoniae and Pasteurella haemolytica. It shuttles 
Fe3 across the periplasmic space and cytoplasmic membrane [1,2]. The effective 
uptake of iron by FBP and related iron transport proteins in these pathogens is related 
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to virulence [3,4]. FBP plays a critical role in meningococcal, gonococcal and a wide 
range of other diseases [5,6]. The recently reported whole genome sequence of 
Neisseria meningitidis suggests that gene sequences coding for iron-regulating 
proteins, including FBP are highly conserved and important for virulence of these 
pathogens [7,8]. 
FBP is a potential chemotherapeutic target, given the recent understanding of 
the mechanism of iron binding revealed by the crystal structure of FBP from 
Haemophilus influenzae [9].  This is supported by the fact that iron acquisition is a 
critical component of bacterial pathogenesis in vivo and FBP is a crucial point for 
high-affinity iron uptake from both free iron sources and iron bound by transferrin, 
lactoferrin and haemglobin within their host. It appears that the mechanism of iron 
binding by FBP is highly conserved between different species, as the core iron-
binding residues can be identified in most of the species containing this protein. This 
makes FBP an attractive target for a broad-spectrum antibacterial target. 
The structural data on hFBP reveal that the 3-D fold of FBP resembles one-
lobe of transferrin with Fe(HI) bound in the cleft between the two domains although 
the iron site in FBP is much more solvent-exposed [9].  The iron(ffl) ligands are the 
side-chains of two Tyr residues (Tyr195 and Tyrl96), I His (His9), Glu residue 
(G1u57), a water molecule and a synergistic anion phosphate [9] (see Figure 1.12 in 
Chapterl). These are almost identical to those in transferrins (two Tyr, 1 His and I 
Asp), but with a bidentate carbonate as synergistic anion [10,11]. 
Promoted by recent findings that Ti(IV) binds strongly to transferrin 
[12,13,14] as well as small chemical compounds containing phenolate and 
carboxylate donors [15,16], reactions of Ti(IV) with FBP are investigated here with a 
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view to exploring Ti(IV) compounds as inhibitors of this protein from pathogenic 
bacteria. This was also encouraged by the biological and medicinal findings that 
Ti(IV) compounds show antibacterial [17,18,19], anticancer and antiviral activities 
[20,21]. 
8.3 Experimental 
Materials. Titanocene dichloride was purchased from Arcos Chemical Co. and was 
used in all the experiments as a freshly prepared DMSO/saline (0.1 M NaCl; 1/9,v/v) 
solution at 277 K, as used in reports in vivo experiments [22,23]. This stock solution 
was Ca. 10-20 mM and was used within 5 h. Ti(IV)-citrate solution was prepared as 
described previously [12]. Fe(NTA) 2 was prepared as described previously [14]. 
The FBP of Neisseria gonorrhoeae was overexpressed in E.coli Top 10 strain 
and purified as described in Chapter 2. Apo-FBP was prepared by treatment of the 
holo-FBP solutions in a Centricon microconcetrator (Amicon) with 250 mM sodium 
citrate, pH 4.5 for 4 times, until no pink colour was observed. The apo-FBP was 
then sequentially washed 4x with 2 ml of 0.1 M KC1. At this point the colourless 
protein, still in the Centricon, was exhaustively exchanged into the buffer to be used 
in different experiments. 
UV-Vis Spectroscopy. All the UV experiments were performed with 1 cm 
cuvettes on a computer-controlled Shimadzu UV-1000 spectrometer with 
temperature control at 298 K or 310 K. UV difference spectra after addition of metal 
complex to apo-FBP were recorded immediately and at different time intervals. For 
titration experiments, aliquots of Ti(IV) complex (0.5-10 p1) were added and the 
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solution was left to equilibrate at 298 K for 30 mm. The binding or release of Ti" 
was monitored by the increase or decrease in absorbance at 320 nm. 
Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES). This 
was performed on a Thermo Jarrell Ash IRIS spectrometer using standard methods. 
Metal-loaded- and apo-proteins were purified by using Centricon 30 (Amicon) 
ultrafilters and washing three times with ultra-purity water followed by ultrafiltration 
after each washing. The final protein solution was diluted with Tris buffer (10 mM), 
and phosphorus and iron contents were measured without digestion of the sample. 
NMR Spectroscopy. FBP samples were dissolved in 0.1 M KCI in D 20/H20 
(10%190%). The pH was adjusted to 7.4 ± 0.1, when necessary, using NaOH and 
HCl (0.1 M). 
'H NMR spectra were recorded on a Bruker DMX 500 spectrometer at 500 
MHz, using 0.6 ml of FBP solution (ca 1 mM) in 5-mm tubes at 298 K, using ca. 
1000 transients, 6 p.s (50°) pulses, 1.8 s recycle time, 16,384 data points, and water 
suppression via a combination of presaturation and pulsed-field gradients. The 
chemical shift reference for 'H was sodium trimethylsilyl-d 4-propionate (TSP). 
Resolution enhancement of the spectra was achieved by processing the free 
induction decays with a combination of unshifted sine-bell and exponential functions 
(line broadening of 1.5-20 Hz) on a Silicon Graphics computer using XWIN-NMR 
software. 
2D [ 1 H, 'H], NOESY (mixing time 100 ms), TOCSY spectra (mixing time 50 
ms) [24,25] were acquired on a Bruker DMX 500 spectrometer at 298 K, using 
4,096 data points in the f2 dimension ('H), 32-64 increments of t,, acquisition time 
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0.2 s, 96 scans and 512 increments in the fi dimension. Qsine functions were used 
in both dimensions for processing data. 
Proton-decoupled 31 P NMR spectra were recorded on a Bruker DMX 500 
spectrometer operating at 202 MHz. Typically 2048 transients were collected using 
a pulsewidth of 6 ts (500),  relaxation delay 2 s, and 16,384 data points. The 31 P 
reference was external 85% H3PO4. The spectra were processed using exponential 
functions (line-broadening of 1-2 Hz). 
X-ray Absorption Spectroscopy—X-ray spectra were recorded at the titanium 
K edge (4.966 keV) on EXAFS station 8.1 at Daresbury Laboratory Synchrotron 
Radiation Source. Data for Ti-FBP were collected using a fixed temperature liquid 
nitrogen cryostat (sample temperature approximately 90 K) in fluorescence mode 
using 13-element germanium solid state detector. Samples are prepared as follows. 
Purified native FBP was concentrated by ultrafiltration (Centricon 10, 10 kDa cut-off) 
and washed three times with 0.1 M KC1. Ti-FBP complex was prepared by loading 
apo-FBP with 2 mol eq. of Cp 2TiCl2(aq) in 0.1 M KC1 (pH 7.4) in the presence of 3 
mM of phosphate. The excess Ti(IV) was removed from the yellowish solution by 
ultrafiltration (Centricon 10) four times with KC1. Data were processed by Dr Ian 
Harvey (Daresbury, Warrington) using EXCALIB, EXBACK [26] and/or 
SPLINE(modified for use with EXCURV) [27], and analyzed by Dr. Ian Harvey 
using the Rehr-Albers approximation [28] in EXCURV98 [29]. 
Crystallization of Ti-FBP and data collection. The Ti-FBP complex used for 
crystallisation was from the same batch as that used in the EXAFS and NMR studies 
(prepared by addition of 2 mol eq of Cp 2TiC12(aq, 10%DMSO-d6:90% saline) in I 
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mM FBP, in the presence of 3 mM NaH 2PO4, 0.1 M KC1, pH 7.4, 298 K). The 
sample was filtered through a 0.22 p.M filter before used in crystallisation. Crystals of 
Ti-FBP were grown at 290 K by hanging drop yapour diffusion from 10 p.1 drops (5 
p.l reservoir solution and 5 p.1 protein solution containing 2-5 mg/ml of Ti-FBP in 0.1 
M KC1, 3 mM NaH2PO4 , pH 7.4). The drops were equilibrated against 1 ml 
reservoirs containing 15- 30% PEG 4000, 0.2 M NaCl, 0.4 M malate/imidazole 
buffer, pH 6.2-7.8, or sodium citrate (0.25 M) buffer. Diffraction quality crystals 
reached their maximum size over a period of weeks to two months and typical 
approximate dimensions were 0.35 mm x 0.2 mm x 0.2 mm. 
The crystals of the Ti-FBP complex were mounted on Cryoloops (Hampton 
Research) and flash frozen in liquid nitrogen. Prior to freezing, they were coated with 
Paraton N oil as a cryoprotectant. Diffraction data were collected at 100 K by Dr 
Dmitriy Alexeev (ICMB, Edinburgh) at Daresbury Laboratory Synchrotron Radiation 
Source (Warrington, U.K.), using a wavelength of ?. = 1.488 A and a MarResearch 
345 mm image plate at Station 7.2, and using wavelength of ?. = 0.87 A and a Nonius - 
CCD at Station 9.6, respectively. Three data sets were obtained using one crystal. 
One high intensity data set was collected between 25.0 A to 2.40 A over 180° with an 
oscillation angle (Ap ) of 1.0° and the crystal to detector distance set at 242 mm at 
Station 9.6. Another lower intensity data set was collected between 25 A to 2.70 A 
over 180° with an oscillation angle of 0.8 1 with the crystal to detector distance set at 
273 mm at Station 7.2. It was followed by a low intensity data set run between 30 A 
and 4.74 A over 180° with Aq = 2.0° at the same Station. All the three diffraction 
data sets were processed using DENZO and scaled together with the SCALEPACK 
[30] software. The crystal belongs to the space group P3 2 12 (a = b = 147.74, c = 
115.26 A) and the diffraction data extended to a resolution of 2.40 A. 
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8.4 Results 
8.4.1 Tin' Binds to Apo-FBP under Physiologically Relevant Conditions 
1.5 
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Figure 8.1 Kinetics of Ti"-cit binding to apo-FBP. Dependence of absorption on 
time for a solution containing apo-FBP (26.8 tM) and 1.0 mol eq of Ti"-citrate in 
physiological buffer (100 mM NaCl, 4 mM phosphate, 25 mM bicarbonate, pH 7.4), 
310 K. The appearance of the broad band centred Ca. 328 nm which increased in 
intensity rapidly over a period of 20 mm, together with the rapid increase in intensity 
of the absorbance centred at 248 nm is indicative of fast reaction between TiN  and 
apo-FBP. Reaction times from bottom to top: 2, 5, 10, 20 and 30 mm (last two 
spectra are almost identical). 
Kinetics of reactions of TiVcit  with apo-FBP. Reactions of Ti"-citrate with 
apo-FBP (26.8 p.M, 1:1) in physiological buffer (100 mM NaC1, 4 mM phosphate, 
25 mM bicarbonate, pH 7.4) produced a new broad band centred ca. 328 nm in the 
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UV-vis spectrum. This band increased in intensity rapidly over a period of 20 mm, 
accompanied with rapid increase in intensity of the absorption centred at 248 nm. 
Figure 8.1 shows the absorption spectra recorded for the reaction at different times 
at 310 K. The reaction was fast, more than 50% of the total absorbance change 
occurring within the first 2 mm, and the reaction was almost complete in 20 mm. 
Stoichiometry of binding of Tifl' to apo-FBP. A titration to investigate 
the stoichiometry of Ti' v binding was performed under similar conditions. Selected 
UV difference spectra after adding Ti"-cit and equilibration for 30 min at 310 K are 
shown in Figure 8.2. A sharp band at 247 nm and a less intense band at 294 nm as 
well as a broad band at 323 nm appeared immediately in the difference spectrum. 
All the three bands increased in intensity with more added Ti" but there was little 
increase in intensity of these bands after a 1:1 mol ratio was reached. 
Plots of AA323 and AA247 against the molar ratio (r) of Ti'v-cit to apo-FBP are 
shown in Figure 8.3. It can be seen that with increase of r, the data for AA323 and 
AA247 are linear up to an r value of 1 and at higher ratios the rise in absorbance is 
less steep. The sharp break at r = 1, suggests strong binding of one Ti"' ion to each 
apo-FBP molecule. The value of the extinction coefficient for the broad band at 323 
nm (E323) is Ca. 3,100 M'cm' based on protein concentration. The resulting yellow 
Ti-FBP solution was stable at ambient temperature (ca. 291 K) for several weeks but 
precipitate appeared after standing overnight at 310 K. 
ICP-AES analysis of Ti content after purifying the Ti-FBP complex revealed a 
Ti/FBP ratio of I .2(± 0.1)/I (mean of 3 measurements), confirming that one Ti binds 

















AA 	 0.75 
tt 
0.5 	294 nm 	I 0.50 323 nm 	
0.25 
Mul 
300 	400 	500 	600 
Wavelength (nm) 
Figure 8.2 Titration of Ti 1"-cit with apo-FBP. Reaction of Ti'-cit with apo-FBP 
gives rise to new bands in the UV difference spectrum after addition of various mol 
equiv of Ti"-cit. Conditions: 40.4 iM apo-FBP in 100 mM NaCl, 25 mM HCO3 , 4 
mM NaH2PO4 , pH 7.4, 298 K. Ratio (TiJFBP) from bottom to top: 0.25, 0.50, 0.75, 
1.00 and 1.50. 
Figure 8.3 Titration curve for the reaction of Ti '-cit with apo-FBP. The increase in 
intensities of the absorbances at 323 nm and 247 nm are plotted against the ratio 
[Ti]/[FBP] (r). Conditions: as Fig. 8.2. 
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8.4.2 Reactions of Fe(III) with Ti-FBP. 
To test whether Ti-FBP can be displaced by Fe(ffl, 1.0 mol eq. of Fe(NTA) 2 
was added to a Ti-FBP solution (28 tM in 10 mM Hepes, 5 mM, NaH2PO4 , pH 7.4) 
and Fe(IIT) binding monitored by the Fe(ffl)-FBP LMCT band near 481 nm. Small 
increase in intensity at > 420 nm accompanied by minor decrease in intensity at <420 
nm with an isobesctic point at 420 nm were observed over a period of 3 h (see Figure 
8.4). This suggests that Fe(III) was displacing Ti(IV) from Ti-FBP. However, the 
change is very small and the final increase in intensity at 481 nm is 0.018 (AA 481 = 
0.018), which accounts for only 26% displacement. This suggests that the Fe(Ill) site 
was blocked by Ti(IV) which competitively inhibits Fe(III) binding. 
MI 
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Figure 8.4 UV-vis spectra of reactions of Fe(HI) with Ti-FBP. Dependence of 
absorbance on time for a solution containing Ti-FBP (28 tM) and 1.0 mol eq of 
Fe(NTA)2 in Hepes buffer (10 mM Hepes, 5 mM NaH2PO4, 50 mM KCI, pH 7.4), 
298 K. The small increase of the absorption at > 420 nm accompanied by decrease of 
the absorption at < 420 nm over 3 h suggest that Fe(III) partially displaced Ti(IV) 
from Ti-FBP. Reaction times from bottom to top: 1, 5, 10, 30, 60 and 120 mm. 
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8.4.3 Displacement of Fe(III) from holo-FBP by .Ti(IV). 
When 1.0 mol equiv of Ti'-citrate was added to an aqueous solution of holo-
FBP (51 tM) in physiological buffer (100 mM NaCl, 4 mM phosphate and 25 mM 
bicarbonate, pH 7.4) at 298 K, there was a small but noticeable increase in the 
absorbances centred at Ca. 318 nm and 254 nm (revealed by difference spectra) over 
a period of about 30 mm (Figure 8.5). But there is no change to the LMCT band of 
Fe(III)-FBP at 481 nm. This is likely due to non-specific binding of Ti(IV) to 
residues like Tyr in the protein (which contains 10 Tyr residues). 
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Figure 8.5 Kinetics of Ti"-cit binding to holo-FBP. Dependence of absorbance on 
time for a solution containing holo-FBP (51 tM) and 1.0 mol eq of Ti"-citrate in 
physiological buffer (100 mM NaCl, 4 mM phosphate, 25 mM bicarbonate, pH 7.4), 
298 K. The small increase of the absorption at 318 and 254 nm over 30 min may be 
due to non-specific binding. Reaction times from bottom to top: 1, 5, 10, 25 and 42 
and 60 mm. 
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A titration was performed under the same conditions and selected UV-vis 
spectra after equilibration of the samples at 298 K for 1 h are shown in Figure 8.6. 
The reactions followed a different course at mol ratios (r,TiIFBP) below and above 
4. It can be seen at r < 4 (Figure 8.6A), with the increase of r, increases in intensity 
occurred at > 400 nm (maximum increase is at 318 nm) accompanied by little 
change to the Fe-FBP LMCT band at 481 nm (the small increase of this band is due 
to the tail of the band at 318 nm). However, at r = 4, the band at 481 nm decreased 
intensity after Ti(IV) was added (see Figure 8.6B), and at r> 4, there was no more 
increase of the band at 318 nm but the Fe-FBP LMCT band at 481 nm markedly 
decreased in intensity. The iron band at 481 nm was almost abolished after 20 mol 
equiv Ti(IV) was added. This suggests that Fe(Ill) is displaced by Ti(IV). 
8.4.4 NMR Studies 
Reactions of Cp 2TiC12 with apo-FBP were followed by 'H and 31 P NMR 
spectroscopy. 
'H NMR. 'H NMR studies were carried out to investigate the structural 
changes in apo-FBP induced by reactions with Cp 2TiCl 2 . Aliquots of a solution of 
Cp2TiCl2 (0-2 mol equiv, freshly prepared in DMSO-d 6/saline, 1/9, v/v) were added 
to a solution of apo-FBP in 0.1 M KC1 (D 201H20, 10%/90%) containing 3 mM 
phosphate, pH 7.4. 'H NMR spectra of apo-FBP are complicated by the overlap of a 
large number of resonances from this large molecule (34 kDa). However, some 
regions such as the high-field region (0.5 to —1 ppm) consisting mainly of ring-
current shifted resonances, characteristics shifts for apo- and holo-forms. This region 
was useful for monitoring specific Ti(IV) binding to the specific iron site of the 
protein. 
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Figure 8.6 Reactions of various mol ratios of Ti"-cit with holo-FBP. Reactions of 
Ti"-cit with holo-FBP at r <4 gave rise to an increase in absorbance centred at 318 
nm. At r ~: 4, the LMCT band of Fe-FBP decreased in intensity with added Ti(IV), 
suggesting Fe(Ill) is displaced from Fe-FBP by Ti(IV). Conditions: 51 iM holo-
FBP in 100 mM NaCl, 25 mM HCO3, 4 mM NaH2PO4, pH 7.4, 298 K. 
* spectrum recorded at once after 4 eq Ti(IV) added, all other spectra were recorded 
1.0 h after reaction. 
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The 500 MHz 'H NMR spectrum of the high field region is shown in Figure 
8.7. It is clear that Ti(IV) binding caused characteristic changes in this region. After 
addition of the first 0.5 mol equiv of Cp2TiCl2, two new sharp peaks appeared at 
0.622 and 0.605 ppm, peaks b (0.369 ppm) and d (0.112 ppm) increased in intensity, 
while peaks c (0.271 ppm) and e (0.057 ppm) decreased in intensity markedly, peak 
a (0.579 ppm) broadened and peak f (-0.600 ppm) broadened and shifted to lower 
field (-0.571 ppm). These changes continued and reached a maximum when the 
second 0.5 mol equiv of Cp2TiC12 was added. No further changes occurred in this 
region on addition of a second mol equivalent of Cp 2TiCl2. The changes indicate 
that only one Ti(IV) binds to apo-FBP specifically and Ti(IV) binding induced 
characteristic structural changes in this protein. 
The 2D TOCSYand 2D NOESY spectra of Ti-FBP are largely over-lapped 
due to the large size of the protein. The high field region below 0 ppm is less 
overlapped and is shown in Figure 8.8. The 2D TOCSY spectrum revealed only one 
pair of cross peaks for each of the strong peaks in the 1D spectrum, which suggests 
that they are from methyl groups of Ala residues. The 2D NOESY spectrum 
revealed connectivities to resonances at low field region (6.5 ppm, 7.2 ppm, typically 
for resonances from side-chain aromatic rings in the protein). Ala 201 (in (X-helix 
and above Trp197) and Ala 90 (also in (x-helix and below Trp95) are some possible 
candidates. However, there are 44 Ala residues in the protein, and it is not possible 
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Figure 8.7 High-field region of the 500 MHz 'H NMR spectrum of apo-FBP (1 mM in 0.1 M 
KC1, 3 mM NaH 2PO4 , pH 7.4) and changes induced by subsequent additions of 0.5, 1.0 and 2.0 
mol equivalent of Cp 2TiC12(aq). The signals in this region are probably from methyl groups 
situated over aromatic rings in the protein. 
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Figure 8.8 The high field region of 2D NMR spectra of Ti-FBP in 0.1 M KCI, 3 mM 
Na1-1 2PO4, 90%H20/10%D 20, pH 7.4, 298 K. Left, TOCSY (t = 100 ms), right, 
NOESY (t = 100 ms). 
'H NMR studies were also carried out to investigate whether the Cp ligands 
are displaced during reaction of Cp 2TiCl2(aq) with apo-FBP. Ti"-bound Cp exhibits 
a singlet at 6.42 ppm at neutral pH, while released Cp (CpH) shows two multiplets at 
6.57, 6.62 ppm and a weak multiplet at 2.95 ppm [31]. 500 MHz 'H NMR spectra of 
the Cp region of apo-FBP and with subsequent additions of 0.5 to 2.0 mol equiv of 
Cp2TiC12(aq) in the presence of 3 thM phosphate at pH*  7.4, 298 K, are shown in 






6.8 6.6 6.4 6.2 p p m 
Figure 8.9 500 MHz 'H NMR spectra showing the displacement of Cp ligands from 
Cp2TiCl2 (aq) when it reacts with apo-FBP (1 mM in 0.1 M KCI, 3 mM NaH 2P041  pH 7.4, 298 K). 
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broad peaks appear at 6.54 and 6.60 ppm, assignable to released Cp (CpH). These 
two peaks increased intensity when 1.0 mol eq of Cp2TiCl2(aq) was added, but no 
peak for Ti-bound Cp was observed at this stage. However, when a second mol 
equiv Cp2TiCl 2(aq) was added, no marked changes occurred for the free Cp 
resonances but a strong singlet assigned for Ti 1"-bound Cp appeared at 6.39 ppm. 
This suggests that only one mol equiv of Ti(IV) binds to apo-FBP and Cp ligands are 
completely displaced during the specific reaction. 
31P NMR studies. To investigate if Ti(IV) binds phosphate as a synergistic 
anion in Ti-FBP, Cp 2TiCl 2(aq) was titrated into apo-FBP containing 3 mol eq of 
phosphate, and monitored by 31 P NMR spectroscopy (see Figure 8.10). Apo-FBP 
shows no 31 P NMR signal. When 3.0 mol eq NaH 2PO4 was added to apo-FBP, a 
31 P NMR peak appeared at 2.62 ppm, in the typical chemical shift range for free 
phosphate under similar conditions. However, the line-width of 15.5 Hz (processed 
with line broadening 1.0 Hz) is much larger than free phosphate under similar 
conditions (line-width 4.9 Hz), suggesting that phosphate binds to apo-F'BP weakly 
and exchanges with free phosphate on the NMR timescale. When 0.5, 1.0 and 2.0 
mol eq of Cp 2TiCl2(aq) were added in this solution, no new 31 P NMR peak nor shift 
of the peak at 2.62 ppm was observed (see Figure 8.10). This suggests that 
phosphate is not bound to Ti(IV) as synergistic anion. However, the 31 P NMR peak 
at 2.62 ppm sharpened after addition of Ti(IV) (8.6 Hz with 0.5 eq Ti(IV), 6.2 Hz 
with 1.0 eq Ti(IV) and 4.9 Hz with 2.0 eq Ti(IV)). This suggests that Ti(IV) 
displaces the weakly bound phosphate from FBP and now the phosphate exists 
completely in the free form. 
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Figure 8.10 3 1  P NMR spectra of apo-FBP (1 mM in 0.1 M KC1, pH 7.4, 298 K) and 
subsequent additions of 3 mol eq of NaH 2PO4 , 0.5 eq and 1.0 eq Cp 2TiCl 2 . 
8.4.5 X-ray Spectroscopy 
These studies were carried out in collaboration with Dr Ian Harvey (CLRC) 
who analyzed the data. 
EXAPS studies. Ti(IV) K-edge EXAFS studies were carried out to investigate 
the environment of Ti in Ti-FBP. The EXAFS spectrum of Ti-FBP and the Fourier 
transforms are shown in Figure 8.11. The Fourier transform shows two intense, 
overlapping peaks at approx. 1.64 A and 1.97 A, and a broad peak at 3.09 A. The two 
peaks at 1.64 A and 1.97 A can be simulated with oxygen back-scatters. These peaks 
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are due to the scattering from the atoms directly coordinated to Ti(IV). The total 
coordination number refines to 6. There is one short bond (1.64 A), typically within 
the range of Ti=O double bond (1.61 A to 1.70 A)[32-35], 2 slightly longer bonds 
(1.80 A) and 3 longer but normal bonds (1 .92 1.99 A), within the range of typical Ti-
0 single bond [14,33,34]. Although each of the six liganding atoms has been 
modelled separately in this case, essentially the same result is obtained when the 2 
atoms at 1.8 A and the 2 atoms at 1.97 A are modelled at single distances (4 distances 















Figure 8.11 EXAFS spectrum (left) of Ti-FBP and Fourier transform (right) of the 
EXAFS spectra. Solid line, experimental; dotted line, calculated. 
Although it is possible to get a partial fit to the broad peak in the Fourier 
transform at approximately 3. 1 A using a single phosphorus atom, the simulation is 
inadequate. The breadth of the peak suggests that there are at least 2 distances 
contributing. A significantly better simulation is obtained with 2 shells of oxygen 
atoms, at approximately 2.9 and 3.3 A. Such a simulation fits the width of the peak 
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Table 8.1 XAFS data for Ti-FBP 
Ti-FBP ligand CN Distance/ A Debye- 
Wailer 
factor (20.2)  
'Inner 
sphere' 
01 1 1.641 0 .001 2 
02 1 1.802 0. 001 2 
03 1 1.803 0 . 001 2 
04(tyrl96)' 1 1.925 0.0012 Ti-O-CZ 117 0 
05 1 1.968 0 . 001 2 
06 1 1.985 0 .001 2 
'Outer 
sphere' 
07 2 2.932 0.001 
08 3. 3.348 0.005 
Fit Index 0.00053 
R factor3 25.99 
1 All atoms of the phenyl ring included in the simulation using constrained 
refinement. Ideal bond lengths and internal angles used, together with multiple 
scattering to give an estimate of the Ti-O-ring bond angle. 
2 Debye-Waller factor for 01-06 refined as a single parameter 
N 	 exp 	th 3R—factor= 1 1/o-(I 	(k)- 1 (k)I)xl00% 
Note The R-factor is not comparable to diffraction R-factor. Typical values are 35-
40% for single sell (single scattering) simulations and 20-25% for all-atom (multiple 
scattering) simulations. 
and better models the beat pattern in the EXAFS at 8 A* Additionally, a lower 
residual R factor (26%) is obtained with oxygens at 2.9 and 3.3 A, compared to a 
phosphorus atom (3 1%). Strong scattering atoms at these distances could have two 
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origins - strong multiple scattering from atoms of the Tyr196 ring, and second sphere' 
coordination. Rigid body (constrained) refinement allows the angle between the Ti 
and the tyrosine ring (Ti-0-CZ) to be refined. Two minima are obtained: 117° and 
175°. The 175° solution, giving an almost linear bond places 2 atoms of the ring at 
approximately 3.2 A, in a strong multiple scattering condition. Thus the only 
additional atoms required are at 2.9 A. However, the crystal structure of Ti-FBP (see 
next section) gives this bond angle as 109°, which is close to the other minimum. In 
this case, 2 additional shells, at 2.9 and 3.3 A are required. The crystal structure 
suggests that apart from Tyr 196, there is no direct coordination between the Ti and 
the protein - that the Ti is 'hydrated' and coordination to the protein is mostly via Ti-
0- bonds. This provides a plausible explanation for the shells of oxygens at 2.9 and 
3.3 A - this second sphere is in-fact the protein ligands bound to titanium oxygens 
observed at 1.8-2.0 A. Although this model (Table 8.1) explains most of the detail in 
the EXAFS data, a small number of details require further work to finalise this model. 
(1) The coordination numbers at 2.9 and 3.3 A are somewhat uncertain, probably 2 
and 3, but possibly also 1 and 2. (2) Either shell may contain mixed 0/N contribution, 
possibly from His9. (3) There is a small unfilled contribution at ca. 2.5 A. 
8.4.6 Crystallization of Ti-FBP. 
Various pH levels, PEG concentrations and protein concentrations were tested 
in this study to find the best conditions for the growth of protein crystals. No crystals 
were obtained in sodium citrate (250 mM, pH 6.4 —7.4) buffer with PEG 4000 (15 - 
30%). Needle crystals appeared in 400 mM imidazole-malate and 0.2 M NaCl buffer 
and the conditions were optimised. Two forms of Ti-FBP crystals were observed. 
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Chunky crystals (form I) appeared between pH 7.1-7.3 and needle crystals (form II) 
were produced between pH 7.5-7.7. Both crystal forms took several weeks to grow. 
The best crystal of form I grew at pH 7.2, 22% PEG4000 and pH 7.3, 23% PEG4000. 
The best needle crystals of form II appeared at pH 7.7, 25% PEG4000 (see Figure 
8.12). The form I crystals gave reasonable diffraction while the needle crystals 





Figure 8.12 Crystals of Ti-FBP produced by the hanging-drop vapour-diffusion 
method. Protein solution (5 j.il of 5 mg/mI in 0.1 M KC1, pH 7.4) was mixed with an 
equal volume of reservoir solution (0.2 M NaCl, 0.4 M malate/imidazole buffer). 
Crystals of form I (left) were obtained in drops of pH 7.2 and 22% PEG; crystals of 
form II (right) were obtained in drops of pH 7.7 and 25% PEG. 
The Ti-FBP crystal of form I diffracted X-rays to the maximum resolution of 
2.40 A at the Synchrotron Radiation Source at Daresbury Lab, station 9.6. Figure 
8.13 shows an example of the diffraction pattern. The symmetry of the diffraction 
pattern is consistent with the hexagonal space group P3 2 12 and the observed unit cell 
parameters are a = b = 147.74 A, c = 115.26 A, a = = 900, y = 1200 . A total of 
496,095 reflections were collected, 55,813 of which were unique reflections. The 
data collection statistics are summarised in TabLe 8.2. 
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Figure 8.13 The diffraction pattern of the Ti-FBP crystal recorded on a Quantum 4 
CCD detector at beamline 9.6 at the Synchrotron Radiation Source at Daresbury 
Laboratory by Dr Dmitriy Alexeev. The crystal diffracts to beyond 2.40 A. 
Table 8.2 Summary of crystallographic data for Ti-FBP 
Crystal data 
crystal system Hexagonal 
space group P3 2 12 
a, b (A) 147.74 
c (A) 115.26 
V(A) 2178866.25 
molecules/asymmetric unit 3 
T(K) lOOK 
Resolution (A) 2.40 
refi. collected/unique 496 095/55 813 
refl. with I > 2o(l) 80.9% 
solvent content 65.6% 
Completeness (%) 98.6% 
Rsym for all data 14.9% 
Overall I/(T 11.5 
Redundancy 8.8 
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8.4.7 Structure Solution of Ti-FBP Complex by Molecular Replacement 
This work was carried out by Dr Dmitriy Alexeev (ICMB, Edinburgh). A 
Patterson map was calculated using the diffraction data in the resolution range 30 A 
to 2.40 A. Inspection of the map revealed a large translation peak at (1/3, 2/3, 0), the 
height of which was one third of the origin peak. This implies that there are 2-3 
translation-related molecules in the asymmetric unit cell. 
The program MOLREP (CCP4, 1994) was used to solve the structure by the 
molecular replacement method. There are three X-ray crystal structures of FBP in the 
PDB (Protein Data Bank) to date: a recently-solved crystal structure of FBP of 
Neisseria gonorrhoeae (holo-form, 2.2 A resolution, PDB code ID9Y, McRee DE, et. 
at., unpublished) and two crystal structures of FBP of Haemophilus influenzae (holo-
form, 1.6 A resolution, PDB code 1RMP [9];  apo-form, 1.75 A resolution, PDB code 
1D9V, McRee DE, et. at., unpublished). Since FBP of Neisseria gonorrhoeae is 
highly homologous (Ca. 72% identity and ca 84% homology) to FBP of Haemophilus 
influenzae, the crystal structure of the apo-form of FBP of Haemophilus influenzae 
was also used as a search model in the molecular replacement attempts. 
Unfortunately, they both failed in the rotation function search and yielded no solution. 
Since FBP consists of two rigid domains connected by a flexible hinge, searches were 
performed using these individual domains separately. The individual domain 
solutions were combined and the matching pair was found. This combined model was 
used as a new model for molecular replacement. A rotation function search with this 
model revealed a single prominent peak, and the translation function calculations 
suggested 3 independent translationally related molecules in the asymmetric unit cell. 
The only stand-alone rotation and translation solution had a correlation coefficient of 
22.3% and an R factor of 59.9% for all data in the resolution range 30.0-2.40 A. 
Rigid body refinement was performed with CNS using the data between 10 to 2.4 A 
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to refine the relative positions of the domains. The Matthew's coefficient [36] for the 
protein mass (V m) was 3.6 A3Da' with three molecules in the asymmetric unit cell. 
This corresponds to a solvent content in the crystal of 65.6%. 
Preliminary Refinement Results. Refinement of the structure is currently 
being attempted by Dr Dmitriy Alexeev (TCMIB, Edinburgh), but the current R factor 
is still extremely high (46.2%). It is suspected that the crystal is twinned and further 
work is in progress to investigate this. 
Figure 8.14 Crystal structure of apo-FBP of Haemophilus influenzae (form PDB, 
code ID9V, McRee et al. unpublished). The iron-binding cleft is in an open 
conformation with phosphate bound. Side chains of the iron-binding residues 
Tyr195(yellow), Tyr196 (yellow), His9(blue), G1u57(red) and the bound phosphate 
(yellow and red) are shown. 
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Unexpectedly, the first electron density maps are very clear and show good 
density for the most parts of the protein, including the side-chains in the metal binding 
site. The relative positions of the Ti-FBP domains are closer to the apo-form FBP 
(see Figure 8.14) of Haemophilus influenzae than to the holo-forms of both FBPs of 
Haemophilus injluenzae and Neisseria gonorrhoeae. Figure 8.15 shows the 
comparison of Ti-FBP with holo-FBP (Fe-bound structure) of Neisseria gonorrhoeae, 




Figure 8.15 Comparison of the conformations of Ti-FBP (red) and holo-FBP (green) 
of Neisseria gonorrhoeae (PDB code ID9Y, McRee et al., unpublished), with their N-
terminal domains aligned. The Fe-binding cleft in Ti-FBP is in an open conformation, 
while in Fe-FBP it is closed. 
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Figure 8.16 displays the overall structure of Ti-FBP with the side-chains of 
the four iron-binding residues (His9, G1u57, Tyr195, Tyr196) highlighted. The metal 
binding cleft of Ti-FBP is fairly open, like that in the open apo-form, but the 
positions of Fe(1ll)-binding residues are more similar to those in the holo-form. The 
conformations of three of the four Fe(IIi)-binding residues, His9, G1u57 and Tyrl96 
are close to the holo-FBP structure. The conformation of Tyr 195 in Ti-FBP is unique 
compared to apo- and holo-FBP structures. The side chain of Tyr195 is shifted away 
from the Fe(III) binding site (see Figure 8.16). Electron density for the Ti(IV) ion 
can be identified (see Figure 8.17). It is located in the Fe(III)-binding cleft and 
Ti(IV) is bound to the 0-donor of the side chain of Tyr196, but not to Tyr 195. Ti(IV) 
is located 4.5 A away from the Fe(III)-binding site, when their N-terminal domains 
are aligned. His9 and G1u57 are not bound to the metal directly, but their 
conformations still resemble those in the Fe-bound holo-form (see Figure 8.17). In 
addition, there is no density for the synergistic anion phosphate in the electron density 
map, suggesting that no phosphate is bound. The open apo-like conformation of the 
domains together with the locked holo-like conformations of the Fe(III)-binding 
residues in Ti-FBP complex suggest that Ti(IV) ion exists as a highly hydrated 
complex, occupying much larger space than Fe(llI) ion in the closed holo-form. 
Although only Tyr196 is the only protein side-chains directly coordinated to 
Ti(IV), other protein residues are close enough to hydrogen-bond to Ti(IV)-bound 
water or OH ligand (or Ti=O). His9 and Glu57 have conformations which resemble 
those in Fe-FBP, and are probably bound to Ti(IV) through hydrogen bonds (within 
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4.5 A of Ti(IV)). Other proteins residues such as Asn 193 and Asn 175 and ArgiOl 
(the former two bind to the synergistic anion phosphate in Fe-FBP), are spacially 
close to Ti(IV) and are likely to be bound to Ti(IV) via hydrogen bonds. 
However, the refinement is still very preliminary and further work is required 
to resolve the details of Ti-binding. 
Figure 8.16 An overall structure for Ti-FBP. Ti is in the cleft but moved 4.5 A 
compared to the Fe position. Tyr196 is the only protein side-chain bound to Ti. 
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Figure 8.17 The electron density map for residues near the Ti site in Ti-FBP structure. 
8.5 Discussion 
Iron is an essential nutrient and iron acquisition plays a significant factor in 
the colonisation of pathogenic bacteria [1]. FBP-mediated high-afimity Fe(IIl) 
transport is a specific and efficient mechanism of iron acquisition, which, in 
combination with other factors, allows pathogenic Neisseria to multiply aggressively 
within the human host. The vigorous host response to the bacterial invasion causes 
the pathology associated with these organisms. Thus FBPs play a critical role in 
gonococcal, menigicoccal and a wide range of other diseases [37]. The recently 
reported whole genome sequence of Neisseria meningitidis suggests that gene 
sequences coding for iron regulating proteins, including FBP, are highly conserved 
and important for the virulence of these pathogens [7,8]. 
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Because FBP is highly conserved among various pathogenic species such as 
Neisseria gonorrhoeae, Neisseria meningitidis (nFBP), Haemophilus influenzae 
(hFBP) [38], Serraria marcescens (sFBP) [39], Yersinia enterocolitica [40], 
Pasteurella haemolytica (pFBP) [41], Actinobacillus pleuropneumoniae [42] and 
Actinobacillus actinomycetemcomitans (aFBP) [43,44], it provides a potential target 
for broad-spectrum antibacterial drug design. Inhibitors of FBP could act as 
antibacterial agents for diseases caused by these pathogens. This novel targeting 
pathway could counter the rapidly growing problem of anti-microbial drug resistance 
[45,46]. 
The experiments performed in this study reveal that Ti(IV) binds specifically 
and strongly to apo-FBP. The changes in the UV spectrum of apo-FBP on reaction 
with Ti(IV)-citrate are very similar to those observed previously for the binding of ,  
Ti(IV) to the specific Fe" sites of apo-hTF. [12,13,14,]. The two sharp new bands 
near 247 and 298 nm are typical of phenolate groups (7c1t*  transitions) generated by 
binding of metal ions to Tyr residues in the specific iron binding sites. The third 
broad band centred near 321 nm, lies in the range typical of LMCT transitions of 
Ti" with phenolate ligands [15,47]. The magnitude of the change in extinction 
coefficient of this LMCT band 0323 = 3100 M'cm') in physiological buffer is in a 
similar range of that for Fe"-FBP (AE481= 2430 M' cm') [48] and Ti 2-hTF [14]. 
The titration curve obtained by monitoring the absorbance change at 323 nm gave a 
sharp break at a ratio of Ti: FBP of 1:1. The same ratio was also obtained by ICP-
AES measurement of bound metal, suggesting that Ti' s' binds to the specific iron 
binding cleft in the protein, and that tyrosine is involved in binding Ti'". Moreover, 
Ti(IV) blocks Fe(III) binding to FBP which provides further evidence for specific 
binding of Ti1" to the Fe(III) site of the protein. 
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In contrast to the slow uptake of Ti(IV) from Ti(IV)-citrate to apo-hTF, which 
takes more than 10 h at 310 K [12], the uptake of Ti" from Ti(IV)citrate by apo-FBP 
is rapid and is complete in 20 min in physiological buffer at 310 K. Moreover, 
Ti(IV) is readily and completely displaced by Fe(IH) from Ti2-hTF complex by 
Fe(NTA) 2 . But this is not the case for FBP, Fe(Ill) only partially displaced Ti(IV) 
from Ti-PB P (<30% when 1.0 mol eq Fe(NTA)2 added to Ti-FBP) and Ti(IV) even 
can displace Fe(III) from the native FBP very quickly. These differences may due to 
the differences between the Fe(III) sites in the human and bacterial proteins. The 
Fe(III) site in transferrin is completely buried within the protein core [10], while the 
crystal structures of FBP show that the active site lies in a deep canyon on the protein 
surface which is solvent-exposed and accessible [9].  This may allow Ti(IV) to attack 
the Fe(III) site from the side in holo-FBP and displace the iron. 
'H NMR spectroscopy shows that the cyclopentadienyl ligands are displaced 
from T1 1"' after reaction of Cp 2TiC1 2 with apo-FBP. It is known that the chloride 
ligands are readily displaced from Cp 2TiC12 in aqueous solution (e.g., by H 20/OH on 
hydrolysis in water) [31], and therefore only the Ti" ion from the drug is taken up 
by the protein. The structural changes in apo-FBP induced by Ti'" binding were 
monitored by 'H NMR. Resonances for apo-FBP and Ti-FBP are in slow exchange 
on the NMR time scale, indicative of strong Ti 1"' binding. 
No 31 P NMR peak was observed for Ti-FBP, which suggests that phosphate 
is not required as a synergistic anion. This is supported by the EXAFS data and 
crystallography data for Ti-FBP in which Ti(IV) appears to be in a highly hydrated 
form occupying the position which was occupied by iron and phosphate in holo- 
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FBP. It has been shown in Chapter 5 [14] that Ti(IV) does not require a synergistic 
anion to bind strongly to hTF, but a synergistic anion is crucial for strong Fe(llI) 
binding to both proteins [3,10]. This could explain why Ti(IV) is not displaced by 
Fe(llI) in Ti-FBP. 
The unique and strong binding of Ti(IV) to apo-FBP could allow Ti(IV) 
complexes to act as inhibitors of this protein from pathogenic bacteria. This novel 
finding will encourage the exploration of Ti(IV) and other similar metal (such as Zr 
and Hf) complexes as potential novel anti-bacterial agents. The final structure of Ti-
FBP will reveal the detailed Ti(IV) coordination and provide a basis for new drug 
design. By designing the metal complexes, the kinetics and thermodynamics of 
reaction between FBP and the metal complexes could be finely controlled, as well as 
other properties required for the use of metal complexes as drugs. This could open 
up a novel route for development of novel antibiotics against a wide range of serious 
diseases which are rapidly acquiring resistance to current organic anti-microbial 
agents [49,50]. 
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Table Al Sequence (in bold) and secondary structure of FBP from Neisseria 
gonorrhoeae (from PDB, code ld9y, McRee, et al., unpublished). Secondary structure 
is calculated and described according to the method of Kabsch and Sander (1983) 
Biopolymers 22, 2577-2637. The assignments are: H=helix; B=residue in isolated beta 
bridge; E=extended beta strand; G=3 1 0 helix; I=pi helix; T=hydrogen bonded turn; 
S=bend. 
1 DITVYNGQHK EAAQAVADAF TRATGIKVKL NCAKGDQLLAG QIKEEGSRSP 
EEEEE S H HHHHHHHHHH HHHH EEE EES HHHHHH HHHHHGGG 
51 ADVFYSEQIP ALATLSAANL LEPLPASTIN ETRGKGVPVA AXKDWVALSG 
SEEEESSHH HHHHHHHTT B 	TTTHH HH TT 	TTS EE EE 
101 RSRVVVYDTR KLSEKDLEKS VLNYATPKWK NRIGYVPTSG AFLEQIVAIV 
EEEEEEEETT T GGGS SS GGGGTTGGGT TTEEEETT H HHHHHHHHHH 
151 KLKGEAAALK WLKGLKEYGK PYAKNSVALQ AVENGEIDAA LINNYYWHAF 
HHHTHHHHHH HHHHHHHHSE EESSHHHHHH HHHTTSSSEE EEETHHHHHH 
201 AREKGVQNVH TRLNFVRHRD PGALVTYSGA AVLKSSQNKD EAKKFVAFLA 
HHHH GGG EEEE TTT GGG EEEEEE EEETT SSHH HHHHHHHHHH 
251 GKEGQRALTA VEAEYPLNPH VVSTFNLEPI AKLEAPQVSA TTVSEKEHAT 




• 	Table A2 FBP_NG sequence by residue type 
FBP_NG Total 309 
TrpW 4 W95 W129 W161 
TyrY 10 Y5 Y55 Y107 
PheF 8 F19 F54 F142 
HIsH 6 H9 H198 H210 
Gly G 20 G7 G25 G35 
G164 G169 G185 
AIaA 44 Al2 A13 A15 
• A67 A68 A76 
A173 A178 A181 
A250 A257 A260 
VaIV 27 V4 V16 V28 
V147 V150 V177 
V272 V288 V293 
Leu L 28 L30 L38 L62 
L152 L159 L162 
L277 L283 L302 
Ilel ii 12 126 142 
SerS 18 S32 S47 S49 
S238 S245 S246 
ProP 13 P50 P60 P73 
P286 
ThrT 17 13 T21 T24 
1274 T291 T292 
GluE 23 Eli E44 E45 
E186 E203 E241 
AspD 9 Dl D18 D36 
AsnN 15 N6 N31 N69 
N248 N268 N276 
GInQ 12 Q8 Q14 Q37 
Arg R 14 R22 R48 R83 
R262 R301 
LysK 29 K10 K27 K29 
K130 K151 K153 
K244 K252 K282 
Met M 1 M308 
CysC 0 
Wi 97 
Y124 Y135 Y168 Y172 Y195 Y196 Y265 
F200 F215 F245 F248 F275 
H218 H270 H298 
G40 G46 G84 G86 G100 G134 G140 G154 
G205 G222 G229 G251 G254 G307 
A17 A19 A23 A33 A39 A51 A61 A63 
A90 A91 • 	A97 A125 A141 A148 A156 A157 A158 
A189 A190 A199 A201 A223 A230 A231 A242 A247 
A263 A281 A285 A290 A298 A306 
V53 V87 V89 V96 V104 V106 V106 V121 V136 
V182 V206 V209 V216 V225 V232 V246 V261 V271 
L65 L70 L71 L74 L98 L112 L117 L122 L143 
L165 L179 L191 L213 L224 L233 L249 L258 L267 
L303 
159 179 1133 1146 1149 1187 	• 1192 1280 
S56 S66 S77 S99 S102 S113 S120 S139 S176 
S273 S289 S294 
P75 P88 P127 P137 P171 P221 P266 P269 P279 
164 T78 182 1109 1126 1138 1211 1226 1259 
1300 
E57 E72 E81 E114 E117 E144 E155 E167 E183 
E253 E264 E278 E284 E295 E297 E304 
D52 D94 D108 D116 D188 D240 
N80 N129 N131 N175 N184 N193 N194 N208 N214 
041 Q58 0145 Q180 0207 Q237 Q255 Q287 Q305 
RiOl R103 RhO R132 R202 R212 R217 • R219 R256 
K34 K43 K85 K92 K93 Kill K115 K119 •K128 
K160 K163 K166 K170 K174 K204 K234 K239 K243 & 
K296 K309 
Appenda 
FBP_NM MKTS—i RYALL AAALTAATPA LADITVYNGQ HKEAAQAVAD AFTRATGIKV 	50 
FBP_NG kT—! RY I. . 	l'rAATPA L.DI I \ 	(.v IIKI 	\D TRAl t;Ik\ 
FBP_HI t)FKHFkL.TE AA IAFSANS FT)ITVYNCQ IIKF.AT. 	K EQErctkv 
KLNSAKGDQL ACQI KEEGSR SPADVFYSEQ IPALATLSAA NLLEPLPAST 	100 
.R(iJQI. I P 	)\ I \.Sl U I PU. 	TI 'A \ I 1 E 	l VAS I 
'I INSGKSEQL I. 	GDK TPU)VfYTI TJFDISE (;IJAPI SEQ 1 
INETRGKGVP VAAKKDWVAL SGRSRVV%YD TRKESEKDLE KSVLNYATPK 	ISO 
M1TRGk''i \\;. 	\! TR 	F k" 
IQQTAQK(.\P LA PIKD\VI U. SGRSRN 	\\ I) HT 	Bk 	%IF kSVLD'V 	FPR 
WKNRICY APT SGAFLEQVVA IVKLKGEAAA LKWLKALKEY (KPYAKNSVA 	200 
\\ lsNkI (.\ 1l'i S(.AILEQI\' IVkLktFAA\ I K\ 	l.KCI I IV kP 
\\k(;KI(.\VSI M,.tIIFQV\ ISI'%Ik 	I)KV I N1.F(;IkEN (KL)KS\ 
LQAVENGEID AALNNYYWH AFAREKGVQN VHTRLNFVRH RDPGALVTYS 	250 
I (J 	kMJ ID LIN\ \ 	\ ii AF.\ 	ik\ Q\ VII riI Ni\ RI! Riii.'d \ T 
I Q.VE' 	VP \EINNYVVV NLKEKGVEN LKSRIYFVRII QDPGAIVSVS 
GA VLKSSQNK DEAKKFVAFL AGKEGQRALT AVRAEYPLNP HVVSTFNLEP 	300 
D 	\Ki".\Il AGI , L 	R' I  
(.S\VLKASKNQ Al 	Qk1\flII AS K Ki 	E 	V R\I) ITRA I)\ \ 'P!\I LI' 
IAKLEAPQVS 	ATTVSEKEHA TRLLEQAGMK 
	
330 I 
tALl I\PQ\S 	.l l\'I'iufl 	TRI 1.1 Q.\IL 
YEKIE.PV\S 	.ETAQI)NF lit 	IKI I 1 E ' LK 
Table A3 Comparison of FBP sequences of Neisseria gonorrhoeae, Neisseria 
meningitidis and Haemophilus influenzae. Amino acid sequences were obtained from 
the Expert Protein Analysis System (: cascIi/). CLUSTAL W was used to 
calculate the amino acid sequence alignment as shown. Note that the sequences 
include a 22 residue periplasmic localisation signal which is cleaved to form the 
mature protein whose N-termini begin. Red colour represents identical residues, blue 
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